code
stringlengths 4
12
| description
stringlengths 2
264
| codetype
stringclasses 8
values | context
stringlengths 160
15.5k
|
|---|---|---|---|
2007 | EPINEPHRINE .1MG/ML | CDM | 1986 China medical record followup Severity not evaluated Nestvold et al., 1974 Central Norway, Prospective identification by surgeons on duty case Survey ranked by length of PTA: None = 1, < 0.5 1988 Akershus County inclusion with neurological symptoms hr = 2, 0.5â6 hr = 3, 6â24 hr = 4, 1â2 days = 5, 3â7 (Oslo) days = 6, > 7 days = 7 Servadei et al., 1981 to Ravenna, Italy ED identification plus hospital admission and record GCS; 3â5, 6â8, 9-12, 13â15 1988 1982 review Badcock, 1984 South Australia Prospective study of all ED visits, hospital admissions and Length of PTA: none, < 5 min, 5â60 min, 1â24 1988 prehospital deaths hrs, 1â7 days, 1â4 wks, > 4 wks Tiret et al., 1986 Aquitaine, Prehospital deaths and hospital admissions survey by Severity by 3 classes based on PTA of coma > 6 1990 France medical staff using 180 possible head injury codes using hrs = severe, PTA 15 min to 6 hrs = moderate, AIS and ISS PTA, 15 min = mild Levi et al., 1984 to Northern Israel Prospective patient identification from referral to GCS used but not recorded 1990 1988 neurological service records Nell and Brown, 1986 Johannesburg, Inpatient admission with screening ICD-9 codes 800â804, GCS, mild = 13â15, moderate = 7â12 and severe = 1991 South Africa 850â854, 293, 294, 310, 870â873, 950â951, 958, 345, 3â6 347, 348, 253.9 75
76 Year(s) Reference of Data Location Case Definition and Data Source TBI Severity Criteria and Scoring Johansson et al., 1984 to Northern Sweden Hospital admissions with ICD 850â854 Severity not evaluated 1991 1985 Annoni et al., 1987 Canton St. Hospitalized patients with intracranial lesions on Severe brain injury only GCS < 7, 7â9, 10â12, > 1992 Gallen, admission CT 12 Switzerland Vazquez- 1988 Cantabria, Spain Hospital admissions with objective neurological findings GCS, minor = 13â15, moderate 9â12, severe 3â8 Barquero et al., such as LOC, skull fracture 1992 Engberg, 1995 1988 Frederiksborg ED and hospital ICUs in 4 hospitals using hospital Severity by PTA: 24 hrs-7 days = severe, very County, Denmark records, Danish Hospital Register and National Register severe 7 days Chiu et al., 1988 to Taiwan Hospital admission with LOC, skull fracture, neurological GCS: mild = 13â5, moderate = 9â12 (or CT pos), 1997 1994 deficit or CT intracranial hemorrhage severe 8 Hillier et al., 1987 South Australia All public and private hospitals with admission ICD-9 GCS: mild = 13â5, moderate = 9â12 (or CT pos), 1997 codes of 348, 800, 803, 804, 850-854 severe = 3â 8; PTA < 30 min = mild, 30â60 min = moderate, > 60 min = severe, PTA < 60 min = mild, 60 min = moderate, 24 hrs = severe Ingebrigtsen et 1993 Northern Norway All patient referral medical records includes ED visits GCS: minimal = 15 no LOC, mild = 14 or 15 plus al., excludes scalp, facial injuries PTA or brief LOC or impaired alertness, moderate 1998 = 9â13 or LOC > 5 min or focal neurological deficit, severe = 5â8, critical = 3â4 Tate et al., 1988 New South Admission to region hospital with ICD-9 codes 310, 800, Severe = PTA > 24 hrs, or GCS of < 9, moderate 1998 Wales, Australia 801, 803, 804, 850â854, 905.0, 907 = PTA 1â24 hrs or GCS 9â12, mild = PTA or LOC < 1 hr Alaranta et al., 1991 to Finland Hospital discharge or register using ICD-9 codes: 800, Severity not evaluated 2000 1995 801, 803, 850â854 (first-time patients only) Pickett et al., 1988 Greater Kingston Computerized ED injury records from the CHIRPP system Severity not reported 2001 Area of Canada Engberg and 1979 to Denmark Danish National Hospital Register using 8th ICD codes Severity not evaluated Teasdale, 1996 800, 801, 803, 850â854, mortality data from National 2001 Death Register using ICD 8th and 10th codes
Year(s) Reference of Data Location Case Definition and Data Source TBI Severity Criteria and Scoring Masson et al., 1996 Aquitaine, France Persons hospital admitted through emergency service with AIS score of 4 or 5 or LOC 6â24 hrs GCS < 9 2001 of any one of 19 hospitals, data from treating hospital Firsching and 1996 Germany Head injury hospital admitted patients including Severity scoring not reported Woischneck, concussion; deaths from Federal Bureau of Statistics 2001 Gururaj, 1999 Bangalore, India Case definitions from the Neurotrauma Registry of GCS used by categories of severity not defined 2002 National Institute of Mental Health and Neuroscience, Bangalore India including LOC or PTA neurological changes, skull fracture, death due to TBI Servadei et al., 1998 Romagna and Hospital admissions with ICD-9 codes 800â800.3, 801â Severity not evaluated 2002b Trentino, Italy 801.3, 803â803.3, 850; 851â851.1, 852â852.1 853â853.1, 854â854.1 Servadei et al., 1998 Romagna, Italy All patients admitted to hospital care with a discharge Mild TBI as defined by Duckin using ICD codes 2002a diagnosis of ICD-9 800â803.0, 801â801.3, 803â804.3, GCS of 14â15 = mild, 9â13 = moderate, < 9 = 850â854. In hospital and prehospital deaths identified severe from hospital records or death certificates Masson et al., 1996 Aquitaine, France Persons admitted to anyone of 19 public hospitals with Severe TBI by GCS of < 9 for at least 24 hrs 2003 prolonged coma determined by LOC > 24 hrs or GCS of < 9 before sedation Kleiven et al., 1987 to Sweden National hospital discharge register using ICD codes 800â Severity not evaluated 2003 2000 804, 850â854, (ICD-9) and S2.0âS2.9, S6.0âS6.9 (ICD- 10) Andersson et al., 1992 to Western Sweden Persons identified from hospitals ED unit, discharge Mix of symptoms defined by American Congress 2003 1993 register, regional neurological clinic and coronerâs records of Rehabilitation Medicine ICD-9, 850â854, 800â804 Baldo et al., 1966 to Northeast Italy Hospital discharges with ICD-9 codes 800, 801.9, 803, ICDMAP-90 used to convert ICD codes to AIS: 2003 2000 804.9, 850â854.1 located on data base for region 1/2 = mild, 3 = moderate, 4/5 = severe Santos et al., 1994, Portugal From National Institute of Statistics using ICD-9 codes Severity not evaluated 2003 1996, 800, 801, 803, 804, 850â854, 907 for hospital discharge 1997 and mortality data 77
78 Year(s) Reference of Data Location Case Definition and Data Source TBI Severity Criteria and Scoring Steudel et al., 1972 to Germany Federal Bureau of Statistics using ICD-9 codes 800-804 Focus of study is on fatal head injury 2005 1998 and 850â854 and ICD-10 S02âS02.9 and S06âS06.9 Tennant, 2005 2001 to England Hospital Episodes Statistics using ICD-10 codes S00â Severity not evaluated 2003 S09.9 for hospital inpatient care plus Primary Care Trusts Chiu et al., 2007 1991, Taipei City and Prospective TBI registry data. Excludes prehospital deaths GCS: severe 9, moderate = 9â15 plus hospital 2001 Hualien County, in 2001 stay at least 48 hrs and had brain surgery or Taiwan abnormal CT scan, mild = all others Yates et al., 1997 to Royal Devon and ED database from one hospital. ICD codes used but not Based on ICD-10 but not defined 2008 2003 Exeter Hospital, stated UK Wu et al., 2008 2004 6 Providences of Hospital admitted patients with data from attending GCS: severe 9, moderate = 9â13, mild = 14, 15 Eastern China physician NOTE: AIS = Abbreviated Injury Scale, CHIRPP = Canadian Hospitals Injury Reporting and Prevention Program, CT = computed tomography, ED = emergency department, GCS = Glasgow Coma Scale, ICD = International Classification of Diseases, ICDMAP = computer algorithm, ICU = intensive care unit, ISS = Injury Severity Score, LOC = loss of consciousness, PTA = posttraumatic amnesia, TBI = traumatic brain injury, UK = United Kingdom. TABLE 3.4 US TBI Incidence Studies Base Year(s) of Number of Population Rate / 105 Reference Data Location Patients (x1000) per year Comments Annegers et al., 1980 1965 to 1974 Olmstead County, MN 3,587 NS 193 Age adjusted to 1970 US population, rate averaged from men only and women only rates Fuortes et al., 1990 1984 to 1986 Iowa NS NS 159 in 1984 Hospital admissions only 133 in 1985 117 in 1986 Rimel, 1981 1977 to 1979 Central Virginia 1,330 NS NS Hospital patients and prehospital deaths Klauber et al., 1981 1978 San Diego, CA 5,055 NS 294 Includes some nonresidents, excludes a few external causes Cooper et al., 1983 1980 to 1981 Bronx, NY 1,209 NS 249 Rate based on sample, age adjusted to 1980 US population Jagger et al., 1984b 1978 North Central Virginia 735 354 208 Rate includes residents and nonresidents; no ED cases or prehospital deaths Kraus et al., 1984 1981 San Diego County, CA 3,358 1862 180 Population based, not age adjusted Whitman et al., 1984 1979 to 1980 Inner city Chicago and 782 213 331 Composite rate from data in publication, Evanston, IL average across race and gender Fife et al., 1986 1979 to 1980 Rhode Island 2,870 947 152 Hospital patients only Fife, 1987 1977 to 1981 US 307,000 226,545 136 Hospital patients only; 1.87 million 1.87 million 805 All injured patients MacKenzie et al., 1989a 1986 Maryland 5,838 NS 132 Hospital patients only MacKenzie et al., 1990 1979 to 1986 Maryland NS NS 114-134 Hospital patients only, range in rates Oklahoma State 1989 Oklahoma 3,672 NS 121 Hospital and fatal cases Department of Health, 1991 Schuster, 1994 1990 Massachusetts 27,819 6,016 10 Mortality rate 86 Hospital admissions 366 ED only Warren et al., 1995 1991 to 1993 Alaska 2,178 457 130 Hospital patients only Diamond, 1996 1988 to 1993 Virginia 46,680 NS NS Only age-specific rates reported Sosin et al., 1996 1991 US 1.54 million NS 618 Total rate 158 Hospitalized 79
80 Base Year(s) of Number of Population Rate / 105 Reference Data Location Patients (x1000) per year Comments 307 ED only 153 No care Thurman et al., 1996 1990 to 1992 Utah 5,782 NS 106 Age adjusted rate to 1990 US population Gabella et al., 1997a 1990 to 1993 Colorado, Missouri, 13,978 13,687 103 Age adjusted rate to 1990 US population Oklahoma, Utah Gabella et al., 1997b 1991 to 1992 Colorado 7056 NS 101 Hospitalized and deaths, age adjusted to US Thurman and Guerrero, 1994 to 1995 US NS NS 98 Hospitalized patients only 1999 Jager et al., 2000 1992 to 1994 US 1.144 million NS 444 ED patients only Schootman et al., 2000 1993 Iowa 2,559 NS 91 Severe TBI rate based capture- recapture; age adjusted rate to 1990 US population Guerrero et al., 2000 1995 to 1996 US 1.027 million NS 392 ED patients only Louisiana Office of 1996 to 1999 Louisiana 16,203 NS 90 Hospitalized patients and prehospital Public Health Injury and deaths Research Prevention Section, 2004 Langlois et al., 2003 1997 14 US states 62,771 NS 70 Live hospital discharges only Langlois et al., 2006 1995 to 2001 US 1.396 million NS 505 Total rate, age adjusted to 2000 US population 235 86 Hospitalized patients only 1.111 million 401 ED visits only Selassie et al., 2004 1996 to 2001 South Carolina 70,671 NS 68 Hospital patients only 220 ED patients only Texas Department of 1998 Texas 20,000 NS NS Hospitalized patients only Health, 2004 Rutland-Brown et al., 2003 US 1.565 million NS 538 Total 2006 421 ED visits only 100 Hospitalization NOTE: CA = California, ED = emergency department, IL = Illinois, MN = Minnesota, NS = not stated, NY = New York, TBI = traumatic brain injury, US = United States. |
1995 | IMP PIST 0.6X4.5MM | CDM | 1986 China medical record followup Severity not evaluated Nestvold et al., 1974 Central Norway, Prospective identification by surgeons on duty case Survey ranked by length of PTA: None = 1, < 0.5 1988 Akershus County inclusion with neurological symptoms hr = 2, 0.5â6 hr = 3, 6â24 hr = 4, 1â2 days = 5, 3â7 (Oslo) days = 6, > 7 days = 7 Servadei et al., 1981 to Ravenna, Italy ED identification plus hospital admission and record GCS; 3â5, 6â8, 9-12, 13â15 1988 1982 review Badcock, 1984 South Australia Prospective study of all ED visits, hospital admissions and Length of PTA: none, < 5 min, 5â60 min, 1â24 1988 prehospital deaths hrs, 1â7 days, 1â4 wks, > 4 wks Tiret et al., 1986 Aquitaine, Prehospital deaths and hospital admissions survey by Severity by 3 classes based on PTA of coma > 6 1990 France medical staff using 180 possible head injury codes using hrs = severe, PTA 15 min to 6 hrs = moderate, AIS and ISS PTA, 15 min = mild Levi et al., 1984 to Northern Israel Prospective patient identification from referral to GCS used but not recorded 1990 1988 neurological service records Nell and Brown, 1986 Johannesburg, Inpatient admission with screening ICD-9 codes 800â804, GCS, mild = 13â15, moderate = 7â12 and severe = 1991 South Africa 850â854, 293, 294, 310, 870â873, 950â951, 958, 345, 3â6 347, 348, 253.9 75
76 Year(s) Reference of Data Location Case Definition and Data Source TBI Severity Criteria and Scoring Johansson et al., 1984 to Northern Sweden Hospital admissions with ICD 850â854 Severity not evaluated 1991 1985 Annoni et al., 1987 Canton St. Hospitalized patients with intracranial lesions on Severe brain injury only GCS < 7, 7â9, 10â12, > 1992 Gallen, admission CT 12 Switzerland Vazquez- 1988 Cantabria, Spain Hospital admissions with objective neurological findings GCS, minor = 13â15, moderate 9â12, severe 3â8 Barquero et al., such as LOC, skull fracture 1992 Engberg, 1995 1988 Frederiksborg ED and hospital ICUs in 4 hospitals using hospital Severity by PTA: 24 hrs-7 days = severe, very County, Denmark records, Danish Hospital Register and National Register severe 7 days Chiu et al., 1988 to Taiwan Hospital admission with LOC, skull fracture, neurological GCS: mild = 13â5, moderate = 9â12 (or CT pos), 1997 1994 deficit or CT intracranial hemorrhage severe 8 Hillier et al., 1987 South Australia All public and private hospitals with admission ICD-9 GCS: mild = 13â5, moderate = 9â12 (or CT pos), 1997 codes of 348, 800, 803, 804, 850-854 severe = 3â 8; PTA < 30 min = mild, 30â60 min = moderate, > 60 min = severe, PTA < 60 min = mild, 60 min = moderate, 24 hrs = severe Ingebrigtsen et 1993 Northern Norway All patient referral medical records includes ED visits GCS: minimal = 15 no LOC, mild = 14 or 15 plus al., excludes scalp, facial injuries PTA or brief LOC or impaired alertness, moderate 1998 = 9â13 or LOC > 5 min or focal neurological deficit, severe = 5â8, critical = 3â4 Tate et al., 1988 New South Admission to region hospital with ICD-9 codes 310, 800, Severe = PTA > 24 hrs, or GCS of < 9, moderate 1998 Wales, Australia 801, 803, 804, 850â854, 905.0, 907 = PTA 1â24 hrs or GCS 9â12, mild = PTA or LOC < 1 hr Alaranta et al., 1991 to Finland Hospital discharge or register using ICD-9 codes: 800, Severity not evaluated 2000 1995 801, 803, 850â854 (first-time patients only) Pickett et al., 1988 Greater Kingston Computerized ED injury records from the CHIRPP system Severity not reported 2001 Area of Canada Engberg and 1979 to Denmark Danish National Hospital Register using 8th ICD codes Severity not evaluated Teasdale, 1996 800, 801, 803, 850â854, mortality data from National 2001 Death Register using ICD 8th and 10th codes
Year(s) Reference of Data Location Case Definition and Data Source TBI Severity Criteria and Scoring Masson et al., 1996 Aquitaine, France Persons hospital admitted through emergency service with AIS score of 4 or 5 or LOC 6â24 hrs GCS < 9 2001 of any one of 19 hospitals, data from treating hospital Firsching and 1996 Germany Head injury hospital admitted patients including Severity scoring not reported Woischneck, concussion; deaths from Federal Bureau of Statistics 2001 Gururaj, 1999 Bangalore, India Case definitions from the Neurotrauma Registry of GCS used by categories of severity not defined 2002 National Institute of Mental Health and Neuroscience, Bangalore India including LOC or PTA neurological changes, skull fracture, death due to TBI Servadei et al., 1998 Romagna and Hospital admissions with ICD-9 codes 800â800.3, 801â Severity not evaluated 2002b Trentino, Italy 801.3, 803â803.3, 850; 851â851.1, 852â852.1 853â853.1, 854â854.1 Servadei et al., 1998 Romagna, Italy All patients admitted to hospital care with a discharge Mild TBI as defined by Duckin using ICD codes 2002a diagnosis of ICD-9 800â803.0, 801â801.3, 803â804.3, GCS of 14â15 = mild, 9â13 = moderate, < 9 = 850â854. In hospital and prehospital deaths identified severe from hospital records or death certificates Masson et al., 1996 Aquitaine, France Persons admitted to anyone of 19 public hospitals with Severe TBI by GCS of < 9 for at least 24 hrs 2003 prolonged coma determined by LOC > 24 hrs or GCS of < 9 before sedation Kleiven et al., 1987 to Sweden National hospital discharge register using ICD codes 800â Severity not evaluated 2003 2000 804, 850â854, (ICD-9) and S2.0âS2.9, S6.0âS6.9 (ICD- 10) Andersson et al., 1992 to Western Sweden Persons identified from hospitals ED unit, discharge Mix of symptoms defined by American Congress 2003 1993 register, regional neurological clinic and coronerâs records of Rehabilitation Medicine ICD-9, 850â854, 800â804 Baldo et al., 1966 to Northeast Italy Hospital discharges with ICD-9 codes 800, 801.9, 803, ICDMAP-90 used to convert ICD codes to AIS: 2003 2000 804.9, 850â854.1 located on data base for region 1/2 = mild, 3 = moderate, 4/5 = severe Santos et al., 1994, Portugal From National Institute of Statistics using ICD-9 codes Severity not evaluated 2003 1996, 800, 801, 803, 804, 850â854, 907 for hospital discharge 1997 and mortality data 77
78 Year(s) Reference of Data Location Case Definition and Data Source TBI Severity Criteria and Scoring Steudel et al., 1972 to Germany Federal Bureau of Statistics using ICD-9 codes 800-804 Focus of study is on fatal head injury 2005 1998 and 850â854 and ICD-10 S02âS02.9 and S06âS06.9 Tennant, 2005 2001 to England Hospital Episodes Statistics using ICD-10 codes S00â Severity not evaluated 2003 S09.9 for hospital inpatient care plus Primary Care Trusts Chiu et al., 2007 1991, Taipei City and Prospective TBI registry data. Excludes prehospital deaths GCS: severe 9, moderate = 9â15 plus hospital 2001 Hualien County, in 2001 stay at least 48 hrs and had brain surgery or Taiwan abnormal CT scan, mild = all others Yates et al., 1997 to Royal Devon and ED database from one hospital. ICD codes used but not Based on ICD-10 but not defined 2008 2003 Exeter Hospital, stated UK Wu et al., 2008 2004 6 Providences of Hospital admitted patients with data from attending GCS: severe 9, moderate = 9â13, mild = 14, 15 Eastern China physician NOTE: AIS = Abbreviated Injury Scale, CHIRPP = Canadian Hospitals Injury Reporting and Prevention Program, CT = computed tomography, ED = emergency department, GCS = Glasgow Coma Scale, ICD = International Classification of Diseases, ICDMAP = computer algorithm, ICU = intensive care unit, ISS = Injury Severity Score, LOC = loss of consciousness, PTA = posttraumatic amnesia, TBI = traumatic brain injury, UK = United Kingdom. TABLE 3.4 US TBI Incidence Studies Base Year(s) of Number of Population Rate / 105 Reference Data Location Patients (x1000) per year Comments Annegers et al., 1980 1965 to 1974 Olmstead County, MN 3,587 NS 193 Age adjusted to 1970 US population, rate averaged from men only and women only rates Fuortes et al., 1990 1984 to 1986 Iowa NS NS 159 in 1984 Hospital admissions only 133 in 1985 117 in 1986 Rimel, 1981 1977 to 1979 Central Virginia 1,330 NS NS Hospital patients and prehospital deaths Klauber et al., 1981 1978 San Diego, CA 5,055 NS 294 Includes some nonresidents, excludes a few external causes Cooper et al., 1983 1980 to 1981 Bronx, NY 1,209 NS 249 Rate based on sample, age adjusted to 1980 US population Jagger et al., 1984b 1978 North Central Virginia 735 354 208 Rate includes residents and nonresidents; no ED cases or prehospital deaths Kraus et al., 1984 1981 San Diego County, CA 3,358 1862 180 Population based, not age adjusted Whitman et al., 1984 1979 to 1980 Inner city Chicago and 782 213 331 Composite rate from data in publication, Evanston, IL average across race and gender Fife et al., 1986 1979 to 1980 Rhode Island 2,870 947 152 Hospital patients only Fife, 1987 1977 to 1981 US 307,000 226,545 136 Hospital patients only; 1.87 million 1.87 million 805 All injured patients MacKenzie et al., 1989a 1986 Maryland 5,838 NS 132 Hospital patients only MacKenzie et al., 1990 1979 to 1986 Maryland NS NS 114-134 Hospital patients only, range in rates Oklahoma State 1989 Oklahoma 3,672 NS 121 Hospital and fatal cases Department of Health, 1991 Schuster, 1994 1990 Massachusetts 27,819 6,016 10 Mortality rate 86 Hospital admissions 366 ED only Warren et al., 1995 1991 to 1993 Alaska 2,178 457 130 Hospital patients only Diamond, 1996 1988 to 1993 Virginia 46,680 NS NS Only age-specific rates reported Sosin et al., 1996 1991 US 1.54 million NS 618 Total rate 158 Hospitalized 79
80 Base Year(s) of Number of Population Rate / 105 Reference Data Location Patients (x1000) per year Comments 307 ED only 153 No care Thurman et al., 1996 1990 to 1992 Utah 5,782 NS 106 Age adjusted rate to 1990 US population Gabella et al., 1997a 1990 to 1993 Colorado, Missouri, 13,978 13,687 103 Age adjusted rate to 1990 US population Oklahoma, Utah Gabella et al., 1997b 1991 to 1992 Colorado 7056 NS 101 Hospitalized and deaths, age adjusted to US Thurman and Guerrero, 1994 to 1995 US NS NS 98 Hospitalized patients only 1999 Jager et al., 2000 1992 to 1994 US 1.144 million NS 444 ED patients only Schootman et al., 2000 1993 Iowa 2,559 NS 91 Severe TBI rate based capture- recapture; age adjusted rate to 1990 US population Guerrero et al., 2000 1995 to 1996 US 1.027 million NS 392 ED patients only Louisiana Office of 1996 to 1999 Louisiana 16,203 NS 90 Hospitalized patients and prehospital Public Health Injury and deaths Research Prevention Section, 2004 Langlois et al., 2003 1997 14 US states 62,771 NS 70 Live hospital discharges only Langlois et al., 2006 1995 to 2001 US 1.396 million NS 505 Total rate, age adjusted to 2000 US population 235 86 Hospitalized patients only 1.111 million 401 ED visits only Selassie et al., 2004 1996 to 2001 South Carolina 70,671 NS 68 Hospital patients only 220 ED patients only Texas Department of 1998 Texas 20,000 NS NS Hospitalized patients only Health, 2004 Rutland-Brown et al., 2003 US 1.565 million NS 538 Total 2006 421 ED visits only 100 Hospitalization NOTE: CA = California, ED = emergency department, IL = Illinois, MN = Minnesota, NS = not stated, NY = New York, TBI = traumatic brain injury, US = United States. |
1993 | IMP EAR RICHARDS 0.6X3.5MM | CDM | 1986 China medical record followup Severity not evaluated Nestvold et al., 1974 Central Norway, Prospective identification by surgeons on duty case Survey ranked by length of PTA: None = 1, < 0.5 1988 Akershus County inclusion with neurological symptoms hr = 2, 0.5â6 hr = 3, 6â24 hr = 4, 1â2 days = 5, 3â7 (Oslo) days = 6, > 7 days = 7 Servadei et al., 1981 to Ravenna, Italy ED identification plus hospital admission and record GCS; 3â5, 6â8, 9-12, 13â15 1988 1982 review Badcock, 1984 South Australia Prospective study of all ED visits, hospital admissions and Length of PTA: none, < 5 min, 5â60 min, 1â24 1988 prehospital deaths hrs, 1â7 days, 1â4 wks, > 4 wks Tiret et al., 1986 Aquitaine, Prehospital deaths and hospital admissions survey by Severity by 3 classes based on PTA of coma > 6 1990 France medical staff using 180 possible head injury codes using hrs = severe, PTA 15 min to 6 hrs = moderate, AIS and ISS PTA, 15 min = mild Levi et al., 1984 to Northern Israel Prospective patient identification from referral to GCS used but not recorded 1990 1988 neurological service records Nell and Brown, 1986 Johannesburg, Inpatient admission with screening ICD-9 codes 800â804, GCS, mild = 13â15, moderate = 7â12 and severe = 1991 South Africa 850â854, 293, 294, 310, 870â873, 950â951, 958, 345, 3â6 347, 348, 253.9 75
76 Year(s) Reference of Data Location Case Definition and Data Source TBI Severity Criteria and Scoring Johansson et al., 1984 to Northern Sweden Hospital admissions with ICD 850â854 Severity not evaluated 1991 1985 Annoni et al., 1987 Canton St. Hospitalized patients with intracranial lesions on Severe brain injury only GCS < 7, 7â9, 10â12, > 1992 Gallen, admission CT 12 Switzerland Vazquez- 1988 Cantabria, Spain Hospital admissions with objective neurological findings GCS, minor = 13â15, moderate 9â12, severe 3â8 Barquero et al., such as LOC, skull fracture 1992 Engberg, 1995 1988 Frederiksborg ED and hospital ICUs in 4 hospitals using hospital Severity by PTA: 24 hrs-7 days = severe, very County, Denmark records, Danish Hospital Register and National Register severe 7 days Chiu et al., 1988 to Taiwan Hospital admission with LOC, skull fracture, neurological GCS: mild = 13â5, moderate = 9â12 (or CT pos), 1997 1994 deficit or CT intracranial hemorrhage severe 8 Hillier et al., 1987 South Australia All public and private hospitals with admission ICD-9 GCS: mild = 13â5, moderate = 9â12 (or CT pos), 1997 codes of 348, 800, 803, 804, 850-854 severe = 3â 8; PTA < 30 min = mild, 30â60 min = moderate, > 60 min = severe, PTA < 60 min = mild, 60 min = moderate, 24 hrs = severe Ingebrigtsen et 1993 Northern Norway All patient referral medical records includes ED visits GCS: minimal = 15 no LOC, mild = 14 or 15 plus al., excludes scalp, facial injuries PTA or brief LOC or impaired alertness, moderate 1998 = 9â13 or LOC > 5 min or focal neurological deficit, severe = 5â8, critical = 3â4 Tate et al., 1988 New South Admission to region hospital with ICD-9 codes 310, 800, Severe = PTA > 24 hrs, or GCS of < 9, moderate 1998 Wales, Australia 801, 803, 804, 850â854, 905.0, 907 = PTA 1â24 hrs or GCS 9â12, mild = PTA or LOC < 1 hr Alaranta et al., 1991 to Finland Hospital discharge or register using ICD-9 codes: 800, Severity not evaluated 2000 1995 801, 803, 850â854 (first-time patients only) Pickett et al., 1988 Greater Kingston Computerized ED injury records from the CHIRPP system Severity not reported 2001 Area of Canada Engberg and 1979 to Denmark Danish National Hospital Register using 8th ICD codes Severity not evaluated Teasdale, 1996 800, 801, 803, 850â854, mortality data from National 2001 Death Register using ICD 8th and 10th codes
Year(s) Reference of Data Location Case Definition and Data Source TBI Severity Criteria and Scoring Masson et al., 1996 Aquitaine, France Persons hospital admitted through emergency service with AIS score of 4 or 5 or LOC 6â24 hrs GCS < 9 2001 of any one of 19 hospitals, data from treating hospital Firsching and 1996 Germany Head injury hospital admitted patients including Severity scoring not reported Woischneck, concussion; deaths from Federal Bureau of Statistics 2001 Gururaj, 1999 Bangalore, India Case definitions from the Neurotrauma Registry of GCS used by categories of severity not defined 2002 National Institute of Mental Health and Neuroscience, Bangalore India including LOC or PTA neurological changes, skull fracture, death due to TBI Servadei et al., 1998 Romagna and Hospital admissions with ICD-9 codes 800â800.3, 801â Severity not evaluated 2002b Trentino, Italy 801.3, 803â803.3, 850; 851â851.1, 852â852.1 853â853.1, 854â854.1 Servadei et al., 1998 Romagna, Italy All patients admitted to hospital care with a discharge Mild TBI as defined by Duckin using ICD codes 2002a diagnosis of ICD-9 800â803.0, 801â801.3, 803â804.3, GCS of 14â15 = mild, 9â13 = moderate, < 9 = 850â854. In hospital and prehospital deaths identified severe from hospital records or death certificates Masson et al., 1996 Aquitaine, France Persons admitted to anyone of 19 public hospitals with Severe TBI by GCS of < 9 for at least 24 hrs 2003 prolonged coma determined by LOC > 24 hrs or GCS of < 9 before sedation Kleiven et al., 1987 to Sweden National hospital discharge register using ICD codes 800â Severity not evaluated 2003 2000 804, 850â854, (ICD-9) and S2.0âS2.9, S6.0âS6.9 (ICD- 10) Andersson et al., 1992 to Western Sweden Persons identified from hospitals ED unit, discharge Mix of symptoms defined by American Congress 2003 1993 register, regional neurological clinic and coronerâs records of Rehabilitation Medicine ICD-9, 850â854, 800â804 Baldo et al., 1966 to Northeast Italy Hospital discharges with ICD-9 codes 800, 801.9, 803, ICDMAP-90 used to convert ICD codes to AIS: 2003 2000 804.9, 850â854.1 located on data base for region 1/2 = mild, 3 = moderate, 4/5 = severe Santos et al., 1994, Portugal From National Institute of Statistics using ICD-9 codes Severity not evaluated 2003 1996, 800, 801, 803, 804, 850â854, 907 for hospital discharge 1997 and mortality data 77
78 Year(s) Reference of Data Location Case Definition and Data Source TBI Severity Criteria and Scoring Steudel et al., 1972 to Germany Federal Bureau of Statistics using ICD-9 codes 800-804 Focus of study is on fatal head injury 2005 1998 and 850â854 and ICD-10 S02âS02.9 and S06âS06.9 Tennant, 2005 2001 to England Hospital Episodes Statistics using ICD-10 codes S00â Severity not evaluated 2003 S09.9 for hospital inpatient care plus Primary Care Trusts Chiu et al., 2007 1991, Taipei City and Prospective TBI registry data. Excludes prehospital deaths GCS: severe 9, moderate = 9â15 plus hospital 2001 Hualien County, in 2001 stay at least 48 hrs and had brain surgery or Taiwan abnormal CT scan, mild = all others Yates et al., 1997 to Royal Devon and ED database from one hospital. ICD codes used but not Based on ICD-10 but not defined 2008 2003 Exeter Hospital, stated UK Wu et al., 2008 2004 6 Providences of Hospital admitted patients with data from attending GCS: severe 9, moderate = 9â13, mild = 14, 15 Eastern China physician NOTE: AIS = Abbreviated Injury Scale, CHIRPP = Canadian Hospitals Injury Reporting and Prevention Program, CT = computed tomography, ED = emergency department, GCS = Glasgow Coma Scale, ICD = International Classification of Diseases, ICDMAP = computer algorithm, ICU = intensive care unit, ISS = Injury Severity Score, LOC = loss of consciousness, PTA = posttraumatic amnesia, TBI = traumatic brain injury, UK = United Kingdom. TABLE 3.4 US TBI Incidence Studies Base Year(s) of Number of Population Rate / 105 Reference Data Location Patients (x1000) per year Comments Annegers et al., 1980 1965 to 1974 Olmstead County, MN 3,587 NS 193 Age adjusted to 1970 US population, rate averaged from men only and women only rates Fuortes et al., 1990 1984 to 1986 Iowa NS NS 159 in 1984 Hospital admissions only 133 in 1985 117 in 1986 Rimel, 1981 1977 to 1979 Central Virginia 1,330 NS NS Hospital patients and prehospital deaths Klauber et al., 1981 1978 San Diego, CA 5,055 NS 294 Includes some nonresidents, excludes a few external causes Cooper et al., 1983 1980 to 1981 Bronx, NY 1,209 NS 249 Rate based on sample, age adjusted to 1980 US population Jagger et al., 1984b 1978 North Central Virginia 735 354 208 Rate includes residents and nonresidents; no ED cases or prehospital deaths Kraus et al., 1984 1981 San Diego County, CA 3,358 1862 180 Population based, not age adjusted Whitman et al., 1984 1979 to 1980 Inner city Chicago and 782 213 331 Composite rate from data in publication, Evanston, IL average across race and gender Fife et al., 1986 1979 to 1980 Rhode Island 2,870 947 152 Hospital patients only Fife, 1987 1977 to 1981 US 307,000 226,545 136 Hospital patients only; 1.87 million 1.87 million 805 All injured patients MacKenzie et al., 1989a 1986 Maryland 5,838 NS 132 Hospital patients only MacKenzie et al., 1990 1979 to 1986 Maryland NS NS 114-134 Hospital patients only, range in rates Oklahoma State 1989 Oklahoma 3,672 NS 121 Hospital and fatal cases Department of Health, 1991 Schuster, 1994 1990 Massachusetts 27,819 6,016 10 Mortality rate 86 Hospital admissions 366 ED only Warren et al., 1995 1991 to 1993 Alaska 2,178 457 130 Hospital patients only Diamond, 1996 1988 to 1993 Virginia 46,680 NS NS Only age-specific rates reported Sosin et al., 1996 1991 US 1.54 million NS 618 Total rate 158 Hospitalized 79
80 Base Year(s) of Number of Population Rate / 105 Reference Data Location Patients (x1000) per year Comments 307 ED only 153 No care Thurman et al., 1996 1990 to 1992 Utah 5,782 NS 106 Age adjusted rate to 1990 US population Gabella et al., 1997a 1990 to 1993 Colorado, Missouri, 13,978 13,687 103 Age adjusted rate to 1990 US population Oklahoma, Utah Gabella et al., 1997b 1991 to 1992 Colorado 7056 NS 101 Hospitalized and deaths, age adjusted to US Thurman and Guerrero, 1994 to 1995 US NS NS 98 Hospitalized patients only 1999 Jager et al., 2000 1992 to 1994 US 1.144 million NS 444 ED patients only Schootman et al., 2000 1993 Iowa 2,559 NS 91 Severe TBI rate based capture- recapture; age adjusted rate to 1990 US population Guerrero et al., 2000 1995 to 1996 US 1.027 million NS 392 ED patients only Louisiana Office of 1996 to 1999 Louisiana 16,203 NS 90 Hospitalized patients and prehospital Public Health Injury and deaths Research Prevention Section, 2004 Langlois et al., 2003 1997 14 US states 62,771 NS 70 Live hospital discharges only Langlois et al., 2006 1995 to 2001 US 1.396 million NS 505 Total rate, age adjusted to 2000 US population 235 86 Hospitalized patients only 1.111 million 401 ED visits only Selassie et al., 2004 1996 to 2001 South Carolina 70,671 NS 68 Hospital patients only 220 ED patients only Texas Department of 1998 Texas 20,000 NS NS Hospitalized patients only Health, 2004 Rutland-Brown et al., 2003 US 1.565 million NS 538 Total 2006 421 ED visits only 100 Hospitalization NOTE: CA = California, ED = emergency department, IL = Illinois, MN = Minnesota, NS = not stated, NY = New York, TBI = traumatic brain injury, US = United States. |
2003 | FILTER VENA CAVA FEM 7X48 SIMON NITINOL | CDM | 1986 China medical record followup Severity not evaluated Nestvold et al., 1974 Central Norway, Prospective identification by surgeons on duty case Survey ranked by length of PTA: None = 1, < 0.5 1988 Akershus County inclusion with neurological symptoms hr = 2, 0.5â6 hr = 3, 6â24 hr = 4, 1â2 days = 5, 3â7 (Oslo) days = 6, > 7 days = 7 Servadei et al., 1981 to Ravenna, Italy ED identification plus hospital admission and record GCS; 3â5, 6â8, 9-12, 13â15 1988 1982 review Badcock, 1984 South Australia Prospective study of all ED visits, hospital admissions and Length of PTA: none, < 5 min, 5â60 min, 1â24 1988 prehospital deaths hrs, 1â7 days, 1â4 wks, > 4 wks Tiret et al., 1986 Aquitaine, Prehospital deaths and hospital admissions survey by Severity by 3 classes based on PTA of coma > 6 1990 France medical staff using 180 possible head injury codes using hrs = severe, PTA 15 min to 6 hrs = moderate, AIS and ISS PTA, 15 min = mild Levi et al., 1984 to Northern Israel Prospective patient identification from referral to GCS used but not recorded 1990 1988 neurological service records Nell and Brown, 1986 Johannesburg, Inpatient admission with screening ICD-9 codes 800â804, GCS, mild = 13â15, moderate = 7â12 and severe = 1991 South Africa 850â854, 293, 294, 310, 870â873, 950â951, 958, 345, 3â6 347, 348, 253.9 75
76 Year(s) Reference of Data Location Case Definition and Data Source TBI Severity Criteria and Scoring Johansson et al., 1984 to Northern Sweden Hospital admissions with ICD 850â854 Severity not evaluated 1991 1985 Annoni et al., 1987 Canton St. Hospitalized patients with intracranial lesions on Severe brain injury only GCS < 7, 7â9, 10â12, > 1992 Gallen, admission CT 12 Switzerland Vazquez- 1988 Cantabria, Spain Hospital admissions with objective neurological findings GCS, minor = 13â15, moderate 9â12, severe 3â8 Barquero et al., such as LOC, skull fracture 1992 Engberg, 1995 1988 Frederiksborg ED and hospital ICUs in 4 hospitals using hospital Severity by PTA: 24 hrs-7 days = severe, very County, Denmark records, Danish Hospital Register and National Register severe 7 days Chiu et al., 1988 to Taiwan Hospital admission with LOC, skull fracture, neurological GCS: mild = 13â5, moderate = 9â12 (or CT pos), 1997 1994 deficit or CT intracranial hemorrhage severe 8 Hillier et al., 1987 South Australia All public and private hospitals with admission ICD-9 GCS: mild = 13â5, moderate = 9â12 (or CT pos), 1997 codes of 348, 800, 803, 804, 850-854 severe = 3â 8; PTA < 30 min = mild, 30â60 min = moderate, > 60 min = severe, PTA < 60 min = mild, 60 min = moderate, 24 hrs = severe Ingebrigtsen et 1993 Northern Norway All patient referral medical records includes ED visits GCS: minimal = 15 no LOC, mild = 14 or 15 plus al., excludes scalp, facial injuries PTA or brief LOC or impaired alertness, moderate 1998 = 9â13 or LOC > 5 min or focal neurological deficit, severe = 5â8, critical = 3â4 Tate et al., 1988 New South Admission to region hospital with ICD-9 codes 310, 800, Severe = PTA > 24 hrs, or GCS of < 9, moderate 1998 Wales, Australia 801, 803, 804, 850â854, 905.0, 907 = PTA 1â24 hrs or GCS 9â12, mild = PTA or LOC < 1 hr Alaranta et al., 1991 to Finland Hospital discharge or register using ICD-9 codes: 800, Severity not evaluated 2000 1995 801, 803, 850â854 (first-time patients only) Pickett et al., 1988 Greater Kingston Computerized ED injury records from the CHIRPP system Severity not reported 2001 Area of Canada Engberg and 1979 to Denmark Danish National Hospital Register using 8th ICD codes Severity not evaluated Teasdale, 1996 800, 801, 803, 850â854, mortality data from National 2001 Death Register using ICD 8th and 10th codes
Year(s) Reference of Data Location Case Definition and Data Source TBI Severity Criteria and Scoring Masson et al., 1996 Aquitaine, France Persons hospital admitted through emergency service with AIS score of 4 or 5 or LOC 6â24 hrs GCS < 9 2001 of any one of 19 hospitals, data from treating hospital Firsching and 1996 Germany Head injury hospital admitted patients including Severity scoring not reported Woischneck, concussion; deaths from Federal Bureau of Statistics 2001 Gururaj, 1999 Bangalore, India Case definitions from the Neurotrauma Registry of GCS used by categories of severity not defined 2002 National Institute of Mental Health and Neuroscience, Bangalore India including LOC or PTA neurological changes, skull fracture, death due to TBI Servadei et al., 1998 Romagna and Hospital admissions with ICD-9 codes 800â800.3, 801â Severity not evaluated 2002b Trentino, Italy 801.3, 803â803.3, 850; 851â851.1, 852â852.1 853â853.1, 854â854.1 Servadei et al., 1998 Romagna, Italy All patients admitted to hospital care with a discharge Mild TBI as defined by Duckin using ICD codes 2002a diagnosis of ICD-9 800â803.0, 801â801.3, 803â804.3, GCS of 14â15 = mild, 9â13 = moderate, < 9 = 850â854. In hospital and prehospital deaths identified severe from hospital records or death certificates Masson et al., 1996 Aquitaine, France Persons admitted to anyone of 19 public hospitals with Severe TBI by GCS of < 9 for at least 24 hrs 2003 prolonged coma determined by LOC > 24 hrs or GCS of < 9 before sedation Kleiven et al., 1987 to Sweden National hospital discharge register using ICD codes 800â Severity not evaluated 2003 2000 804, 850â854, (ICD-9) and S2.0âS2.9, S6.0âS6.9 (ICD- 10) Andersson et al., 1992 to Western Sweden Persons identified from hospitals ED unit, discharge Mix of symptoms defined by American Congress 2003 1993 register, regional neurological clinic and coronerâs records of Rehabilitation Medicine ICD-9, 850â854, 800â804 Baldo et al., 1966 to Northeast Italy Hospital discharges with ICD-9 codes 800, 801.9, 803, ICDMAP-90 used to convert ICD codes to AIS: 2003 2000 804.9, 850â854.1 located on data base for region 1/2 = mild, 3 = moderate, 4/5 = severe Santos et al., 1994, Portugal From National Institute of Statistics using ICD-9 codes Severity not evaluated 2003 1996, 800, 801, 803, 804, 850â854, 907 for hospital discharge 1997 and mortality data 77
78 Year(s) Reference of Data Location Case Definition and Data Source TBI Severity Criteria and Scoring Steudel et al., 1972 to Germany Federal Bureau of Statistics using ICD-9 codes 800-804 Focus of study is on fatal head injury 2005 1998 and 850â854 and ICD-10 S02âS02.9 and S06âS06.9 Tennant, 2005 2001 to England Hospital Episodes Statistics using ICD-10 codes S00â Severity not evaluated 2003 S09.9 for hospital inpatient care plus Primary Care Trusts Chiu et al., 2007 1991, Taipei City and Prospective TBI registry data. Excludes prehospital deaths GCS: severe 9, moderate = 9â15 plus hospital 2001 Hualien County, in 2001 stay at least 48 hrs and had brain surgery or Taiwan abnormal CT scan, mild = all others Yates et al., 1997 to Royal Devon and ED database from one hospital. ICD codes used but not Based on ICD-10 but not defined 2008 2003 Exeter Hospital, stated UK Wu et al., 2008 2004 6 Providences of Hospital admitted patients with data from attending GCS: severe 9, moderate = 9â13, mild = 14, 15 Eastern China physician NOTE: AIS = Abbreviated Injury Scale, CHIRPP = Canadian Hospitals Injury Reporting and Prevention Program, CT = computed tomography, ED = emergency department, GCS = Glasgow Coma Scale, ICD = International Classification of Diseases, ICDMAP = computer algorithm, ICU = intensive care unit, ISS = Injury Severity Score, LOC = loss of consciousness, PTA = posttraumatic amnesia, TBI = traumatic brain injury, UK = United Kingdom. TABLE 3.4 US TBI Incidence Studies Base Year(s) of Number of Population Rate / 105 Reference Data Location Patients (x1000) per year Comments Annegers et al., 1980 1965 to 1974 Olmstead County, MN 3,587 NS 193 Age adjusted to 1970 US population, rate averaged from men only and women only rates Fuortes et al., 1990 1984 to 1986 Iowa NS NS 159 in 1984 Hospital admissions only 133 in 1985 117 in 1986 Rimel, 1981 1977 to 1979 Central Virginia 1,330 NS NS Hospital patients and prehospital deaths Klauber et al., 1981 1978 San Diego, CA 5,055 NS 294 Includes some nonresidents, excludes a few external causes Cooper et al., 1983 1980 to 1981 Bronx, NY 1,209 NS 249 Rate based on sample, age adjusted to 1980 US population Jagger et al., 1984b 1978 North Central Virginia 735 354 208 Rate includes residents and nonresidents; no ED cases or prehospital deaths Kraus et al., 1984 1981 San Diego County, CA 3,358 1862 180 Population based, not age adjusted Whitman et al., 1984 1979 to 1980 Inner city Chicago and 782 213 331 Composite rate from data in publication, Evanston, IL average across race and gender Fife et al., 1986 1979 to 1980 Rhode Island 2,870 947 152 Hospital patients only Fife, 1987 1977 to 1981 US 307,000 226,545 136 Hospital patients only; 1.87 million 1.87 million 805 All injured patients MacKenzie et al., 1989a 1986 Maryland 5,838 NS 132 Hospital patients only MacKenzie et al., 1990 1979 to 1986 Maryland NS NS 114-134 Hospital patients only, range in rates Oklahoma State 1989 Oklahoma 3,672 NS 121 Hospital and fatal cases Department of Health, 1991 Schuster, 1994 1990 Massachusetts 27,819 6,016 10 Mortality rate 86 Hospital admissions 366 ED only Warren et al., 1995 1991 to 1993 Alaska 2,178 457 130 Hospital patients only Diamond, 1996 1988 to 1993 Virginia 46,680 NS NS Only age-specific rates reported Sosin et al., 1996 1991 US 1.54 million NS 618 Total rate 158 Hospitalized 79
80 Base Year(s) of Number of Population Rate / 105 Reference Data Location Patients (x1000) per year Comments 307 ED only 153 No care Thurman et al., 1996 1990 to 1992 Utah 5,782 NS 106 Age adjusted rate to 1990 US population Gabella et al., 1997a 1990 to 1993 Colorado, Missouri, 13,978 13,687 103 Age adjusted rate to 1990 US population Oklahoma, Utah Gabella et al., 1997b 1991 to 1992 Colorado 7056 NS 101 Hospitalized and deaths, age adjusted to US Thurman and Guerrero, 1994 to 1995 US NS NS 98 Hospitalized patients only 1999 Jager et al., 2000 1992 to 1994 US 1.144 million NS 444 ED patients only Schootman et al., 2000 1993 Iowa 2,559 NS 91 Severe TBI rate based capture- recapture; age adjusted rate to 1990 US population Guerrero et al., 2000 1995 to 1996 US 1.027 million NS 392 ED patients only Louisiana Office of 1996 to 1999 Louisiana 16,203 NS 90 Hospitalized patients and prehospital Public Health Injury and deaths Research Prevention Section, 2004 Langlois et al., 2003 1997 14 US states 62,771 NS 70 Live hospital discharges only Langlois et al., 2006 1995 to 2001 US 1.396 million NS 505 Total rate, age adjusted to 2000 US population 235 86 Hospitalized patients only 1.111 million 401 ED visits only Selassie et al., 2004 1996 to 2001 South Carolina 70,671 NS 68 Hospital patients only 220 ED patients only Texas Department of 1998 Texas 20,000 NS NS Hospitalized patients only Health, 2004 Rutland-Brown et al., 2003 US 1.565 million NS 538 Total 2006 421 ED visits only 100 Hospitalization NOTE: CA = California, ED = emergency department, IL = Illinois, MN = Minnesota, NS = not stated, NY = New York, TBI = traumatic brain injury, US = United States. |
1994 | IMP PIST RICHARDS 0.6X4MM | CDM | In hospital and prehospital deaths identified severe from hospital records or death certificates Masson et al., 1996 Aquitaine, France Persons admitted to anyone of 19 public hospitals with Severe TBI by GCS of < 9 for at least 24 hrs 2003 prolonged coma determined by LOC > 24 hrs or GCS of < 9 before sedation Kleiven et al., 1987 to Sweden National hospital discharge register using ICD codes 800â Severity not evaluated 2003 2000 804, 850â854, (ICD-9) and S2.0âS2.9, S6.0âS6.9 (ICD- 10) Andersson et al., 1992 to Western Sweden Persons identified from hospitals ED unit, discharge Mix of symptoms defined by American Congress 2003 1993 register, regional neurological clinic and coronerâs records of Rehabilitation Medicine ICD-9, 850â854, 800â804 Baldo et al., 1966 to Northeast Italy Hospital discharges with ICD-9 codes 800, 801.9, 803, ICDMAP-90 used to convert ICD codes to AIS: 2003 2000 804.9, 850â854.1 located on data base for region 1/2 = mild, 3 = moderate, 4/5 = severe Santos et al., 1994, Portugal From National Institute of Statistics using ICD-9 codes Severity not evaluated 2003 1996, 800, 801, 803, 804, 850â854, 907 for hospital discharge 1997 and mortality data 77
78 Year(s) Reference of Data Location Case Definition and Data Source TBI Severity Criteria and Scoring Steudel et al., 1972 to Germany Federal Bureau of Statistics using ICD-9 codes 800-804 Focus of study is on fatal head injury 2005 1998 and 850â854 and ICD-10 S02âS02.9 and S06âS06.9 Tennant, 2005 2001 to England Hospital Episodes Statistics using ICD-10 codes S00â Severity not evaluated 2003 S09.9 for hospital inpatient care plus Primary Care Trusts Chiu et al., 2007 1991, Taipei City and Prospective TBI registry data. Excludes prehospital deaths GCS: severe 9, moderate = 9â15 plus hospital 2001 Hualien County, in 2001 stay at least 48 hrs and had brain surgery or Taiwan abnormal CT scan, mild = all others Yates et al., 1997 to Royal Devon and ED database from one hospital. ICD codes used but not Based on ICD-10 but not defined 2008 2003 Exeter Hospital, stated UK Wu et al., 2008 2004 6 Providences of Hospital admitted patients with data from attending GCS: severe 9, moderate = 9â13, mild = 14, 15 Eastern China physician NOTE: AIS = Abbreviated Injury Scale, CHIRPP = Canadian Hospitals Injury Reporting and Prevention Program, CT = computed tomography, ED = emergency department, GCS = Glasgow Coma Scale, ICD = International Classification of Diseases, ICDMAP = computer algorithm, ICU = intensive care unit, ISS = Injury Severity Score, LOC = loss of consciousness, PTA = posttraumatic amnesia, TBI = traumatic brain injury, UK = United Kingdom. TABLE 3.4 US TBI Incidence Studies Base Year(s) of Number of Population Rate / 105 Reference Data Location Patients (x1000) per year Comments Annegers et al., 1980 1965 to 1974 Olmstead County, MN 3,587 NS 193 Age adjusted to 1970 US population, rate averaged from men only and women only rates Fuortes et al., 1990 1984 to 1986 Iowa NS NS 159 in 1984 Hospital admissions only 133 in 1985 117 in 1986 Rimel, 1981 1977 to 1979 Central Virginia 1,330 NS NS Hospital patients and prehospital deaths Klauber et al., 1981 1978 San Diego, CA 5,055 NS 294 Includes some nonresidents, excludes a few external causes Cooper et al., 1983 1980 to 1981 Bronx, NY 1,209 NS 249 Rate based on sample, age adjusted to 1980 US population Jagger et al., 1984b 1978 North Central Virginia 735 354 208 Rate includes residents and nonresidents; no ED cases or prehospital deaths Kraus et al., 1984 1981 San Diego County, CA 3,358 1862 180 Population based, not age adjusted Whitman et al., 1984 1979 to 1980 Inner city Chicago and 782 213 331 Composite rate from data in publication, Evanston, IL average across race and gender Fife et al., 1986 1979 to 1980 Rhode Island 2,870 947 152 Hospital patients only Fife, 1987 1977 to 1981 US 307,000 226,545 136 Hospital patients only; 1.87 million 1.87 million 805 All injured patients MacKenzie et al., 1989a 1986 Maryland 5,838 NS 132 Hospital patients only MacKenzie et al., 1990 1979 to 1986 Maryland NS NS 114-134 Hospital patients only, range in rates Oklahoma State 1989 Oklahoma 3,672 NS 121 Hospital and fatal cases Department of Health, 1991 Schuster, 1994 1990 Massachusetts 27,819 6,016 10 Mortality rate 86 Hospital admissions 366 ED only Warren et al., 1995 1991 to 1993 Alaska 2,178 457 130 Hospital patients only Diamond, 1996 1988 to 1993 Virginia 46,680 NS NS Only age-specific rates reported Sosin et al., 1996 1991 US 1.54 million NS 618 Total rate 158 Hospitalized 79
80 Base Year(s) of Number of Population Rate / 105 Reference Data Location Patients (x1000) per year Comments 307 ED only 153 No care Thurman et al., 1996 1990 to 1992 Utah 5,782 NS 106 Age adjusted rate to 1990 US population Gabella et al., 1997a 1990 to 1993 Colorado, Missouri, 13,978 13,687 103 Age adjusted rate to 1990 US population Oklahoma, Utah Gabella et al., 1997b 1991 to 1992 Colorado 7056 NS 101 Hospitalized and deaths, age adjusted to US Thurman and Guerrero, 1994 to 1995 US NS NS 98 Hospitalized patients only 1999 Jager et al., 2000 1992 to 1994 US 1.144 million NS 444 ED patients only Schootman et al., 2000 1993 Iowa 2,559 NS 91 Severe TBI rate based capture- recapture; age adjusted rate to 1990 US population Guerrero et al., 2000 1995 to 1996 US 1.027 million NS 392 ED patients only Louisiana Office of 1996 to 1999 Louisiana 16,203 NS 90 Hospitalized patients and prehospital Public Health Injury and deaths Research Prevention Section, 2004 Langlois et al., 2003 1997 14 US states 62,771 NS 70 Live hospital discharges only Langlois et al., 2006 1995 to 2001 US 1.396 million NS 505 Total rate, age adjusted to 2000 US population 235 86 Hospitalized patients only 1.111 million 401 ED visits only Selassie et al., 2004 1996 to 2001 South Carolina 70,671 NS 68 Hospital patients only 220 ED patients only Texas Department of 1998 Texas 20,000 NS NS Hospitalized patients only Health, 2004 Rutland-Brown et al., 2003 US 1.565 million NS 538 Total 2006 421 ED visits only 100 Hospitalization NOTE: CA = California, ED = emergency department, IL = Illinois, MN = Minnesota, NS = not stated, NY = New York, TBI = traumatic brain injury, US = United States. TABLE 3.5 Non-US TBI Incidence Data Base Year(s) of Number of Population Rate / 105 Reference Data Location Patients (x1000) per year Comments Jennett and MacMillan, 1974 England, Wales and NS NS 270 in Annual rates based on sample weeks, 1981 Scotland England and rates not age adjusted Wales 313 in Scotland Selecki et al., 1981 1977 New South Wales, 18,678 4,960 377 Hospital admissions only excludes Australia prehospitalized deaths Servadei et al., 1985 1981 to 1982 San Marino 327 23.5 468 Hospital admissions Wang et al., 1986 1982 Urban areas of China 35 63 56 Rates based on samples of households in city communities Nestvold et al., 1988 1974 Central Norway 488 350 236 Hospital admissions Badcock, 1988 1984 South Australia 1,698 NS 520 Includes ED visits, admissions and prehospital deaths Servadei et al., 1988 1984 Ravenna, Italy 644 172 372 Hospitalized cases only excludes ED treated and released Levi et al., 1990 1984 to 1988 Northern Israel 1,370 1,200 25 Rate in person-years Tiret et al., 1990 1986 Aquitaine, France 8,940 2,700 281 Hospital admissions and deaths Johansson et al., 1991 1984 to 1985 Northern Sweden 242 70 242 Ages 16-60 only, hospital admissions Nell and Brown, 1991 1986 Johannesburg, South 5,106 NS 316 Rate based on population estimates Africa Annoni et al., 1992 1987 St. |
2007 | EPINEPHRINE .1MG/ML | CDM | In hospital and prehospital deaths identified severe from hospital records or death certificates Masson et al., 1996 Aquitaine, France Persons admitted to anyone of 19 public hospitals with Severe TBI by GCS of < 9 for at least 24 hrs 2003 prolonged coma determined by LOC > 24 hrs or GCS of < 9 before sedation Kleiven et al., 1987 to Sweden National hospital discharge register using ICD codes 800â Severity not evaluated 2003 2000 804, 850â854, (ICD-9) and S2.0âS2.9, S6.0âS6.9 (ICD- 10) Andersson et al., 1992 to Western Sweden Persons identified from hospitals ED unit, discharge Mix of symptoms defined by American Congress 2003 1993 register, regional neurological clinic and coronerâs records of Rehabilitation Medicine ICD-9, 850â854, 800â804 Baldo et al., 1966 to Northeast Italy Hospital discharges with ICD-9 codes 800, 801.9, 803, ICDMAP-90 used to convert ICD codes to AIS: 2003 2000 804.9, 850â854.1 located on data base for region 1/2 = mild, 3 = moderate, 4/5 = severe Santos et al., 1994, Portugal From National Institute of Statistics using ICD-9 codes Severity not evaluated 2003 1996, 800, 801, 803, 804, 850â854, 907 for hospital discharge 1997 and mortality data 77
78 Year(s) Reference of Data Location Case Definition and Data Source TBI Severity Criteria and Scoring Steudel et al., 1972 to Germany Federal Bureau of Statistics using ICD-9 codes 800-804 Focus of study is on fatal head injury 2005 1998 and 850â854 and ICD-10 S02âS02.9 and S06âS06.9 Tennant, 2005 2001 to England Hospital Episodes Statistics using ICD-10 codes S00â Severity not evaluated 2003 S09.9 for hospital inpatient care plus Primary Care Trusts Chiu et al., 2007 1991, Taipei City and Prospective TBI registry data. Excludes prehospital deaths GCS: severe 9, moderate = 9â15 plus hospital 2001 Hualien County, in 2001 stay at least 48 hrs and had brain surgery or Taiwan abnormal CT scan, mild = all others Yates et al., 1997 to Royal Devon and ED database from one hospital. ICD codes used but not Based on ICD-10 but not defined 2008 2003 Exeter Hospital, stated UK Wu et al., 2008 2004 6 Providences of Hospital admitted patients with data from attending GCS: severe 9, moderate = 9â13, mild = 14, 15 Eastern China physician NOTE: AIS = Abbreviated Injury Scale, CHIRPP = Canadian Hospitals Injury Reporting and Prevention Program, CT = computed tomography, ED = emergency department, GCS = Glasgow Coma Scale, ICD = International Classification of Diseases, ICDMAP = computer algorithm, ICU = intensive care unit, ISS = Injury Severity Score, LOC = loss of consciousness, PTA = posttraumatic amnesia, TBI = traumatic brain injury, UK = United Kingdom. TABLE 3.4 US TBI Incidence Studies Base Year(s) of Number of Population Rate / 105 Reference Data Location Patients (x1000) per year Comments Annegers et al., 1980 1965 to 1974 Olmstead County, MN 3,587 NS 193 Age adjusted to 1970 US population, rate averaged from men only and women only rates Fuortes et al., 1990 1984 to 1986 Iowa NS NS 159 in 1984 Hospital admissions only 133 in 1985 117 in 1986 Rimel, 1981 1977 to 1979 Central Virginia 1,330 NS NS Hospital patients and prehospital deaths Klauber et al., 1981 1978 San Diego, CA 5,055 NS 294 Includes some nonresidents, excludes a few external causes Cooper et al., 1983 1980 to 1981 Bronx, NY 1,209 NS 249 Rate based on sample, age adjusted to 1980 US population Jagger et al., 1984b 1978 North Central Virginia 735 354 208 Rate includes residents and nonresidents; no ED cases or prehospital deaths Kraus et al., 1984 1981 San Diego County, CA 3,358 1862 180 Population based, not age adjusted Whitman et al., 1984 1979 to 1980 Inner city Chicago and 782 213 331 Composite rate from data in publication, Evanston, IL average across race and gender Fife et al., 1986 1979 to 1980 Rhode Island 2,870 947 152 Hospital patients only Fife, 1987 1977 to 1981 US 307,000 226,545 136 Hospital patients only; 1.87 million 1.87 million 805 All injured patients MacKenzie et al., 1989a 1986 Maryland 5,838 NS 132 Hospital patients only MacKenzie et al., 1990 1979 to 1986 Maryland NS NS 114-134 Hospital patients only, range in rates Oklahoma State 1989 Oklahoma 3,672 NS 121 Hospital and fatal cases Department of Health, 1991 Schuster, 1994 1990 Massachusetts 27,819 6,016 10 Mortality rate 86 Hospital admissions 366 ED only Warren et al., 1995 1991 to 1993 Alaska 2,178 457 130 Hospital patients only Diamond, 1996 1988 to 1993 Virginia 46,680 NS NS Only age-specific rates reported Sosin et al., 1996 1991 US 1.54 million NS 618 Total rate 158 Hospitalized 79
80 Base Year(s) of Number of Population Rate / 105 Reference Data Location Patients (x1000) per year Comments 307 ED only 153 No care Thurman et al., 1996 1990 to 1992 Utah 5,782 NS 106 Age adjusted rate to 1990 US population Gabella et al., 1997a 1990 to 1993 Colorado, Missouri, 13,978 13,687 103 Age adjusted rate to 1990 US population Oklahoma, Utah Gabella et al., 1997b 1991 to 1992 Colorado 7056 NS 101 Hospitalized and deaths, age adjusted to US Thurman and Guerrero, 1994 to 1995 US NS NS 98 Hospitalized patients only 1999 Jager et al., 2000 1992 to 1994 US 1.144 million NS 444 ED patients only Schootman et al., 2000 1993 Iowa 2,559 NS 91 Severe TBI rate based capture- recapture; age adjusted rate to 1990 US population Guerrero et al., 2000 1995 to 1996 US 1.027 million NS 392 ED patients only Louisiana Office of 1996 to 1999 Louisiana 16,203 NS 90 Hospitalized patients and prehospital Public Health Injury and deaths Research Prevention Section, 2004 Langlois et al., 2003 1997 14 US states 62,771 NS 70 Live hospital discharges only Langlois et al., 2006 1995 to 2001 US 1.396 million NS 505 Total rate, age adjusted to 2000 US population 235 86 Hospitalized patients only 1.111 million 401 ED visits only Selassie et al., 2004 1996 to 2001 South Carolina 70,671 NS 68 Hospital patients only 220 ED patients only Texas Department of 1998 Texas 20,000 NS NS Hospitalized patients only Health, 2004 Rutland-Brown et al., 2003 US 1.565 million NS 538 Total 2006 421 ED visits only 100 Hospitalization NOTE: CA = California, ED = emergency department, IL = Illinois, MN = Minnesota, NS = not stated, NY = New York, TBI = traumatic brain injury, US = United States. TABLE 3.5 Non-US TBI Incidence Data Base Year(s) of Number of Population Rate / 105 Reference Data Location Patients (x1000) per year Comments Jennett and MacMillan, 1974 England, Wales and NS NS 270 in Annual rates based on sample weeks, 1981 Scotland England and rates not age adjusted Wales 313 in Scotland Selecki et al., 1981 1977 New South Wales, 18,678 4,960 377 Hospital admissions only excludes Australia prehospitalized deaths Servadei et al., 1985 1981 to 1982 San Marino 327 23.5 468 Hospital admissions Wang et al., 1986 1982 Urban areas of China 35 63 56 Rates based on samples of households in city communities Nestvold et al., 1988 1974 Central Norway 488 350 236 Hospital admissions Badcock, 1988 1984 South Australia 1,698 NS 520 Includes ED visits, admissions and prehospital deaths Servadei et al., 1988 1984 Ravenna, Italy 644 172 372 Hospitalized cases only excludes ED treated and released Levi et al., 1990 1984 to 1988 Northern Israel 1,370 1,200 25 Rate in person-years Tiret et al., 1990 1986 Aquitaine, France 8,940 2,700 281 Hospital admissions and deaths Johansson et al., 1991 1984 to 1985 Northern Sweden 242 70 242 Ages 16-60 only, hospital admissions Nell and Brown, 1991 1986 Johannesburg, South 5,106 NS 316 Rate based on population estimates Africa Annoni et al., 1992 1987 St. |
1995 | IMP PIST 0.6X4.5MM | CDM | In hospital and prehospital deaths identified severe from hospital records or death certificates Masson et al., 1996 Aquitaine, France Persons admitted to anyone of 19 public hospitals with Severe TBI by GCS of < 9 for at least 24 hrs 2003 prolonged coma determined by LOC > 24 hrs or GCS of < 9 before sedation Kleiven et al., 1987 to Sweden National hospital discharge register using ICD codes 800â Severity not evaluated 2003 2000 804, 850â854, (ICD-9) and S2.0âS2.9, S6.0âS6.9 (ICD- 10) Andersson et al., 1992 to Western Sweden Persons identified from hospitals ED unit, discharge Mix of symptoms defined by American Congress 2003 1993 register, regional neurological clinic and coronerâs records of Rehabilitation Medicine ICD-9, 850â854, 800â804 Baldo et al., 1966 to Northeast Italy Hospital discharges with ICD-9 codes 800, 801.9, 803, ICDMAP-90 used to convert ICD codes to AIS: 2003 2000 804.9, 850â854.1 located on data base for region 1/2 = mild, 3 = moderate, 4/5 = severe Santos et al., 1994, Portugal From National Institute of Statistics using ICD-9 codes Severity not evaluated 2003 1996, 800, 801, 803, 804, 850â854, 907 for hospital discharge 1997 and mortality data 77
78 Year(s) Reference of Data Location Case Definition and Data Source TBI Severity Criteria and Scoring Steudel et al., 1972 to Germany Federal Bureau of Statistics using ICD-9 codes 800-804 Focus of study is on fatal head injury 2005 1998 and 850â854 and ICD-10 S02âS02.9 and S06âS06.9 Tennant, 2005 2001 to England Hospital Episodes Statistics using ICD-10 codes S00â Severity not evaluated 2003 S09.9 for hospital inpatient care plus Primary Care Trusts Chiu et al., 2007 1991, Taipei City and Prospective TBI registry data. Excludes prehospital deaths GCS: severe 9, moderate = 9â15 plus hospital 2001 Hualien County, in 2001 stay at least 48 hrs and had brain surgery or Taiwan abnormal CT scan, mild = all others Yates et al., 1997 to Royal Devon and ED database from one hospital. ICD codes used but not Based on ICD-10 but not defined 2008 2003 Exeter Hospital, stated UK Wu et al., 2008 2004 6 Providences of Hospital admitted patients with data from attending GCS: severe 9, moderate = 9â13, mild = 14, 15 Eastern China physician NOTE: AIS = Abbreviated Injury Scale, CHIRPP = Canadian Hospitals Injury Reporting and Prevention Program, CT = computed tomography, ED = emergency department, GCS = Glasgow Coma Scale, ICD = International Classification of Diseases, ICDMAP = computer algorithm, ICU = intensive care unit, ISS = Injury Severity Score, LOC = loss of consciousness, PTA = posttraumatic amnesia, TBI = traumatic brain injury, UK = United Kingdom. TABLE 3.4 US TBI Incidence Studies Base Year(s) of Number of Population Rate / 105 Reference Data Location Patients (x1000) per year Comments Annegers et al., 1980 1965 to 1974 Olmstead County, MN 3,587 NS 193 Age adjusted to 1970 US population, rate averaged from men only and women only rates Fuortes et al., 1990 1984 to 1986 Iowa NS NS 159 in 1984 Hospital admissions only 133 in 1985 117 in 1986 Rimel, 1981 1977 to 1979 Central Virginia 1,330 NS NS Hospital patients and prehospital deaths Klauber et al., 1981 1978 San Diego, CA 5,055 NS 294 Includes some nonresidents, excludes a few external causes Cooper et al., 1983 1980 to 1981 Bronx, NY 1,209 NS 249 Rate based on sample, age adjusted to 1980 US population Jagger et al., 1984b 1978 North Central Virginia 735 354 208 Rate includes residents and nonresidents; no ED cases or prehospital deaths Kraus et al., 1984 1981 San Diego County, CA 3,358 1862 180 Population based, not age adjusted Whitman et al., 1984 1979 to 1980 Inner city Chicago and 782 213 331 Composite rate from data in publication, Evanston, IL average across race and gender Fife et al., 1986 1979 to 1980 Rhode Island 2,870 947 152 Hospital patients only Fife, 1987 1977 to 1981 US 307,000 226,545 136 Hospital patients only; 1.87 million 1.87 million 805 All injured patients MacKenzie et al., 1989a 1986 Maryland 5,838 NS 132 Hospital patients only MacKenzie et al., 1990 1979 to 1986 Maryland NS NS 114-134 Hospital patients only, range in rates Oklahoma State 1989 Oklahoma 3,672 NS 121 Hospital and fatal cases Department of Health, 1991 Schuster, 1994 1990 Massachusetts 27,819 6,016 10 Mortality rate 86 Hospital admissions 366 ED only Warren et al., 1995 1991 to 1993 Alaska 2,178 457 130 Hospital patients only Diamond, 1996 1988 to 1993 Virginia 46,680 NS NS Only age-specific rates reported Sosin et al., 1996 1991 US 1.54 million NS 618 Total rate 158 Hospitalized 79
80 Base Year(s) of Number of Population Rate / 105 Reference Data Location Patients (x1000) per year Comments 307 ED only 153 No care Thurman et al., 1996 1990 to 1992 Utah 5,782 NS 106 Age adjusted rate to 1990 US population Gabella et al., 1997a 1990 to 1993 Colorado, Missouri, 13,978 13,687 103 Age adjusted rate to 1990 US population Oklahoma, Utah Gabella et al., 1997b 1991 to 1992 Colorado 7056 NS 101 Hospitalized and deaths, age adjusted to US Thurman and Guerrero, 1994 to 1995 US NS NS 98 Hospitalized patients only 1999 Jager et al., 2000 1992 to 1994 US 1.144 million NS 444 ED patients only Schootman et al., 2000 1993 Iowa 2,559 NS 91 Severe TBI rate based capture- recapture; age adjusted rate to 1990 US population Guerrero et al., 2000 1995 to 1996 US 1.027 million NS 392 ED patients only Louisiana Office of 1996 to 1999 Louisiana 16,203 NS 90 Hospitalized patients and prehospital Public Health Injury and deaths Research Prevention Section, 2004 Langlois et al., 2003 1997 14 US states 62,771 NS 70 Live hospital discharges only Langlois et al., 2006 1995 to 2001 US 1.396 million NS 505 Total rate, age adjusted to 2000 US population 235 86 Hospitalized patients only 1.111 million 401 ED visits only Selassie et al., 2004 1996 to 2001 South Carolina 70,671 NS 68 Hospital patients only 220 ED patients only Texas Department of 1998 Texas 20,000 NS NS Hospitalized patients only Health, 2004 Rutland-Brown et al., 2003 US 1.565 million NS 538 Total 2006 421 ED visits only 100 Hospitalization NOTE: CA = California, ED = emergency department, IL = Illinois, MN = Minnesota, NS = not stated, NY = New York, TBI = traumatic brain injury, US = United States. TABLE 3.5 Non-US TBI Incidence Data Base Year(s) of Number of Population Rate / 105 Reference Data Location Patients (x1000) per year Comments Jennett and MacMillan, 1974 England, Wales and NS NS 270 in Annual rates based on sample weeks, 1981 Scotland England and rates not age adjusted Wales 313 in Scotland Selecki et al., 1981 1977 New South Wales, 18,678 4,960 377 Hospital admissions only excludes Australia prehospitalized deaths Servadei et al., 1985 1981 to 1982 San Marino 327 23.5 468 Hospital admissions Wang et al., 1986 1982 Urban areas of China 35 63 56 Rates based on samples of households in city communities Nestvold et al., 1988 1974 Central Norway 488 350 236 Hospital admissions Badcock, 1988 1984 South Australia 1,698 NS 520 Includes ED visits, admissions and prehospital deaths Servadei et al., 1988 1984 Ravenna, Italy 644 172 372 Hospitalized cases only excludes ED treated and released Levi et al., 1990 1984 to 1988 Northern Israel 1,370 1,200 25 Rate in person-years Tiret et al., 1990 1986 Aquitaine, France 8,940 2,700 281 Hospital admissions and deaths Johansson et al., 1991 1984 to 1985 Northern Sweden 242 70 242 Ages 16-60 only, hospital admissions Nell and Brown, 1991 1986 Johannesburg, South 5,106 NS 316 Rate based on population estimates Africa Annoni et al., 1992 1987 St. |
1993 | IMP EAR RICHARDS 0.6X3.5MM | CDM | In hospital and prehospital deaths identified severe from hospital records or death certificates Masson et al., 1996 Aquitaine, France Persons admitted to anyone of 19 public hospitals with Severe TBI by GCS of < 9 for at least 24 hrs 2003 prolonged coma determined by LOC > 24 hrs or GCS of < 9 before sedation Kleiven et al., 1987 to Sweden National hospital discharge register using ICD codes 800â Severity not evaluated 2003 2000 804, 850â854, (ICD-9) and S2.0âS2.9, S6.0âS6.9 (ICD- 10) Andersson et al., 1992 to Western Sweden Persons identified from hospitals ED unit, discharge Mix of symptoms defined by American Congress 2003 1993 register, regional neurological clinic and coronerâs records of Rehabilitation Medicine ICD-9, 850â854, 800â804 Baldo et al., 1966 to Northeast Italy Hospital discharges with ICD-9 codes 800, 801.9, 803, ICDMAP-90 used to convert ICD codes to AIS: 2003 2000 804.9, 850â854.1 located on data base for region 1/2 = mild, 3 = moderate, 4/5 = severe Santos et al., 1994, Portugal From National Institute of Statistics using ICD-9 codes Severity not evaluated 2003 1996, 800, 801, 803, 804, 850â854, 907 for hospital discharge 1997 and mortality data 77
78 Year(s) Reference of Data Location Case Definition and Data Source TBI Severity Criteria and Scoring Steudel et al., 1972 to Germany Federal Bureau of Statistics using ICD-9 codes 800-804 Focus of study is on fatal head injury 2005 1998 and 850â854 and ICD-10 S02âS02.9 and S06âS06.9 Tennant, 2005 2001 to England Hospital Episodes Statistics using ICD-10 codes S00â Severity not evaluated 2003 S09.9 for hospital inpatient care plus Primary Care Trusts Chiu et al., 2007 1991, Taipei City and Prospective TBI registry data. Excludes prehospital deaths GCS: severe 9, moderate = 9â15 plus hospital 2001 Hualien County, in 2001 stay at least 48 hrs and had brain surgery or Taiwan abnormal CT scan, mild = all others Yates et al., 1997 to Royal Devon and ED database from one hospital. ICD codes used but not Based on ICD-10 but not defined 2008 2003 Exeter Hospital, stated UK Wu et al., 2008 2004 6 Providences of Hospital admitted patients with data from attending GCS: severe 9, moderate = 9â13, mild = 14, 15 Eastern China physician NOTE: AIS = Abbreviated Injury Scale, CHIRPP = Canadian Hospitals Injury Reporting and Prevention Program, CT = computed tomography, ED = emergency department, GCS = Glasgow Coma Scale, ICD = International Classification of Diseases, ICDMAP = computer algorithm, ICU = intensive care unit, ISS = Injury Severity Score, LOC = loss of consciousness, PTA = posttraumatic amnesia, TBI = traumatic brain injury, UK = United Kingdom. TABLE 3.4 US TBI Incidence Studies Base Year(s) of Number of Population Rate / 105 Reference Data Location Patients (x1000) per year Comments Annegers et al., 1980 1965 to 1974 Olmstead County, MN 3,587 NS 193 Age adjusted to 1970 US population, rate averaged from men only and women only rates Fuortes et al., 1990 1984 to 1986 Iowa NS NS 159 in 1984 Hospital admissions only 133 in 1985 117 in 1986 Rimel, 1981 1977 to 1979 Central Virginia 1,330 NS NS Hospital patients and prehospital deaths Klauber et al., 1981 1978 San Diego, CA 5,055 NS 294 Includes some nonresidents, excludes a few external causes Cooper et al., 1983 1980 to 1981 Bronx, NY 1,209 NS 249 Rate based on sample, age adjusted to 1980 US population Jagger et al., 1984b 1978 North Central Virginia 735 354 208 Rate includes residents and nonresidents; no ED cases or prehospital deaths Kraus et al., 1984 1981 San Diego County, CA 3,358 1862 180 Population based, not age adjusted Whitman et al., 1984 1979 to 1980 Inner city Chicago and 782 213 331 Composite rate from data in publication, Evanston, IL average across race and gender Fife et al., 1986 1979 to 1980 Rhode Island 2,870 947 152 Hospital patients only Fife, 1987 1977 to 1981 US 307,000 226,545 136 Hospital patients only; 1.87 million 1.87 million 805 All injured patients MacKenzie et al., 1989a 1986 Maryland 5,838 NS 132 Hospital patients only MacKenzie et al., 1990 1979 to 1986 Maryland NS NS 114-134 Hospital patients only, range in rates Oklahoma State 1989 Oklahoma 3,672 NS 121 Hospital and fatal cases Department of Health, 1991 Schuster, 1994 1990 Massachusetts 27,819 6,016 10 Mortality rate 86 Hospital admissions 366 ED only Warren et al., 1995 1991 to 1993 Alaska 2,178 457 130 Hospital patients only Diamond, 1996 1988 to 1993 Virginia 46,680 NS NS Only age-specific rates reported Sosin et al., 1996 1991 US 1.54 million NS 618 Total rate 158 Hospitalized 79
80 Base Year(s) of Number of Population Rate / 105 Reference Data Location Patients (x1000) per year Comments 307 ED only 153 No care Thurman et al., 1996 1990 to 1992 Utah 5,782 NS 106 Age adjusted rate to 1990 US population Gabella et al., 1997a 1990 to 1993 Colorado, Missouri, 13,978 13,687 103 Age adjusted rate to 1990 US population Oklahoma, Utah Gabella et al., 1997b 1991 to 1992 Colorado 7056 NS 101 Hospitalized and deaths, age adjusted to US Thurman and Guerrero, 1994 to 1995 US NS NS 98 Hospitalized patients only 1999 Jager et al., 2000 1992 to 1994 US 1.144 million NS 444 ED patients only Schootman et al., 2000 1993 Iowa 2,559 NS 91 Severe TBI rate based capture- recapture; age adjusted rate to 1990 US population Guerrero et al., 2000 1995 to 1996 US 1.027 million NS 392 ED patients only Louisiana Office of 1996 to 1999 Louisiana 16,203 NS 90 Hospitalized patients and prehospital Public Health Injury and deaths Research Prevention Section, 2004 Langlois et al., 2003 1997 14 US states 62,771 NS 70 Live hospital discharges only Langlois et al., 2006 1995 to 2001 US 1.396 million NS 505 Total rate, age adjusted to 2000 US population 235 86 Hospitalized patients only 1.111 million 401 ED visits only Selassie et al., 2004 1996 to 2001 South Carolina 70,671 NS 68 Hospital patients only 220 ED patients only Texas Department of 1998 Texas 20,000 NS NS Hospitalized patients only Health, 2004 Rutland-Brown et al., 2003 US 1.565 million NS 538 Total 2006 421 ED visits only 100 Hospitalization NOTE: CA = California, ED = emergency department, IL = Illinois, MN = Minnesota, NS = not stated, NY = New York, TBI = traumatic brain injury, US = United States. TABLE 3.5 Non-US TBI Incidence Data Base Year(s) of Number of Population Rate / 105 Reference Data Location Patients (x1000) per year Comments Jennett and MacMillan, 1974 England, Wales and NS NS 270 in Annual rates based on sample weeks, 1981 Scotland England and rates not age adjusted Wales 313 in Scotland Selecki et al., 1981 1977 New South Wales, 18,678 4,960 377 Hospital admissions only excludes Australia prehospitalized deaths Servadei et al., 1985 1981 to 1982 San Marino 327 23.5 468 Hospital admissions Wang et al., 1986 1982 Urban areas of China 35 63 56 Rates based on samples of households in city communities Nestvold et al., 1988 1974 Central Norway 488 350 236 Hospital admissions Badcock, 1988 1984 South Australia 1,698 NS 520 Includes ED visits, admissions and prehospital deaths Servadei et al., 1988 1984 Ravenna, Italy 644 172 372 Hospitalized cases only excludes ED treated and released Levi et al., 1990 1984 to 1988 Northern Israel 1,370 1,200 25 Rate in person-years Tiret et al., 1990 1986 Aquitaine, France 8,940 2,700 281 Hospital admissions and deaths Johansson et al., 1991 1984 to 1985 Northern Sweden 242 70 242 Ages 16-60 only, hospital admissions Nell and Brown, 1991 1986 Johannesburg, South 5,106 NS 316 Rate based on population estimates Africa Annoni et al., 1992 1987 St. |
2003 | FILTER VENA CAVA FEM 7X48 SIMON NITINOL | CDM | In hospital and prehospital deaths identified severe from hospital records or death certificates Masson et al., 1996 Aquitaine, France Persons admitted to anyone of 19 public hospitals with Severe TBI by GCS of < 9 for at least 24 hrs 2003 prolonged coma determined by LOC > 24 hrs or GCS of < 9 before sedation Kleiven et al., 1987 to Sweden National hospital discharge register using ICD codes 800â Severity not evaluated 2003 2000 804, 850â854, (ICD-9) and S2.0âS2.9, S6.0âS6.9 (ICD- 10) Andersson et al., 1992 to Western Sweden Persons identified from hospitals ED unit, discharge Mix of symptoms defined by American Congress 2003 1993 register, regional neurological clinic and coronerâs records of Rehabilitation Medicine ICD-9, 850â854, 800â804 Baldo et al., 1966 to Northeast Italy Hospital discharges with ICD-9 codes 800, 801.9, 803, ICDMAP-90 used to convert ICD codes to AIS: 2003 2000 804.9, 850â854.1 located on data base for region 1/2 = mild, 3 = moderate, 4/5 = severe Santos et al., 1994, Portugal From National Institute of Statistics using ICD-9 codes Severity not evaluated 2003 1996, 800, 801, 803, 804, 850â854, 907 for hospital discharge 1997 and mortality data 77
78 Year(s) Reference of Data Location Case Definition and Data Source TBI Severity Criteria and Scoring Steudel et al., 1972 to Germany Federal Bureau of Statistics using ICD-9 codes 800-804 Focus of study is on fatal head injury 2005 1998 and 850â854 and ICD-10 S02âS02.9 and S06âS06.9 Tennant, 2005 2001 to England Hospital Episodes Statistics using ICD-10 codes S00â Severity not evaluated 2003 S09.9 for hospital inpatient care plus Primary Care Trusts Chiu et al., 2007 1991, Taipei City and Prospective TBI registry data. Excludes prehospital deaths GCS: severe 9, moderate = 9â15 plus hospital 2001 Hualien County, in 2001 stay at least 48 hrs and had brain surgery or Taiwan abnormal CT scan, mild = all others Yates et al., 1997 to Royal Devon and ED database from one hospital. ICD codes used but not Based on ICD-10 but not defined 2008 2003 Exeter Hospital, stated UK Wu et al., 2008 2004 6 Providences of Hospital admitted patients with data from attending GCS: severe 9, moderate = 9â13, mild = 14, 15 Eastern China physician NOTE: AIS = Abbreviated Injury Scale, CHIRPP = Canadian Hospitals Injury Reporting and Prevention Program, CT = computed tomography, ED = emergency department, GCS = Glasgow Coma Scale, ICD = International Classification of Diseases, ICDMAP = computer algorithm, ICU = intensive care unit, ISS = Injury Severity Score, LOC = loss of consciousness, PTA = posttraumatic amnesia, TBI = traumatic brain injury, UK = United Kingdom. TABLE 3.4 US TBI Incidence Studies Base Year(s) of Number of Population Rate / 105 Reference Data Location Patients (x1000) per year Comments Annegers et al., 1980 1965 to 1974 Olmstead County, MN 3,587 NS 193 Age adjusted to 1970 US population, rate averaged from men only and women only rates Fuortes et al., 1990 1984 to 1986 Iowa NS NS 159 in 1984 Hospital admissions only 133 in 1985 117 in 1986 Rimel, 1981 1977 to 1979 Central Virginia 1,330 NS NS Hospital patients and prehospital deaths Klauber et al., 1981 1978 San Diego, CA 5,055 NS 294 Includes some nonresidents, excludes a few external causes Cooper et al., 1983 1980 to 1981 Bronx, NY 1,209 NS 249 Rate based on sample, age adjusted to 1980 US population Jagger et al., 1984b 1978 North Central Virginia 735 354 208 Rate includes residents and nonresidents; no ED cases or prehospital deaths Kraus et al., 1984 1981 San Diego County, CA 3,358 1862 180 Population based, not age adjusted Whitman et al., 1984 1979 to 1980 Inner city Chicago and 782 213 331 Composite rate from data in publication, Evanston, IL average across race and gender Fife et al., 1986 1979 to 1980 Rhode Island 2,870 947 152 Hospital patients only Fife, 1987 1977 to 1981 US 307,000 226,545 136 Hospital patients only; 1.87 million 1.87 million 805 All injured patients MacKenzie et al., 1989a 1986 Maryland 5,838 NS 132 Hospital patients only MacKenzie et al., 1990 1979 to 1986 Maryland NS NS 114-134 Hospital patients only, range in rates Oklahoma State 1989 Oklahoma 3,672 NS 121 Hospital and fatal cases Department of Health, 1991 Schuster, 1994 1990 Massachusetts 27,819 6,016 10 Mortality rate 86 Hospital admissions 366 ED only Warren et al., 1995 1991 to 1993 Alaska 2,178 457 130 Hospital patients only Diamond, 1996 1988 to 1993 Virginia 46,680 NS NS Only age-specific rates reported Sosin et al., 1996 1991 US 1.54 million NS 618 Total rate 158 Hospitalized 79
80 Base Year(s) of Number of Population Rate / 105 Reference Data Location Patients (x1000) per year Comments 307 ED only 153 No care Thurman et al., 1996 1990 to 1992 Utah 5,782 NS 106 Age adjusted rate to 1990 US population Gabella et al., 1997a 1990 to 1993 Colorado, Missouri, 13,978 13,687 103 Age adjusted rate to 1990 US population Oklahoma, Utah Gabella et al., 1997b 1991 to 1992 Colorado 7056 NS 101 Hospitalized and deaths, age adjusted to US Thurman and Guerrero, 1994 to 1995 US NS NS 98 Hospitalized patients only 1999 Jager et al., 2000 1992 to 1994 US 1.144 million NS 444 ED patients only Schootman et al., 2000 1993 Iowa 2,559 NS 91 Severe TBI rate based capture- recapture; age adjusted rate to 1990 US population Guerrero et al., 2000 1995 to 1996 US 1.027 million NS 392 ED patients only Louisiana Office of 1996 to 1999 Louisiana 16,203 NS 90 Hospitalized patients and prehospital Public Health Injury and deaths Research Prevention Section, 2004 Langlois et al., 2003 1997 14 US states 62,771 NS 70 Live hospital discharges only Langlois et al., 2006 1995 to 2001 US 1.396 million NS 505 Total rate, age adjusted to 2000 US population 235 86 Hospitalized patients only 1.111 million 401 ED visits only Selassie et al., 2004 1996 to 2001 South Carolina 70,671 NS 68 Hospital patients only 220 ED patients only Texas Department of 1998 Texas 20,000 NS NS Hospitalized patients only Health, 2004 Rutland-Brown et al., 2003 US 1.565 million NS 538 Total 2006 421 ED visits only 100 Hospitalization NOTE: CA = California, ED = emergency department, IL = Illinois, MN = Minnesota, NS = not stated, NY = New York, TBI = traumatic brain injury, US = United States. TABLE 3.5 Non-US TBI Incidence Data Base Year(s) of Number of Population Rate / 105 Reference Data Location Patients (x1000) per year Comments Jennett and MacMillan, 1974 England, Wales and NS NS 270 in Annual rates based on sample weeks, 1981 Scotland England and rates not age adjusted Wales 313 in Scotland Selecki et al., 1981 1977 New South Wales, 18,678 4,960 377 Hospital admissions only excludes Australia prehospitalized deaths Servadei et al., 1985 1981 to 1982 San Marino 327 23.5 468 Hospital admissions Wang et al., 1986 1982 Urban areas of China 35 63 56 Rates based on samples of households in city communities Nestvold et al., 1988 1974 Central Norway 488 350 236 Hospital admissions Badcock, 1988 1984 South Australia 1,698 NS 520 Includes ED visits, admissions and prehospital deaths Servadei et al., 1988 1984 Ravenna, Italy 644 172 372 Hospitalized cases only excludes ED treated and released Levi et al., 1990 1984 to 1988 Northern Israel 1,370 1,200 25 Rate in person-years Tiret et al., 1990 1986 Aquitaine, France 8,940 2,700 281 Hospital admissions and deaths Johansson et al., 1991 1984 to 1985 Northern Sweden 242 70 242 Ages 16-60 only, hospital admissions Nell and Brown, 1991 1986 Johannesburg, South 5,106 NS 316 Rate based on population estimates Africa Annoni et al., 1992 1987 St. |
1994 | IMP PIST RICHARDS 0.6X4MM | CDM | Excludes prehospital deaths GCS: severe 9, moderate = 9â15 plus hospital 2001 Hualien County, in 2001 stay at least 48 hrs and had brain surgery or Taiwan abnormal CT scan, mild = all others Yates et al., 1997 to Royal Devon and ED database from one hospital. ICD codes used but not Based on ICD-10 but not defined 2008 2003 Exeter Hospital, stated UK Wu et al., 2008 2004 6 Providences of Hospital admitted patients with data from attending GCS: severe 9, moderate = 9â13, mild = 14, 15 Eastern China physician NOTE: AIS = Abbreviated Injury Scale, CHIRPP = Canadian Hospitals Injury Reporting and Prevention Program, CT = computed tomography, ED = emergency department, GCS = Glasgow Coma Scale, ICD = International Classification of Diseases, ICDMAP = computer algorithm, ICU = intensive care unit, ISS = Injury Severity Score, LOC = loss of consciousness, PTA = posttraumatic amnesia, TBI = traumatic brain injury, UK = United Kingdom. TABLE 3.4 US TBI Incidence Studies Base Year(s) of Number of Population Rate / 105 Reference Data Location Patients (x1000) per year Comments Annegers et al., 1980 1965 to 1974 Olmstead County, MN 3,587 NS 193 Age adjusted to 1970 US population, rate averaged from men only and women only rates Fuortes et al., 1990 1984 to 1986 Iowa NS NS 159 in 1984 Hospital admissions only 133 in 1985 117 in 1986 Rimel, 1981 1977 to 1979 Central Virginia 1,330 NS NS Hospital patients and prehospital deaths Klauber et al., 1981 1978 San Diego, CA 5,055 NS 294 Includes some nonresidents, excludes a few external causes Cooper et al., 1983 1980 to 1981 Bronx, NY 1,209 NS 249 Rate based on sample, age adjusted to 1980 US population Jagger et al., 1984b 1978 North Central Virginia 735 354 208 Rate includes residents and nonresidents; no ED cases or prehospital deaths Kraus et al., 1984 1981 San Diego County, CA 3,358 1862 180 Population based, not age adjusted Whitman et al., 1984 1979 to 1980 Inner city Chicago and 782 213 331 Composite rate from data in publication, Evanston, IL average across race and gender Fife et al., 1986 1979 to 1980 Rhode Island 2,870 947 152 Hospital patients only Fife, 1987 1977 to 1981 US 307,000 226,545 136 Hospital patients only; 1.87 million 1.87 million 805 All injured patients MacKenzie et al., 1989a 1986 Maryland 5,838 NS 132 Hospital patients only MacKenzie et al., 1990 1979 to 1986 Maryland NS NS 114-134 Hospital patients only, range in rates Oklahoma State 1989 Oklahoma 3,672 NS 121 Hospital and fatal cases Department of Health, 1991 Schuster, 1994 1990 Massachusetts 27,819 6,016 10 Mortality rate 86 Hospital admissions 366 ED only Warren et al., 1995 1991 to 1993 Alaska 2,178 457 130 Hospital patients only Diamond, 1996 1988 to 1993 Virginia 46,680 NS NS Only age-specific rates reported Sosin et al., 1996 1991 US 1.54 million NS 618 Total rate 158 Hospitalized 79
80 Base Year(s) of Number of Population Rate / 105 Reference Data Location Patients (x1000) per year Comments 307 ED only 153 No care Thurman et al., 1996 1990 to 1992 Utah 5,782 NS 106 Age adjusted rate to 1990 US population Gabella et al., 1997a 1990 to 1993 Colorado, Missouri, 13,978 13,687 103 Age adjusted rate to 1990 US population Oklahoma, Utah Gabella et al., 1997b 1991 to 1992 Colorado 7056 NS 101 Hospitalized and deaths, age adjusted to US Thurman and Guerrero, 1994 to 1995 US NS NS 98 Hospitalized patients only 1999 Jager et al., 2000 1992 to 1994 US 1.144 million NS 444 ED patients only Schootman et al., 2000 1993 Iowa 2,559 NS 91 Severe TBI rate based capture- recapture; age adjusted rate to 1990 US population Guerrero et al., 2000 1995 to 1996 US 1.027 million NS 392 ED patients only Louisiana Office of 1996 to 1999 Louisiana 16,203 NS 90 Hospitalized patients and prehospital Public Health Injury and deaths Research Prevention Section, 2004 Langlois et al., 2003 1997 14 US states 62,771 NS 70 Live hospital discharges only Langlois et al., 2006 1995 to 2001 US 1.396 million NS 505 Total rate, age adjusted to 2000 US population 235 86 Hospitalized patients only 1.111 million 401 ED visits only Selassie et al., 2004 1996 to 2001 South Carolina 70,671 NS 68 Hospital patients only 220 ED patients only Texas Department of 1998 Texas 20,000 NS NS Hospitalized patients only Health, 2004 Rutland-Brown et al., 2003 US 1.565 million NS 538 Total 2006 421 ED visits only 100 Hospitalization NOTE: CA = California, ED = emergency department, IL = Illinois, MN = Minnesota, NS = not stated, NY = New York, TBI = traumatic brain injury, US = United States. TABLE 3.5 Non-US TBI Incidence Data Base Year(s) of Number of Population Rate / 105 Reference Data Location Patients (x1000) per year Comments Jennett and MacMillan, 1974 England, Wales and NS NS 270 in Annual rates based on sample weeks, 1981 Scotland England and rates not age adjusted Wales 313 in Scotland Selecki et al., 1981 1977 New South Wales, 18,678 4,960 377 Hospital admissions only excludes Australia prehospitalized deaths Servadei et al., 1985 1981 to 1982 San Marino 327 23.5 468 Hospital admissions Wang et al., 1986 1982 Urban areas of China 35 63 56 Rates based on samples of households in city communities Nestvold et al., 1988 1974 Central Norway 488 350 236 Hospital admissions Badcock, 1988 1984 South Australia 1,698 NS 520 Includes ED visits, admissions and prehospital deaths Servadei et al., 1988 1984 Ravenna, Italy 644 172 372 Hospitalized cases only excludes ED treated and released Levi et al., 1990 1984 to 1988 Northern Israel 1,370 1,200 25 Rate in person-years Tiret et al., 1990 1986 Aquitaine, France 8,940 2,700 281 Hospital admissions and deaths Johansson et al., 1991 1984 to 1985 Northern Sweden 242 70 242 Ages 16-60 only, hospital admissions Nell and Brown, 1991 1986 Johannesburg, South 5,106 NS 316 Rate based on population estimates Africa Annoni et al., 1992 1987 St. Gallon Canton of 80 410 20 Rate based on sample of hospital Switzerland weeks of data collection Vazquez-Barquero et al., 1988 Cantabria, Spain 477 523 91 Hospital admissions only 1992 Engberg, 1995 1988 Frederiksborg County, NS 340 22.6 (7.1) ICD 851-4 only (PTA > 7 days) Denmark Chiu et al., 1997 1988 to 1994 Taiwan 58,563 NS Taipei: 220 Number of patients excludes Hualien Co: prehospital deaths; rates include 30 nonhospital deaths Hillier et al., 1997 1987 South Australia 4,486 1,393 322 Rate for persons 16+, excludes prehospital deaths 81
82 Base Year(s) of Number of Population Rate / 105 Reference Data Location Patients (x1000) per year Comments Ingebrigtsen et al., 1998 1993 Northern Norway 247 108 229 Hospital referred patients Tate et al., 1998 1988 New South Wales 1,259 NS 100 Hospital admitted patients excludes prehospital deaths Alaranta et al., 2000 1991 to 1995 Finland 24,497 5,100 95â100 Hospital discharge first-time TBI patients only, rate range over 5 years Engberg and Teasdale, 1979 to 1996 Denmark NS NS 265, 224, Hospitalized patients trend from 1979â 2001 157 1981, 1985â1987, 1991â1993, excludes prehospital deaths Firsching and Woischneck, 1996 Germany 279,000 82,000 350 Hospital admitted patients only 2001 Masson et al., 2001 1996 Aquitaine, France 497 2,800 17.3 Total AIS 4 and 5, Severe TBI (AIS4 = 7.2 AIS5 = 10.1) Pickett et al., 2001 1998 Kingston, Canada 760 176 431 Rate calculated from published data (115) (potential head injuries) Gururaj, 2002 1999 Bangalore, India NS NS 160 Hospital admitted patients only Servadei et al., 2002b 1998 Romagna and Trentino, 3,554 1,439 314 Total for residence (Romagna, Italy (2,421, (969, 470) (297, Trentino) hospitalization rates 1,133) 332) Servadei et al., 2002a 1998 Romagna, Italy 2,430 971 250 Hospital admitted patients only Andersson et al., 2003 1992 to 1993 Western Sweden 753 138 546 Include ED, hospital admitted and coroner records Baldo et al., 2003 1996 to 2000 Northeast Italy 55,368 NS 301â212 Hospital admissions 1996â2000 Kleiven et al., 2003 1987 to 2000 Sweden 22,000 8,400â8,900 259 Average over 14 years hospital per yr discharged patients Masson et al., 2003 1996 Aquitaine, France 248 2,800 8.5 Coma patients only Santos et al., 2003 1994, 1996, Portugal 40,633 9,500 151 (1994), All hospital discharges for 1994â1997, 1997 137 (1996, plus TBI deaths 1997) Steudel et al., 2005 1998 Germany 276,584 82,000 337 Hospitalized cases and incidence rate; ICD 9 codes 800â804, 850â854 Tennant, 2005 2001 to 2002 England 112,718 NS 229 Hospitalized incidence rate
Base Year(s) of Number of Population Rate / 105 Reference Data Location Patients (x1000) per year Comments Chiu et al., 2007 2001 Taipei and Hualien 5,754, 2,634 218, 417 Excludes prehospital deaths County, Taiwan 1,474 353 Wu et al., 2008 2004 6 Provinces of Eastern 14,948 NS NS Hospital admitted cases China Yates et al., 2006 1997 to 2003 England NS 345 453 From an ED database including hospital admitted NOTE: AIS = Abbreviated Injury Scale, Co = county, ED = emergency department, ICD = International Classification of Diseases, PTA = posttraumatic amnesia, TBI = traumatic brain injury. |
2007 | EPINEPHRINE .1MG/ML | CDM | Excludes prehospital deaths GCS: severe 9, moderate = 9â15 plus hospital 2001 Hualien County, in 2001 stay at least 48 hrs and had brain surgery or Taiwan abnormal CT scan, mild = all others Yates et al., 1997 to Royal Devon and ED database from one hospital. ICD codes used but not Based on ICD-10 but not defined 2008 2003 Exeter Hospital, stated UK Wu et al., 2008 2004 6 Providences of Hospital admitted patients with data from attending GCS: severe 9, moderate = 9â13, mild = 14, 15 Eastern China physician NOTE: AIS = Abbreviated Injury Scale, CHIRPP = Canadian Hospitals Injury Reporting and Prevention Program, CT = computed tomography, ED = emergency department, GCS = Glasgow Coma Scale, ICD = International Classification of Diseases, ICDMAP = computer algorithm, ICU = intensive care unit, ISS = Injury Severity Score, LOC = loss of consciousness, PTA = posttraumatic amnesia, TBI = traumatic brain injury, UK = United Kingdom. TABLE 3.4 US TBI Incidence Studies Base Year(s) of Number of Population Rate / 105 Reference Data Location Patients (x1000) per year Comments Annegers et al., 1980 1965 to 1974 Olmstead County, MN 3,587 NS 193 Age adjusted to 1970 US population, rate averaged from men only and women only rates Fuortes et al., 1990 1984 to 1986 Iowa NS NS 159 in 1984 Hospital admissions only 133 in 1985 117 in 1986 Rimel, 1981 1977 to 1979 Central Virginia 1,330 NS NS Hospital patients and prehospital deaths Klauber et al., 1981 1978 San Diego, CA 5,055 NS 294 Includes some nonresidents, excludes a few external causes Cooper et al., 1983 1980 to 1981 Bronx, NY 1,209 NS 249 Rate based on sample, age adjusted to 1980 US population Jagger et al., 1984b 1978 North Central Virginia 735 354 208 Rate includes residents and nonresidents; no ED cases or prehospital deaths Kraus et al., 1984 1981 San Diego County, CA 3,358 1862 180 Population based, not age adjusted Whitman et al., 1984 1979 to 1980 Inner city Chicago and 782 213 331 Composite rate from data in publication, Evanston, IL average across race and gender Fife et al., 1986 1979 to 1980 Rhode Island 2,870 947 152 Hospital patients only Fife, 1987 1977 to 1981 US 307,000 226,545 136 Hospital patients only; 1.87 million 1.87 million 805 All injured patients MacKenzie et al., 1989a 1986 Maryland 5,838 NS 132 Hospital patients only MacKenzie et al., 1990 1979 to 1986 Maryland NS NS 114-134 Hospital patients only, range in rates Oklahoma State 1989 Oklahoma 3,672 NS 121 Hospital and fatal cases Department of Health, 1991 Schuster, 1994 1990 Massachusetts 27,819 6,016 10 Mortality rate 86 Hospital admissions 366 ED only Warren et al., 1995 1991 to 1993 Alaska 2,178 457 130 Hospital patients only Diamond, 1996 1988 to 1993 Virginia 46,680 NS NS Only age-specific rates reported Sosin et al., 1996 1991 US 1.54 million NS 618 Total rate 158 Hospitalized 79
80 Base Year(s) of Number of Population Rate / 105 Reference Data Location Patients (x1000) per year Comments 307 ED only 153 No care Thurman et al., 1996 1990 to 1992 Utah 5,782 NS 106 Age adjusted rate to 1990 US population Gabella et al., 1997a 1990 to 1993 Colorado, Missouri, 13,978 13,687 103 Age adjusted rate to 1990 US population Oklahoma, Utah Gabella et al., 1997b 1991 to 1992 Colorado 7056 NS 101 Hospitalized and deaths, age adjusted to US Thurman and Guerrero, 1994 to 1995 US NS NS 98 Hospitalized patients only 1999 Jager et al., 2000 1992 to 1994 US 1.144 million NS 444 ED patients only Schootman et al., 2000 1993 Iowa 2,559 NS 91 Severe TBI rate based capture- recapture; age adjusted rate to 1990 US population Guerrero et al., 2000 1995 to 1996 US 1.027 million NS 392 ED patients only Louisiana Office of 1996 to 1999 Louisiana 16,203 NS 90 Hospitalized patients and prehospital Public Health Injury and deaths Research Prevention Section, 2004 Langlois et al., 2003 1997 14 US states 62,771 NS 70 Live hospital discharges only Langlois et al., 2006 1995 to 2001 US 1.396 million NS 505 Total rate, age adjusted to 2000 US population 235 86 Hospitalized patients only 1.111 million 401 ED visits only Selassie et al., 2004 1996 to 2001 South Carolina 70,671 NS 68 Hospital patients only 220 ED patients only Texas Department of 1998 Texas 20,000 NS NS Hospitalized patients only Health, 2004 Rutland-Brown et al., 2003 US 1.565 million NS 538 Total 2006 421 ED visits only 100 Hospitalization NOTE: CA = California, ED = emergency department, IL = Illinois, MN = Minnesota, NS = not stated, NY = New York, TBI = traumatic brain injury, US = United States. TABLE 3.5 Non-US TBI Incidence Data Base Year(s) of Number of Population Rate / 105 Reference Data Location Patients (x1000) per year Comments Jennett and MacMillan, 1974 England, Wales and NS NS 270 in Annual rates based on sample weeks, 1981 Scotland England and rates not age adjusted Wales 313 in Scotland Selecki et al., 1981 1977 New South Wales, 18,678 4,960 377 Hospital admissions only excludes Australia prehospitalized deaths Servadei et al., 1985 1981 to 1982 San Marino 327 23.5 468 Hospital admissions Wang et al., 1986 1982 Urban areas of China 35 63 56 Rates based on samples of households in city communities Nestvold et al., 1988 1974 Central Norway 488 350 236 Hospital admissions Badcock, 1988 1984 South Australia 1,698 NS 520 Includes ED visits, admissions and prehospital deaths Servadei et al., 1988 1984 Ravenna, Italy 644 172 372 Hospitalized cases only excludes ED treated and released Levi et al., 1990 1984 to 1988 Northern Israel 1,370 1,200 25 Rate in person-years Tiret et al., 1990 1986 Aquitaine, France 8,940 2,700 281 Hospital admissions and deaths Johansson et al., 1991 1984 to 1985 Northern Sweden 242 70 242 Ages 16-60 only, hospital admissions Nell and Brown, 1991 1986 Johannesburg, South 5,106 NS 316 Rate based on population estimates Africa Annoni et al., 1992 1987 St. Gallon Canton of 80 410 20 Rate based on sample of hospital Switzerland weeks of data collection Vazquez-Barquero et al., 1988 Cantabria, Spain 477 523 91 Hospital admissions only 1992 Engberg, 1995 1988 Frederiksborg County, NS 340 22.6 (7.1) ICD 851-4 only (PTA > 7 days) Denmark Chiu et al., 1997 1988 to 1994 Taiwan 58,563 NS Taipei: 220 Number of patients excludes Hualien Co: prehospital deaths; rates include 30 nonhospital deaths Hillier et al., 1997 1987 South Australia 4,486 1,393 322 Rate for persons 16+, excludes prehospital deaths 81
82 Base Year(s) of Number of Population Rate / 105 Reference Data Location Patients (x1000) per year Comments Ingebrigtsen et al., 1998 1993 Northern Norway 247 108 229 Hospital referred patients Tate et al., 1998 1988 New South Wales 1,259 NS 100 Hospital admitted patients excludes prehospital deaths Alaranta et al., 2000 1991 to 1995 Finland 24,497 5,100 95â100 Hospital discharge first-time TBI patients only, rate range over 5 years Engberg and Teasdale, 1979 to 1996 Denmark NS NS 265, 224, Hospitalized patients trend from 1979â 2001 157 1981, 1985â1987, 1991â1993, excludes prehospital deaths Firsching and Woischneck, 1996 Germany 279,000 82,000 350 Hospital admitted patients only 2001 Masson et al., 2001 1996 Aquitaine, France 497 2,800 17.3 Total AIS 4 and 5, Severe TBI (AIS4 = 7.2 AIS5 = 10.1) Pickett et al., 2001 1998 Kingston, Canada 760 176 431 Rate calculated from published data (115) (potential head injuries) Gururaj, 2002 1999 Bangalore, India NS NS 160 Hospital admitted patients only Servadei et al., 2002b 1998 Romagna and Trentino, 3,554 1,439 314 Total for residence (Romagna, Italy (2,421, (969, 470) (297, Trentino) hospitalization rates 1,133) 332) Servadei et al., 2002a 1998 Romagna, Italy 2,430 971 250 Hospital admitted patients only Andersson et al., 2003 1992 to 1993 Western Sweden 753 138 546 Include ED, hospital admitted and coroner records Baldo et al., 2003 1996 to 2000 Northeast Italy 55,368 NS 301â212 Hospital admissions 1996â2000 Kleiven et al., 2003 1987 to 2000 Sweden 22,000 8,400â8,900 259 Average over 14 years hospital per yr discharged patients Masson et al., 2003 1996 Aquitaine, France 248 2,800 8.5 Coma patients only Santos et al., 2003 1994, 1996, Portugal 40,633 9,500 151 (1994), All hospital discharges for 1994â1997, 1997 137 (1996, plus TBI deaths 1997) Steudel et al., 2005 1998 Germany 276,584 82,000 337 Hospitalized cases and incidence rate; ICD 9 codes 800â804, 850â854 Tennant, 2005 2001 to 2002 England 112,718 NS 229 Hospitalized incidence rate
Base Year(s) of Number of Population Rate / 105 Reference Data Location Patients (x1000) per year Comments Chiu et al., 2007 2001 Taipei and Hualien 5,754, 2,634 218, 417 Excludes prehospital deaths County, Taiwan 1,474 353 Wu et al., 2008 2004 6 Provinces of Eastern 14,948 NS NS Hospital admitted cases China Yates et al., 2006 1997 to 2003 England NS 345 453 From an ED database including hospital admitted NOTE: AIS = Abbreviated Injury Scale, Co = county, ED = emergency department, ICD = International Classification of Diseases, PTA = posttraumatic amnesia, TBI = traumatic brain injury. |
1995 | IMP PIST 0.6X4.5MM | CDM | Excludes prehospital deaths GCS: severe 9, moderate = 9â15 plus hospital 2001 Hualien County, in 2001 stay at least 48 hrs and had brain surgery or Taiwan abnormal CT scan, mild = all others Yates et al., 1997 to Royal Devon and ED database from one hospital. ICD codes used but not Based on ICD-10 but not defined 2008 2003 Exeter Hospital, stated UK Wu et al., 2008 2004 6 Providences of Hospital admitted patients with data from attending GCS: severe 9, moderate = 9â13, mild = 14, 15 Eastern China physician NOTE: AIS = Abbreviated Injury Scale, CHIRPP = Canadian Hospitals Injury Reporting and Prevention Program, CT = computed tomography, ED = emergency department, GCS = Glasgow Coma Scale, ICD = International Classification of Diseases, ICDMAP = computer algorithm, ICU = intensive care unit, ISS = Injury Severity Score, LOC = loss of consciousness, PTA = posttraumatic amnesia, TBI = traumatic brain injury, UK = United Kingdom. TABLE 3.4 US TBI Incidence Studies Base Year(s) of Number of Population Rate / 105 Reference Data Location Patients (x1000) per year Comments Annegers et al., 1980 1965 to 1974 Olmstead County, MN 3,587 NS 193 Age adjusted to 1970 US population, rate averaged from men only and women only rates Fuortes et al., 1990 1984 to 1986 Iowa NS NS 159 in 1984 Hospital admissions only 133 in 1985 117 in 1986 Rimel, 1981 1977 to 1979 Central Virginia 1,330 NS NS Hospital patients and prehospital deaths Klauber et al., 1981 1978 San Diego, CA 5,055 NS 294 Includes some nonresidents, excludes a few external causes Cooper et al., 1983 1980 to 1981 Bronx, NY 1,209 NS 249 Rate based on sample, age adjusted to 1980 US population Jagger et al., 1984b 1978 North Central Virginia 735 354 208 Rate includes residents and nonresidents; no ED cases or prehospital deaths Kraus et al., 1984 1981 San Diego County, CA 3,358 1862 180 Population based, not age adjusted Whitman et al., 1984 1979 to 1980 Inner city Chicago and 782 213 331 Composite rate from data in publication, Evanston, IL average across race and gender Fife et al., 1986 1979 to 1980 Rhode Island 2,870 947 152 Hospital patients only Fife, 1987 1977 to 1981 US 307,000 226,545 136 Hospital patients only; 1.87 million 1.87 million 805 All injured patients MacKenzie et al., 1989a 1986 Maryland 5,838 NS 132 Hospital patients only MacKenzie et al., 1990 1979 to 1986 Maryland NS NS 114-134 Hospital patients only, range in rates Oklahoma State 1989 Oklahoma 3,672 NS 121 Hospital and fatal cases Department of Health, 1991 Schuster, 1994 1990 Massachusetts 27,819 6,016 10 Mortality rate 86 Hospital admissions 366 ED only Warren et al., 1995 1991 to 1993 Alaska 2,178 457 130 Hospital patients only Diamond, 1996 1988 to 1993 Virginia 46,680 NS NS Only age-specific rates reported Sosin et al., 1996 1991 US 1.54 million NS 618 Total rate 158 Hospitalized 79
80 Base Year(s) of Number of Population Rate / 105 Reference Data Location Patients (x1000) per year Comments 307 ED only 153 No care Thurman et al., 1996 1990 to 1992 Utah 5,782 NS 106 Age adjusted rate to 1990 US population Gabella et al., 1997a 1990 to 1993 Colorado, Missouri, 13,978 13,687 103 Age adjusted rate to 1990 US population Oklahoma, Utah Gabella et al., 1997b 1991 to 1992 Colorado 7056 NS 101 Hospitalized and deaths, age adjusted to US Thurman and Guerrero, 1994 to 1995 US NS NS 98 Hospitalized patients only 1999 Jager et al., 2000 1992 to 1994 US 1.144 million NS 444 ED patients only Schootman et al., 2000 1993 Iowa 2,559 NS 91 Severe TBI rate based capture- recapture; age adjusted rate to 1990 US population Guerrero et al., 2000 1995 to 1996 US 1.027 million NS 392 ED patients only Louisiana Office of 1996 to 1999 Louisiana 16,203 NS 90 Hospitalized patients and prehospital Public Health Injury and deaths Research Prevention Section, 2004 Langlois et al., 2003 1997 14 US states 62,771 NS 70 Live hospital discharges only Langlois et al., 2006 1995 to 2001 US 1.396 million NS 505 Total rate, age adjusted to 2000 US population 235 86 Hospitalized patients only 1.111 million 401 ED visits only Selassie et al., 2004 1996 to 2001 South Carolina 70,671 NS 68 Hospital patients only 220 ED patients only Texas Department of 1998 Texas 20,000 NS NS Hospitalized patients only Health, 2004 Rutland-Brown et al., 2003 US 1.565 million NS 538 Total 2006 421 ED visits only 100 Hospitalization NOTE: CA = California, ED = emergency department, IL = Illinois, MN = Minnesota, NS = not stated, NY = New York, TBI = traumatic brain injury, US = United States. TABLE 3.5 Non-US TBI Incidence Data Base Year(s) of Number of Population Rate / 105 Reference Data Location Patients (x1000) per year Comments Jennett and MacMillan, 1974 England, Wales and NS NS 270 in Annual rates based on sample weeks, 1981 Scotland England and rates not age adjusted Wales 313 in Scotland Selecki et al., 1981 1977 New South Wales, 18,678 4,960 377 Hospital admissions only excludes Australia prehospitalized deaths Servadei et al., 1985 1981 to 1982 San Marino 327 23.5 468 Hospital admissions Wang et al., 1986 1982 Urban areas of China 35 63 56 Rates based on samples of households in city communities Nestvold et al., 1988 1974 Central Norway 488 350 236 Hospital admissions Badcock, 1988 1984 South Australia 1,698 NS 520 Includes ED visits, admissions and prehospital deaths Servadei et al., 1988 1984 Ravenna, Italy 644 172 372 Hospitalized cases only excludes ED treated and released Levi et al., 1990 1984 to 1988 Northern Israel 1,370 1,200 25 Rate in person-years Tiret et al., 1990 1986 Aquitaine, France 8,940 2,700 281 Hospital admissions and deaths Johansson et al., 1991 1984 to 1985 Northern Sweden 242 70 242 Ages 16-60 only, hospital admissions Nell and Brown, 1991 1986 Johannesburg, South 5,106 NS 316 Rate based on population estimates Africa Annoni et al., 1992 1987 St. Gallon Canton of 80 410 20 Rate based on sample of hospital Switzerland weeks of data collection Vazquez-Barquero et al., 1988 Cantabria, Spain 477 523 91 Hospital admissions only 1992 Engberg, 1995 1988 Frederiksborg County, NS 340 22.6 (7.1) ICD 851-4 only (PTA > 7 days) Denmark Chiu et al., 1997 1988 to 1994 Taiwan 58,563 NS Taipei: 220 Number of patients excludes Hualien Co: prehospital deaths; rates include 30 nonhospital deaths Hillier et al., 1997 1987 South Australia 4,486 1,393 322 Rate for persons 16+, excludes prehospital deaths 81
82 Base Year(s) of Number of Population Rate / 105 Reference Data Location Patients (x1000) per year Comments Ingebrigtsen et al., 1998 1993 Northern Norway 247 108 229 Hospital referred patients Tate et al., 1998 1988 New South Wales 1,259 NS 100 Hospital admitted patients excludes prehospital deaths Alaranta et al., 2000 1991 to 1995 Finland 24,497 5,100 95â100 Hospital discharge first-time TBI patients only, rate range over 5 years Engberg and Teasdale, 1979 to 1996 Denmark NS NS 265, 224, Hospitalized patients trend from 1979â 2001 157 1981, 1985â1987, 1991â1993, excludes prehospital deaths Firsching and Woischneck, 1996 Germany 279,000 82,000 350 Hospital admitted patients only 2001 Masson et al., 2001 1996 Aquitaine, France 497 2,800 17.3 Total AIS 4 and 5, Severe TBI (AIS4 = 7.2 AIS5 = 10.1) Pickett et al., 2001 1998 Kingston, Canada 760 176 431 Rate calculated from published data (115) (potential head injuries) Gururaj, 2002 1999 Bangalore, India NS NS 160 Hospital admitted patients only Servadei et al., 2002b 1998 Romagna and Trentino, 3,554 1,439 314 Total for residence (Romagna, Italy (2,421, (969, 470) (297, Trentino) hospitalization rates 1,133) 332) Servadei et al., 2002a 1998 Romagna, Italy 2,430 971 250 Hospital admitted patients only Andersson et al., 2003 1992 to 1993 Western Sweden 753 138 546 Include ED, hospital admitted and coroner records Baldo et al., 2003 1996 to 2000 Northeast Italy 55,368 NS 301â212 Hospital admissions 1996â2000 Kleiven et al., 2003 1987 to 2000 Sweden 22,000 8,400â8,900 259 Average over 14 years hospital per yr discharged patients Masson et al., 2003 1996 Aquitaine, France 248 2,800 8.5 Coma patients only Santos et al., 2003 1994, 1996, Portugal 40,633 9,500 151 (1994), All hospital discharges for 1994â1997, 1997 137 (1996, plus TBI deaths 1997) Steudel et al., 2005 1998 Germany 276,584 82,000 337 Hospitalized cases and incidence rate; ICD 9 codes 800â804, 850â854 Tennant, 2005 2001 to 2002 England 112,718 NS 229 Hospitalized incidence rate
Base Year(s) of Number of Population Rate / 105 Reference Data Location Patients (x1000) per year Comments Chiu et al., 2007 2001 Taipei and Hualien 5,754, 2,634 218, 417 Excludes prehospital deaths County, Taiwan 1,474 353 Wu et al., 2008 2004 6 Provinces of Eastern 14,948 NS NS Hospital admitted cases China Yates et al., 2006 1997 to 2003 England NS 345 453 From an ED database including hospital admitted NOTE: AIS = Abbreviated Injury Scale, Co = county, ED = emergency department, ICD = International Classification of Diseases, PTA = posttraumatic amnesia, TBI = traumatic brain injury. |
1993 | IMP EAR RICHARDS 0.6X3.5MM | CDM | Excludes prehospital deaths GCS: severe 9, moderate = 9â15 plus hospital 2001 Hualien County, in 2001 stay at least 48 hrs and had brain surgery or Taiwan abnormal CT scan, mild = all others Yates et al., 1997 to Royal Devon and ED database from one hospital. ICD codes used but not Based on ICD-10 but not defined 2008 2003 Exeter Hospital, stated UK Wu et al., 2008 2004 6 Providences of Hospital admitted patients with data from attending GCS: severe 9, moderate = 9â13, mild = 14, 15 Eastern China physician NOTE: AIS = Abbreviated Injury Scale, CHIRPP = Canadian Hospitals Injury Reporting and Prevention Program, CT = computed tomography, ED = emergency department, GCS = Glasgow Coma Scale, ICD = International Classification of Diseases, ICDMAP = computer algorithm, ICU = intensive care unit, ISS = Injury Severity Score, LOC = loss of consciousness, PTA = posttraumatic amnesia, TBI = traumatic brain injury, UK = United Kingdom. TABLE 3.4 US TBI Incidence Studies Base Year(s) of Number of Population Rate / 105 Reference Data Location Patients (x1000) per year Comments Annegers et al., 1980 1965 to 1974 Olmstead County, MN 3,587 NS 193 Age adjusted to 1970 US population, rate averaged from men only and women only rates Fuortes et al., 1990 1984 to 1986 Iowa NS NS 159 in 1984 Hospital admissions only 133 in 1985 117 in 1986 Rimel, 1981 1977 to 1979 Central Virginia 1,330 NS NS Hospital patients and prehospital deaths Klauber et al., 1981 1978 San Diego, CA 5,055 NS 294 Includes some nonresidents, excludes a few external causes Cooper et al., 1983 1980 to 1981 Bronx, NY 1,209 NS 249 Rate based on sample, age adjusted to 1980 US population Jagger et al., 1984b 1978 North Central Virginia 735 354 208 Rate includes residents and nonresidents; no ED cases or prehospital deaths Kraus et al., 1984 1981 San Diego County, CA 3,358 1862 180 Population based, not age adjusted Whitman et al., 1984 1979 to 1980 Inner city Chicago and 782 213 331 Composite rate from data in publication, Evanston, IL average across race and gender Fife et al., 1986 1979 to 1980 Rhode Island 2,870 947 152 Hospital patients only Fife, 1987 1977 to 1981 US 307,000 226,545 136 Hospital patients only; 1.87 million 1.87 million 805 All injured patients MacKenzie et al., 1989a 1986 Maryland 5,838 NS 132 Hospital patients only MacKenzie et al., 1990 1979 to 1986 Maryland NS NS 114-134 Hospital patients only, range in rates Oklahoma State 1989 Oklahoma 3,672 NS 121 Hospital and fatal cases Department of Health, 1991 Schuster, 1994 1990 Massachusetts 27,819 6,016 10 Mortality rate 86 Hospital admissions 366 ED only Warren et al., 1995 1991 to 1993 Alaska 2,178 457 130 Hospital patients only Diamond, 1996 1988 to 1993 Virginia 46,680 NS NS Only age-specific rates reported Sosin et al., 1996 1991 US 1.54 million NS 618 Total rate 158 Hospitalized 79
80 Base Year(s) of Number of Population Rate / 105 Reference Data Location Patients (x1000) per year Comments 307 ED only 153 No care Thurman et al., 1996 1990 to 1992 Utah 5,782 NS 106 Age adjusted rate to 1990 US population Gabella et al., 1997a 1990 to 1993 Colorado, Missouri, 13,978 13,687 103 Age adjusted rate to 1990 US population Oklahoma, Utah Gabella et al., 1997b 1991 to 1992 Colorado 7056 NS 101 Hospitalized and deaths, age adjusted to US Thurman and Guerrero, 1994 to 1995 US NS NS 98 Hospitalized patients only 1999 Jager et al., 2000 1992 to 1994 US 1.144 million NS 444 ED patients only Schootman et al., 2000 1993 Iowa 2,559 NS 91 Severe TBI rate based capture- recapture; age adjusted rate to 1990 US population Guerrero et al., 2000 1995 to 1996 US 1.027 million NS 392 ED patients only Louisiana Office of 1996 to 1999 Louisiana 16,203 NS 90 Hospitalized patients and prehospital Public Health Injury and deaths Research Prevention Section, 2004 Langlois et al., 2003 1997 14 US states 62,771 NS 70 Live hospital discharges only Langlois et al., 2006 1995 to 2001 US 1.396 million NS 505 Total rate, age adjusted to 2000 US population 235 86 Hospitalized patients only 1.111 million 401 ED visits only Selassie et al., 2004 1996 to 2001 South Carolina 70,671 NS 68 Hospital patients only 220 ED patients only Texas Department of 1998 Texas 20,000 NS NS Hospitalized patients only Health, 2004 Rutland-Brown et al., 2003 US 1.565 million NS 538 Total 2006 421 ED visits only 100 Hospitalization NOTE: CA = California, ED = emergency department, IL = Illinois, MN = Minnesota, NS = not stated, NY = New York, TBI = traumatic brain injury, US = United States. TABLE 3.5 Non-US TBI Incidence Data Base Year(s) of Number of Population Rate / 105 Reference Data Location Patients (x1000) per year Comments Jennett and MacMillan, 1974 England, Wales and NS NS 270 in Annual rates based on sample weeks, 1981 Scotland England and rates not age adjusted Wales 313 in Scotland Selecki et al., 1981 1977 New South Wales, 18,678 4,960 377 Hospital admissions only excludes Australia prehospitalized deaths Servadei et al., 1985 1981 to 1982 San Marino 327 23.5 468 Hospital admissions Wang et al., 1986 1982 Urban areas of China 35 63 56 Rates based on samples of households in city communities Nestvold et al., 1988 1974 Central Norway 488 350 236 Hospital admissions Badcock, 1988 1984 South Australia 1,698 NS 520 Includes ED visits, admissions and prehospital deaths Servadei et al., 1988 1984 Ravenna, Italy 644 172 372 Hospitalized cases only excludes ED treated and released Levi et al., 1990 1984 to 1988 Northern Israel 1,370 1,200 25 Rate in person-years Tiret et al., 1990 1986 Aquitaine, France 8,940 2,700 281 Hospital admissions and deaths Johansson et al., 1991 1984 to 1985 Northern Sweden 242 70 242 Ages 16-60 only, hospital admissions Nell and Brown, 1991 1986 Johannesburg, South 5,106 NS 316 Rate based on population estimates Africa Annoni et al., 1992 1987 St. Gallon Canton of 80 410 20 Rate based on sample of hospital Switzerland weeks of data collection Vazquez-Barquero et al., 1988 Cantabria, Spain 477 523 91 Hospital admissions only 1992 Engberg, 1995 1988 Frederiksborg County, NS 340 22.6 (7.1) ICD 851-4 only (PTA > 7 days) Denmark Chiu et al., 1997 1988 to 1994 Taiwan 58,563 NS Taipei: 220 Number of patients excludes Hualien Co: prehospital deaths; rates include 30 nonhospital deaths Hillier et al., 1997 1987 South Australia 4,486 1,393 322 Rate for persons 16+, excludes prehospital deaths 81
82 Base Year(s) of Number of Population Rate / 105 Reference Data Location Patients (x1000) per year Comments Ingebrigtsen et al., 1998 1993 Northern Norway 247 108 229 Hospital referred patients Tate et al., 1998 1988 New South Wales 1,259 NS 100 Hospital admitted patients excludes prehospital deaths Alaranta et al., 2000 1991 to 1995 Finland 24,497 5,100 95â100 Hospital discharge first-time TBI patients only, rate range over 5 years Engberg and Teasdale, 1979 to 1996 Denmark NS NS 265, 224, Hospitalized patients trend from 1979â 2001 157 1981, 1985â1987, 1991â1993, excludes prehospital deaths Firsching and Woischneck, 1996 Germany 279,000 82,000 350 Hospital admitted patients only 2001 Masson et al., 2001 1996 Aquitaine, France 497 2,800 17.3 Total AIS 4 and 5, Severe TBI (AIS4 = 7.2 AIS5 = 10.1) Pickett et al., 2001 1998 Kingston, Canada 760 176 431 Rate calculated from published data (115) (potential head injuries) Gururaj, 2002 1999 Bangalore, India NS NS 160 Hospital admitted patients only Servadei et al., 2002b 1998 Romagna and Trentino, 3,554 1,439 314 Total for residence (Romagna, Italy (2,421, (969, 470) (297, Trentino) hospitalization rates 1,133) 332) Servadei et al., 2002a 1998 Romagna, Italy 2,430 971 250 Hospital admitted patients only Andersson et al., 2003 1992 to 1993 Western Sweden 753 138 546 Include ED, hospital admitted and coroner records Baldo et al., 2003 1996 to 2000 Northeast Italy 55,368 NS 301â212 Hospital admissions 1996â2000 Kleiven et al., 2003 1987 to 2000 Sweden 22,000 8,400â8,900 259 Average over 14 years hospital per yr discharged patients Masson et al., 2003 1996 Aquitaine, France 248 2,800 8.5 Coma patients only Santos et al., 2003 1994, 1996, Portugal 40,633 9,500 151 (1994), All hospital discharges for 1994â1997, 1997 137 (1996, plus TBI deaths 1997) Steudel et al., 2005 1998 Germany 276,584 82,000 337 Hospitalized cases and incidence rate; ICD 9 codes 800â804, 850â854 Tennant, 2005 2001 to 2002 England 112,718 NS 229 Hospitalized incidence rate
Base Year(s) of Number of Population Rate / 105 Reference Data Location Patients (x1000) per year Comments Chiu et al., 2007 2001 Taipei and Hualien 5,754, 2,634 218, 417 Excludes prehospital deaths County, Taiwan 1,474 353 Wu et al., 2008 2004 6 Provinces of Eastern 14,948 NS NS Hospital admitted cases China Yates et al., 2006 1997 to 2003 England NS 345 453 From an ED database including hospital admitted NOTE: AIS = Abbreviated Injury Scale, Co = county, ED = emergency department, ICD = International Classification of Diseases, PTA = posttraumatic amnesia, TBI = traumatic brain injury. |
2003 | FILTER VENA CAVA FEM 7X48 SIMON NITINOL | CDM | Excludes prehospital deaths GCS: severe 9, moderate = 9â15 plus hospital 2001 Hualien County, in 2001 stay at least 48 hrs and had brain surgery or Taiwan abnormal CT scan, mild = all others Yates et al., 1997 to Royal Devon and ED database from one hospital. ICD codes used but not Based on ICD-10 but not defined 2008 2003 Exeter Hospital, stated UK Wu et al., 2008 2004 6 Providences of Hospital admitted patients with data from attending GCS: severe 9, moderate = 9â13, mild = 14, 15 Eastern China physician NOTE: AIS = Abbreviated Injury Scale, CHIRPP = Canadian Hospitals Injury Reporting and Prevention Program, CT = computed tomography, ED = emergency department, GCS = Glasgow Coma Scale, ICD = International Classification of Diseases, ICDMAP = computer algorithm, ICU = intensive care unit, ISS = Injury Severity Score, LOC = loss of consciousness, PTA = posttraumatic amnesia, TBI = traumatic brain injury, UK = United Kingdom. TABLE 3.4 US TBI Incidence Studies Base Year(s) of Number of Population Rate / 105 Reference Data Location Patients (x1000) per year Comments Annegers et al., 1980 1965 to 1974 Olmstead County, MN 3,587 NS 193 Age adjusted to 1970 US population, rate averaged from men only and women only rates Fuortes et al., 1990 1984 to 1986 Iowa NS NS 159 in 1984 Hospital admissions only 133 in 1985 117 in 1986 Rimel, 1981 1977 to 1979 Central Virginia 1,330 NS NS Hospital patients and prehospital deaths Klauber et al., 1981 1978 San Diego, CA 5,055 NS 294 Includes some nonresidents, excludes a few external causes Cooper et al., 1983 1980 to 1981 Bronx, NY 1,209 NS 249 Rate based on sample, age adjusted to 1980 US population Jagger et al., 1984b 1978 North Central Virginia 735 354 208 Rate includes residents and nonresidents; no ED cases or prehospital deaths Kraus et al., 1984 1981 San Diego County, CA 3,358 1862 180 Population based, not age adjusted Whitman et al., 1984 1979 to 1980 Inner city Chicago and 782 213 331 Composite rate from data in publication, Evanston, IL average across race and gender Fife et al., 1986 1979 to 1980 Rhode Island 2,870 947 152 Hospital patients only Fife, 1987 1977 to 1981 US 307,000 226,545 136 Hospital patients only; 1.87 million 1.87 million 805 All injured patients MacKenzie et al., 1989a 1986 Maryland 5,838 NS 132 Hospital patients only MacKenzie et al., 1990 1979 to 1986 Maryland NS NS 114-134 Hospital patients only, range in rates Oklahoma State 1989 Oklahoma 3,672 NS 121 Hospital and fatal cases Department of Health, 1991 Schuster, 1994 1990 Massachusetts 27,819 6,016 10 Mortality rate 86 Hospital admissions 366 ED only Warren et al., 1995 1991 to 1993 Alaska 2,178 457 130 Hospital patients only Diamond, 1996 1988 to 1993 Virginia 46,680 NS NS Only age-specific rates reported Sosin et al., 1996 1991 US 1.54 million NS 618 Total rate 158 Hospitalized 79
80 Base Year(s) of Number of Population Rate / 105 Reference Data Location Patients (x1000) per year Comments 307 ED only 153 No care Thurman et al., 1996 1990 to 1992 Utah 5,782 NS 106 Age adjusted rate to 1990 US population Gabella et al., 1997a 1990 to 1993 Colorado, Missouri, 13,978 13,687 103 Age adjusted rate to 1990 US population Oklahoma, Utah Gabella et al., 1997b 1991 to 1992 Colorado 7056 NS 101 Hospitalized and deaths, age adjusted to US Thurman and Guerrero, 1994 to 1995 US NS NS 98 Hospitalized patients only 1999 Jager et al., 2000 1992 to 1994 US 1.144 million NS 444 ED patients only Schootman et al., 2000 1993 Iowa 2,559 NS 91 Severe TBI rate based capture- recapture; age adjusted rate to 1990 US population Guerrero et al., 2000 1995 to 1996 US 1.027 million NS 392 ED patients only Louisiana Office of 1996 to 1999 Louisiana 16,203 NS 90 Hospitalized patients and prehospital Public Health Injury and deaths Research Prevention Section, 2004 Langlois et al., 2003 1997 14 US states 62,771 NS 70 Live hospital discharges only Langlois et al., 2006 1995 to 2001 US 1.396 million NS 505 Total rate, age adjusted to 2000 US population 235 86 Hospitalized patients only 1.111 million 401 ED visits only Selassie et al., 2004 1996 to 2001 South Carolina 70,671 NS 68 Hospital patients only 220 ED patients only Texas Department of 1998 Texas 20,000 NS NS Hospitalized patients only Health, 2004 Rutland-Brown et al., 2003 US 1.565 million NS 538 Total 2006 421 ED visits only 100 Hospitalization NOTE: CA = California, ED = emergency department, IL = Illinois, MN = Minnesota, NS = not stated, NY = New York, TBI = traumatic brain injury, US = United States. TABLE 3.5 Non-US TBI Incidence Data Base Year(s) of Number of Population Rate / 105 Reference Data Location Patients (x1000) per year Comments Jennett and MacMillan, 1974 England, Wales and NS NS 270 in Annual rates based on sample weeks, 1981 Scotland England and rates not age adjusted Wales 313 in Scotland Selecki et al., 1981 1977 New South Wales, 18,678 4,960 377 Hospital admissions only excludes Australia prehospitalized deaths Servadei et al., 1985 1981 to 1982 San Marino 327 23.5 468 Hospital admissions Wang et al., 1986 1982 Urban areas of China 35 63 56 Rates based on samples of households in city communities Nestvold et al., 1988 1974 Central Norway 488 350 236 Hospital admissions Badcock, 1988 1984 South Australia 1,698 NS 520 Includes ED visits, admissions and prehospital deaths Servadei et al., 1988 1984 Ravenna, Italy 644 172 372 Hospitalized cases only excludes ED treated and released Levi et al., 1990 1984 to 1988 Northern Israel 1,370 1,200 25 Rate in person-years Tiret et al., 1990 1986 Aquitaine, France 8,940 2,700 281 Hospital admissions and deaths Johansson et al., 1991 1984 to 1985 Northern Sweden 242 70 242 Ages 16-60 only, hospital admissions Nell and Brown, 1991 1986 Johannesburg, South 5,106 NS 316 Rate based on population estimates Africa Annoni et al., 1992 1987 St. Gallon Canton of 80 410 20 Rate based on sample of hospital Switzerland weeks of data collection Vazquez-Barquero et al., 1988 Cantabria, Spain 477 523 91 Hospital admissions only 1992 Engberg, 1995 1988 Frederiksborg County, NS 340 22.6 (7.1) ICD 851-4 only (PTA > 7 days) Denmark Chiu et al., 1997 1988 to 1994 Taiwan 58,563 NS Taipei: 220 Number of patients excludes Hualien Co: prehospital deaths; rates include 30 nonhospital deaths Hillier et al., 1997 1987 South Australia 4,486 1,393 322 Rate for persons 16+, excludes prehospital deaths 81
82 Base Year(s) of Number of Population Rate / 105 Reference Data Location Patients (x1000) per year Comments Ingebrigtsen et al., 1998 1993 Northern Norway 247 108 229 Hospital referred patients Tate et al., 1998 1988 New South Wales 1,259 NS 100 Hospital admitted patients excludes prehospital deaths Alaranta et al., 2000 1991 to 1995 Finland 24,497 5,100 95â100 Hospital discharge first-time TBI patients only, rate range over 5 years Engberg and Teasdale, 1979 to 1996 Denmark NS NS 265, 224, Hospitalized patients trend from 1979â 2001 157 1981, 1985â1987, 1991â1993, excludes prehospital deaths Firsching and Woischneck, 1996 Germany 279,000 82,000 350 Hospital admitted patients only 2001 Masson et al., 2001 1996 Aquitaine, France 497 2,800 17.3 Total AIS 4 and 5, Severe TBI (AIS4 = 7.2 AIS5 = 10.1) Pickett et al., 2001 1998 Kingston, Canada 760 176 431 Rate calculated from published data (115) (potential head injuries) Gururaj, 2002 1999 Bangalore, India NS NS 160 Hospital admitted patients only Servadei et al., 2002b 1998 Romagna and Trentino, 3,554 1,439 314 Total for residence (Romagna, Italy (2,421, (969, 470) (297, Trentino) hospitalization rates 1,133) 332) Servadei et al., 2002a 1998 Romagna, Italy 2,430 971 250 Hospital admitted patients only Andersson et al., 2003 1992 to 1993 Western Sweden 753 138 546 Include ED, hospital admitted and coroner records Baldo et al., 2003 1996 to 2000 Northeast Italy 55,368 NS 301â212 Hospital admissions 1996â2000 Kleiven et al., 2003 1987 to 2000 Sweden 22,000 8,400â8,900 259 Average over 14 years hospital per yr discharged patients Masson et al., 2003 1996 Aquitaine, France 248 2,800 8.5 Coma patients only Santos et al., 2003 1994, 1996, Portugal 40,633 9,500 151 (1994), All hospital discharges for 1994â1997, 1997 137 (1996, plus TBI deaths 1997) Steudel et al., 2005 1998 Germany 276,584 82,000 337 Hospitalized cases and incidence rate; ICD 9 codes 800â804, 850â854 Tennant, 2005 2001 to 2002 England 112,718 NS 229 Hospitalized incidence rate
Base Year(s) of Number of Population Rate / 105 Reference Data Location Patients (x1000) per year Comments Chiu et al., 2007 2001 Taipei and Hualien 5,754, 2,634 218, 417 Excludes prehospital deaths County, Taiwan 1,474 353 Wu et al., 2008 2004 6 Provinces of Eastern 14,948 NS NS Hospital admitted cases China Yates et al., 2006 1997 to 2003 England NS 345 453 From an ED database including hospital admitted NOTE: AIS = Abbreviated Injury Scale, Co = county, ED = emergency department, ICD = International Classification of Diseases, PTA = posttraumatic amnesia, TBI = traumatic brain injury. |
1994 | IMP PIST RICHARDS 0.6X4MM | CDM | ICD codes used but not Based on ICD-10 but not defined 2008 2003 Exeter Hospital, stated UK Wu et al., 2008 2004 6 Providences of Hospital admitted patients with data from attending GCS: severe 9, moderate = 9â13, mild = 14, 15 Eastern China physician NOTE: AIS = Abbreviated Injury Scale, CHIRPP = Canadian Hospitals Injury Reporting and Prevention Program, CT = computed tomography, ED = emergency department, GCS = Glasgow Coma Scale, ICD = International Classification of Diseases, ICDMAP = computer algorithm, ICU = intensive care unit, ISS = Injury Severity Score, LOC = loss of consciousness, PTA = posttraumatic amnesia, TBI = traumatic brain injury, UK = United Kingdom. TABLE 3.4 US TBI Incidence Studies Base Year(s) of Number of Population Rate / 105 Reference Data Location Patients (x1000) per year Comments Annegers et al., 1980 1965 to 1974 Olmstead County, MN 3,587 NS 193 Age adjusted to 1970 US population, rate averaged from men only and women only rates Fuortes et al., 1990 1984 to 1986 Iowa NS NS 159 in 1984 Hospital admissions only 133 in 1985 117 in 1986 Rimel, 1981 1977 to 1979 Central Virginia 1,330 NS NS Hospital patients and prehospital deaths Klauber et al., 1981 1978 San Diego, CA 5,055 NS 294 Includes some nonresidents, excludes a few external causes Cooper et al., 1983 1980 to 1981 Bronx, NY 1,209 NS 249 Rate based on sample, age adjusted to 1980 US population Jagger et al., 1984b 1978 North Central Virginia 735 354 208 Rate includes residents and nonresidents; no ED cases or prehospital deaths Kraus et al., 1984 1981 San Diego County, CA 3,358 1862 180 Population based, not age adjusted Whitman et al., 1984 1979 to 1980 Inner city Chicago and 782 213 331 Composite rate from data in publication, Evanston, IL average across race and gender Fife et al., 1986 1979 to 1980 Rhode Island 2,870 947 152 Hospital patients only Fife, 1987 1977 to 1981 US 307,000 226,545 136 Hospital patients only; 1.87 million 1.87 million 805 All injured patients MacKenzie et al., 1989a 1986 Maryland 5,838 NS 132 Hospital patients only MacKenzie et al., 1990 1979 to 1986 Maryland NS NS 114-134 Hospital patients only, range in rates Oklahoma State 1989 Oklahoma 3,672 NS 121 Hospital and fatal cases Department of Health, 1991 Schuster, 1994 1990 Massachusetts 27,819 6,016 10 Mortality rate 86 Hospital admissions 366 ED only Warren et al., 1995 1991 to 1993 Alaska 2,178 457 130 Hospital patients only Diamond, 1996 1988 to 1993 Virginia 46,680 NS NS Only age-specific rates reported Sosin et al., 1996 1991 US 1.54 million NS 618 Total rate 158 Hospitalized 79
80 Base Year(s) of Number of Population Rate / 105 Reference Data Location Patients (x1000) per year Comments 307 ED only 153 No care Thurman et al., 1996 1990 to 1992 Utah 5,782 NS 106 Age adjusted rate to 1990 US population Gabella et al., 1997a 1990 to 1993 Colorado, Missouri, 13,978 13,687 103 Age adjusted rate to 1990 US population Oklahoma, Utah Gabella et al., 1997b 1991 to 1992 Colorado 7056 NS 101 Hospitalized and deaths, age adjusted to US Thurman and Guerrero, 1994 to 1995 US NS NS 98 Hospitalized patients only 1999 Jager et al., 2000 1992 to 1994 US 1.144 million NS 444 ED patients only Schootman et al., 2000 1993 Iowa 2,559 NS 91 Severe TBI rate based capture- recapture; age adjusted rate to 1990 US population Guerrero et al., 2000 1995 to 1996 US 1.027 million NS 392 ED patients only Louisiana Office of 1996 to 1999 Louisiana 16,203 NS 90 Hospitalized patients and prehospital Public Health Injury and deaths Research Prevention Section, 2004 Langlois et al., 2003 1997 14 US states 62,771 NS 70 Live hospital discharges only Langlois et al., 2006 1995 to 2001 US 1.396 million NS 505 Total rate, age adjusted to 2000 US population 235 86 Hospitalized patients only 1.111 million 401 ED visits only Selassie et al., 2004 1996 to 2001 South Carolina 70,671 NS 68 Hospital patients only 220 ED patients only Texas Department of 1998 Texas 20,000 NS NS Hospitalized patients only Health, 2004 Rutland-Brown et al., 2003 US 1.565 million NS 538 Total 2006 421 ED visits only 100 Hospitalization NOTE: CA = California, ED = emergency department, IL = Illinois, MN = Minnesota, NS = not stated, NY = New York, TBI = traumatic brain injury, US = United States. TABLE 3.5 Non-US TBI Incidence Data Base Year(s) of Number of Population Rate / 105 Reference Data Location Patients (x1000) per year Comments Jennett and MacMillan, 1974 England, Wales and NS NS 270 in Annual rates based on sample weeks, 1981 Scotland England and rates not age adjusted Wales 313 in Scotland Selecki et al., 1981 1977 New South Wales, 18,678 4,960 377 Hospital admissions only excludes Australia prehospitalized deaths Servadei et al., 1985 1981 to 1982 San Marino 327 23.5 468 Hospital admissions Wang et al., 1986 1982 Urban areas of China 35 63 56 Rates based on samples of households in city communities Nestvold et al., 1988 1974 Central Norway 488 350 236 Hospital admissions Badcock, 1988 1984 South Australia 1,698 NS 520 Includes ED visits, admissions and prehospital deaths Servadei et al., 1988 1984 Ravenna, Italy 644 172 372 Hospitalized cases only excludes ED treated and released Levi et al., 1990 1984 to 1988 Northern Israel 1,370 1,200 25 Rate in person-years Tiret et al., 1990 1986 Aquitaine, France 8,940 2,700 281 Hospital admissions and deaths Johansson et al., 1991 1984 to 1985 Northern Sweden 242 70 242 Ages 16-60 only, hospital admissions Nell and Brown, 1991 1986 Johannesburg, South 5,106 NS 316 Rate based on population estimates Africa Annoni et al., 1992 1987 St. Gallon Canton of 80 410 20 Rate based on sample of hospital Switzerland weeks of data collection Vazquez-Barquero et al., 1988 Cantabria, Spain 477 523 91 Hospital admissions only 1992 Engberg, 1995 1988 Frederiksborg County, NS 340 22.6 (7.1) ICD 851-4 only (PTA > 7 days) Denmark Chiu et al., 1997 1988 to 1994 Taiwan 58,563 NS Taipei: 220 Number of patients excludes Hualien Co: prehospital deaths; rates include 30 nonhospital deaths Hillier et al., 1997 1987 South Australia 4,486 1,393 322 Rate for persons 16+, excludes prehospital deaths 81
82 Base Year(s) of Number of Population Rate / 105 Reference Data Location Patients (x1000) per year Comments Ingebrigtsen et al., 1998 1993 Northern Norway 247 108 229 Hospital referred patients Tate et al., 1998 1988 New South Wales 1,259 NS 100 Hospital admitted patients excludes prehospital deaths Alaranta et al., 2000 1991 to 1995 Finland 24,497 5,100 95â100 Hospital discharge first-time TBI patients only, rate range over 5 years Engberg and Teasdale, 1979 to 1996 Denmark NS NS 265, 224, Hospitalized patients trend from 1979â 2001 157 1981, 1985â1987, 1991â1993, excludes prehospital deaths Firsching and Woischneck, 1996 Germany 279,000 82,000 350 Hospital admitted patients only 2001 Masson et al., 2001 1996 Aquitaine, France 497 2,800 17.3 Total AIS 4 and 5, Severe TBI (AIS4 = 7.2 AIS5 = 10.1) Pickett et al., 2001 1998 Kingston, Canada 760 176 431 Rate calculated from published data (115) (potential head injuries) Gururaj, 2002 1999 Bangalore, India NS NS 160 Hospital admitted patients only Servadei et al., 2002b 1998 Romagna and Trentino, 3,554 1,439 314 Total for residence (Romagna, Italy (2,421, (969, 470) (297, Trentino) hospitalization rates 1,133) 332) Servadei et al., 2002a 1998 Romagna, Italy 2,430 971 250 Hospital admitted patients only Andersson et al., 2003 1992 to 1993 Western Sweden 753 138 546 Include ED, hospital admitted and coroner records Baldo et al., 2003 1996 to 2000 Northeast Italy 55,368 NS 301â212 Hospital admissions 1996â2000 Kleiven et al., 2003 1987 to 2000 Sweden 22,000 8,400â8,900 259 Average over 14 years hospital per yr discharged patients Masson et al., 2003 1996 Aquitaine, France 248 2,800 8.5 Coma patients only Santos et al., 2003 1994, 1996, Portugal 40,633 9,500 151 (1994), All hospital discharges for 1994â1997, 1997 137 (1996, plus TBI deaths 1997) Steudel et al., 2005 1998 Germany 276,584 82,000 337 Hospitalized cases and incidence rate; ICD 9 codes 800â804, 850â854 Tennant, 2005 2001 to 2002 England 112,718 NS 229 Hospitalized incidence rate
Base Year(s) of Number of Population Rate / 105 Reference Data Location Patients (x1000) per year Comments Chiu et al., 2007 2001 Taipei and Hualien 5,754, 2,634 218, 417 Excludes prehospital deaths County, Taiwan 1,474 353 Wu et al., 2008 2004 6 Provinces of Eastern 14,948 NS NS Hospital admitted cases China Yates et al., 2006 1997 to 2003 England NS 345 453 From an ED database including hospital admitted NOTE: AIS = Abbreviated Injury Scale, Co = county, ED = emergency department, ICD = International Classification of Diseases, PTA = posttraumatic amnesia, TBI = traumatic brain injury. 83
84 TABLE 3.6 US TBI Deaths and Mortality Rates Number of Reference Year(s) of Data Location Deaths Rate / 105 per year Comments Annegers et al., 1980 1965 to 1974 Olmsted County, Minnesota 446 Male: 32 Average rates per year Female: 9 Klauber et al., 1981 1978 San Diego County, California 381 22 Excludes gunshot deaths Cooper et al., 1983 1980 to 1981 Bronx, New York NS 28 50% from violence, 75% before hospital admission Kraus et al., 1984 1981 San Diego County, California 562 30 Includes inhospital and prehospital deaths Whitman et al., 1984 1979 to 1980 Inner city Chicago and 54 19 Evanston blacks Average rates per year Evanston, IL 11 Evanston whites 32 Inner city Fife et al., 1986 1979 to 1980 Rhode Island 248 26/year Rate derived from data in text Cowan et al., 1990 1990 Delaware 122 18 59% from motor vehicle crashes Sosin et al., 1996 1979 to 1986 US 39,416 per yr 17 Death certificate review, average over 8 yrs Sosin et al., 1996 1979 to 1992 US 52,000 25 in 1979 Average number of deaths per yr 19 in 1992 Thurman et al., 1996 1990 to 1992 Utah 1,067 20 Average rate per yr Gabella et al., 1997b 1991 to 1992 Colorado 1,312 18 in urban regions 34 in rural regions Gabella et al., 1997a 1990 to 1992 Colorado, Missouri, 3,172 23 Average rate per yr Oklahoma, Utah Thurman et al., 1999 1994 US 51,350 20 Data source is state TBI registry Adekoya et al., 2002 1989 to 1998 US 53,288 per yr 21 22 in 1989 19 in 1998 Langlois et al., 2006 1995 to 2001 US 49,900 per yr 18 Average rate over 7 years Rutland-Brown et al., 2003 US 51,000 18 2006 NOTE: IL = Illinois, TBI = traumatic brain injury, US = United States. |
2007 | EPINEPHRINE .1MG/ML | CDM | ICD codes used but not Based on ICD-10 but not defined 2008 2003 Exeter Hospital, stated UK Wu et al., 2008 2004 6 Providences of Hospital admitted patients with data from attending GCS: severe 9, moderate = 9â13, mild = 14, 15 Eastern China physician NOTE: AIS = Abbreviated Injury Scale, CHIRPP = Canadian Hospitals Injury Reporting and Prevention Program, CT = computed tomography, ED = emergency department, GCS = Glasgow Coma Scale, ICD = International Classification of Diseases, ICDMAP = computer algorithm, ICU = intensive care unit, ISS = Injury Severity Score, LOC = loss of consciousness, PTA = posttraumatic amnesia, TBI = traumatic brain injury, UK = United Kingdom. TABLE 3.4 US TBI Incidence Studies Base Year(s) of Number of Population Rate / 105 Reference Data Location Patients (x1000) per year Comments Annegers et al., 1980 1965 to 1974 Olmstead County, MN 3,587 NS 193 Age adjusted to 1970 US population, rate averaged from men only and women only rates Fuortes et al., 1990 1984 to 1986 Iowa NS NS 159 in 1984 Hospital admissions only 133 in 1985 117 in 1986 Rimel, 1981 1977 to 1979 Central Virginia 1,330 NS NS Hospital patients and prehospital deaths Klauber et al., 1981 1978 San Diego, CA 5,055 NS 294 Includes some nonresidents, excludes a few external causes Cooper et al., 1983 1980 to 1981 Bronx, NY 1,209 NS 249 Rate based on sample, age adjusted to 1980 US population Jagger et al., 1984b 1978 North Central Virginia 735 354 208 Rate includes residents and nonresidents; no ED cases or prehospital deaths Kraus et al., 1984 1981 San Diego County, CA 3,358 1862 180 Population based, not age adjusted Whitman et al., 1984 1979 to 1980 Inner city Chicago and 782 213 331 Composite rate from data in publication, Evanston, IL average across race and gender Fife et al., 1986 1979 to 1980 Rhode Island 2,870 947 152 Hospital patients only Fife, 1987 1977 to 1981 US 307,000 226,545 136 Hospital patients only; 1.87 million 1.87 million 805 All injured patients MacKenzie et al., 1989a 1986 Maryland 5,838 NS 132 Hospital patients only MacKenzie et al., 1990 1979 to 1986 Maryland NS NS 114-134 Hospital patients only, range in rates Oklahoma State 1989 Oklahoma 3,672 NS 121 Hospital and fatal cases Department of Health, 1991 Schuster, 1994 1990 Massachusetts 27,819 6,016 10 Mortality rate 86 Hospital admissions 366 ED only Warren et al., 1995 1991 to 1993 Alaska 2,178 457 130 Hospital patients only Diamond, 1996 1988 to 1993 Virginia 46,680 NS NS Only age-specific rates reported Sosin et al., 1996 1991 US 1.54 million NS 618 Total rate 158 Hospitalized 79
80 Base Year(s) of Number of Population Rate / 105 Reference Data Location Patients (x1000) per year Comments 307 ED only 153 No care Thurman et al., 1996 1990 to 1992 Utah 5,782 NS 106 Age adjusted rate to 1990 US population Gabella et al., 1997a 1990 to 1993 Colorado, Missouri, 13,978 13,687 103 Age adjusted rate to 1990 US population Oklahoma, Utah Gabella et al., 1997b 1991 to 1992 Colorado 7056 NS 101 Hospitalized and deaths, age adjusted to US Thurman and Guerrero, 1994 to 1995 US NS NS 98 Hospitalized patients only 1999 Jager et al., 2000 1992 to 1994 US 1.144 million NS 444 ED patients only Schootman et al., 2000 1993 Iowa 2,559 NS 91 Severe TBI rate based capture- recapture; age adjusted rate to 1990 US population Guerrero et al., 2000 1995 to 1996 US 1.027 million NS 392 ED patients only Louisiana Office of 1996 to 1999 Louisiana 16,203 NS 90 Hospitalized patients and prehospital Public Health Injury and deaths Research Prevention Section, 2004 Langlois et al., 2003 1997 14 US states 62,771 NS 70 Live hospital discharges only Langlois et al., 2006 1995 to 2001 US 1.396 million NS 505 Total rate, age adjusted to 2000 US population 235 86 Hospitalized patients only 1.111 million 401 ED visits only Selassie et al., 2004 1996 to 2001 South Carolina 70,671 NS 68 Hospital patients only 220 ED patients only Texas Department of 1998 Texas 20,000 NS NS Hospitalized patients only Health, 2004 Rutland-Brown et al., 2003 US 1.565 million NS 538 Total 2006 421 ED visits only 100 Hospitalization NOTE: CA = California, ED = emergency department, IL = Illinois, MN = Minnesota, NS = not stated, NY = New York, TBI = traumatic brain injury, US = United States. TABLE 3.5 Non-US TBI Incidence Data Base Year(s) of Number of Population Rate / 105 Reference Data Location Patients (x1000) per year Comments Jennett and MacMillan, 1974 England, Wales and NS NS 270 in Annual rates based on sample weeks, 1981 Scotland England and rates not age adjusted Wales 313 in Scotland Selecki et al., 1981 1977 New South Wales, 18,678 4,960 377 Hospital admissions only excludes Australia prehospitalized deaths Servadei et al., 1985 1981 to 1982 San Marino 327 23.5 468 Hospital admissions Wang et al., 1986 1982 Urban areas of China 35 63 56 Rates based on samples of households in city communities Nestvold et al., 1988 1974 Central Norway 488 350 236 Hospital admissions Badcock, 1988 1984 South Australia 1,698 NS 520 Includes ED visits, admissions and prehospital deaths Servadei et al., 1988 1984 Ravenna, Italy 644 172 372 Hospitalized cases only excludes ED treated and released Levi et al., 1990 1984 to 1988 Northern Israel 1,370 1,200 25 Rate in person-years Tiret et al., 1990 1986 Aquitaine, France 8,940 2,700 281 Hospital admissions and deaths Johansson et al., 1991 1984 to 1985 Northern Sweden 242 70 242 Ages 16-60 only, hospital admissions Nell and Brown, 1991 1986 Johannesburg, South 5,106 NS 316 Rate based on population estimates Africa Annoni et al., 1992 1987 St. Gallon Canton of 80 410 20 Rate based on sample of hospital Switzerland weeks of data collection Vazquez-Barquero et al., 1988 Cantabria, Spain 477 523 91 Hospital admissions only 1992 Engberg, 1995 1988 Frederiksborg County, NS 340 22.6 (7.1) ICD 851-4 only (PTA > 7 days) Denmark Chiu et al., 1997 1988 to 1994 Taiwan 58,563 NS Taipei: 220 Number of patients excludes Hualien Co: prehospital deaths; rates include 30 nonhospital deaths Hillier et al., 1997 1987 South Australia 4,486 1,393 322 Rate for persons 16+, excludes prehospital deaths 81
82 Base Year(s) of Number of Population Rate / 105 Reference Data Location Patients (x1000) per year Comments Ingebrigtsen et al., 1998 1993 Northern Norway 247 108 229 Hospital referred patients Tate et al., 1998 1988 New South Wales 1,259 NS 100 Hospital admitted patients excludes prehospital deaths Alaranta et al., 2000 1991 to 1995 Finland 24,497 5,100 95â100 Hospital discharge first-time TBI patients only, rate range over 5 years Engberg and Teasdale, 1979 to 1996 Denmark NS NS 265, 224, Hospitalized patients trend from 1979â 2001 157 1981, 1985â1987, 1991â1993, excludes prehospital deaths Firsching and Woischneck, 1996 Germany 279,000 82,000 350 Hospital admitted patients only 2001 Masson et al., 2001 1996 Aquitaine, France 497 2,800 17.3 Total AIS 4 and 5, Severe TBI (AIS4 = 7.2 AIS5 = 10.1) Pickett et al., 2001 1998 Kingston, Canada 760 176 431 Rate calculated from published data (115) (potential head injuries) Gururaj, 2002 1999 Bangalore, India NS NS 160 Hospital admitted patients only Servadei et al., 2002b 1998 Romagna and Trentino, 3,554 1,439 314 Total for residence (Romagna, Italy (2,421, (969, 470) (297, Trentino) hospitalization rates 1,133) 332) Servadei et al., 2002a 1998 Romagna, Italy 2,430 971 250 Hospital admitted patients only Andersson et al., 2003 1992 to 1993 Western Sweden 753 138 546 Include ED, hospital admitted and coroner records Baldo et al., 2003 1996 to 2000 Northeast Italy 55,368 NS 301â212 Hospital admissions 1996â2000 Kleiven et al., 2003 1987 to 2000 Sweden 22,000 8,400â8,900 259 Average over 14 years hospital per yr discharged patients Masson et al., 2003 1996 Aquitaine, France 248 2,800 8.5 Coma patients only Santos et al., 2003 1994, 1996, Portugal 40,633 9,500 151 (1994), All hospital discharges for 1994â1997, 1997 137 (1996, plus TBI deaths 1997) Steudel et al., 2005 1998 Germany 276,584 82,000 337 Hospitalized cases and incidence rate; ICD 9 codes 800â804, 850â854 Tennant, 2005 2001 to 2002 England 112,718 NS 229 Hospitalized incidence rate
Base Year(s) of Number of Population Rate / 105 Reference Data Location Patients (x1000) per year Comments Chiu et al., 2007 2001 Taipei and Hualien 5,754, 2,634 218, 417 Excludes prehospital deaths County, Taiwan 1,474 353 Wu et al., 2008 2004 6 Provinces of Eastern 14,948 NS NS Hospital admitted cases China Yates et al., 2006 1997 to 2003 England NS 345 453 From an ED database including hospital admitted NOTE: AIS = Abbreviated Injury Scale, Co = county, ED = emergency department, ICD = International Classification of Diseases, PTA = posttraumatic amnesia, TBI = traumatic brain injury. 83
84 TABLE 3.6 US TBI Deaths and Mortality Rates Number of Reference Year(s) of Data Location Deaths Rate / 105 per year Comments Annegers et al., 1980 1965 to 1974 Olmsted County, Minnesota 446 Male: 32 Average rates per year Female: 9 Klauber et al., 1981 1978 San Diego County, California 381 22 Excludes gunshot deaths Cooper et al., 1983 1980 to 1981 Bronx, New York NS 28 50% from violence, 75% before hospital admission Kraus et al., 1984 1981 San Diego County, California 562 30 Includes inhospital and prehospital deaths Whitman et al., 1984 1979 to 1980 Inner city Chicago and 54 19 Evanston blacks Average rates per year Evanston, IL 11 Evanston whites 32 Inner city Fife et al., 1986 1979 to 1980 Rhode Island 248 26/year Rate derived from data in text Cowan et al., 1990 1990 Delaware 122 18 59% from motor vehicle crashes Sosin et al., 1996 1979 to 1986 US 39,416 per yr 17 Death certificate review, average over 8 yrs Sosin et al., 1996 1979 to 1992 US 52,000 25 in 1979 Average number of deaths per yr 19 in 1992 Thurman et al., 1996 1990 to 1992 Utah 1,067 20 Average rate per yr Gabella et al., 1997b 1991 to 1992 Colorado 1,312 18 in urban regions 34 in rural regions Gabella et al., 1997a 1990 to 1992 Colorado, Missouri, 3,172 23 Average rate per yr Oklahoma, Utah Thurman et al., 1999 1994 US 51,350 20 Data source is state TBI registry Adekoya et al., 2002 1989 to 1998 US 53,288 per yr 21 22 in 1989 19 in 1998 Langlois et al., 2006 1995 to 2001 US 49,900 per yr 18 Average rate over 7 years Rutland-Brown et al., 2003 US 51,000 18 2006 NOTE: IL = Illinois, TBI = traumatic brain injury, US = United States. |
1995 | IMP PIST 0.6X4.5MM | CDM | ICD codes used but not Based on ICD-10 but not defined 2008 2003 Exeter Hospital, stated UK Wu et al., 2008 2004 6 Providences of Hospital admitted patients with data from attending GCS: severe 9, moderate = 9â13, mild = 14, 15 Eastern China physician NOTE: AIS = Abbreviated Injury Scale, CHIRPP = Canadian Hospitals Injury Reporting and Prevention Program, CT = computed tomography, ED = emergency department, GCS = Glasgow Coma Scale, ICD = International Classification of Diseases, ICDMAP = computer algorithm, ICU = intensive care unit, ISS = Injury Severity Score, LOC = loss of consciousness, PTA = posttraumatic amnesia, TBI = traumatic brain injury, UK = United Kingdom. TABLE 3.4 US TBI Incidence Studies Base Year(s) of Number of Population Rate / 105 Reference Data Location Patients (x1000) per year Comments Annegers et al., 1980 1965 to 1974 Olmstead County, MN 3,587 NS 193 Age adjusted to 1970 US population, rate averaged from men only and women only rates Fuortes et al., 1990 1984 to 1986 Iowa NS NS 159 in 1984 Hospital admissions only 133 in 1985 117 in 1986 Rimel, 1981 1977 to 1979 Central Virginia 1,330 NS NS Hospital patients and prehospital deaths Klauber et al., 1981 1978 San Diego, CA 5,055 NS 294 Includes some nonresidents, excludes a few external causes Cooper et al., 1983 1980 to 1981 Bronx, NY 1,209 NS 249 Rate based on sample, age adjusted to 1980 US population Jagger et al., 1984b 1978 North Central Virginia 735 354 208 Rate includes residents and nonresidents; no ED cases or prehospital deaths Kraus et al., 1984 1981 San Diego County, CA 3,358 1862 180 Population based, not age adjusted Whitman et al., 1984 1979 to 1980 Inner city Chicago and 782 213 331 Composite rate from data in publication, Evanston, IL average across race and gender Fife et al., 1986 1979 to 1980 Rhode Island 2,870 947 152 Hospital patients only Fife, 1987 1977 to 1981 US 307,000 226,545 136 Hospital patients only; 1.87 million 1.87 million 805 All injured patients MacKenzie et al., 1989a 1986 Maryland 5,838 NS 132 Hospital patients only MacKenzie et al., 1990 1979 to 1986 Maryland NS NS 114-134 Hospital patients only, range in rates Oklahoma State 1989 Oklahoma 3,672 NS 121 Hospital and fatal cases Department of Health, 1991 Schuster, 1994 1990 Massachusetts 27,819 6,016 10 Mortality rate 86 Hospital admissions 366 ED only Warren et al., 1995 1991 to 1993 Alaska 2,178 457 130 Hospital patients only Diamond, 1996 1988 to 1993 Virginia 46,680 NS NS Only age-specific rates reported Sosin et al., 1996 1991 US 1.54 million NS 618 Total rate 158 Hospitalized 79
80 Base Year(s) of Number of Population Rate / 105 Reference Data Location Patients (x1000) per year Comments 307 ED only 153 No care Thurman et al., 1996 1990 to 1992 Utah 5,782 NS 106 Age adjusted rate to 1990 US population Gabella et al., 1997a 1990 to 1993 Colorado, Missouri, 13,978 13,687 103 Age adjusted rate to 1990 US population Oklahoma, Utah Gabella et al., 1997b 1991 to 1992 Colorado 7056 NS 101 Hospitalized and deaths, age adjusted to US Thurman and Guerrero, 1994 to 1995 US NS NS 98 Hospitalized patients only 1999 Jager et al., 2000 1992 to 1994 US 1.144 million NS 444 ED patients only Schootman et al., 2000 1993 Iowa 2,559 NS 91 Severe TBI rate based capture- recapture; age adjusted rate to 1990 US population Guerrero et al., 2000 1995 to 1996 US 1.027 million NS 392 ED patients only Louisiana Office of 1996 to 1999 Louisiana 16,203 NS 90 Hospitalized patients and prehospital Public Health Injury and deaths Research Prevention Section, 2004 Langlois et al., 2003 1997 14 US states 62,771 NS 70 Live hospital discharges only Langlois et al., 2006 1995 to 2001 US 1.396 million NS 505 Total rate, age adjusted to 2000 US population 235 86 Hospitalized patients only 1.111 million 401 ED visits only Selassie et al., 2004 1996 to 2001 South Carolina 70,671 NS 68 Hospital patients only 220 ED patients only Texas Department of 1998 Texas 20,000 NS NS Hospitalized patients only Health, 2004 Rutland-Brown et al., 2003 US 1.565 million NS 538 Total 2006 421 ED visits only 100 Hospitalization NOTE: CA = California, ED = emergency department, IL = Illinois, MN = Minnesota, NS = not stated, NY = New York, TBI = traumatic brain injury, US = United States. TABLE 3.5 Non-US TBI Incidence Data Base Year(s) of Number of Population Rate / 105 Reference Data Location Patients (x1000) per year Comments Jennett and MacMillan, 1974 England, Wales and NS NS 270 in Annual rates based on sample weeks, 1981 Scotland England and rates not age adjusted Wales 313 in Scotland Selecki et al., 1981 1977 New South Wales, 18,678 4,960 377 Hospital admissions only excludes Australia prehospitalized deaths Servadei et al., 1985 1981 to 1982 San Marino 327 23.5 468 Hospital admissions Wang et al., 1986 1982 Urban areas of China 35 63 56 Rates based on samples of households in city communities Nestvold et al., 1988 1974 Central Norway 488 350 236 Hospital admissions Badcock, 1988 1984 South Australia 1,698 NS 520 Includes ED visits, admissions and prehospital deaths Servadei et al., 1988 1984 Ravenna, Italy 644 172 372 Hospitalized cases only excludes ED treated and released Levi et al., 1990 1984 to 1988 Northern Israel 1,370 1,200 25 Rate in person-years Tiret et al., 1990 1986 Aquitaine, France 8,940 2,700 281 Hospital admissions and deaths Johansson et al., 1991 1984 to 1985 Northern Sweden 242 70 242 Ages 16-60 only, hospital admissions Nell and Brown, 1991 1986 Johannesburg, South 5,106 NS 316 Rate based on population estimates Africa Annoni et al., 1992 1987 St. Gallon Canton of 80 410 20 Rate based on sample of hospital Switzerland weeks of data collection Vazquez-Barquero et al., 1988 Cantabria, Spain 477 523 91 Hospital admissions only 1992 Engberg, 1995 1988 Frederiksborg County, NS 340 22.6 (7.1) ICD 851-4 only (PTA > 7 days) Denmark Chiu et al., 1997 1988 to 1994 Taiwan 58,563 NS Taipei: 220 Number of patients excludes Hualien Co: prehospital deaths; rates include 30 nonhospital deaths Hillier et al., 1997 1987 South Australia 4,486 1,393 322 Rate for persons 16+, excludes prehospital deaths 81
82 Base Year(s) of Number of Population Rate / 105 Reference Data Location Patients (x1000) per year Comments Ingebrigtsen et al., 1998 1993 Northern Norway 247 108 229 Hospital referred patients Tate et al., 1998 1988 New South Wales 1,259 NS 100 Hospital admitted patients excludes prehospital deaths Alaranta et al., 2000 1991 to 1995 Finland 24,497 5,100 95â100 Hospital discharge first-time TBI patients only, rate range over 5 years Engberg and Teasdale, 1979 to 1996 Denmark NS NS 265, 224, Hospitalized patients trend from 1979â 2001 157 1981, 1985â1987, 1991â1993, excludes prehospital deaths Firsching and Woischneck, 1996 Germany 279,000 82,000 350 Hospital admitted patients only 2001 Masson et al., 2001 1996 Aquitaine, France 497 2,800 17.3 Total AIS 4 and 5, Severe TBI (AIS4 = 7.2 AIS5 = 10.1) Pickett et al., 2001 1998 Kingston, Canada 760 176 431 Rate calculated from published data (115) (potential head injuries) Gururaj, 2002 1999 Bangalore, India NS NS 160 Hospital admitted patients only Servadei et al., 2002b 1998 Romagna and Trentino, 3,554 1,439 314 Total for residence (Romagna, Italy (2,421, (969, 470) (297, Trentino) hospitalization rates 1,133) 332) Servadei et al., 2002a 1998 Romagna, Italy 2,430 971 250 Hospital admitted patients only Andersson et al., 2003 1992 to 1993 Western Sweden 753 138 546 Include ED, hospital admitted and coroner records Baldo et al., 2003 1996 to 2000 Northeast Italy 55,368 NS 301â212 Hospital admissions 1996â2000 Kleiven et al., 2003 1987 to 2000 Sweden 22,000 8,400â8,900 259 Average over 14 years hospital per yr discharged patients Masson et al., 2003 1996 Aquitaine, France 248 2,800 8.5 Coma patients only Santos et al., 2003 1994, 1996, Portugal 40,633 9,500 151 (1994), All hospital discharges for 1994â1997, 1997 137 (1996, plus TBI deaths 1997) Steudel et al., 2005 1998 Germany 276,584 82,000 337 Hospitalized cases and incidence rate; ICD 9 codes 800â804, 850â854 Tennant, 2005 2001 to 2002 England 112,718 NS 229 Hospitalized incidence rate
Base Year(s) of Number of Population Rate / 105 Reference Data Location Patients (x1000) per year Comments Chiu et al., 2007 2001 Taipei and Hualien 5,754, 2,634 218, 417 Excludes prehospital deaths County, Taiwan 1,474 353 Wu et al., 2008 2004 6 Provinces of Eastern 14,948 NS NS Hospital admitted cases China Yates et al., 2006 1997 to 2003 England NS 345 453 From an ED database including hospital admitted NOTE: AIS = Abbreviated Injury Scale, Co = county, ED = emergency department, ICD = International Classification of Diseases, PTA = posttraumatic amnesia, TBI = traumatic brain injury. 83
84 TABLE 3.6 US TBI Deaths and Mortality Rates Number of Reference Year(s) of Data Location Deaths Rate / 105 per year Comments Annegers et al., 1980 1965 to 1974 Olmsted County, Minnesota 446 Male: 32 Average rates per year Female: 9 Klauber et al., 1981 1978 San Diego County, California 381 22 Excludes gunshot deaths Cooper et al., 1983 1980 to 1981 Bronx, New York NS 28 50% from violence, 75% before hospital admission Kraus et al., 1984 1981 San Diego County, California 562 30 Includes inhospital and prehospital deaths Whitman et al., 1984 1979 to 1980 Inner city Chicago and 54 19 Evanston blacks Average rates per year Evanston, IL 11 Evanston whites 32 Inner city Fife et al., 1986 1979 to 1980 Rhode Island 248 26/year Rate derived from data in text Cowan et al., 1990 1990 Delaware 122 18 59% from motor vehicle crashes Sosin et al., 1996 1979 to 1986 US 39,416 per yr 17 Death certificate review, average over 8 yrs Sosin et al., 1996 1979 to 1992 US 52,000 25 in 1979 Average number of deaths per yr 19 in 1992 Thurman et al., 1996 1990 to 1992 Utah 1,067 20 Average rate per yr Gabella et al., 1997b 1991 to 1992 Colorado 1,312 18 in urban regions 34 in rural regions Gabella et al., 1997a 1990 to 1992 Colorado, Missouri, 3,172 23 Average rate per yr Oklahoma, Utah Thurman et al., 1999 1994 US 51,350 20 Data source is state TBI registry Adekoya et al., 2002 1989 to 1998 US 53,288 per yr 21 22 in 1989 19 in 1998 Langlois et al., 2006 1995 to 2001 US 49,900 per yr 18 Average rate over 7 years Rutland-Brown et al., 2003 US 51,000 18 2006 NOTE: IL = Illinois, TBI = traumatic brain injury, US = United States. |
1993 | IMP EAR RICHARDS 0.6X3.5MM | CDM | ICD codes used but not Based on ICD-10 but not defined 2008 2003 Exeter Hospital, stated UK Wu et al., 2008 2004 6 Providences of Hospital admitted patients with data from attending GCS: severe 9, moderate = 9â13, mild = 14, 15 Eastern China physician NOTE: AIS = Abbreviated Injury Scale, CHIRPP = Canadian Hospitals Injury Reporting and Prevention Program, CT = computed tomography, ED = emergency department, GCS = Glasgow Coma Scale, ICD = International Classification of Diseases, ICDMAP = computer algorithm, ICU = intensive care unit, ISS = Injury Severity Score, LOC = loss of consciousness, PTA = posttraumatic amnesia, TBI = traumatic brain injury, UK = United Kingdom. TABLE 3.4 US TBI Incidence Studies Base Year(s) of Number of Population Rate / 105 Reference Data Location Patients (x1000) per year Comments Annegers et al., 1980 1965 to 1974 Olmstead County, MN 3,587 NS 193 Age adjusted to 1970 US population, rate averaged from men only and women only rates Fuortes et al., 1990 1984 to 1986 Iowa NS NS 159 in 1984 Hospital admissions only 133 in 1985 117 in 1986 Rimel, 1981 1977 to 1979 Central Virginia 1,330 NS NS Hospital patients and prehospital deaths Klauber et al., 1981 1978 San Diego, CA 5,055 NS 294 Includes some nonresidents, excludes a few external causes Cooper et al., 1983 1980 to 1981 Bronx, NY 1,209 NS 249 Rate based on sample, age adjusted to 1980 US population Jagger et al., 1984b 1978 North Central Virginia 735 354 208 Rate includes residents and nonresidents; no ED cases or prehospital deaths Kraus et al., 1984 1981 San Diego County, CA 3,358 1862 180 Population based, not age adjusted Whitman et al., 1984 1979 to 1980 Inner city Chicago and 782 213 331 Composite rate from data in publication, Evanston, IL average across race and gender Fife et al., 1986 1979 to 1980 Rhode Island 2,870 947 152 Hospital patients only Fife, 1987 1977 to 1981 US 307,000 226,545 136 Hospital patients only; 1.87 million 1.87 million 805 All injured patients MacKenzie et al., 1989a 1986 Maryland 5,838 NS 132 Hospital patients only MacKenzie et al., 1990 1979 to 1986 Maryland NS NS 114-134 Hospital patients only, range in rates Oklahoma State 1989 Oklahoma 3,672 NS 121 Hospital and fatal cases Department of Health, 1991 Schuster, 1994 1990 Massachusetts 27,819 6,016 10 Mortality rate 86 Hospital admissions 366 ED only Warren et al., 1995 1991 to 1993 Alaska 2,178 457 130 Hospital patients only Diamond, 1996 1988 to 1993 Virginia 46,680 NS NS Only age-specific rates reported Sosin et al., 1996 1991 US 1.54 million NS 618 Total rate 158 Hospitalized 79
80 Base Year(s) of Number of Population Rate / 105 Reference Data Location Patients (x1000) per year Comments 307 ED only 153 No care Thurman et al., 1996 1990 to 1992 Utah 5,782 NS 106 Age adjusted rate to 1990 US population Gabella et al., 1997a 1990 to 1993 Colorado, Missouri, 13,978 13,687 103 Age adjusted rate to 1990 US population Oklahoma, Utah Gabella et al., 1997b 1991 to 1992 Colorado 7056 NS 101 Hospitalized and deaths, age adjusted to US Thurman and Guerrero, 1994 to 1995 US NS NS 98 Hospitalized patients only 1999 Jager et al., 2000 1992 to 1994 US 1.144 million NS 444 ED patients only Schootman et al., 2000 1993 Iowa 2,559 NS 91 Severe TBI rate based capture- recapture; age adjusted rate to 1990 US population Guerrero et al., 2000 1995 to 1996 US 1.027 million NS 392 ED patients only Louisiana Office of 1996 to 1999 Louisiana 16,203 NS 90 Hospitalized patients and prehospital Public Health Injury and deaths Research Prevention Section, 2004 Langlois et al., 2003 1997 14 US states 62,771 NS 70 Live hospital discharges only Langlois et al., 2006 1995 to 2001 US 1.396 million NS 505 Total rate, age adjusted to 2000 US population 235 86 Hospitalized patients only 1.111 million 401 ED visits only Selassie et al., 2004 1996 to 2001 South Carolina 70,671 NS 68 Hospital patients only 220 ED patients only Texas Department of 1998 Texas 20,000 NS NS Hospitalized patients only Health, 2004 Rutland-Brown et al., 2003 US 1.565 million NS 538 Total 2006 421 ED visits only 100 Hospitalization NOTE: CA = California, ED = emergency department, IL = Illinois, MN = Minnesota, NS = not stated, NY = New York, TBI = traumatic brain injury, US = United States. TABLE 3.5 Non-US TBI Incidence Data Base Year(s) of Number of Population Rate / 105 Reference Data Location Patients (x1000) per year Comments Jennett and MacMillan, 1974 England, Wales and NS NS 270 in Annual rates based on sample weeks, 1981 Scotland England and rates not age adjusted Wales 313 in Scotland Selecki et al., 1981 1977 New South Wales, 18,678 4,960 377 Hospital admissions only excludes Australia prehospitalized deaths Servadei et al., 1985 1981 to 1982 San Marino 327 23.5 468 Hospital admissions Wang et al., 1986 1982 Urban areas of China 35 63 56 Rates based on samples of households in city communities Nestvold et al., 1988 1974 Central Norway 488 350 236 Hospital admissions Badcock, 1988 1984 South Australia 1,698 NS 520 Includes ED visits, admissions and prehospital deaths Servadei et al., 1988 1984 Ravenna, Italy 644 172 372 Hospitalized cases only excludes ED treated and released Levi et al., 1990 1984 to 1988 Northern Israel 1,370 1,200 25 Rate in person-years Tiret et al., 1990 1986 Aquitaine, France 8,940 2,700 281 Hospital admissions and deaths Johansson et al., 1991 1984 to 1985 Northern Sweden 242 70 242 Ages 16-60 only, hospital admissions Nell and Brown, 1991 1986 Johannesburg, South 5,106 NS 316 Rate based on population estimates Africa Annoni et al., 1992 1987 St. Gallon Canton of 80 410 20 Rate based on sample of hospital Switzerland weeks of data collection Vazquez-Barquero et al., 1988 Cantabria, Spain 477 523 91 Hospital admissions only 1992 Engberg, 1995 1988 Frederiksborg County, NS 340 22.6 (7.1) ICD 851-4 only (PTA > 7 days) Denmark Chiu et al., 1997 1988 to 1994 Taiwan 58,563 NS Taipei: 220 Number of patients excludes Hualien Co: prehospital deaths; rates include 30 nonhospital deaths Hillier et al., 1997 1987 South Australia 4,486 1,393 322 Rate for persons 16+, excludes prehospital deaths 81
82 Base Year(s) of Number of Population Rate / 105 Reference Data Location Patients (x1000) per year Comments Ingebrigtsen et al., 1998 1993 Northern Norway 247 108 229 Hospital referred patients Tate et al., 1998 1988 New South Wales 1,259 NS 100 Hospital admitted patients excludes prehospital deaths Alaranta et al., 2000 1991 to 1995 Finland 24,497 5,100 95â100 Hospital discharge first-time TBI patients only, rate range over 5 years Engberg and Teasdale, 1979 to 1996 Denmark NS NS 265, 224, Hospitalized patients trend from 1979â 2001 157 1981, 1985â1987, 1991â1993, excludes prehospital deaths Firsching and Woischneck, 1996 Germany 279,000 82,000 350 Hospital admitted patients only 2001 Masson et al., 2001 1996 Aquitaine, France 497 2,800 17.3 Total AIS 4 and 5, Severe TBI (AIS4 = 7.2 AIS5 = 10.1) Pickett et al., 2001 1998 Kingston, Canada 760 176 431 Rate calculated from published data (115) (potential head injuries) Gururaj, 2002 1999 Bangalore, India NS NS 160 Hospital admitted patients only Servadei et al., 2002b 1998 Romagna and Trentino, 3,554 1,439 314 Total for residence (Romagna, Italy (2,421, (969, 470) (297, Trentino) hospitalization rates 1,133) 332) Servadei et al., 2002a 1998 Romagna, Italy 2,430 971 250 Hospital admitted patients only Andersson et al., 2003 1992 to 1993 Western Sweden 753 138 546 Include ED, hospital admitted and coroner records Baldo et al., 2003 1996 to 2000 Northeast Italy 55,368 NS 301â212 Hospital admissions 1996â2000 Kleiven et al., 2003 1987 to 2000 Sweden 22,000 8,400â8,900 259 Average over 14 years hospital per yr discharged patients Masson et al., 2003 1996 Aquitaine, France 248 2,800 8.5 Coma patients only Santos et al., 2003 1994, 1996, Portugal 40,633 9,500 151 (1994), All hospital discharges for 1994â1997, 1997 137 (1996, plus TBI deaths 1997) Steudel et al., 2005 1998 Germany 276,584 82,000 337 Hospitalized cases and incidence rate; ICD 9 codes 800â804, 850â854 Tennant, 2005 2001 to 2002 England 112,718 NS 229 Hospitalized incidence rate
Base Year(s) of Number of Population Rate / 105 Reference Data Location Patients (x1000) per year Comments Chiu et al., 2007 2001 Taipei and Hualien 5,754, 2,634 218, 417 Excludes prehospital deaths County, Taiwan 1,474 353 Wu et al., 2008 2004 6 Provinces of Eastern 14,948 NS NS Hospital admitted cases China Yates et al., 2006 1997 to 2003 England NS 345 453 From an ED database including hospital admitted NOTE: AIS = Abbreviated Injury Scale, Co = county, ED = emergency department, ICD = International Classification of Diseases, PTA = posttraumatic amnesia, TBI = traumatic brain injury. 83
84 TABLE 3.6 US TBI Deaths and Mortality Rates Number of Reference Year(s) of Data Location Deaths Rate / 105 per year Comments Annegers et al., 1980 1965 to 1974 Olmsted County, Minnesota 446 Male: 32 Average rates per year Female: 9 Klauber et al., 1981 1978 San Diego County, California 381 22 Excludes gunshot deaths Cooper et al., 1983 1980 to 1981 Bronx, New York NS 28 50% from violence, 75% before hospital admission Kraus et al., 1984 1981 San Diego County, California 562 30 Includes inhospital and prehospital deaths Whitman et al., 1984 1979 to 1980 Inner city Chicago and 54 19 Evanston blacks Average rates per year Evanston, IL 11 Evanston whites 32 Inner city Fife et al., 1986 1979 to 1980 Rhode Island 248 26/year Rate derived from data in text Cowan et al., 1990 1990 Delaware 122 18 59% from motor vehicle crashes Sosin et al., 1996 1979 to 1986 US 39,416 per yr 17 Death certificate review, average over 8 yrs Sosin et al., 1996 1979 to 1992 US 52,000 25 in 1979 Average number of deaths per yr 19 in 1992 Thurman et al., 1996 1990 to 1992 Utah 1,067 20 Average rate per yr Gabella et al., 1997b 1991 to 1992 Colorado 1,312 18 in urban regions 34 in rural regions Gabella et al., 1997a 1990 to 1992 Colorado, Missouri, 3,172 23 Average rate per yr Oklahoma, Utah Thurman et al., 1999 1994 US 51,350 20 Data source is state TBI registry Adekoya et al., 2002 1989 to 1998 US 53,288 per yr 21 22 in 1989 19 in 1998 Langlois et al., 2006 1995 to 2001 US 49,900 per yr 18 Average rate over 7 years Rutland-Brown et al., 2003 US 51,000 18 2006 NOTE: IL = Illinois, TBI = traumatic brain injury, US = United States. |
2003 | FILTER VENA CAVA FEM 7X48 SIMON NITINOL | CDM | ICD codes used but not Based on ICD-10 but not defined 2008 2003 Exeter Hospital, stated UK Wu et al., 2008 2004 6 Providences of Hospital admitted patients with data from attending GCS: severe 9, moderate = 9â13, mild = 14, 15 Eastern China physician NOTE: AIS = Abbreviated Injury Scale, CHIRPP = Canadian Hospitals Injury Reporting and Prevention Program, CT = computed tomography, ED = emergency department, GCS = Glasgow Coma Scale, ICD = International Classification of Diseases, ICDMAP = computer algorithm, ICU = intensive care unit, ISS = Injury Severity Score, LOC = loss of consciousness, PTA = posttraumatic amnesia, TBI = traumatic brain injury, UK = United Kingdom. TABLE 3.4 US TBI Incidence Studies Base Year(s) of Number of Population Rate / 105 Reference Data Location Patients (x1000) per year Comments Annegers et al., 1980 1965 to 1974 Olmstead County, MN 3,587 NS 193 Age adjusted to 1970 US population, rate averaged from men only and women only rates Fuortes et al., 1990 1984 to 1986 Iowa NS NS 159 in 1984 Hospital admissions only 133 in 1985 117 in 1986 Rimel, 1981 1977 to 1979 Central Virginia 1,330 NS NS Hospital patients and prehospital deaths Klauber et al., 1981 1978 San Diego, CA 5,055 NS 294 Includes some nonresidents, excludes a few external causes Cooper et al., 1983 1980 to 1981 Bronx, NY 1,209 NS 249 Rate based on sample, age adjusted to 1980 US population Jagger et al., 1984b 1978 North Central Virginia 735 354 208 Rate includes residents and nonresidents; no ED cases or prehospital deaths Kraus et al., 1984 1981 San Diego County, CA 3,358 1862 180 Population based, not age adjusted Whitman et al., 1984 1979 to 1980 Inner city Chicago and 782 213 331 Composite rate from data in publication, Evanston, IL average across race and gender Fife et al., 1986 1979 to 1980 Rhode Island 2,870 947 152 Hospital patients only Fife, 1987 1977 to 1981 US 307,000 226,545 136 Hospital patients only; 1.87 million 1.87 million 805 All injured patients MacKenzie et al., 1989a 1986 Maryland 5,838 NS 132 Hospital patients only MacKenzie et al., 1990 1979 to 1986 Maryland NS NS 114-134 Hospital patients only, range in rates Oklahoma State 1989 Oklahoma 3,672 NS 121 Hospital and fatal cases Department of Health, 1991 Schuster, 1994 1990 Massachusetts 27,819 6,016 10 Mortality rate 86 Hospital admissions 366 ED only Warren et al., 1995 1991 to 1993 Alaska 2,178 457 130 Hospital patients only Diamond, 1996 1988 to 1993 Virginia 46,680 NS NS Only age-specific rates reported Sosin et al., 1996 1991 US 1.54 million NS 618 Total rate 158 Hospitalized 79
80 Base Year(s) of Number of Population Rate / 105 Reference Data Location Patients (x1000) per year Comments 307 ED only 153 No care Thurman et al., 1996 1990 to 1992 Utah 5,782 NS 106 Age adjusted rate to 1990 US population Gabella et al., 1997a 1990 to 1993 Colorado, Missouri, 13,978 13,687 103 Age adjusted rate to 1990 US population Oklahoma, Utah Gabella et al., 1997b 1991 to 1992 Colorado 7056 NS 101 Hospitalized and deaths, age adjusted to US Thurman and Guerrero, 1994 to 1995 US NS NS 98 Hospitalized patients only 1999 Jager et al., 2000 1992 to 1994 US 1.144 million NS 444 ED patients only Schootman et al., 2000 1993 Iowa 2,559 NS 91 Severe TBI rate based capture- recapture; age adjusted rate to 1990 US population Guerrero et al., 2000 1995 to 1996 US 1.027 million NS 392 ED patients only Louisiana Office of 1996 to 1999 Louisiana 16,203 NS 90 Hospitalized patients and prehospital Public Health Injury and deaths Research Prevention Section, 2004 Langlois et al., 2003 1997 14 US states 62,771 NS 70 Live hospital discharges only Langlois et al., 2006 1995 to 2001 US 1.396 million NS 505 Total rate, age adjusted to 2000 US population 235 86 Hospitalized patients only 1.111 million 401 ED visits only Selassie et al., 2004 1996 to 2001 South Carolina 70,671 NS 68 Hospital patients only 220 ED patients only Texas Department of 1998 Texas 20,000 NS NS Hospitalized patients only Health, 2004 Rutland-Brown et al., 2003 US 1.565 million NS 538 Total 2006 421 ED visits only 100 Hospitalization NOTE: CA = California, ED = emergency department, IL = Illinois, MN = Minnesota, NS = not stated, NY = New York, TBI = traumatic brain injury, US = United States. TABLE 3.5 Non-US TBI Incidence Data Base Year(s) of Number of Population Rate / 105 Reference Data Location Patients (x1000) per year Comments Jennett and MacMillan, 1974 England, Wales and NS NS 270 in Annual rates based on sample weeks, 1981 Scotland England and rates not age adjusted Wales 313 in Scotland Selecki et al., 1981 1977 New South Wales, 18,678 4,960 377 Hospital admissions only excludes Australia prehospitalized deaths Servadei et al., 1985 1981 to 1982 San Marino 327 23.5 468 Hospital admissions Wang et al., 1986 1982 Urban areas of China 35 63 56 Rates based on samples of households in city communities Nestvold et al., 1988 1974 Central Norway 488 350 236 Hospital admissions Badcock, 1988 1984 South Australia 1,698 NS 520 Includes ED visits, admissions and prehospital deaths Servadei et al., 1988 1984 Ravenna, Italy 644 172 372 Hospitalized cases only excludes ED treated and released Levi et al., 1990 1984 to 1988 Northern Israel 1,370 1,200 25 Rate in person-years Tiret et al., 1990 1986 Aquitaine, France 8,940 2,700 281 Hospital admissions and deaths Johansson et al., 1991 1984 to 1985 Northern Sweden 242 70 242 Ages 16-60 only, hospital admissions Nell and Brown, 1991 1986 Johannesburg, South 5,106 NS 316 Rate based on population estimates Africa Annoni et al., 1992 1987 St. Gallon Canton of 80 410 20 Rate based on sample of hospital Switzerland weeks of data collection Vazquez-Barquero et al., 1988 Cantabria, Spain 477 523 91 Hospital admissions only 1992 Engberg, 1995 1988 Frederiksborg County, NS 340 22.6 (7.1) ICD 851-4 only (PTA > 7 days) Denmark Chiu et al., 1997 1988 to 1994 Taiwan 58,563 NS Taipei: 220 Number of patients excludes Hualien Co: prehospital deaths; rates include 30 nonhospital deaths Hillier et al., 1997 1987 South Australia 4,486 1,393 322 Rate for persons 16+, excludes prehospital deaths 81
82 Base Year(s) of Number of Population Rate / 105 Reference Data Location Patients (x1000) per year Comments Ingebrigtsen et al., 1998 1993 Northern Norway 247 108 229 Hospital referred patients Tate et al., 1998 1988 New South Wales 1,259 NS 100 Hospital admitted patients excludes prehospital deaths Alaranta et al., 2000 1991 to 1995 Finland 24,497 5,100 95â100 Hospital discharge first-time TBI patients only, rate range over 5 years Engberg and Teasdale, 1979 to 1996 Denmark NS NS 265, 224, Hospitalized patients trend from 1979â 2001 157 1981, 1985â1987, 1991â1993, excludes prehospital deaths Firsching and Woischneck, 1996 Germany 279,000 82,000 350 Hospital admitted patients only 2001 Masson et al., 2001 1996 Aquitaine, France 497 2,800 17.3 Total AIS 4 and 5, Severe TBI (AIS4 = 7.2 AIS5 = 10.1) Pickett et al., 2001 1998 Kingston, Canada 760 176 431 Rate calculated from published data (115) (potential head injuries) Gururaj, 2002 1999 Bangalore, India NS NS 160 Hospital admitted patients only Servadei et al., 2002b 1998 Romagna and Trentino, 3,554 1,439 314 Total for residence (Romagna, Italy (2,421, (969, 470) (297, Trentino) hospitalization rates 1,133) 332) Servadei et al., 2002a 1998 Romagna, Italy 2,430 971 250 Hospital admitted patients only Andersson et al., 2003 1992 to 1993 Western Sweden 753 138 546 Include ED, hospital admitted and coroner records Baldo et al., 2003 1996 to 2000 Northeast Italy 55,368 NS 301â212 Hospital admissions 1996â2000 Kleiven et al., 2003 1987 to 2000 Sweden 22,000 8,400â8,900 259 Average over 14 years hospital per yr discharged patients Masson et al., 2003 1996 Aquitaine, France 248 2,800 8.5 Coma patients only Santos et al., 2003 1994, 1996, Portugal 40,633 9,500 151 (1994), All hospital discharges for 1994â1997, 1997 137 (1996, plus TBI deaths 1997) Steudel et al., 2005 1998 Germany 276,584 82,000 337 Hospitalized cases and incidence rate; ICD 9 codes 800â804, 850â854 Tennant, 2005 2001 to 2002 England 112,718 NS 229 Hospitalized incidence rate
Base Year(s) of Number of Population Rate / 105 Reference Data Location Patients (x1000) per year Comments Chiu et al., 2007 2001 Taipei and Hualien 5,754, 2,634 218, 417 Excludes prehospital deaths County, Taiwan 1,474 353 Wu et al., 2008 2004 6 Provinces of Eastern 14,948 NS NS Hospital admitted cases China Yates et al., 2006 1997 to 2003 England NS 345 453 From an ED database including hospital admitted NOTE: AIS = Abbreviated Injury Scale, Co = county, ED = emergency department, ICD = International Classification of Diseases, PTA = posttraumatic amnesia, TBI = traumatic brain injury. 83
84 TABLE 3.6 US TBI Deaths and Mortality Rates Number of Reference Year(s) of Data Location Deaths Rate / 105 per year Comments Annegers et al., 1980 1965 to 1974 Olmsted County, Minnesota 446 Male: 32 Average rates per year Female: 9 Klauber et al., 1981 1978 San Diego County, California 381 22 Excludes gunshot deaths Cooper et al., 1983 1980 to 1981 Bronx, New York NS 28 50% from violence, 75% before hospital admission Kraus et al., 1984 1981 San Diego County, California 562 30 Includes inhospital and prehospital deaths Whitman et al., 1984 1979 to 1980 Inner city Chicago and 54 19 Evanston blacks Average rates per year Evanston, IL 11 Evanston whites 32 Inner city Fife et al., 1986 1979 to 1980 Rhode Island 248 26/year Rate derived from data in text Cowan et al., 1990 1990 Delaware 122 18 59% from motor vehicle crashes Sosin et al., 1996 1979 to 1986 US 39,416 per yr 17 Death certificate review, average over 8 yrs Sosin et al., 1996 1979 to 1992 US 52,000 25 in 1979 Average number of deaths per yr 19 in 1992 Thurman et al., 1996 1990 to 1992 Utah 1,067 20 Average rate per yr Gabella et al., 1997b 1991 to 1992 Colorado 1,312 18 in urban regions 34 in rural regions Gabella et al., 1997a 1990 to 1992 Colorado, Missouri, 3,172 23 Average rate per yr Oklahoma, Utah Thurman et al., 1999 1994 US 51,350 20 Data source is state TBI registry Adekoya et al., 2002 1989 to 1998 US 53,288 per yr 21 22 in 1989 19 in 1998 Langlois et al., 2006 1995 to 2001 US 49,900 per yr 18 Average rate over 7 years Rutland-Brown et al., 2003 US 51,000 18 2006 NOTE: IL = Illinois, TBI = traumatic brain injury, US = United States. |
30233G3 | TRANSFUSION OF ALLOGENEIC UNRELATED BONE MARROW INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH Tandem Autologous Allogeneic Unrelated Non ICU | ICD | When bone marrow or peripheral blood stem cell transplantation is non-covered, none of the steps are covered. (CMS Publication 100-03, Medicare National Coverage Determinations(NCD) Manual, Chapter 1, Part 2: Section 110.23). The CMS National Coverage Determination (NCD) for Stem Cell Transplantation describes nationally covered indications for stem cell transplant, the details of which will not be repeated here. This Medical policy article describes additional locally covered indications for stem cell transplant. Indications and Limitations:
Hematopoietic Progenitor Cell (HPC);Allogeneic Transplantation
The ICD-10-PCS Procedure codes are: 30233G2, 30233G3, 30233Y2, 30233Y3, 30243G2, 30243G3, 30243Y2 and 30243Y3. |
30243Y2 | TRANSFUSION OF ALLOGENEIC RELATED HEMATOPOIETIC STEM CELLS INTO CENTRAL VEIN, PERCUTANEOUS APPROACH Reduced Intensity Medsurg | ICD | When bone marrow or peripheral blood stem cell transplantation is non-covered, none of the steps are covered. (CMS Publication 100-03, Medicare National Coverage Determinations(NCD) Manual, Chapter 1, Part 2: Section 110.23). The CMS National Coverage Determination (NCD) for Stem Cell Transplantation describes nationally covered indications for stem cell transplant, the details of which will not be repeated here. This Medical policy article describes additional locally covered indications for stem cell transplant. Indications and Limitations:
Hematopoietic Progenitor Cell (HPC);Allogeneic Transplantation
The ICD-10-PCS Procedure codes are: 30233G2, 30233G3, 30233Y2, 30233Y3, 30243G2, 30243G3, 30243Y2 and 30243Y3. |
30233Y3 | TRANSFUSION OF ALLOGENEIC UNRELATED HAMATOPOIETIC STEM CELLS INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH Tandem Autologous Allogeneic Unrelated Non ICU | ICD | When bone marrow or peripheral blood stem cell transplantation is non-covered, none of the steps are covered. (CMS Publication 100-03, Medicare National Coverage Determinations(NCD) Manual, Chapter 1, Part 2: Section 110.23). The CMS National Coverage Determination (NCD) for Stem Cell Transplantation describes nationally covered indications for stem cell transplant, the details of which will not be repeated here. This Medical policy article describes additional locally covered indications for stem cell transplant. Indications and Limitations:
Hematopoietic Progenitor Cell (HPC);Allogeneic Transplantation
The ICD-10-PCS Procedure codes are: 30233G2, 30233G3, 30233Y2, 30233Y3, 30243G2, 30243G3, 30243Y2 and 30243Y3. |
30243G2 | TRANSFUSION OF ALLOGENEIC RELATED BONE MARROW INTO CENTRAL VEIN, PERCUTANEOUS APPROACH Reduced Intensity Medsurg | ICD | When bone marrow or peripheral blood stem cell transplantation is non-covered, none of the steps are covered. (CMS Publication 100-03, Medicare National Coverage Determinations(NCD) Manual, Chapter 1, Part 2: Section 110.23). The CMS National Coverage Determination (NCD) for Stem Cell Transplantation describes nationally covered indications for stem cell transplant, the details of which will not be repeated here. This Medical policy article describes additional locally covered indications for stem cell transplant. Indications and Limitations:
Hematopoietic Progenitor Cell (HPC);Allogeneic Transplantation
The ICD-10-PCS Procedure codes are: 30233G2, 30233G3, 30233Y2, 30233Y3, 30243G2, 30243G3, 30243Y2 and 30243Y3. |
30233G2 | TRANSFUSION OF ALLOGENEIC RELATED BONE MARROW INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH Reduced Intensity Medsurg | ICD | When bone marrow or peripheral blood stem cell transplantation is non-covered, none of the steps are covered. (CMS Publication 100-03, Medicare National Coverage Determinations(NCD) Manual, Chapter 1, Part 2: Section 110.23). The CMS National Coverage Determination (NCD) for Stem Cell Transplantation describes nationally covered indications for stem cell transplant, the details of which will not be repeated here. This Medical policy article describes additional locally covered indications for stem cell transplant. Indications and Limitations:
Hematopoietic Progenitor Cell (HPC);Allogeneic Transplantation
The ICD-10-PCS Procedure codes are: 30233G2, 30233G3, 30233Y2, 30233Y3, 30243G2, 30243G3, 30243Y2 and 30243Y3. |
30233Y2 | TRANSFUSION OF ALLOGENEIC RELATED HEMATOPOIETIC STEM CELLS INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH Reduced Intensity Medsurg | ICD | When bone marrow or peripheral blood stem cell transplantation is non-covered, none of the steps are covered. (CMS Publication 100-03, Medicare National Coverage Determinations(NCD) Manual, Chapter 1, Part 2: Section 110.23). The CMS National Coverage Determination (NCD) for Stem Cell Transplantation describes nationally covered indications for stem cell transplant, the details of which will not be repeated here. This Medical policy article describes additional locally covered indications for stem cell transplant. Indications and Limitations:
Hematopoietic Progenitor Cell (HPC);Allogeneic Transplantation
The ICD-10-PCS Procedure codes are: 30233G2, 30233G3, 30233Y2, 30233Y3, 30243G2, 30243G3, 30243Y2 and 30243Y3. |
30243Y3 | TRANSFUSION OF ALLOGENEIC UNRELATED HEMATOPOIETIC STEM CELLS INTO CENTRAL VEIN, PERCUTANEOUS APPROACH Tandem Autologous Allogeneic Unrelated Non ICU | ICD | When bone marrow or peripheral blood stem cell transplantation is non-covered, none of the steps are covered. (CMS Publication 100-03, Medicare National Coverage Determinations(NCD) Manual, Chapter 1, Part 2: Section 110.23). The CMS National Coverage Determination (NCD) for Stem Cell Transplantation describes nationally covered indications for stem cell transplant, the details of which will not be repeated here. This Medical policy article describes additional locally covered indications for stem cell transplant. Indications and Limitations:
Hematopoietic Progenitor Cell (HPC);Allogeneic Transplantation
The ICD-10-PCS Procedure codes are: 30233G2, 30233G3, 30233Y2, 30233Y3, 30243G2, 30243G3, 30243Y2 and 30243Y3. |
30243G3 | TRANSFUSION OF ALLOGENEIC UNRELATED BONE MARROW INTO CENTRAL VEIN, PERCUTANEOUS APPROACH Tandem Autologous Allogeneic Unrelated Non ICU | ICD | When bone marrow or peripheral blood stem cell transplantation is non-covered, none of the steps are covered. (CMS Publication 100-03, Medicare National Coverage Determinations(NCD) Manual, Chapter 1, Part 2: Section 110.23). The CMS National Coverage Determination (NCD) for Stem Cell Transplantation describes nationally covered indications for stem cell transplant, the details of which will not be repeated here. This Medical policy article describes additional locally covered indications for stem cell transplant. Indications and Limitations:
Hematopoietic Progenitor Cell (HPC);Allogeneic Transplantation
The ICD-10-PCS Procedure codes are: 30233G2, 30233G3, 30233Y2, 30233Y3, 30243G2, 30243G3, 30243Y2 and 30243Y3. |
30233G3 | TRANSFUSION OF ALLOGENEIC UNRELATED BONE MARROW INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH Tandem Autologous Allogeneic Unrelated Non ICU | ICD | The CMS National Coverage Determination (NCD) for Stem Cell Transplantation describes nationally covered indications for stem cell transplant, the details of which will not be repeated here. This Medical policy article describes additional locally covered indications for stem cell transplant. Indications and Limitations:
Hematopoietic Progenitor Cell (HPC);Allogeneic Transplantation
The ICD-10-PCS Procedure codes are: 30233G2, 30233G3, 30233Y2, 30233Y3, 30243G2, 30243G3, 30243Y2 and 30243Y3. The NCD lists the following nationally covered indications:
- Leukemia in remission;
- Aplastic anemia;
- Severe combined immunodeficiency disease (SCID); and
- Wiskott-Aldrich syndrome. - Effective for services performed on or after August 4, 2010, for the treatment of Myelodysplastic Syndromes (MDS) pursuant to Coverage with Evidence Development (CED) in the context of a Medicare-approved, prospective clinical study. |
30243Y2 | TRANSFUSION OF ALLOGENEIC RELATED HEMATOPOIETIC STEM CELLS INTO CENTRAL VEIN, PERCUTANEOUS APPROACH Reduced Intensity Medsurg | ICD | The CMS National Coverage Determination (NCD) for Stem Cell Transplantation describes nationally covered indications for stem cell transplant, the details of which will not be repeated here. This Medical policy article describes additional locally covered indications for stem cell transplant. Indications and Limitations:
Hematopoietic Progenitor Cell (HPC);Allogeneic Transplantation
The ICD-10-PCS Procedure codes are: 30233G2, 30233G3, 30233Y2, 30233Y3, 30243G2, 30243G3, 30243Y2 and 30243Y3. The NCD lists the following nationally covered indications:
- Leukemia in remission;
- Aplastic anemia;
- Severe combined immunodeficiency disease (SCID); and
- Wiskott-Aldrich syndrome. - Effective for services performed on or after August 4, 2010, for the treatment of Myelodysplastic Syndromes (MDS) pursuant to Coverage with Evidence Development (CED) in the context of a Medicare-approved, prospective clinical study. |
30233Y3 | TRANSFUSION OF ALLOGENEIC UNRELATED HAMATOPOIETIC STEM CELLS INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH Tandem Autologous Allogeneic Unrelated Non ICU | ICD | The CMS National Coverage Determination (NCD) for Stem Cell Transplantation describes nationally covered indications for stem cell transplant, the details of which will not be repeated here. This Medical policy article describes additional locally covered indications for stem cell transplant. Indications and Limitations:
Hematopoietic Progenitor Cell (HPC);Allogeneic Transplantation
The ICD-10-PCS Procedure codes are: 30233G2, 30233G3, 30233Y2, 30233Y3, 30243G2, 30243G3, 30243Y2 and 30243Y3. The NCD lists the following nationally covered indications:
- Leukemia in remission;
- Aplastic anemia;
- Severe combined immunodeficiency disease (SCID); and
- Wiskott-Aldrich syndrome. - Effective for services performed on or after August 4, 2010, for the treatment of Myelodysplastic Syndromes (MDS) pursuant to Coverage with Evidence Development (CED) in the context of a Medicare-approved, prospective clinical study. |
30243G2 | TRANSFUSION OF ALLOGENEIC RELATED BONE MARROW INTO CENTRAL VEIN, PERCUTANEOUS APPROACH Reduced Intensity Medsurg | ICD | The CMS National Coverage Determination (NCD) for Stem Cell Transplantation describes nationally covered indications for stem cell transplant, the details of which will not be repeated here. This Medical policy article describes additional locally covered indications for stem cell transplant. Indications and Limitations:
Hematopoietic Progenitor Cell (HPC);Allogeneic Transplantation
The ICD-10-PCS Procedure codes are: 30233G2, 30233G3, 30233Y2, 30233Y3, 30243G2, 30243G3, 30243Y2 and 30243Y3. The NCD lists the following nationally covered indications:
- Leukemia in remission;
- Aplastic anemia;
- Severe combined immunodeficiency disease (SCID); and
- Wiskott-Aldrich syndrome. - Effective for services performed on or after August 4, 2010, for the treatment of Myelodysplastic Syndromes (MDS) pursuant to Coverage with Evidence Development (CED) in the context of a Medicare-approved, prospective clinical study. |
30233G2 | TRANSFUSION OF ALLOGENEIC RELATED BONE MARROW INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH Reduced Intensity Medsurg | ICD | The CMS National Coverage Determination (NCD) for Stem Cell Transplantation describes nationally covered indications for stem cell transplant, the details of which will not be repeated here. This Medical policy article describes additional locally covered indications for stem cell transplant. Indications and Limitations:
Hematopoietic Progenitor Cell (HPC);Allogeneic Transplantation
The ICD-10-PCS Procedure codes are: 30233G2, 30233G3, 30233Y2, 30233Y3, 30243G2, 30243G3, 30243Y2 and 30243Y3. The NCD lists the following nationally covered indications:
- Leukemia in remission;
- Aplastic anemia;
- Severe combined immunodeficiency disease (SCID); and
- Wiskott-Aldrich syndrome. - Effective for services performed on or after August 4, 2010, for the treatment of Myelodysplastic Syndromes (MDS) pursuant to Coverage with Evidence Development (CED) in the context of a Medicare-approved, prospective clinical study. |
30233Y2 | TRANSFUSION OF ALLOGENEIC RELATED HEMATOPOIETIC STEM CELLS INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH Reduced Intensity Medsurg | ICD | The CMS National Coverage Determination (NCD) for Stem Cell Transplantation describes nationally covered indications for stem cell transplant, the details of which will not be repeated here. This Medical policy article describes additional locally covered indications for stem cell transplant. Indications and Limitations:
Hematopoietic Progenitor Cell (HPC);Allogeneic Transplantation
The ICD-10-PCS Procedure codes are: 30233G2, 30233G3, 30233Y2, 30233Y3, 30243G2, 30243G3, 30243Y2 and 30243Y3. The NCD lists the following nationally covered indications:
- Leukemia in remission;
- Aplastic anemia;
- Severe combined immunodeficiency disease (SCID); and
- Wiskott-Aldrich syndrome. - Effective for services performed on or after August 4, 2010, for the treatment of Myelodysplastic Syndromes (MDS) pursuant to Coverage with Evidence Development (CED) in the context of a Medicare-approved, prospective clinical study. |
30243Y3 | TRANSFUSION OF ALLOGENEIC UNRELATED HEMATOPOIETIC STEM CELLS INTO CENTRAL VEIN, PERCUTANEOUS APPROACH Tandem Autologous Allogeneic Unrelated Non ICU | ICD | The CMS National Coverage Determination (NCD) for Stem Cell Transplantation describes nationally covered indications for stem cell transplant, the details of which will not be repeated here. This Medical policy article describes additional locally covered indications for stem cell transplant. Indications and Limitations:
Hematopoietic Progenitor Cell (HPC);Allogeneic Transplantation
The ICD-10-PCS Procedure codes are: 30233G2, 30233G3, 30233Y2, 30233Y3, 30243G2, 30243G3, 30243Y2 and 30243Y3. The NCD lists the following nationally covered indications:
- Leukemia in remission;
- Aplastic anemia;
- Severe combined immunodeficiency disease (SCID); and
- Wiskott-Aldrich syndrome. - Effective for services performed on or after August 4, 2010, for the treatment of Myelodysplastic Syndromes (MDS) pursuant to Coverage with Evidence Development (CED) in the context of a Medicare-approved, prospective clinical study. |
30243G3 | TRANSFUSION OF ALLOGENEIC UNRELATED BONE MARROW INTO CENTRAL VEIN, PERCUTANEOUS APPROACH Tandem Autologous Allogeneic Unrelated Non ICU | ICD | The CMS National Coverage Determination (NCD) for Stem Cell Transplantation describes nationally covered indications for stem cell transplant, the details of which will not be repeated here. This Medical policy article describes additional locally covered indications for stem cell transplant. Indications and Limitations:
Hematopoietic Progenitor Cell (HPC);Allogeneic Transplantation
The ICD-10-PCS Procedure codes are: 30233G2, 30233G3, 30233Y2, 30233Y3, 30243G2, 30243G3, 30243Y2 and 30243Y3. The NCD lists the following nationally covered indications:
- Leukemia in remission;
- Aplastic anemia;
- Severe combined immunodeficiency disease (SCID); and
- Wiskott-Aldrich syndrome. - Effective for services performed on or after August 4, 2010, for the treatment of Myelodysplastic Syndromes (MDS) pursuant to Coverage with Evidence Development (CED) in the context of a Medicare-approved, prospective clinical study. |
30233G3 | TRANSFUSION OF ALLOGENEIC UNRELATED BONE MARROW INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH Tandem Autologous Allogeneic Unrelated Non ICU | ICD | This Medical policy article describes additional locally covered indications for stem cell transplant. Indications and Limitations:
Hematopoietic Progenitor Cell (HPC);Allogeneic Transplantation
The ICD-10-PCS Procedure codes are: 30233G2, 30233G3, 30233Y2, 30233Y3, 30243G2, 30243G3, 30243Y2 and 30243Y3. The NCD lists the following nationally covered indications:
- Leukemia in remission;
- Aplastic anemia;
- Severe combined immunodeficiency disease (SCID); and
- Wiskott-Aldrich syndrome. - Effective for services performed on or after August 4, 2010, for the treatment of Myelodysplastic Syndromes (MDS) pursuant to Coverage with Evidence Development (CED) in the context of a Medicare-approved, prospective clinical study. (Please refer to CMS Publication 100-03, Medicare National Coverage Determinations (NCD) Manual, Chapter 1, Part 2: Section 110.23). |
30243Y2 | TRANSFUSION OF ALLOGENEIC RELATED HEMATOPOIETIC STEM CELLS INTO CENTRAL VEIN, PERCUTANEOUS APPROACH Reduced Intensity Medsurg | ICD | This Medical policy article describes additional locally covered indications for stem cell transplant. Indications and Limitations:
Hematopoietic Progenitor Cell (HPC);Allogeneic Transplantation
The ICD-10-PCS Procedure codes are: 30233G2, 30233G3, 30233Y2, 30233Y3, 30243G2, 30243G3, 30243Y2 and 30243Y3. The NCD lists the following nationally covered indications:
- Leukemia in remission;
- Aplastic anemia;
- Severe combined immunodeficiency disease (SCID); and
- Wiskott-Aldrich syndrome. - Effective for services performed on or after August 4, 2010, for the treatment of Myelodysplastic Syndromes (MDS) pursuant to Coverage with Evidence Development (CED) in the context of a Medicare-approved, prospective clinical study. (Please refer to CMS Publication 100-03, Medicare National Coverage Determinations (NCD) Manual, Chapter 1, Part 2: Section 110.23). |
30233Y3 | TRANSFUSION OF ALLOGENEIC UNRELATED HAMATOPOIETIC STEM CELLS INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH Tandem Autologous Allogeneic Unrelated Non ICU | ICD | This Medical policy article describes additional locally covered indications for stem cell transplant. Indications and Limitations:
Hematopoietic Progenitor Cell (HPC);Allogeneic Transplantation
The ICD-10-PCS Procedure codes are: 30233G2, 30233G3, 30233Y2, 30233Y3, 30243G2, 30243G3, 30243Y2 and 30243Y3. The NCD lists the following nationally covered indications:
- Leukemia in remission;
- Aplastic anemia;
- Severe combined immunodeficiency disease (SCID); and
- Wiskott-Aldrich syndrome. - Effective for services performed on or after August 4, 2010, for the treatment of Myelodysplastic Syndromes (MDS) pursuant to Coverage with Evidence Development (CED) in the context of a Medicare-approved, prospective clinical study. (Please refer to CMS Publication 100-03, Medicare National Coverage Determinations (NCD) Manual, Chapter 1, Part 2: Section 110.23). |
30243G2 | TRANSFUSION OF ALLOGENEIC RELATED BONE MARROW INTO CENTRAL VEIN, PERCUTANEOUS APPROACH Reduced Intensity Medsurg | ICD | This Medical policy article describes additional locally covered indications for stem cell transplant. Indications and Limitations:
Hematopoietic Progenitor Cell (HPC);Allogeneic Transplantation
The ICD-10-PCS Procedure codes are: 30233G2, 30233G3, 30233Y2, 30233Y3, 30243G2, 30243G3, 30243Y2 and 30243Y3. The NCD lists the following nationally covered indications:
- Leukemia in remission;
- Aplastic anemia;
- Severe combined immunodeficiency disease (SCID); and
- Wiskott-Aldrich syndrome. - Effective for services performed on or after August 4, 2010, for the treatment of Myelodysplastic Syndromes (MDS) pursuant to Coverage with Evidence Development (CED) in the context of a Medicare-approved, prospective clinical study. (Please refer to CMS Publication 100-03, Medicare National Coverage Determinations (NCD) Manual, Chapter 1, Part 2: Section 110.23). |
30233G2 | TRANSFUSION OF ALLOGENEIC RELATED BONE MARROW INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH Reduced Intensity Medsurg | ICD | This Medical policy article describes additional locally covered indications for stem cell transplant. Indications and Limitations:
Hematopoietic Progenitor Cell (HPC);Allogeneic Transplantation
The ICD-10-PCS Procedure codes are: 30233G2, 30233G3, 30233Y2, 30233Y3, 30243G2, 30243G3, 30243Y2 and 30243Y3. The NCD lists the following nationally covered indications:
- Leukemia in remission;
- Aplastic anemia;
- Severe combined immunodeficiency disease (SCID); and
- Wiskott-Aldrich syndrome. - Effective for services performed on or after August 4, 2010, for the treatment of Myelodysplastic Syndromes (MDS) pursuant to Coverage with Evidence Development (CED) in the context of a Medicare-approved, prospective clinical study. (Please refer to CMS Publication 100-03, Medicare National Coverage Determinations (NCD) Manual, Chapter 1, Part 2: Section 110.23). |
30233Y2 | TRANSFUSION OF ALLOGENEIC RELATED HEMATOPOIETIC STEM CELLS INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH Reduced Intensity Medsurg | ICD | This Medical policy article describes additional locally covered indications for stem cell transplant. Indications and Limitations:
Hematopoietic Progenitor Cell (HPC);Allogeneic Transplantation
The ICD-10-PCS Procedure codes are: 30233G2, 30233G3, 30233Y2, 30233Y3, 30243G2, 30243G3, 30243Y2 and 30243Y3. The NCD lists the following nationally covered indications:
- Leukemia in remission;
- Aplastic anemia;
- Severe combined immunodeficiency disease (SCID); and
- Wiskott-Aldrich syndrome. - Effective for services performed on or after August 4, 2010, for the treatment of Myelodysplastic Syndromes (MDS) pursuant to Coverage with Evidence Development (CED) in the context of a Medicare-approved, prospective clinical study. (Please refer to CMS Publication 100-03, Medicare National Coverage Determinations (NCD) Manual, Chapter 1, Part 2: Section 110.23). |
30243Y3 | TRANSFUSION OF ALLOGENEIC UNRELATED HEMATOPOIETIC STEM CELLS INTO CENTRAL VEIN, PERCUTANEOUS APPROACH Tandem Autologous Allogeneic Unrelated Non ICU | ICD | This Medical policy article describes additional locally covered indications for stem cell transplant. Indications and Limitations:
Hematopoietic Progenitor Cell (HPC);Allogeneic Transplantation
The ICD-10-PCS Procedure codes are: 30233G2, 30233G3, 30233Y2, 30233Y3, 30243G2, 30243G3, 30243Y2 and 30243Y3. The NCD lists the following nationally covered indications:
- Leukemia in remission;
- Aplastic anemia;
- Severe combined immunodeficiency disease (SCID); and
- Wiskott-Aldrich syndrome. - Effective for services performed on or after August 4, 2010, for the treatment of Myelodysplastic Syndromes (MDS) pursuant to Coverage with Evidence Development (CED) in the context of a Medicare-approved, prospective clinical study. (Please refer to CMS Publication 100-03, Medicare National Coverage Determinations (NCD) Manual, Chapter 1, Part 2: Section 110.23). |
30243G3 | TRANSFUSION OF ALLOGENEIC UNRELATED BONE MARROW INTO CENTRAL VEIN, PERCUTANEOUS APPROACH Tandem Autologous Allogeneic Unrelated Non ICU | ICD | This Medical policy article describes additional locally covered indications for stem cell transplant. Indications and Limitations:
Hematopoietic Progenitor Cell (HPC);Allogeneic Transplantation
The ICD-10-PCS Procedure codes are: 30233G2, 30233G3, 30233Y2, 30233Y3, 30243G2, 30243G3, 30243Y2 and 30243Y3. The NCD lists the following nationally covered indications:
- Leukemia in remission;
- Aplastic anemia;
- Severe combined immunodeficiency disease (SCID); and
- Wiskott-Aldrich syndrome. - Effective for services performed on or after August 4, 2010, for the treatment of Myelodysplastic Syndromes (MDS) pursuant to Coverage with Evidence Development (CED) in the context of a Medicare-approved, prospective clinical study. (Please refer to CMS Publication 100-03, Medicare National Coverage Determinations (NCD) Manual, Chapter 1, Part 2: Section 110.23). |
30233G3 | TRANSFUSION OF ALLOGENEIC UNRELATED BONE MARROW INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH Tandem Autologous Allogeneic Unrelated Non ICU | ICD | Indications and Limitations:
Hematopoietic Progenitor Cell (HPC);Allogeneic Transplantation
The ICD-10-PCS Procedure codes are: 30233G2, 30233G3, 30233Y2, 30233Y3, 30243G2, 30243G3, 30243Y2 and 30243Y3. The NCD lists the following nationally covered indications:
- Leukemia in remission;
- Aplastic anemia;
- Severe combined immunodeficiency disease (SCID); and
- Wiskott-Aldrich syndrome. - Effective for services performed on or after August 4, 2010, for the treatment of Myelodysplastic Syndromes (MDS) pursuant to Coverage with Evidence Development (CED) in the context of a Medicare-approved, prospective clinical study. (Please refer to CMS Publication 100-03, Medicare National Coverage Determinations (NCD) Manual, Chapter 1, Part 2: Section 110.23). Allogeneic HSCT is covered only for Medicare beneficiaries with the following indications when participating in an approved prospective clinical study meeting specific criteria under the CED paradigm:
- Multiple myeloma only for beneficiaries with Durie-Salmon Stage II or III multiple myeloma, or International Staging System (ISS) Stage II or Stage III multiple myeloma;
- Myelofibrosis (MF) only for beneficiaries with Dynamic International Prognostic Scoring System (DIPSSplus) intermediate-2 or High primary or secondary MF or
- Sickle cell disease (SCD) only for beneficiaries with severe, symptomatic SCD who participate in an approved prospective clinical study meeting specific criteria under the CED paradigm. |
30243Y2 | TRANSFUSION OF ALLOGENEIC RELATED HEMATOPOIETIC STEM CELLS INTO CENTRAL VEIN, PERCUTANEOUS APPROACH Reduced Intensity Medsurg | ICD | Indications and Limitations:
Hematopoietic Progenitor Cell (HPC);Allogeneic Transplantation
The ICD-10-PCS Procedure codes are: 30233G2, 30233G3, 30233Y2, 30233Y3, 30243G2, 30243G3, 30243Y2 and 30243Y3. The NCD lists the following nationally covered indications:
- Leukemia in remission;
- Aplastic anemia;
- Severe combined immunodeficiency disease (SCID); and
- Wiskott-Aldrich syndrome. - Effective for services performed on or after August 4, 2010, for the treatment of Myelodysplastic Syndromes (MDS) pursuant to Coverage with Evidence Development (CED) in the context of a Medicare-approved, prospective clinical study. (Please refer to CMS Publication 100-03, Medicare National Coverage Determinations (NCD) Manual, Chapter 1, Part 2: Section 110.23). Allogeneic HSCT is covered only for Medicare beneficiaries with the following indications when participating in an approved prospective clinical study meeting specific criteria under the CED paradigm:
- Multiple myeloma only for beneficiaries with Durie-Salmon Stage II or III multiple myeloma, or International Staging System (ISS) Stage II or Stage III multiple myeloma;
- Myelofibrosis (MF) only for beneficiaries with Dynamic International Prognostic Scoring System (DIPSSplus) intermediate-2 or High primary or secondary MF or
- Sickle cell disease (SCD) only for beneficiaries with severe, symptomatic SCD who participate in an approved prospective clinical study meeting specific criteria under the CED paradigm. |
30233Y3 | TRANSFUSION OF ALLOGENEIC UNRELATED HAMATOPOIETIC STEM CELLS INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH Tandem Autologous Allogeneic Unrelated Non ICU | ICD | Indications and Limitations:
Hematopoietic Progenitor Cell (HPC);Allogeneic Transplantation
The ICD-10-PCS Procedure codes are: 30233G2, 30233G3, 30233Y2, 30233Y3, 30243G2, 30243G3, 30243Y2 and 30243Y3. The NCD lists the following nationally covered indications:
- Leukemia in remission;
- Aplastic anemia;
- Severe combined immunodeficiency disease (SCID); and
- Wiskott-Aldrich syndrome. - Effective for services performed on or after August 4, 2010, for the treatment of Myelodysplastic Syndromes (MDS) pursuant to Coverage with Evidence Development (CED) in the context of a Medicare-approved, prospective clinical study. (Please refer to CMS Publication 100-03, Medicare National Coverage Determinations (NCD) Manual, Chapter 1, Part 2: Section 110.23). Allogeneic HSCT is covered only for Medicare beneficiaries with the following indications when participating in an approved prospective clinical study meeting specific criteria under the CED paradigm:
- Multiple myeloma only for beneficiaries with Durie-Salmon Stage II or III multiple myeloma, or International Staging System (ISS) Stage II or Stage III multiple myeloma;
- Myelofibrosis (MF) only for beneficiaries with Dynamic International Prognostic Scoring System (DIPSSplus) intermediate-2 or High primary or secondary MF or
- Sickle cell disease (SCD) only for beneficiaries with severe, symptomatic SCD who participate in an approved prospective clinical study meeting specific criteria under the CED paradigm. |
30243G2 | TRANSFUSION OF ALLOGENEIC RELATED BONE MARROW INTO CENTRAL VEIN, PERCUTANEOUS APPROACH Reduced Intensity Medsurg | ICD | Indications and Limitations:
Hematopoietic Progenitor Cell (HPC);Allogeneic Transplantation
The ICD-10-PCS Procedure codes are: 30233G2, 30233G3, 30233Y2, 30233Y3, 30243G2, 30243G3, 30243Y2 and 30243Y3. The NCD lists the following nationally covered indications:
- Leukemia in remission;
- Aplastic anemia;
- Severe combined immunodeficiency disease (SCID); and
- Wiskott-Aldrich syndrome. - Effective for services performed on or after August 4, 2010, for the treatment of Myelodysplastic Syndromes (MDS) pursuant to Coverage with Evidence Development (CED) in the context of a Medicare-approved, prospective clinical study. (Please refer to CMS Publication 100-03, Medicare National Coverage Determinations (NCD) Manual, Chapter 1, Part 2: Section 110.23). Allogeneic HSCT is covered only for Medicare beneficiaries with the following indications when participating in an approved prospective clinical study meeting specific criteria under the CED paradigm:
- Multiple myeloma only for beneficiaries with Durie-Salmon Stage II or III multiple myeloma, or International Staging System (ISS) Stage II or Stage III multiple myeloma;
- Myelofibrosis (MF) only for beneficiaries with Dynamic International Prognostic Scoring System (DIPSSplus) intermediate-2 or High primary or secondary MF or
- Sickle cell disease (SCD) only for beneficiaries with severe, symptomatic SCD who participate in an approved prospective clinical study meeting specific criteria under the CED paradigm. |
30233G2 | TRANSFUSION OF ALLOGENEIC RELATED BONE MARROW INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH Reduced Intensity Medsurg | ICD | Indications and Limitations:
Hematopoietic Progenitor Cell (HPC);Allogeneic Transplantation
The ICD-10-PCS Procedure codes are: 30233G2, 30233G3, 30233Y2, 30233Y3, 30243G2, 30243G3, 30243Y2 and 30243Y3. The NCD lists the following nationally covered indications:
- Leukemia in remission;
- Aplastic anemia;
- Severe combined immunodeficiency disease (SCID); and
- Wiskott-Aldrich syndrome. - Effective for services performed on or after August 4, 2010, for the treatment of Myelodysplastic Syndromes (MDS) pursuant to Coverage with Evidence Development (CED) in the context of a Medicare-approved, prospective clinical study. (Please refer to CMS Publication 100-03, Medicare National Coverage Determinations (NCD) Manual, Chapter 1, Part 2: Section 110.23). Allogeneic HSCT is covered only for Medicare beneficiaries with the following indications when participating in an approved prospective clinical study meeting specific criteria under the CED paradigm:
- Multiple myeloma only for beneficiaries with Durie-Salmon Stage II or III multiple myeloma, or International Staging System (ISS) Stage II or Stage III multiple myeloma;
- Myelofibrosis (MF) only for beneficiaries with Dynamic International Prognostic Scoring System (DIPSSplus) intermediate-2 or High primary or secondary MF or
- Sickle cell disease (SCD) only for beneficiaries with severe, symptomatic SCD who participate in an approved prospective clinical study meeting specific criteria under the CED paradigm. |
30233Y2 | TRANSFUSION OF ALLOGENEIC RELATED HEMATOPOIETIC STEM CELLS INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH Reduced Intensity Medsurg | ICD | Indications and Limitations:
Hematopoietic Progenitor Cell (HPC);Allogeneic Transplantation
The ICD-10-PCS Procedure codes are: 30233G2, 30233G3, 30233Y2, 30233Y3, 30243G2, 30243G3, 30243Y2 and 30243Y3. The NCD lists the following nationally covered indications:
- Leukemia in remission;
- Aplastic anemia;
- Severe combined immunodeficiency disease (SCID); and
- Wiskott-Aldrich syndrome. - Effective for services performed on or after August 4, 2010, for the treatment of Myelodysplastic Syndromes (MDS) pursuant to Coverage with Evidence Development (CED) in the context of a Medicare-approved, prospective clinical study. (Please refer to CMS Publication 100-03, Medicare National Coverage Determinations (NCD) Manual, Chapter 1, Part 2: Section 110.23). Allogeneic HSCT is covered only for Medicare beneficiaries with the following indications when participating in an approved prospective clinical study meeting specific criteria under the CED paradigm:
- Multiple myeloma only for beneficiaries with Durie-Salmon Stage II or III multiple myeloma, or International Staging System (ISS) Stage II or Stage III multiple myeloma;
- Myelofibrosis (MF) only for beneficiaries with Dynamic International Prognostic Scoring System (DIPSSplus) intermediate-2 or High primary or secondary MF or
- Sickle cell disease (SCD) only for beneficiaries with severe, symptomatic SCD who participate in an approved prospective clinical study meeting specific criteria under the CED paradigm. |
30243Y3 | TRANSFUSION OF ALLOGENEIC UNRELATED HEMATOPOIETIC STEM CELLS INTO CENTRAL VEIN, PERCUTANEOUS APPROACH Tandem Autologous Allogeneic Unrelated Non ICU | ICD | Indications and Limitations:
Hematopoietic Progenitor Cell (HPC);Allogeneic Transplantation
The ICD-10-PCS Procedure codes are: 30233G2, 30233G3, 30233Y2, 30233Y3, 30243G2, 30243G3, 30243Y2 and 30243Y3. The NCD lists the following nationally covered indications:
- Leukemia in remission;
- Aplastic anemia;
- Severe combined immunodeficiency disease (SCID); and
- Wiskott-Aldrich syndrome. - Effective for services performed on or after August 4, 2010, for the treatment of Myelodysplastic Syndromes (MDS) pursuant to Coverage with Evidence Development (CED) in the context of a Medicare-approved, prospective clinical study. (Please refer to CMS Publication 100-03, Medicare National Coverage Determinations (NCD) Manual, Chapter 1, Part 2: Section 110.23). Allogeneic HSCT is covered only for Medicare beneficiaries with the following indications when participating in an approved prospective clinical study meeting specific criteria under the CED paradigm:
- Multiple myeloma only for beneficiaries with Durie-Salmon Stage II or III multiple myeloma, or International Staging System (ISS) Stage II or Stage III multiple myeloma;
- Myelofibrosis (MF) only for beneficiaries with Dynamic International Prognostic Scoring System (DIPSSplus) intermediate-2 or High primary or secondary MF or
- Sickle cell disease (SCD) only for beneficiaries with severe, symptomatic SCD who participate in an approved prospective clinical study meeting specific criteria under the CED paradigm. |
30243G3 | TRANSFUSION OF ALLOGENEIC UNRELATED BONE MARROW INTO CENTRAL VEIN, PERCUTANEOUS APPROACH Tandem Autologous Allogeneic Unrelated Non ICU | ICD | Indications and Limitations:
Hematopoietic Progenitor Cell (HPC);Allogeneic Transplantation
The ICD-10-PCS Procedure codes are: 30233G2, 30233G3, 30233Y2, 30233Y3, 30243G2, 30243G3, 30243Y2 and 30243Y3. The NCD lists the following nationally covered indications:
- Leukemia in remission;
- Aplastic anemia;
- Severe combined immunodeficiency disease (SCID); and
- Wiskott-Aldrich syndrome. - Effective for services performed on or after August 4, 2010, for the treatment of Myelodysplastic Syndromes (MDS) pursuant to Coverage with Evidence Development (CED) in the context of a Medicare-approved, prospective clinical study. (Please refer to CMS Publication 100-03, Medicare National Coverage Determinations (NCD) Manual, Chapter 1, Part 2: Section 110.23). Allogeneic HSCT is covered only for Medicare beneficiaries with the following indications when participating in an approved prospective clinical study meeting specific criteria under the CED paradigm:
- Multiple myeloma only for beneficiaries with Durie-Salmon Stage II or III multiple myeloma, or International Staging System (ISS) Stage II or Stage III multiple myeloma;
- Myelofibrosis (MF) only for beneficiaries with Dynamic International Prognostic Scoring System (DIPSSplus) intermediate-2 or High primary or secondary MF or
- Sickle cell disease (SCD) only for beneficiaries with severe, symptomatic SCD who participate in an approved prospective clinical study meeting specific criteria under the CED paradigm. |
30243C0 | Transfusion of Autologous Hematopoietic Stem/Progenitor Cells, Genetically Modified into Central Vein, Percutaneous Approach Tandem Autologous Allogeneic Unrelated Non ICU | ICD | (Please refer to CMS Publication 100-03, Medicare National Coverage Determinations (NCD) Manual, Chapter 1, Part 2: Section 110.23). Allogeneic HSCT is covered only for Medicare beneficiaries with the following indications when participating in an approved prospective clinical study meeting specific criteria under the CED paradigm:
- Multiple myeloma only for beneficiaries with Durie-Salmon Stage II or III multiple myeloma, or International Staging System (ISS) Stage II or Stage III multiple myeloma;
- Myelofibrosis (MF) only for beneficiaries with Dynamic International Prognostic Scoring System (DIPSSplus) intermediate-2 or High primary or secondary MF or
- Sickle cell disease (SCD) only for beneficiaries with severe, symptomatic SCD who participate in an approved prospective clinical study meeting specific criteria under the CED paradigm. (Please refer to CMS Publication 100-03, Medicare National Coverage Determinations (NCD) Manual, Chapter 1, Part 2: Section 110.23). In addition to the nationally covered indications for HPC, allogenic, the following indications will be covered locally, for those jurisdictions or providers for whom this Medical Policy article applies, when medically necessary:
- Primary refractory Hodgkin's and non-Hodgkin's lymphoma; and
- Thalassemia major for patients with minimal or no portal fibrosis, hepatomegaly, or active hepatitis. Hematopoietic Progenitor Cell (HPC);Autologous Transplantation
(ICD-10-PCS Procedure codes 30233C0, 30233G0, 30243C0, 30243G0, 30233Y0, and 30243Y0)
The NCD lists the following nationally covered indications:
- Acute leukemia in remission in patients who have a high probability of relapse and who have no human leucocyte antigens (HLA)-matched donor;
- Resistant non-Hodgkin's lymphomas or those presenting with poor prognostic features following an initial response;
- Recurrent or refractory neuroblastoma;
- Advanced Hodgkin's disease who have failed conventional therapy and have no HLA-matched donor;
- Single HPC, autologous is only covered for Durie-Salmon Stage II or III patients that fit the following requirements:
- Newly diagnosed or responsive multiple myeloma. |
30233G0 | Transfusion of Autologous Bone Marrow into Peripheral Vein, Percutaneous Approach Tandem Autologous Allogeneic Unrelated Non ICU | ICD | (Please refer to CMS Publication 100-03, Medicare National Coverage Determinations (NCD) Manual, Chapter 1, Part 2: Section 110.23). Allogeneic HSCT is covered only for Medicare beneficiaries with the following indications when participating in an approved prospective clinical study meeting specific criteria under the CED paradigm:
- Multiple myeloma only for beneficiaries with Durie-Salmon Stage II or III multiple myeloma, or International Staging System (ISS) Stage II or Stage III multiple myeloma;
- Myelofibrosis (MF) only for beneficiaries with Dynamic International Prognostic Scoring System (DIPSSplus) intermediate-2 or High primary or secondary MF or
- Sickle cell disease (SCD) only for beneficiaries with severe, symptomatic SCD who participate in an approved prospective clinical study meeting specific criteria under the CED paradigm. (Please refer to CMS Publication 100-03, Medicare National Coverage Determinations (NCD) Manual, Chapter 1, Part 2: Section 110.23). In addition to the nationally covered indications for HPC, allogenic, the following indications will be covered locally, for those jurisdictions or providers for whom this Medical Policy article applies, when medically necessary:
- Primary refractory Hodgkin's and non-Hodgkin's lymphoma; and
- Thalassemia major for patients with minimal or no portal fibrosis, hepatomegaly, or active hepatitis. Hematopoietic Progenitor Cell (HPC);Autologous Transplantation
(ICD-10-PCS Procedure codes 30233C0, 30233G0, 30243C0, 30243G0, 30233Y0, and 30243Y0)
The NCD lists the following nationally covered indications:
- Acute leukemia in remission in patients who have a high probability of relapse and who have no human leucocyte antigens (HLA)-matched donor;
- Resistant non-Hodgkin's lymphomas or those presenting with poor prognostic features following an initial response;
- Recurrent or refractory neuroblastoma;
- Advanced Hodgkin's disease who have failed conventional therapy and have no HLA-matched donor;
- Single HPC, autologous is only covered for Durie-Salmon Stage II or III patients that fit the following requirements:
- Newly diagnosed or responsive multiple myeloma. |
30243G0 | Transfusion of Autologous Bone Marrow into Central Vein, Percutaneous Approach Tandem Autologous Allogeneic Unrelated Non ICU | ICD | (Please refer to CMS Publication 100-03, Medicare National Coverage Determinations (NCD) Manual, Chapter 1, Part 2: Section 110.23). Allogeneic HSCT is covered only for Medicare beneficiaries with the following indications when participating in an approved prospective clinical study meeting specific criteria under the CED paradigm:
- Multiple myeloma only for beneficiaries with Durie-Salmon Stage II or III multiple myeloma, or International Staging System (ISS) Stage II or Stage III multiple myeloma;
- Myelofibrosis (MF) only for beneficiaries with Dynamic International Prognostic Scoring System (DIPSSplus) intermediate-2 or High primary or secondary MF or
- Sickle cell disease (SCD) only for beneficiaries with severe, symptomatic SCD who participate in an approved prospective clinical study meeting specific criteria under the CED paradigm. (Please refer to CMS Publication 100-03, Medicare National Coverage Determinations (NCD) Manual, Chapter 1, Part 2: Section 110.23). In addition to the nationally covered indications for HPC, allogenic, the following indications will be covered locally, for those jurisdictions or providers for whom this Medical Policy article applies, when medically necessary:
- Primary refractory Hodgkin's and non-Hodgkin's lymphoma; and
- Thalassemia major for patients with minimal or no portal fibrosis, hepatomegaly, or active hepatitis. Hematopoietic Progenitor Cell (HPC);Autologous Transplantation
(ICD-10-PCS Procedure codes 30233C0, 30233G0, 30243C0, 30243G0, 30233Y0, and 30243Y0)
The NCD lists the following nationally covered indications:
- Acute leukemia in remission in patients who have a high probability of relapse and who have no human leucocyte antigens (HLA)-matched donor;
- Resistant non-Hodgkin's lymphomas or those presenting with poor prognostic features following an initial response;
- Recurrent or refractory neuroblastoma;
- Advanced Hodgkin's disease who have failed conventional therapy and have no HLA-matched donor;
- Single HPC, autologous is only covered for Durie-Salmon Stage II or III patients that fit the following requirements:
- Newly diagnosed or responsive multiple myeloma. |
30233Y0 | Transfusion of Autologous Hematopoietic Stem Cells into Peripheral Vein, Percutaneous Approach Tandem Autologous Allogeneic Unrelated Non ICU | ICD | (Please refer to CMS Publication 100-03, Medicare National Coverage Determinations (NCD) Manual, Chapter 1, Part 2: Section 110.23). Allogeneic HSCT is covered only for Medicare beneficiaries with the following indications when participating in an approved prospective clinical study meeting specific criteria under the CED paradigm:
- Multiple myeloma only for beneficiaries with Durie-Salmon Stage II or III multiple myeloma, or International Staging System (ISS) Stage II or Stage III multiple myeloma;
- Myelofibrosis (MF) only for beneficiaries with Dynamic International Prognostic Scoring System (DIPSSplus) intermediate-2 or High primary or secondary MF or
- Sickle cell disease (SCD) only for beneficiaries with severe, symptomatic SCD who participate in an approved prospective clinical study meeting specific criteria under the CED paradigm. (Please refer to CMS Publication 100-03, Medicare National Coverage Determinations (NCD) Manual, Chapter 1, Part 2: Section 110.23). In addition to the nationally covered indications for HPC, allogenic, the following indications will be covered locally, for those jurisdictions or providers for whom this Medical Policy article applies, when medically necessary:
- Primary refractory Hodgkin's and non-Hodgkin's lymphoma; and
- Thalassemia major for patients with minimal or no portal fibrosis, hepatomegaly, or active hepatitis. Hematopoietic Progenitor Cell (HPC);Autologous Transplantation
(ICD-10-PCS Procedure codes 30233C0, 30233G0, 30243C0, 30243G0, 30233Y0, and 30243Y0)
The NCD lists the following nationally covered indications:
- Acute leukemia in remission in patients who have a high probability of relapse and who have no human leucocyte antigens (HLA)-matched donor;
- Resistant non-Hodgkin's lymphomas or those presenting with poor prognostic features following an initial response;
- Recurrent or refractory neuroblastoma;
- Advanced Hodgkin's disease who have failed conventional therapy and have no HLA-matched donor;
- Single HPC, autologous is only covered for Durie-Salmon Stage II or III patients that fit the following requirements:
- Newly diagnosed or responsive multiple myeloma. |
30243Y0 | Transfusion of Autologous Hematopoietic Stem Cells into Central Vein, Percutaneous Approach Tandem Autologous Allogeneic Unrelated Non ICU | ICD | (Please refer to CMS Publication 100-03, Medicare National Coverage Determinations (NCD) Manual, Chapter 1, Part 2: Section 110.23). Allogeneic HSCT is covered only for Medicare beneficiaries with the following indications when participating in an approved prospective clinical study meeting specific criteria under the CED paradigm:
- Multiple myeloma only for beneficiaries with Durie-Salmon Stage II or III multiple myeloma, or International Staging System (ISS) Stage II or Stage III multiple myeloma;
- Myelofibrosis (MF) only for beneficiaries with Dynamic International Prognostic Scoring System (DIPSSplus) intermediate-2 or High primary or secondary MF or
- Sickle cell disease (SCD) only for beneficiaries with severe, symptomatic SCD who participate in an approved prospective clinical study meeting specific criteria under the CED paradigm. (Please refer to CMS Publication 100-03, Medicare National Coverage Determinations (NCD) Manual, Chapter 1, Part 2: Section 110.23). In addition to the nationally covered indications for HPC, allogenic, the following indications will be covered locally, for those jurisdictions or providers for whom this Medical Policy article applies, when medically necessary:
- Primary refractory Hodgkin's and non-Hodgkin's lymphoma; and
- Thalassemia major for patients with minimal or no portal fibrosis, hepatomegaly, or active hepatitis. Hematopoietic Progenitor Cell (HPC);Autologous Transplantation
(ICD-10-PCS Procedure codes 30233C0, 30233G0, 30243C0, 30243G0, 30233Y0, and 30243Y0)
The NCD lists the following nationally covered indications:
- Acute leukemia in remission in patients who have a high probability of relapse and who have no human leucocyte antigens (HLA)-matched donor;
- Resistant non-Hodgkin's lymphomas or those presenting with poor prognostic features following an initial response;
- Recurrent or refractory neuroblastoma;
- Advanced Hodgkin's disease who have failed conventional therapy and have no HLA-matched donor;
- Single HPC, autologous is only covered for Durie-Salmon Stage II or III patients that fit the following requirements:
- Newly diagnosed or responsive multiple myeloma. |
30233C0 | Transfusion of Autologous Hematopoietic Stem/Progenitor Cells, Genetically Modified into Peripheral Vein, Percutaneous Approach Tandem Autologous Allogeneic Unrelated Non ICU | ICD | (Please refer to CMS Publication 100-03, Medicare National Coverage Determinations (NCD) Manual, Chapter 1, Part 2: Section 110.23). Allogeneic HSCT is covered only for Medicare beneficiaries with the following indications when participating in an approved prospective clinical study meeting specific criteria under the CED paradigm:
- Multiple myeloma only for beneficiaries with Durie-Salmon Stage II or III multiple myeloma, or International Staging System (ISS) Stage II or Stage III multiple myeloma;
- Myelofibrosis (MF) only for beneficiaries with Dynamic International Prognostic Scoring System (DIPSSplus) intermediate-2 or High primary or secondary MF or
- Sickle cell disease (SCD) only for beneficiaries with severe, symptomatic SCD who participate in an approved prospective clinical study meeting specific criteria under the CED paradigm. (Please refer to CMS Publication 100-03, Medicare National Coverage Determinations (NCD) Manual, Chapter 1, Part 2: Section 110.23). In addition to the nationally covered indications for HPC, allogenic, the following indications will be covered locally, for those jurisdictions or providers for whom this Medical Policy article applies, when medically necessary:
- Primary refractory Hodgkin's and non-Hodgkin's lymphoma; and
- Thalassemia major for patients with minimal or no portal fibrosis, hepatomegaly, or active hepatitis. Hematopoietic Progenitor Cell (HPC);Autologous Transplantation
(ICD-10-PCS Procedure codes 30233C0, 30233G0, 30243C0, 30243G0, 30233Y0, and 30243Y0)
The NCD lists the following nationally covered indications:
- Acute leukemia in remission in patients who have a high probability of relapse and who have no human leucocyte antigens (HLA)-matched donor;
- Resistant non-Hodgkin's lymphomas or those presenting with poor prognostic features following an initial response;
- Recurrent or refractory neuroblastoma;
- Advanced Hodgkin's disease who have failed conventional therapy and have no HLA-matched donor;
- Single HPC, autologous is only covered for Durie-Salmon Stage II or III patients that fit the following requirements:
- Newly diagnosed or responsive multiple myeloma. |
30243C0 | Transfusion of Autologous Hematopoietic Stem/Progenitor Cells, Genetically Modified into Central Vein, Percutaneous Approach Tandem Autologous Allogeneic Unrelated Non ICU | ICD | (Please refer to CMS Publication 100-03, Medicare National Coverage Determinations (NCD) Manual, Chapter 1, Part 2: Section 110.23). In addition to the nationally covered indications for HPC, allogenic, the following indications will be covered locally, for those jurisdictions or providers for whom this Medical Policy article applies, when medically necessary:
- Primary refractory Hodgkin's and non-Hodgkin's lymphoma; and
- Thalassemia major for patients with minimal or no portal fibrosis, hepatomegaly, or active hepatitis. Hematopoietic Progenitor Cell (HPC);Autologous Transplantation
(ICD-10-PCS Procedure codes 30233C0, 30233G0, 30243C0, 30243G0, 30233Y0, and 30243Y0)
The NCD lists the following nationally covered indications:
- Acute leukemia in remission in patients who have a high probability of relapse and who have no human leucocyte antigens (HLA)-matched donor;
- Resistant non-Hodgkin's lymphomas or those presenting with poor prognostic features following an initial response;
- Recurrent or refractory neuroblastoma;
- Advanced Hodgkin's disease who have failed conventional therapy and have no HLA-matched donor;
- Single HPC, autologous is only covered for Durie-Salmon Stage II or III patients that fit the following requirements:
- Newly diagnosed or responsive multiple myeloma. This includes those patients with previously untreated disease, those with at least a partial response to prior chemotherapy (defined as a 50% decrease either in measurable paraprotein [serum and/or urine] or in bone marrow infiltration, sustained for at least 1 month), and those in responsive relapse; and
- Adequate cardiac, renal, pulmonary, and hepatic function. - HPC, autologous in combination with high dose melphalan for patients with primary amyloid light chain amyloidosis, with amyloid deposition in two or fewer organs and a cardiac left ventricular ejection fraction greater than 45%. |
30233G0 | Transfusion of Autologous Bone Marrow into Peripheral Vein, Percutaneous Approach Tandem Autologous Allogeneic Unrelated Non ICU | ICD | (Please refer to CMS Publication 100-03, Medicare National Coverage Determinations (NCD) Manual, Chapter 1, Part 2: Section 110.23). In addition to the nationally covered indications for HPC, allogenic, the following indications will be covered locally, for those jurisdictions or providers for whom this Medical Policy article applies, when medically necessary:
- Primary refractory Hodgkin's and non-Hodgkin's lymphoma; and
- Thalassemia major for patients with minimal or no portal fibrosis, hepatomegaly, or active hepatitis. Hematopoietic Progenitor Cell (HPC);Autologous Transplantation
(ICD-10-PCS Procedure codes 30233C0, 30233G0, 30243C0, 30243G0, 30233Y0, and 30243Y0)
The NCD lists the following nationally covered indications:
- Acute leukemia in remission in patients who have a high probability of relapse and who have no human leucocyte antigens (HLA)-matched donor;
- Resistant non-Hodgkin's lymphomas or those presenting with poor prognostic features following an initial response;
- Recurrent or refractory neuroblastoma;
- Advanced Hodgkin's disease who have failed conventional therapy and have no HLA-matched donor;
- Single HPC, autologous is only covered for Durie-Salmon Stage II or III patients that fit the following requirements:
- Newly diagnosed or responsive multiple myeloma. This includes those patients with previously untreated disease, those with at least a partial response to prior chemotherapy (defined as a 50% decrease either in measurable paraprotein [serum and/or urine] or in bone marrow infiltration, sustained for at least 1 month), and those in responsive relapse; and
- Adequate cardiac, renal, pulmonary, and hepatic function. - HPC, autologous in combination with high dose melphalan for patients with primary amyloid light chain amyloidosis, with amyloid deposition in two or fewer organs and a cardiac left ventricular ejection fraction greater than 45%. |
30243G0 | Transfusion of Autologous Bone Marrow into Central Vein, Percutaneous Approach Tandem Autologous Allogeneic Unrelated Non ICU | ICD | (Please refer to CMS Publication 100-03, Medicare National Coverage Determinations (NCD) Manual, Chapter 1, Part 2: Section 110.23). In addition to the nationally covered indications for HPC, allogenic, the following indications will be covered locally, for those jurisdictions or providers for whom this Medical Policy article applies, when medically necessary:
- Primary refractory Hodgkin's and non-Hodgkin's lymphoma; and
- Thalassemia major for patients with minimal or no portal fibrosis, hepatomegaly, or active hepatitis. Hematopoietic Progenitor Cell (HPC);Autologous Transplantation
(ICD-10-PCS Procedure codes 30233C0, 30233G0, 30243C0, 30243G0, 30233Y0, and 30243Y0)
The NCD lists the following nationally covered indications:
- Acute leukemia in remission in patients who have a high probability of relapse and who have no human leucocyte antigens (HLA)-matched donor;
- Resistant non-Hodgkin's lymphomas or those presenting with poor prognostic features following an initial response;
- Recurrent or refractory neuroblastoma;
- Advanced Hodgkin's disease who have failed conventional therapy and have no HLA-matched donor;
- Single HPC, autologous is only covered for Durie-Salmon Stage II or III patients that fit the following requirements:
- Newly diagnosed or responsive multiple myeloma. This includes those patients with previously untreated disease, those with at least a partial response to prior chemotherapy (defined as a 50% decrease either in measurable paraprotein [serum and/or urine] or in bone marrow infiltration, sustained for at least 1 month), and those in responsive relapse; and
- Adequate cardiac, renal, pulmonary, and hepatic function. - HPC, autologous in combination with high dose melphalan for patients with primary amyloid light chain amyloidosis, with amyloid deposition in two or fewer organs and a cardiac left ventricular ejection fraction greater than 45%. |
30233Y0 | Transfusion of Autologous Hematopoietic Stem Cells into Peripheral Vein, Percutaneous Approach Tandem Autologous Allogeneic Unrelated Non ICU | ICD | (Please refer to CMS Publication 100-03, Medicare National Coverage Determinations (NCD) Manual, Chapter 1, Part 2: Section 110.23). In addition to the nationally covered indications for HPC, allogenic, the following indications will be covered locally, for those jurisdictions or providers for whom this Medical Policy article applies, when medically necessary:
- Primary refractory Hodgkin's and non-Hodgkin's lymphoma; and
- Thalassemia major for patients with minimal or no portal fibrosis, hepatomegaly, or active hepatitis. Hematopoietic Progenitor Cell (HPC);Autologous Transplantation
(ICD-10-PCS Procedure codes 30233C0, 30233G0, 30243C0, 30243G0, 30233Y0, and 30243Y0)
The NCD lists the following nationally covered indications:
- Acute leukemia in remission in patients who have a high probability of relapse and who have no human leucocyte antigens (HLA)-matched donor;
- Resistant non-Hodgkin's lymphomas or those presenting with poor prognostic features following an initial response;
- Recurrent or refractory neuroblastoma;
- Advanced Hodgkin's disease who have failed conventional therapy and have no HLA-matched donor;
- Single HPC, autologous is only covered for Durie-Salmon Stage II or III patients that fit the following requirements:
- Newly diagnosed or responsive multiple myeloma. This includes those patients with previously untreated disease, those with at least a partial response to prior chemotherapy (defined as a 50% decrease either in measurable paraprotein [serum and/or urine] or in bone marrow infiltration, sustained for at least 1 month), and those in responsive relapse; and
- Adequate cardiac, renal, pulmonary, and hepatic function. - HPC, autologous in combination with high dose melphalan for patients with primary amyloid light chain amyloidosis, with amyloid deposition in two or fewer organs and a cardiac left ventricular ejection fraction greater than 45%. |
30243Y0 | Transfusion of Autologous Hematopoietic Stem Cells into Central Vein, Percutaneous Approach Tandem Autologous Allogeneic Unrelated Non ICU | ICD | (Please refer to CMS Publication 100-03, Medicare National Coverage Determinations (NCD) Manual, Chapter 1, Part 2: Section 110.23). In addition to the nationally covered indications for HPC, allogenic, the following indications will be covered locally, for those jurisdictions or providers for whom this Medical Policy article applies, when medically necessary:
- Primary refractory Hodgkin's and non-Hodgkin's lymphoma; and
- Thalassemia major for patients with minimal or no portal fibrosis, hepatomegaly, or active hepatitis. Hematopoietic Progenitor Cell (HPC);Autologous Transplantation
(ICD-10-PCS Procedure codes 30233C0, 30233G0, 30243C0, 30243G0, 30233Y0, and 30243Y0)
The NCD lists the following nationally covered indications:
- Acute leukemia in remission in patients who have a high probability of relapse and who have no human leucocyte antigens (HLA)-matched donor;
- Resistant non-Hodgkin's lymphomas or those presenting with poor prognostic features following an initial response;
- Recurrent or refractory neuroblastoma;
- Advanced Hodgkin's disease who have failed conventional therapy and have no HLA-matched donor;
- Single HPC, autologous is only covered for Durie-Salmon Stage II or III patients that fit the following requirements:
- Newly diagnosed or responsive multiple myeloma. This includes those patients with previously untreated disease, those with at least a partial response to prior chemotherapy (defined as a 50% decrease either in measurable paraprotein [serum and/or urine] or in bone marrow infiltration, sustained for at least 1 month), and those in responsive relapse; and
- Adequate cardiac, renal, pulmonary, and hepatic function. - HPC, autologous in combination with high dose melphalan for patients with primary amyloid light chain amyloidosis, with amyloid deposition in two or fewer organs and a cardiac left ventricular ejection fraction greater than 45%. |
30233C0 | Transfusion of Autologous Hematopoietic Stem/Progenitor Cells, Genetically Modified into Peripheral Vein, Percutaneous Approach Tandem Autologous Allogeneic Unrelated Non ICU | ICD | (Please refer to CMS Publication 100-03, Medicare National Coverage Determinations (NCD) Manual, Chapter 1, Part 2: Section 110.23). In addition to the nationally covered indications for HPC, allogenic, the following indications will be covered locally, for those jurisdictions or providers for whom this Medical Policy article applies, when medically necessary:
- Primary refractory Hodgkin's and non-Hodgkin's lymphoma; and
- Thalassemia major for patients with minimal or no portal fibrosis, hepatomegaly, or active hepatitis. Hematopoietic Progenitor Cell (HPC);Autologous Transplantation
(ICD-10-PCS Procedure codes 30233C0, 30233G0, 30243C0, 30243G0, 30233Y0, and 30243Y0)
The NCD lists the following nationally covered indications:
- Acute leukemia in remission in patients who have a high probability of relapse and who have no human leucocyte antigens (HLA)-matched donor;
- Resistant non-Hodgkin's lymphomas or those presenting with poor prognostic features following an initial response;
- Recurrent or refractory neuroblastoma;
- Advanced Hodgkin's disease who have failed conventional therapy and have no HLA-matched donor;
- Single HPC, autologous is only covered for Durie-Salmon Stage II or III patients that fit the following requirements:
- Newly diagnosed or responsive multiple myeloma. This includes those patients with previously untreated disease, those with at least a partial response to prior chemotherapy (defined as a 50% decrease either in measurable paraprotein [serum and/or urine] or in bone marrow infiltration, sustained for at least 1 month), and those in responsive relapse; and
- Adequate cardiac, renal, pulmonary, and hepatic function. - HPC, autologous in combination with high dose melphalan for patients with primary amyloid light chain amyloidosis, with amyloid deposition in two or fewer organs and a cardiac left ventricular ejection fraction greater than 45%. |
30243C0 | Transfusion of Autologous Hematopoietic Stem/Progenitor Cells, Genetically Modified into Central Vein, Percutaneous Approach Tandem Autologous Allogeneic Unrelated Non ICU | ICD | In addition to the nationally covered indications for HPC, allogenic, the following indications will be covered locally, for those jurisdictions or providers for whom this Medical Policy article applies, when medically necessary:
- Primary refractory Hodgkin's and non-Hodgkin's lymphoma; and
- Thalassemia major for patients with minimal or no portal fibrosis, hepatomegaly, or active hepatitis. Hematopoietic Progenitor Cell (HPC);Autologous Transplantation
(ICD-10-PCS Procedure codes 30233C0, 30233G0, 30243C0, 30243G0, 30233Y0, and 30243Y0)
The NCD lists the following nationally covered indications:
- Acute leukemia in remission in patients who have a high probability of relapse and who have no human leucocyte antigens (HLA)-matched donor;
- Resistant non-Hodgkin's lymphomas or those presenting with poor prognostic features following an initial response;
- Recurrent or refractory neuroblastoma;
- Advanced Hodgkin's disease who have failed conventional therapy and have no HLA-matched donor;
- Single HPC, autologous is only covered for Durie-Salmon Stage II or III patients that fit the following requirements:
- Newly diagnosed or responsive multiple myeloma. This includes those patients with previously untreated disease, those with at least a partial response to prior chemotherapy (defined as a 50% decrease either in measurable paraprotein [serum and/or urine] or in bone marrow infiltration, sustained for at least 1 month), and those in responsive relapse; and
- Adequate cardiac, renal, pulmonary, and hepatic function. - HPC, autologous in combination with high dose melphalan for patients with primary amyloid light chain amyloidosis, with amyloid deposition in two or fewer organs and a cardiac left ventricular ejection fraction greater than 45%. In addition to the nationally covered indications for HPC, autologous, the following indication will be covered locally, for those jurisdictions or providers for whom this Medical Policy article applies, when medically necessary:
- Anaplastic large cell lymphoma
- Large cell lymphoma/B-cell lymphoma
- Peripheral T-cell lymphoma
- Primary central nervous system lymphoma
- Testicular cancer
- Waldenström macroglobulinemia
The NCD lists the following nationally non-covered indications:
- Acute leukemia not in remission;
- Chronic granulocytic leukemia;
- Solid tumors (other than neuroblastoma); and
- Tandem transplantation (multiple rounds of HPC, autologous) for patients with multiple myeloma
Procedure codes may be subject to National Correct Coding Initiative (NCCI) edits or OPPS packaging edits. |
30233G0 | Transfusion of Autologous Bone Marrow into Peripheral Vein, Percutaneous Approach Tandem Autologous Allogeneic Unrelated Non ICU | ICD | In addition to the nationally covered indications for HPC, allogenic, the following indications will be covered locally, for those jurisdictions or providers for whom this Medical Policy article applies, when medically necessary:
- Primary refractory Hodgkin's and non-Hodgkin's lymphoma; and
- Thalassemia major for patients with minimal or no portal fibrosis, hepatomegaly, or active hepatitis. Hematopoietic Progenitor Cell (HPC);Autologous Transplantation
(ICD-10-PCS Procedure codes 30233C0, 30233G0, 30243C0, 30243G0, 30233Y0, and 30243Y0)
The NCD lists the following nationally covered indications:
- Acute leukemia in remission in patients who have a high probability of relapse and who have no human leucocyte antigens (HLA)-matched donor;
- Resistant non-Hodgkin's lymphomas or those presenting with poor prognostic features following an initial response;
- Recurrent or refractory neuroblastoma;
- Advanced Hodgkin's disease who have failed conventional therapy and have no HLA-matched donor;
- Single HPC, autologous is only covered for Durie-Salmon Stage II or III patients that fit the following requirements:
- Newly diagnosed or responsive multiple myeloma. This includes those patients with previously untreated disease, those with at least a partial response to prior chemotherapy (defined as a 50% decrease either in measurable paraprotein [serum and/or urine] or in bone marrow infiltration, sustained for at least 1 month), and those in responsive relapse; and
- Adequate cardiac, renal, pulmonary, and hepatic function. - HPC, autologous in combination with high dose melphalan for patients with primary amyloid light chain amyloidosis, with amyloid deposition in two or fewer organs and a cardiac left ventricular ejection fraction greater than 45%. In addition to the nationally covered indications for HPC, autologous, the following indication will be covered locally, for those jurisdictions or providers for whom this Medical Policy article applies, when medically necessary:
- Anaplastic large cell lymphoma
- Large cell lymphoma/B-cell lymphoma
- Peripheral T-cell lymphoma
- Primary central nervous system lymphoma
- Testicular cancer
- Waldenström macroglobulinemia
The NCD lists the following nationally non-covered indications:
- Acute leukemia not in remission;
- Chronic granulocytic leukemia;
- Solid tumors (other than neuroblastoma); and
- Tandem transplantation (multiple rounds of HPC, autologous) for patients with multiple myeloma
Procedure codes may be subject to National Correct Coding Initiative (NCCI) edits or OPPS packaging edits. |
30243G0 | Transfusion of Autologous Bone Marrow into Central Vein, Percutaneous Approach Tandem Autologous Allogeneic Unrelated Non ICU | ICD | In addition to the nationally covered indications for HPC, allogenic, the following indications will be covered locally, for those jurisdictions or providers for whom this Medical Policy article applies, when medically necessary:
- Primary refractory Hodgkin's and non-Hodgkin's lymphoma; and
- Thalassemia major for patients with minimal or no portal fibrosis, hepatomegaly, or active hepatitis. Hematopoietic Progenitor Cell (HPC);Autologous Transplantation
(ICD-10-PCS Procedure codes 30233C0, 30233G0, 30243C0, 30243G0, 30233Y0, and 30243Y0)
The NCD lists the following nationally covered indications:
- Acute leukemia in remission in patients who have a high probability of relapse and who have no human leucocyte antigens (HLA)-matched donor;
- Resistant non-Hodgkin's lymphomas or those presenting with poor prognostic features following an initial response;
- Recurrent or refractory neuroblastoma;
- Advanced Hodgkin's disease who have failed conventional therapy and have no HLA-matched donor;
- Single HPC, autologous is only covered for Durie-Salmon Stage II or III patients that fit the following requirements:
- Newly diagnosed or responsive multiple myeloma. This includes those patients with previously untreated disease, those with at least a partial response to prior chemotherapy (defined as a 50% decrease either in measurable paraprotein [serum and/or urine] or in bone marrow infiltration, sustained for at least 1 month), and those in responsive relapse; and
- Adequate cardiac, renal, pulmonary, and hepatic function. - HPC, autologous in combination with high dose melphalan for patients with primary amyloid light chain amyloidosis, with amyloid deposition in two or fewer organs and a cardiac left ventricular ejection fraction greater than 45%. In addition to the nationally covered indications for HPC, autologous, the following indication will be covered locally, for those jurisdictions or providers for whom this Medical Policy article applies, when medically necessary:
- Anaplastic large cell lymphoma
- Large cell lymphoma/B-cell lymphoma
- Peripheral T-cell lymphoma
- Primary central nervous system lymphoma
- Testicular cancer
- Waldenström macroglobulinemia
The NCD lists the following nationally non-covered indications:
- Acute leukemia not in remission;
- Chronic granulocytic leukemia;
- Solid tumors (other than neuroblastoma); and
- Tandem transplantation (multiple rounds of HPC, autologous) for patients with multiple myeloma
Procedure codes may be subject to National Correct Coding Initiative (NCCI) edits or OPPS packaging edits. |
30233Y0 | Transfusion of Autologous Hematopoietic Stem Cells into Peripheral Vein, Percutaneous Approach Tandem Autologous Allogeneic Unrelated Non ICU | ICD | In addition to the nationally covered indications for HPC, allogenic, the following indications will be covered locally, for those jurisdictions or providers for whom this Medical Policy article applies, when medically necessary:
- Primary refractory Hodgkin's and non-Hodgkin's lymphoma; and
- Thalassemia major for patients with minimal or no portal fibrosis, hepatomegaly, or active hepatitis. Hematopoietic Progenitor Cell (HPC);Autologous Transplantation
(ICD-10-PCS Procedure codes 30233C0, 30233G0, 30243C0, 30243G0, 30233Y0, and 30243Y0)
The NCD lists the following nationally covered indications:
- Acute leukemia in remission in patients who have a high probability of relapse and who have no human leucocyte antigens (HLA)-matched donor;
- Resistant non-Hodgkin's lymphomas or those presenting with poor prognostic features following an initial response;
- Recurrent or refractory neuroblastoma;
- Advanced Hodgkin's disease who have failed conventional therapy and have no HLA-matched donor;
- Single HPC, autologous is only covered for Durie-Salmon Stage II or III patients that fit the following requirements:
- Newly diagnosed or responsive multiple myeloma. This includes those patients with previously untreated disease, those with at least a partial response to prior chemotherapy (defined as a 50% decrease either in measurable paraprotein [serum and/or urine] or in bone marrow infiltration, sustained for at least 1 month), and those in responsive relapse; and
- Adequate cardiac, renal, pulmonary, and hepatic function. - HPC, autologous in combination with high dose melphalan for patients with primary amyloid light chain amyloidosis, with amyloid deposition in two or fewer organs and a cardiac left ventricular ejection fraction greater than 45%. In addition to the nationally covered indications for HPC, autologous, the following indication will be covered locally, for those jurisdictions or providers for whom this Medical Policy article applies, when medically necessary:
- Anaplastic large cell lymphoma
- Large cell lymphoma/B-cell lymphoma
- Peripheral T-cell lymphoma
- Primary central nervous system lymphoma
- Testicular cancer
- Waldenström macroglobulinemia
The NCD lists the following nationally non-covered indications:
- Acute leukemia not in remission;
- Chronic granulocytic leukemia;
- Solid tumors (other than neuroblastoma); and
- Tandem transplantation (multiple rounds of HPC, autologous) for patients with multiple myeloma
Procedure codes may be subject to National Correct Coding Initiative (NCCI) edits or OPPS packaging edits. |
30243Y0 | Transfusion of Autologous Hematopoietic Stem Cells into Central Vein, Percutaneous Approach Tandem Autologous Allogeneic Unrelated Non ICU | ICD | In addition to the nationally covered indications for HPC, allogenic, the following indications will be covered locally, for those jurisdictions or providers for whom this Medical Policy article applies, when medically necessary:
- Primary refractory Hodgkin's and non-Hodgkin's lymphoma; and
- Thalassemia major for patients with minimal or no portal fibrosis, hepatomegaly, or active hepatitis. Hematopoietic Progenitor Cell (HPC);Autologous Transplantation
(ICD-10-PCS Procedure codes 30233C0, 30233G0, 30243C0, 30243G0, 30233Y0, and 30243Y0)
The NCD lists the following nationally covered indications:
- Acute leukemia in remission in patients who have a high probability of relapse and who have no human leucocyte antigens (HLA)-matched donor;
- Resistant non-Hodgkin's lymphomas or those presenting with poor prognostic features following an initial response;
- Recurrent or refractory neuroblastoma;
- Advanced Hodgkin's disease who have failed conventional therapy and have no HLA-matched donor;
- Single HPC, autologous is only covered for Durie-Salmon Stage II or III patients that fit the following requirements:
- Newly diagnosed or responsive multiple myeloma. This includes those patients with previously untreated disease, those with at least a partial response to prior chemotherapy (defined as a 50% decrease either in measurable paraprotein [serum and/or urine] or in bone marrow infiltration, sustained for at least 1 month), and those in responsive relapse; and
- Adequate cardiac, renal, pulmonary, and hepatic function. - HPC, autologous in combination with high dose melphalan for patients with primary amyloid light chain amyloidosis, with amyloid deposition in two or fewer organs and a cardiac left ventricular ejection fraction greater than 45%. In addition to the nationally covered indications for HPC, autologous, the following indication will be covered locally, for those jurisdictions or providers for whom this Medical Policy article applies, when medically necessary:
- Anaplastic large cell lymphoma
- Large cell lymphoma/B-cell lymphoma
- Peripheral T-cell lymphoma
- Primary central nervous system lymphoma
- Testicular cancer
- Waldenström macroglobulinemia
The NCD lists the following nationally non-covered indications:
- Acute leukemia not in remission;
- Chronic granulocytic leukemia;
- Solid tumors (other than neuroblastoma); and
- Tandem transplantation (multiple rounds of HPC, autologous) for patients with multiple myeloma
Procedure codes may be subject to National Correct Coding Initiative (NCCI) edits or OPPS packaging edits. |
30233C0 | Transfusion of Autologous Hematopoietic Stem/Progenitor Cells, Genetically Modified into Peripheral Vein, Percutaneous Approach Tandem Autologous Allogeneic Unrelated Non ICU | ICD | In addition to the nationally covered indications for HPC, allogenic, the following indications will be covered locally, for those jurisdictions or providers for whom this Medical Policy article applies, when medically necessary:
- Primary refractory Hodgkin's and non-Hodgkin's lymphoma; and
- Thalassemia major for patients with minimal or no portal fibrosis, hepatomegaly, or active hepatitis. Hematopoietic Progenitor Cell (HPC);Autologous Transplantation
(ICD-10-PCS Procedure codes 30233C0, 30233G0, 30243C0, 30243G0, 30233Y0, and 30243Y0)
The NCD lists the following nationally covered indications:
- Acute leukemia in remission in patients who have a high probability of relapse and who have no human leucocyte antigens (HLA)-matched donor;
- Resistant non-Hodgkin's lymphomas or those presenting with poor prognostic features following an initial response;
- Recurrent or refractory neuroblastoma;
- Advanced Hodgkin's disease who have failed conventional therapy and have no HLA-matched donor;
- Single HPC, autologous is only covered for Durie-Salmon Stage II or III patients that fit the following requirements:
- Newly diagnosed or responsive multiple myeloma. This includes those patients with previously untreated disease, those with at least a partial response to prior chemotherapy (defined as a 50% decrease either in measurable paraprotein [serum and/or urine] or in bone marrow infiltration, sustained for at least 1 month), and those in responsive relapse; and
- Adequate cardiac, renal, pulmonary, and hepatic function. - HPC, autologous in combination with high dose melphalan for patients with primary amyloid light chain amyloidosis, with amyloid deposition in two or fewer organs and a cardiac left ventricular ejection fraction greater than 45%. In addition to the nationally covered indications for HPC, autologous, the following indication will be covered locally, for those jurisdictions or providers for whom this Medical Policy article applies, when medically necessary:
- Anaplastic large cell lymphoma
- Large cell lymphoma/B-cell lymphoma
- Peripheral T-cell lymphoma
- Primary central nervous system lymphoma
- Testicular cancer
- Waldenström macroglobulinemia
The NCD lists the following nationally non-covered indications:
- Acute leukemia not in remission;
- Chronic granulocytic leukemia;
- Solid tumors (other than neuroblastoma); and
- Tandem transplantation (multiple rounds of HPC, autologous) for patients with multiple myeloma
Procedure codes may be subject to National Correct Coding Initiative (NCCI) edits or OPPS packaging edits. |
J9020 | Injection, asparaginase, not otherwise specified, 10,000 units | HCPCS | 2007;49(1):34-40. - National Comprehensive Cancer Network (NCCN). Central Nervous System Cancers 2014; http://www.nccn.org/professionals/physician_gls/PDF/cns.pdf. Accessed September 10, 2014. |CPT||38204||Management of recipient hematopoietic cell donor search and cell acquisition|
|38205||Blood-derived hematopoietic progenitor cell harvesting for transplantaion, per collection, allogeneic|
|38208||Transplant preparation of hematopoietic progenitor cells; thawing of previously frozen harvest, without washing, per donor|
|38209||;thawing of previously frozen harvest with washing, per donor|
|38210||Specific cell depletion with harvest, T cell depletion|
|38211||Tumor cell depletion|
|38212||Red blood cell removal|
|38214||Plasma (volume) depletion|
|38215||Cell concentration in plasma, mononuclear, or buffy coat layer|
|38220||Bone marrow; aspiration only|
|38221||Bone marrow; biopsy, needle or trocar|
|38230||Bone marrow harvesting for transplantation; allogeneic|
|38232||bone marrow harvesting for transplnation; autologous|
|38240||Bone marrow or blod-derived [eropheral stem-cell transplatation; allogeneic|
|ICD-9 Procedure||41.00||Bone marrow transplant, not otherwise specified|
|41.01||Autologous bone marrow transplant without purging|
|41.02||Allogeneic hone marrow transplant with purging|
|41.03||Allogeneic bone marrow transplant without purging|
|41.04||Autologous hematopoietic stem-cell transplant without purging|
|41.05||Allogeneic hematopoietic stem cell transplant without purging|
|41.06||Cord blood stem cell transplant|
|41.07||Autologous hematopoietic stem-cell transplant with purging|
|41.08||Allogeneic hematopoietic stem-cell transplant with purging|
|41.09||Autologous bone marrow transplant with purging|
|41.91||Aspiration of bone marrow from donor for transplant|
|99.79||Other therapeutic apheresis (includes harvest of stem cells)|
|ICD-9 Diagnosis||191.0–191.9||Malignant neoplasm of brain code range|
|HCPCS||Q0083, Q0084, Q0085||Chemotherapy administration code range|
J9000, J9001, J9010, J9015, J9017, J9020, J9025, J9027, J9031, J9035, J9041, J9045, J9050, J9055, J9060, J9062, J9065, J9070, J9080, J9090, J9091, J9092, J9093, J9094, J9095, J9096, J9097, J9098, J9100, J9110, J9120, J9130, J9140, J9150, J9151, J9160, J9165, J9170, J9175, J9178, J9181, J9182, J9185, J9190, J9200, J9201, J9202, J9206, J9208, J9209, J9211, J9212, J9213, J9214, J9215, J9216, J9217, J9218, J9219, J9225, J9226, J9230, J9245, J9250, J9260, J9261, J9263, J9264, J9265, J9266, J9268, J9270, J9280, J9290, J9291, J9293, J9300, J9303, J9305, J9310, J9320, J9340, J9350, J9355, J9357, J9360, J9370, J9375, J9380, J9390, J9395, J9600, J9999
|Chemotherapy drugs code range|
|G0265||Bryopreservation, freezing and storage of cells for thereapeutic use, each cell line|
|G0266||Thawing and expansion of frozen cells for therapeuticuse, each cell line|
|G0267||Bone marrow or peripheral stem-cell harvest, modification or treatment to eliminate cell type(s) (e.g., T cells, metastic carcinoma)|
|S2150||Bone marrow or blood-derived peripheral stem-cell harvesting and transplantation, allogeneic or autologous, including pheresis, high-dose chemotherapy, and the number of days of post-transplant care in the global definition (including drugs; hospitalization; medical surgical, diagnostic and emergency services)|
|ICD-10-CM (effective 10/1/15)||C71.0-C71.9||Malignant neoplasm of brain|
|ICD-10-PCS (effective 10/1/15)||ICD-10-PCS codes are only used for inpatient services.|
|30243G0, 30243X0, 30243Y0||Percutaneous transfusion, central vein, bone marrow or stem cells, autologous, code list|
|30243G1, 30243X1, 30243Y1||Percutaneous transfusion, central vein, bone marrow or stem cells, nonautologous, code list|
|07DQ0ZZ, 07DQ3ZZ, 07DR0ZZ, 07DR3ZZ, 07DS0ZZ, 07DS3ZZ||Surgical, lymphatic and hemic systems, extraction, bone marrow, code list|
|Type of Service||Therapy|
|Place of Service||Inpatient/Outpatient|
Ependymoma, High-dose Chemotherapy
Ependymoblastoma, High-dose Chemotherapy
High-dose chemotherapy with autologous stem-cell support for PNET and ependymoma
Medulloblastoma, High-dose Chemotherapy
Neuroblastoma, Central, High-dose Chemotherapy
Pinealblastoma, High-dose Chemotherapy
Primitive Neuroectodermal Tumors (PNET), High-dose Chemotherapy
|12/01/99||Add to Therapy section||New policy
Policy represents revision of 8.01.15 to focus entirely on PNET. |
J9041 | INJECTION, BORTEZOMIB, 0.1 MG | HCPCS | 2007;49(1):34-40. - National Comprehensive Cancer Network (NCCN). Central Nervous System Cancers 2014; http://www.nccn.org/professionals/physician_gls/PDF/cns.pdf. Accessed September 10, 2014. |CPT||38204||Management of recipient hematopoietic cell donor search and cell acquisition|
|38205||Blood-derived hematopoietic progenitor cell harvesting for transplantaion, per collection, allogeneic|
|38208||Transplant preparation of hematopoietic progenitor cells; thawing of previously frozen harvest, without washing, per donor|
|38209||;thawing of previously frozen harvest with washing, per donor|
|38210||Specific cell depletion with harvest, T cell depletion|
|38211||Tumor cell depletion|
|38212||Red blood cell removal|
|38214||Plasma (volume) depletion|
|38215||Cell concentration in plasma, mononuclear, or buffy coat layer|
|38220||Bone marrow; aspiration only|
|38221||Bone marrow; biopsy, needle or trocar|
|38230||Bone marrow harvesting for transplantation; allogeneic|
|38232||bone marrow harvesting for transplnation; autologous|
|38240||Bone marrow or blod-derived [eropheral stem-cell transplatation; allogeneic|
|ICD-9 Procedure||41.00||Bone marrow transplant, not otherwise specified|
|41.01||Autologous bone marrow transplant without purging|
|41.02||Allogeneic hone marrow transplant with purging|
|41.03||Allogeneic bone marrow transplant without purging|
|41.04||Autologous hematopoietic stem-cell transplant without purging|
|41.05||Allogeneic hematopoietic stem cell transplant without purging|
|41.06||Cord blood stem cell transplant|
|41.07||Autologous hematopoietic stem-cell transplant with purging|
|41.08||Allogeneic hematopoietic stem-cell transplant with purging|
|41.09||Autologous bone marrow transplant with purging|
|41.91||Aspiration of bone marrow from donor for transplant|
|99.79||Other therapeutic apheresis (includes harvest of stem cells)|
|ICD-9 Diagnosis||191.0–191.9||Malignant neoplasm of brain code range|
|HCPCS||Q0083, Q0084, Q0085||Chemotherapy administration code range|
J9000, J9001, J9010, J9015, J9017, J9020, J9025, J9027, J9031, J9035, J9041, J9045, J9050, J9055, J9060, J9062, J9065, J9070, J9080, J9090, J9091, J9092, J9093, J9094, J9095, J9096, J9097, J9098, J9100, J9110, J9120, J9130, J9140, J9150, J9151, J9160, J9165, J9170, J9175, J9178, J9181, J9182, J9185, J9190, J9200, J9201, J9202, J9206, J9208, J9209, J9211, J9212, J9213, J9214, J9215, J9216, J9217, J9218, J9219, J9225, J9226, J9230, J9245, J9250, J9260, J9261, J9263, J9264, J9265, J9266, J9268, J9270, J9280, J9290, J9291, J9293, J9300, J9303, J9305, J9310, J9320, J9340, J9350, J9355, J9357, J9360, J9370, J9375, J9380, J9390, J9395, J9600, J9999
|Chemotherapy drugs code range|
|G0265||Bryopreservation, freezing and storage of cells for thereapeutic use, each cell line|
|G0266||Thawing and expansion of frozen cells for therapeuticuse, each cell line|
|G0267||Bone marrow or peripheral stem-cell harvest, modification or treatment to eliminate cell type(s) (e.g., T cells, metastic carcinoma)|
|S2150||Bone marrow or blood-derived peripheral stem-cell harvesting and transplantation, allogeneic or autologous, including pheresis, high-dose chemotherapy, and the number of days of post-transplant care in the global definition (including drugs; hospitalization; medical surgical, diagnostic and emergency services)|
|ICD-10-CM (effective 10/1/15)||C71.0-C71.9||Malignant neoplasm of brain|
|ICD-10-PCS (effective 10/1/15)||ICD-10-PCS codes are only used for inpatient services.|
|30243G0, 30243X0, 30243Y0||Percutaneous transfusion, central vein, bone marrow or stem cells, autologous, code list|
|30243G1, 30243X1, 30243Y1||Percutaneous transfusion, central vein, bone marrow or stem cells, nonautologous, code list|
|07DQ0ZZ, 07DQ3ZZ, 07DR0ZZ, 07DR3ZZ, 07DS0ZZ, 07DS3ZZ||Surgical, lymphatic and hemic systems, extraction, bone marrow, code list|
|Type of Service||Therapy|
|Place of Service||Inpatient/Outpatient|
Ependymoma, High-dose Chemotherapy
Ependymoblastoma, High-dose Chemotherapy
High-dose chemotherapy with autologous stem-cell support for PNET and ependymoma
Medulloblastoma, High-dose Chemotherapy
Neuroblastoma, Central, High-dose Chemotherapy
Pinealblastoma, High-dose Chemotherapy
Primitive Neuroectodermal Tumors (PNET), High-dose Chemotherapy
|12/01/99||Add to Therapy section||New policy
Policy represents revision of 8.01.15 to focus entirely on PNET. |
J9055 | INJECTION, CETUXIMAB, 10 MG | HCPCS | 2007;49(1):34-40. - National Comprehensive Cancer Network (NCCN). Central Nervous System Cancers 2014; http://www.nccn.org/professionals/physician_gls/PDF/cns.pdf. Accessed September 10, 2014. |CPT||38204||Management of recipient hematopoietic cell donor search and cell acquisition|
|38205||Blood-derived hematopoietic progenitor cell harvesting for transplantaion, per collection, allogeneic|
|38208||Transplant preparation of hematopoietic progenitor cells; thawing of previously frozen harvest, without washing, per donor|
|38209||;thawing of previously frozen harvest with washing, per donor|
|38210||Specific cell depletion with harvest, T cell depletion|
|38211||Tumor cell depletion|
|38212||Red blood cell removal|
|38214||Plasma (volume) depletion|
|38215||Cell concentration in plasma, mononuclear, or buffy coat layer|
|38220||Bone marrow; aspiration only|
|38221||Bone marrow; biopsy, needle or trocar|
|38230||Bone marrow harvesting for transplantation; allogeneic|
|38232||bone marrow harvesting for transplnation; autologous|
|38240||Bone marrow or blod-derived [eropheral stem-cell transplatation; allogeneic|
|ICD-9 Procedure||41.00||Bone marrow transplant, not otherwise specified|
|41.01||Autologous bone marrow transplant without purging|
|41.02||Allogeneic hone marrow transplant with purging|
|41.03||Allogeneic bone marrow transplant without purging|
|41.04||Autologous hematopoietic stem-cell transplant without purging|
|41.05||Allogeneic hematopoietic stem cell transplant without purging|
|41.06||Cord blood stem cell transplant|
|41.07||Autologous hematopoietic stem-cell transplant with purging|
|41.08||Allogeneic hematopoietic stem-cell transplant with purging|
|41.09||Autologous bone marrow transplant with purging|
|41.91||Aspiration of bone marrow from donor for transplant|
|99.79||Other therapeutic apheresis (includes harvest of stem cells)|
|ICD-9 Diagnosis||191.0–191.9||Malignant neoplasm of brain code range|
|HCPCS||Q0083, Q0084, Q0085||Chemotherapy administration code range|
J9000, J9001, J9010, J9015, J9017, J9020, J9025, J9027, J9031, J9035, J9041, J9045, J9050, J9055, J9060, J9062, J9065, J9070, J9080, J9090, J9091, J9092, J9093, J9094, J9095, J9096, J9097, J9098, J9100, J9110, J9120, J9130, J9140, J9150, J9151, J9160, J9165, J9170, J9175, J9178, J9181, J9182, J9185, J9190, J9200, J9201, J9202, J9206, J9208, J9209, J9211, J9212, J9213, J9214, J9215, J9216, J9217, J9218, J9219, J9225, J9226, J9230, J9245, J9250, J9260, J9261, J9263, J9264, J9265, J9266, J9268, J9270, J9280, J9290, J9291, J9293, J9300, J9303, J9305, J9310, J9320, J9340, J9350, J9355, J9357, J9360, J9370, J9375, J9380, J9390, J9395, J9600, J9999
|Chemotherapy drugs code range|
|G0265||Bryopreservation, freezing and storage of cells for thereapeutic use, each cell line|
|G0266||Thawing and expansion of frozen cells for therapeuticuse, each cell line|
|G0267||Bone marrow or peripheral stem-cell harvest, modification or treatment to eliminate cell type(s) (e.g., T cells, metastic carcinoma)|
|S2150||Bone marrow or blood-derived peripheral stem-cell harvesting and transplantation, allogeneic or autologous, including pheresis, high-dose chemotherapy, and the number of days of post-transplant care in the global definition (including drugs; hospitalization; medical surgical, diagnostic and emergency services)|
|ICD-10-CM (effective 10/1/15)||C71.0-C71.9||Malignant neoplasm of brain|
|ICD-10-PCS (effective 10/1/15)||ICD-10-PCS codes are only used for inpatient services.|
|30243G0, 30243X0, 30243Y0||Percutaneous transfusion, central vein, bone marrow or stem cells, autologous, code list|
|30243G1, 30243X1, 30243Y1||Percutaneous transfusion, central vein, bone marrow or stem cells, nonautologous, code list|
|07DQ0ZZ, 07DQ3ZZ, 07DR0ZZ, 07DR3ZZ, 07DS0ZZ, 07DS3ZZ||Surgical, lymphatic and hemic systems, extraction, bone marrow, code list|
|Type of Service||Therapy|
|Place of Service||Inpatient/Outpatient|
Ependymoma, High-dose Chemotherapy
Ependymoblastoma, High-dose Chemotherapy
High-dose chemotherapy with autologous stem-cell support for PNET and ependymoma
Medulloblastoma, High-dose Chemotherapy
Neuroblastoma, Central, High-dose Chemotherapy
Pinealblastoma, High-dose Chemotherapy
Primitive Neuroectodermal Tumors (PNET), High-dose Chemotherapy
|12/01/99||Add to Therapy section||New policy
Policy represents revision of 8.01.15 to focus entirely on PNET. |
J9062 | Cisplatin 50 MG injection | HCPCS | 2007;49(1):34-40. - National Comprehensive Cancer Network (NCCN). Central Nervous System Cancers 2014; http://www.nccn.org/professionals/physician_gls/PDF/cns.pdf. Accessed September 10, 2014. |CPT||38204||Management of recipient hematopoietic cell donor search and cell acquisition|
|38205||Blood-derived hematopoietic progenitor cell harvesting for transplantaion, per collection, allogeneic|
|38208||Transplant preparation of hematopoietic progenitor cells; thawing of previously frozen harvest, without washing, per donor|
|38209||;thawing of previously frozen harvest with washing, per donor|
|38210||Specific cell depletion with harvest, T cell depletion|
|38211||Tumor cell depletion|
|38212||Red blood cell removal|
|38214||Plasma (volume) depletion|
|38215||Cell concentration in plasma, mononuclear, or buffy coat layer|
|38220||Bone marrow; aspiration only|
|38221||Bone marrow; biopsy, needle or trocar|
|38230||Bone marrow harvesting for transplantation; allogeneic|
|38232||bone marrow harvesting for transplnation; autologous|
|38240||Bone marrow or blod-derived [eropheral stem-cell transplatation; allogeneic|
|ICD-9 Procedure||41.00||Bone marrow transplant, not otherwise specified|
|41.01||Autologous bone marrow transplant without purging|
|41.02||Allogeneic hone marrow transplant with purging|
|41.03||Allogeneic bone marrow transplant without purging|
|41.04||Autologous hematopoietic stem-cell transplant without purging|
|41.05||Allogeneic hematopoietic stem cell transplant without purging|
|41.06||Cord blood stem cell transplant|
|41.07||Autologous hematopoietic stem-cell transplant with purging|
|41.08||Allogeneic hematopoietic stem-cell transplant with purging|
|41.09||Autologous bone marrow transplant with purging|
|41.91||Aspiration of bone marrow from donor for transplant|
|99.79||Other therapeutic apheresis (includes harvest of stem cells)|
|ICD-9 Diagnosis||191.0–191.9||Malignant neoplasm of brain code range|
|HCPCS||Q0083, Q0084, Q0085||Chemotherapy administration code range|
J9000, J9001, J9010, J9015, J9017, J9020, J9025, J9027, J9031, J9035, J9041, J9045, J9050, J9055, J9060, J9062, J9065, J9070, J9080, J9090, J9091, J9092, J9093, J9094, J9095, J9096, J9097, J9098, J9100, J9110, J9120, J9130, J9140, J9150, J9151, J9160, J9165, J9170, J9175, J9178, J9181, J9182, J9185, J9190, J9200, J9201, J9202, J9206, J9208, J9209, J9211, J9212, J9213, J9214, J9215, J9216, J9217, J9218, J9219, J9225, J9226, J9230, J9245, J9250, J9260, J9261, J9263, J9264, J9265, J9266, J9268, J9270, J9280, J9290, J9291, J9293, J9300, J9303, J9305, J9310, J9320, J9340, J9350, J9355, J9357, J9360, J9370, J9375, J9380, J9390, J9395, J9600, J9999
|Chemotherapy drugs code range|
|G0265||Bryopreservation, freezing and storage of cells for thereapeutic use, each cell line|
|G0266||Thawing and expansion of frozen cells for therapeuticuse, each cell line|
|G0267||Bone marrow or peripheral stem-cell harvest, modification or treatment to eliminate cell type(s) (e.g., T cells, metastic carcinoma)|
|S2150||Bone marrow or blood-derived peripheral stem-cell harvesting and transplantation, allogeneic or autologous, including pheresis, high-dose chemotherapy, and the number of days of post-transplant care in the global definition (including drugs; hospitalization; medical surgical, diagnostic and emergency services)|
|ICD-10-CM (effective 10/1/15)||C71.0-C71.9||Malignant neoplasm of brain|
|ICD-10-PCS (effective 10/1/15)||ICD-10-PCS codes are only used for inpatient services.|
|30243G0, 30243X0, 30243Y0||Percutaneous transfusion, central vein, bone marrow or stem cells, autologous, code list|
|30243G1, 30243X1, 30243Y1||Percutaneous transfusion, central vein, bone marrow or stem cells, nonautologous, code list|
|07DQ0ZZ, 07DQ3ZZ, 07DR0ZZ, 07DR3ZZ, 07DS0ZZ, 07DS3ZZ||Surgical, lymphatic and hemic systems, extraction, bone marrow, code list|
|Type of Service||Therapy|
|Place of Service||Inpatient/Outpatient|
Ependymoma, High-dose Chemotherapy
Ependymoblastoma, High-dose Chemotherapy
High-dose chemotherapy with autologous stem-cell support for PNET and ependymoma
Medulloblastoma, High-dose Chemotherapy
Neuroblastoma, Central, High-dose Chemotherapy
Pinealblastoma, High-dose Chemotherapy
Primitive Neuroectodermal Tumors (PNET), High-dose Chemotherapy
|12/01/99||Add to Therapy section||New policy
Policy represents revision of 8.01.15 to focus entirely on PNET. |
J9045 | INJECTION, CARBOPLATIN, 50 MG | HCPCS | 2007;49(1):34-40. - National Comprehensive Cancer Network (NCCN). Central Nervous System Cancers 2014; http://www.nccn.org/professionals/physician_gls/PDF/cns.pdf. Accessed September 10, 2014. |CPT||38204||Management of recipient hematopoietic cell donor search and cell acquisition|
|38205||Blood-derived hematopoietic progenitor cell harvesting for transplantaion, per collection, allogeneic|
|38208||Transplant preparation of hematopoietic progenitor cells; thawing of previously frozen harvest, without washing, per donor|
|38209||;thawing of previously frozen harvest with washing, per donor|
|38210||Specific cell depletion with harvest, T cell depletion|
|38211||Tumor cell depletion|
|38212||Red blood cell removal|
|38214||Plasma (volume) depletion|
|38215||Cell concentration in plasma, mononuclear, or buffy coat layer|
|38220||Bone marrow; aspiration only|
|38221||Bone marrow; biopsy, needle or trocar|
|38230||Bone marrow harvesting for transplantation; allogeneic|
|38232||bone marrow harvesting for transplnation; autologous|
|38240||Bone marrow or blod-derived [eropheral stem-cell transplatation; allogeneic|
|ICD-9 Procedure||41.00||Bone marrow transplant, not otherwise specified|
|41.01||Autologous bone marrow transplant without purging|
|41.02||Allogeneic hone marrow transplant with purging|
|41.03||Allogeneic bone marrow transplant without purging|
|41.04||Autologous hematopoietic stem-cell transplant without purging|
|41.05||Allogeneic hematopoietic stem cell transplant without purging|
|41.06||Cord blood stem cell transplant|
|41.07||Autologous hematopoietic stem-cell transplant with purging|
|41.08||Allogeneic hematopoietic stem-cell transplant with purging|
|41.09||Autologous bone marrow transplant with purging|
|41.91||Aspiration of bone marrow from donor for transplant|
|99.79||Other therapeutic apheresis (includes harvest of stem cells)|
|ICD-9 Diagnosis||191.0–191.9||Malignant neoplasm of brain code range|
|HCPCS||Q0083, Q0084, Q0085||Chemotherapy administration code range|
J9000, J9001, J9010, J9015, J9017, J9020, J9025, J9027, J9031, J9035, J9041, J9045, J9050, J9055, J9060, J9062, J9065, J9070, J9080, J9090, J9091, J9092, J9093, J9094, J9095, J9096, J9097, J9098, J9100, J9110, J9120, J9130, J9140, J9150, J9151, J9160, J9165, J9170, J9175, J9178, J9181, J9182, J9185, J9190, J9200, J9201, J9202, J9206, J9208, J9209, J9211, J9212, J9213, J9214, J9215, J9216, J9217, J9218, J9219, J9225, J9226, J9230, J9245, J9250, J9260, J9261, J9263, J9264, J9265, J9266, J9268, J9270, J9280, J9290, J9291, J9293, J9300, J9303, J9305, J9310, J9320, J9340, J9350, J9355, J9357, J9360, J9370, J9375, J9380, J9390, J9395, J9600, J9999
|Chemotherapy drugs code range|
|G0265||Bryopreservation, freezing and storage of cells for thereapeutic use, each cell line|
|G0266||Thawing and expansion of frozen cells for therapeuticuse, each cell line|
|G0267||Bone marrow or peripheral stem-cell harvest, modification or treatment to eliminate cell type(s) (e.g., T cells, metastic carcinoma)|
|S2150||Bone marrow or blood-derived peripheral stem-cell harvesting and transplantation, allogeneic or autologous, including pheresis, high-dose chemotherapy, and the number of days of post-transplant care in the global definition (including drugs; hospitalization; medical surgical, diagnostic and emergency services)|
|ICD-10-CM (effective 10/1/15)||C71.0-C71.9||Malignant neoplasm of brain|
|ICD-10-PCS (effective 10/1/15)||ICD-10-PCS codes are only used for inpatient services.|
|30243G0, 30243X0, 30243Y0||Percutaneous transfusion, central vein, bone marrow or stem cells, autologous, code list|
|30243G1, 30243X1, 30243Y1||Percutaneous transfusion, central vein, bone marrow or stem cells, nonautologous, code list|
|07DQ0ZZ, 07DQ3ZZ, 07DR0ZZ, 07DR3ZZ, 07DS0ZZ, 07DS3ZZ||Surgical, lymphatic and hemic systems, extraction, bone marrow, code list|
|Type of Service||Therapy|
|Place of Service||Inpatient/Outpatient|
Ependymoma, High-dose Chemotherapy
Ependymoblastoma, High-dose Chemotherapy
High-dose chemotherapy with autologous stem-cell support for PNET and ependymoma
Medulloblastoma, High-dose Chemotherapy
Neuroblastoma, Central, High-dose Chemotherapy
Pinealblastoma, High-dose Chemotherapy
Primitive Neuroectodermal Tumors (PNET), High-dose Chemotherapy
|12/01/99||Add to Therapy section||New policy
Policy represents revision of 8.01.15 to focus entirely on PNET. |
J9263 | oxaliplatin per 0.5 mg | HCPCS | 2007;49(1):34-40. - National Comprehensive Cancer Network (NCCN). Central Nervous System Cancers 2014; http://www.nccn.org/professionals/physician_gls/PDF/cns.pdf. Accessed September 10, 2014. |CPT||38204||Management of recipient hematopoietic cell donor search and cell acquisition|
|38205||Blood-derived hematopoietic progenitor cell harvesting for transplantaion, per collection, allogeneic|
|38208||Transplant preparation of hematopoietic progenitor cells; thawing of previously frozen harvest, without washing, per donor|
|38209||;thawing of previously frozen harvest with washing, per donor|
|38210||Specific cell depletion with harvest, T cell depletion|
|38211||Tumor cell depletion|
|38212||Red blood cell removal|
|38214||Plasma (volume) depletion|
|38215||Cell concentration in plasma, mononuclear, or buffy coat layer|
|38220||Bone marrow; aspiration only|
|38221||Bone marrow; biopsy, needle or trocar|
|38230||Bone marrow harvesting for transplantation; allogeneic|
|38232||bone marrow harvesting for transplnation; autologous|
|38240||Bone marrow or blod-derived [eropheral stem-cell transplatation; allogeneic|
|ICD-9 Procedure||41.00||Bone marrow transplant, not otherwise specified|
|41.01||Autologous bone marrow transplant without purging|
|41.02||Allogeneic hone marrow transplant with purging|
|41.03||Allogeneic bone marrow transplant without purging|
|41.04||Autologous hematopoietic stem-cell transplant without purging|
|41.05||Allogeneic hematopoietic stem cell transplant without purging|
|41.06||Cord blood stem cell transplant|
|41.07||Autologous hematopoietic stem-cell transplant with purging|
|41.08||Allogeneic hematopoietic stem-cell transplant with purging|
|41.09||Autologous bone marrow transplant with purging|
|41.91||Aspiration of bone marrow from donor for transplant|
|99.79||Other therapeutic apheresis (includes harvest of stem cells)|
|ICD-9 Diagnosis||191.0–191.9||Malignant neoplasm of brain code range|
|HCPCS||Q0083, Q0084, Q0085||Chemotherapy administration code range|
J9000, J9001, J9010, J9015, J9017, J9020, J9025, J9027, J9031, J9035, J9041, J9045, J9050, J9055, J9060, J9062, J9065, J9070, J9080, J9090, J9091, J9092, J9093, J9094, J9095, J9096, J9097, J9098, J9100, J9110, J9120, J9130, J9140, J9150, J9151, J9160, J9165, J9170, J9175, J9178, J9181, J9182, J9185, J9190, J9200, J9201, J9202, J9206, J9208, J9209, J9211, J9212, J9213, J9214, J9215, J9216, J9217, J9218, J9219, J9225, J9226, J9230, J9245, J9250, J9260, J9261, J9263, J9264, J9265, J9266, J9268, J9270, J9280, J9290, J9291, J9293, J9300, J9303, J9305, J9310, J9320, J9340, J9350, J9355, J9357, J9360, J9370, J9375, J9380, J9390, J9395, J9600, J9999
|Chemotherapy drugs code range|
|G0265||Bryopreservation, freezing and storage of cells for thereapeutic use, each cell line|
|G0266||Thawing and expansion of frozen cells for therapeuticuse, each cell line|
|G0267||Bone marrow or peripheral stem-cell harvest, modification or treatment to eliminate cell type(s) (e.g., T cells, metastic carcinoma)|
|S2150||Bone marrow or blood-derived peripheral stem-cell harvesting and transplantation, allogeneic or autologous, including pheresis, high-dose chemotherapy, and the number of days of post-transplant care in the global definition (including drugs; hospitalization; medical surgical, diagnostic and emergency services)|
|ICD-10-CM (effective 10/1/15)||C71.0-C71.9||Malignant neoplasm of brain|
|ICD-10-PCS (effective 10/1/15)||ICD-10-PCS codes are only used for inpatient services.|
|30243G0, 30243X0, 30243Y0||Percutaneous transfusion, central vein, bone marrow or stem cells, autologous, code list|
|30243G1, 30243X1, 30243Y1||Percutaneous transfusion, central vein, bone marrow or stem cells, nonautologous, code list|
|07DQ0ZZ, 07DQ3ZZ, 07DR0ZZ, 07DR3ZZ, 07DS0ZZ, 07DS3ZZ||Surgical, lymphatic and hemic systems, extraction, bone marrow, code list|
|Type of Service||Therapy|
|Place of Service||Inpatient/Outpatient|
Ependymoma, High-dose Chemotherapy
Ependymoblastoma, High-dose Chemotherapy
High-dose chemotherapy with autologous stem-cell support for PNET and ependymoma
Medulloblastoma, High-dose Chemotherapy
Neuroblastoma, Central, High-dose Chemotherapy
Pinealblastoma, High-dose Chemotherapy
Primitive Neuroectodermal Tumors (PNET), High-dose Chemotherapy
|12/01/99||Add to Therapy section||New policy
Policy represents revision of 8.01.15 to focus entirely on PNET. |
J9060 | INJECTION, CISPLATIN, POWDER OR SOLUTION, 10 MG | HCPCS | 2007;49(1):34-40. - National Comprehensive Cancer Network (NCCN). Central Nervous System Cancers 2014; http://www.nccn.org/professionals/physician_gls/PDF/cns.pdf. Accessed September 10, 2014. |CPT||38204||Management of recipient hematopoietic cell donor search and cell acquisition|
|38205||Blood-derived hematopoietic progenitor cell harvesting for transplantaion, per collection, allogeneic|
|38208||Transplant preparation of hematopoietic progenitor cells; thawing of previously frozen harvest, without washing, per donor|
|38209||;thawing of previously frozen harvest with washing, per donor|
|38210||Specific cell depletion with harvest, T cell depletion|
|38211||Tumor cell depletion|
|38212||Red blood cell removal|
|38214||Plasma (volume) depletion|
|38215||Cell concentration in plasma, mononuclear, or buffy coat layer|
|38220||Bone marrow; aspiration only|
|38221||Bone marrow; biopsy, needle or trocar|
|38230||Bone marrow harvesting for transplantation; allogeneic|
|38232||bone marrow harvesting for transplnation; autologous|
|38240||Bone marrow or blod-derived [eropheral stem-cell transplatation; allogeneic|
|ICD-9 Procedure||41.00||Bone marrow transplant, not otherwise specified|
|41.01||Autologous bone marrow transplant without purging|
|41.02||Allogeneic hone marrow transplant with purging|
|41.03||Allogeneic bone marrow transplant without purging|
|41.04||Autologous hematopoietic stem-cell transplant without purging|
|41.05||Allogeneic hematopoietic stem cell transplant without purging|
|41.06||Cord blood stem cell transplant|
|41.07||Autologous hematopoietic stem-cell transplant with purging|
|41.08||Allogeneic hematopoietic stem-cell transplant with purging|
|41.09||Autologous bone marrow transplant with purging|
|41.91||Aspiration of bone marrow from donor for transplant|
|99.79||Other therapeutic apheresis (includes harvest of stem cells)|
|ICD-9 Diagnosis||191.0–191.9||Malignant neoplasm of brain code range|
|HCPCS||Q0083, Q0084, Q0085||Chemotherapy administration code range|
J9000, J9001, J9010, J9015, J9017, J9020, J9025, J9027, J9031, J9035, J9041, J9045, J9050, J9055, J9060, J9062, J9065, J9070, J9080, J9090, J9091, J9092, J9093, J9094, J9095, J9096, J9097, J9098, J9100, J9110, J9120, J9130, J9140, J9150, J9151, J9160, J9165, J9170, J9175, J9178, J9181, J9182, J9185, J9190, J9200, J9201, J9202, J9206, J9208, J9209, J9211, J9212, J9213, J9214, J9215, J9216, J9217, J9218, J9219, J9225, J9226, J9230, J9245, J9250, J9260, J9261, J9263, J9264, J9265, J9266, J9268, J9270, J9280, J9290, J9291, J9293, J9300, J9303, J9305, J9310, J9320, J9340, J9350, J9355, J9357, J9360, J9370, J9375, J9380, J9390, J9395, J9600, J9999
|Chemotherapy drugs code range|
|G0265||Bryopreservation, freezing and storage of cells for thereapeutic use, each cell line|
|G0266||Thawing and expansion of frozen cells for therapeuticuse, each cell line|
|G0267||Bone marrow or peripheral stem-cell harvest, modification or treatment to eliminate cell type(s) (e.g., T cells, metastic carcinoma)|
|S2150||Bone marrow or blood-derived peripheral stem-cell harvesting and transplantation, allogeneic or autologous, including pheresis, high-dose chemotherapy, and the number of days of post-transplant care in the global definition (including drugs; hospitalization; medical surgical, diagnostic and emergency services)|
|ICD-10-CM (effective 10/1/15)||C71.0-C71.9||Malignant neoplasm of brain|
|ICD-10-PCS (effective 10/1/15)||ICD-10-PCS codes are only used for inpatient services.|
|30243G0, 30243X0, 30243Y0||Percutaneous transfusion, central vein, bone marrow or stem cells, autologous, code list|
|30243G1, 30243X1, 30243Y1||Percutaneous transfusion, central vein, bone marrow or stem cells, nonautologous, code list|
|07DQ0ZZ, 07DQ3ZZ, 07DR0ZZ, 07DR3ZZ, 07DS0ZZ, 07DS3ZZ||Surgical, lymphatic and hemic systems, extraction, bone marrow, code list|
|Type of Service||Therapy|
|Place of Service||Inpatient/Outpatient|
Ependymoma, High-dose Chemotherapy
Ependymoblastoma, High-dose Chemotherapy
High-dose chemotherapy with autologous stem-cell support for PNET and ependymoma
Medulloblastoma, High-dose Chemotherapy
Neuroblastoma, Central, High-dose Chemotherapy
Pinealblastoma, High-dose Chemotherapy
Primitive Neuroectodermal Tumors (PNET), High-dose Chemotherapy
|12/01/99||Add to Therapy section||New policy
Policy represents revision of 8.01.15 to focus entirely on PNET. |
G0265 | Cryopresevation Freeze+stora | CPT | 2007;49(1):34-40. - National Comprehensive Cancer Network (NCCN). Central Nervous System Cancers 2014; http://www.nccn.org/professionals/physician_gls/PDF/cns.pdf. Accessed September 10, 2014. |CPT||38204||Management of recipient hematopoietic cell donor search and cell acquisition|
|38205||Blood-derived hematopoietic progenitor cell harvesting for transplantaion, per collection, allogeneic|
|38208||Transplant preparation of hematopoietic progenitor cells; thawing of previously frozen harvest, without washing, per donor|
|38209||;thawing of previously frozen harvest with washing, per donor|
|38210||Specific cell depletion with harvest, T cell depletion|
|38211||Tumor cell depletion|
|38212||Red blood cell removal|
|38214||Plasma (volume) depletion|
|38215||Cell concentration in plasma, mononuclear, or buffy coat layer|
|38220||Bone marrow; aspiration only|
|38221||Bone marrow; biopsy, needle or trocar|
|38230||Bone marrow harvesting for transplantation; allogeneic|
|38232||bone marrow harvesting for transplnation; autologous|
|38240||Bone marrow or blod-derived [eropheral stem-cell transplatation; allogeneic|
|ICD-9 Procedure||41.00||Bone marrow transplant, not otherwise specified|
|41.01||Autologous bone marrow transplant without purging|
|41.02||Allogeneic hone marrow transplant with purging|
|41.03||Allogeneic bone marrow transplant without purging|
|41.04||Autologous hematopoietic stem-cell transplant without purging|
|41.05||Allogeneic hematopoietic stem cell transplant without purging|
|41.06||Cord blood stem cell transplant|
|41.07||Autologous hematopoietic stem-cell transplant with purging|
|41.08||Allogeneic hematopoietic stem-cell transplant with purging|
|41.09||Autologous bone marrow transplant with purging|
|41.91||Aspiration of bone marrow from donor for transplant|
|99.79||Other therapeutic apheresis (includes harvest of stem cells)|
|ICD-9 Diagnosis||191.0–191.9||Malignant neoplasm of brain code range|
|HCPCS||Q0083, Q0084, Q0085||Chemotherapy administration code range|
J9000, J9001, J9010, J9015, J9017, J9020, J9025, J9027, J9031, J9035, J9041, J9045, J9050, J9055, J9060, J9062, J9065, J9070, J9080, J9090, J9091, J9092, J9093, J9094, J9095, J9096, J9097, J9098, J9100, J9110, J9120, J9130, J9140, J9150, J9151, J9160, J9165, J9170, J9175, J9178, J9181, J9182, J9185, J9190, J9200, J9201, J9202, J9206, J9208, J9209, J9211, J9212, J9213, J9214, J9215, J9216, J9217, J9218, J9219, J9225, J9226, J9230, J9245, J9250, J9260, J9261, J9263, J9264, J9265, J9266, J9268, J9270, J9280, J9290, J9291, J9293, J9300, J9303, J9305, J9310, J9320, J9340, J9350, J9355, J9357, J9360, J9370, J9375, J9380, J9390, J9395, J9600, J9999
|Chemotherapy drugs code range|
|G0265||Bryopreservation, freezing and storage of cells for thereapeutic use, each cell line|
|G0266||Thawing and expansion of frozen cells for therapeuticuse, each cell line|
|G0267||Bone marrow or peripheral stem-cell harvest, modification or treatment to eliminate cell type(s) (e.g., T cells, metastic carcinoma)|
|S2150||Bone marrow or blood-derived peripheral stem-cell harvesting and transplantation, allogeneic or autologous, including pheresis, high-dose chemotherapy, and the number of days of post-transplant care in the global definition (including drugs; hospitalization; medical surgical, diagnostic and emergency services)|
|ICD-10-CM (effective 10/1/15)||C71.0-C71.9||Malignant neoplasm of brain|
|ICD-10-PCS (effective 10/1/15)||ICD-10-PCS codes are only used for inpatient services.|
|30243G0, 30243X0, 30243Y0||Percutaneous transfusion, central vein, bone marrow or stem cells, autologous, code list|
|30243G1, 30243X1, 30243Y1||Percutaneous transfusion, central vein, bone marrow or stem cells, nonautologous, code list|
|07DQ0ZZ, 07DQ3ZZ, 07DR0ZZ, 07DR3ZZ, 07DS0ZZ, 07DS3ZZ||Surgical, lymphatic and hemic systems, extraction, bone marrow, code list|
|Type of Service||Therapy|
|Place of Service||Inpatient/Outpatient|
Ependymoma, High-dose Chemotherapy
Ependymoblastoma, High-dose Chemotherapy
High-dose chemotherapy with autologous stem-cell support for PNET and ependymoma
Medulloblastoma, High-dose Chemotherapy
Neuroblastoma, Central, High-dose Chemotherapy
Pinealblastoma, High-dose Chemotherapy
Primitive Neuroectodermal Tumors (PNET), High-dose Chemotherapy
|12/01/99||Add to Therapy section||New policy
Policy represents revision of 8.01.15 to focus entirely on PNET. |
J9151 | Injection, daunorubicin citrate, liposomal formulation, 10 mg | HCPCS | 2007;49(1):34-40. - National Comprehensive Cancer Network (NCCN). Central Nervous System Cancers 2014; http://www.nccn.org/professionals/physician_gls/PDF/cns.pdf. Accessed September 10, 2014. |CPT||38204||Management of recipient hematopoietic cell donor search and cell acquisition|
|38205||Blood-derived hematopoietic progenitor cell harvesting for transplantaion, per collection, allogeneic|
|38208||Transplant preparation of hematopoietic progenitor cells; thawing of previously frozen harvest, without washing, per donor|
|38209||;thawing of previously frozen harvest with washing, per donor|
|38210||Specific cell depletion with harvest, T cell depletion|
|38211||Tumor cell depletion|
|38212||Red blood cell removal|
|38214||Plasma (volume) depletion|
|38215||Cell concentration in plasma, mononuclear, or buffy coat layer|
|38220||Bone marrow; aspiration only|
|38221||Bone marrow; biopsy, needle or trocar|
|38230||Bone marrow harvesting for transplantation; allogeneic|
|38232||bone marrow harvesting for transplnation; autologous|
|38240||Bone marrow or blod-derived [eropheral stem-cell transplatation; allogeneic|
|ICD-9 Procedure||41.00||Bone marrow transplant, not otherwise specified|
|41.01||Autologous bone marrow transplant without purging|
|41.02||Allogeneic hone marrow transplant with purging|
|41.03||Allogeneic bone marrow transplant without purging|
|41.04||Autologous hematopoietic stem-cell transplant without purging|
|41.05||Allogeneic hematopoietic stem cell transplant without purging|
|41.06||Cord blood stem cell transplant|
|41.07||Autologous hematopoietic stem-cell transplant with purging|
|41.08||Allogeneic hematopoietic stem-cell transplant with purging|
|41.09||Autologous bone marrow transplant with purging|
|41.91||Aspiration of bone marrow from donor for transplant|
|99.79||Other therapeutic apheresis (includes harvest of stem cells)|
|ICD-9 Diagnosis||191.0–191.9||Malignant neoplasm of brain code range|
|HCPCS||Q0083, Q0084, Q0085||Chemotherapy administration code range|
J9000, J9001, J9010, J9015, J9017, J9020, J9025, J9027, J9031, J9035, J9041, J9045, J9050, J9055, J9060, J9062, J9065, J9070, J9080, J9090, J9091, J9092, J9093, J9094, J9095, J9096, J9097, J9098, J9100, J9110, J9120, J9130, J9140, J9150, J9151, J9160, J9165, J9170, J9175, J9178, J9181, J9182, J9185, J9190, J9200, J9201, J9202, J9206, J9208, J9209, J9211, J9212, J9213, J9214, J9215, J9216, J9217, J9218, J9219, J9225, J9226, J9230, J9245, J9250, J9260, J9261, J9263, J9264, J9265, J9266, J9268, J9270, J9280, J9290, J9291, J9293, J9300, J9303, J9305, J9310, J9320, J9340, J9350, J9355, J9357, J9360, J9370, J9375, J9380, J9390, J9395, J9600, J9999
|Chemotherapy drugs code range|
|G0265||Bryopreservation, freezing and storage of cells for thereapeutic use, each cell line|
|G0266||Thawing and expansion of frozen cells for therapeuticuse, each cell line|
|G0267||Bone marrow or peripheral stem-cell harvest, modification or treatment to eliminate cell type(s) (e.g., T cells, metastic carcinoma)|
|S2150||Bone marrow or blood-derived peripheral stem-cell harvesting and transplantation, allogeneic or autologous, including pheresis, high-dose chemotherapy, and the number of days of post-transplant care in the global definition (including drugs; hospitalization; medical surgical, diagnostic and emergency services)|
|ICD-10-CM (effective 10/1/15)||C71.0-C71.9||Malignant neoplasm of brain|
|ICD-10-PCS (effective 10/1/15)||ICD-10-PCS codes are only used for inpatient services.|
|30243G0, 30243X0, 30243Y0||Percutaneous transfusion, central vein, bone marrow or stem cells, autologous, code list|
|30243G1, 30243X1, 30243Y1||Percutaneous transfusion, central vein, bone marrow or stem cells, nonautologous, code list|
|07DQ0ZZ, 07DQ3ZZ, 07DR0ZZ, 07DR3ZZ, 07DS0ZZ, 07DS3ZZ||Surgical, lymphatic and hemic systems, extraction, bone marrow, code list|
|Type of Service||Therapy|
|Place of Service||Inpatient/Outpatient|
Ependymoma, High-dose Chemotherapy
Ependymoblastoma, High-dose Chemotherapy
High-dose chemotherapy with autologous stem-cell support for PNET and ependymoma
Medulloblastoma, High-dose Chemotherapy
Neuroblastoma, Central, High-dose Chemotherapy
Pinealblastoma, High-dose Chemotherapy
Primitive Neuroectodermal Tumors (PNET), High-dose Chemotherapy
|12/01/99||Add to Therapy section||New policy
Policy represents revision of 8.01.15 to focus entirely on PNET. |
J9230 | Mechlorethamine hcl inj | HCPCS | 2007;49(1):34-40. - National Comprehensive Cancer Network (NCCN). Central Nervous System Cancers 2014; http://www.nccn.org/professionals/physician_gls/PDF/cns.pdf. Accessed September 10, 2014. |CPT||38204||Management of recipient hematopoietic cell donor search and cell acquisition|
|38205||Blood-derived hematopoietic progenitor cell harvesting for transplantaion, per collection, allogeneic|
|38208||Transplant preparation of hematopoietic progenitor cells; thawing of previously frozen harvest, without washing, per donor|
|38209||;thawing of previously frozen harvest with washing, per donor|
|38210||Specific cell depletion with harvest, T cell depletion|
|38211||Tumor cell depletion|
|38212||Red blood cell removal|
|38214||Plasma (volume) depletion|
|38215||Cell concentration in plasma, mononuclear, or buffy coat layer|
|38220||Bone marrow; aspiration only|
|38221||Bone marrow; biopsy, needle or trocar|
|38230||Bone marrow harvesting for transplantation; allogeneic|
|38232||bone marrow harvesting for transplnation; autologous|
|38240||Bone marrow or blod-derived [eropheral stem-cell transplatation; allogeneic|
|ICD-9 Procedure||41.00||Bone marrow transplant, not otherwise specified|
|41.01||Autologous bone marrow transplant without purging|
|41.02||Allogeneic hone marrow transplant with purging|
|41.03||Allogeneic bone marrow transplant without purging|
|41.04||Autologous hematopoietic stem-cell transplant without purging|
|41.05||Allogeneic hematopoietic stem cell transplant without purging|
|41.06||Cord blood stem cell transplant|
|41.07||Autologous hematopoietic stem-cell transplant with purging|
|41.08||Allogeneic hematopoietic stem-cell transplant with purging|
|41.09||Autologous bone marrow transplant with purging|
|41.91||Aspiration of bone marrow from donor for transplant|
|99.79||Other therapeutic apheresis (includes harvest of stem cells)|
|ICD-9 Diagnosis||191.0–191.9||Malignant neoplasm of brain code range|
|HCPCS||Q0083, Q0084, Q0085||Chemotherapy administration code range|
J9000, J9001, J9010, J9015, J9017, J9020, J9025, J9027, J9031, J9035, J9041, J9045, J9050, J9055, J9060, J9062, J9065, J9070, J9080, J9090, J9091, J9092, J9093, J9094, J9095, J9096, J9097, J9098, J9100, J9110, J9120, J9130, J9140, J9150, J9151, J9160, J9165, J9170, J9175, J9178, J9181, J9182, J9185, J9190, J9200, J9201, J9202, J9206, J9208, J9209, J9211, J9212, J9213, J9214, J9215, J9216, J9217, J9218, J9219, J9225, J9226, J9230, J9245, J9250, J9260, J9261, J9263, J9264, J9265, J9266, J9268, J9270, J9280, J9290, J9291, J9293, J9300, J9303, J9305, J9310, J9320, J9340, J9350, J9355, J9357, J9360, J9370, J9375, J9380, J9390, J9395, J9600, J9999
|Chemotherapy drugs code range|
|G0265||Bryopreservation, freezing and storage of cells for thereapeutic use, each cell line|
|G0266||Thawing and expansion of frozen cells for therapeuticuse, each cell line|
|G0267||Bone marrow or peripheral stem-cell harvest, modification or treatment to eliminate cell type(s) (e.g., T cells, metastic carcinoma)|
|S2150||Bone marrow or blood-derived peripheral stem-cell harvesting and transplantation, allogeneic or autologous, including pheresis, high-dose chemotherapy, and the number of days of post-transplant care in the global definition (including drugs; hospitalization; medical surgical, diagnostic and emergency services)|
|ICD-10-CM (effective 10/1/15)||C71.0-C71.9||Malignant neoplasm of brain|
|ICD-10-PCS (effective 10/1/15)||ICD-10-PCS codes are only used for inpatient services.|
|30243G0, 30243X0, 30243Y0||Percutaneous transfusion, central vein, bone marrow or stem cells, autologous, code list|
|30243G1, 30243X1, 30243Y1||Percutaneous transfusion, central vein, bone marrow or stem cells, nonautologous, code list|
|07DQ0ZZ, 07DQ3ZZ, 07DR0ZZ, 07DR3ZZ, 07DS0ZZ, 07DS3ZZ||Surgical, lymphatic and hemic systems, extraction, bone marrow, code list|
|Type of Service||Therapy|
|Place of Service||Inpatient/Outpatient|
Ependymoma, High-dose Chemotherapy
Ependymoblastoma, High-dose Chemotherapy
High-dose chemotherapy with autologous stem-cell support for PNET and ependymoma
Medulloblastoma, High-dose Chemotherapy
Neuroblastoma, Central, High-dose Chemotherapy
Pinealblastoma, High-dose Chemotherapy
Primitive Neuroectodermal Tumors (PNET), High-dose Chemotherapy
|12/01/99||Add to Therapy section||New policy
Policy represents revision of 8.01.15 to focus entirely on PNET. |
38221 | PR DIAGNOSTIC BONE MARROW BIOPSIES | HCPCS | 2007;49(1):34-40. - National Comprehensive Cancer Network (NCCN). Central Nervous System Cancers 2014; http://www.nccn.org/professionals/physician_gls/PDF/cns.pdf. Accessed September 10, 2014. |CPT||38204||Management of recipient hematopoietic cell donor search and cell acquisition|
|38205||Blood-derived hematopoietic progenitor cell harvesting for transplantaion, per collection, allogeneic|
|38208||Transplant preparation of hematopoietic progenitor cells; thawing of previously frozen harvest, without washing, per donor|
|38209||;thawing of previously frozen harvest with washing, per donor|
|38210||Specific cell depletion with harvest, T cell depletion|
|38211||Tumor cell depletion|
|38212||Red blood cell removal|
|38214||Plasma (volume) depletion|
|38215||Cell concentration in plasma, mononuclear, or buffy coat layer|
|38220||Bone marrow; aspiration only|
|38221||Bone marrow; biopsy, needle or trocar|
|38230||Bone marrow harvesting for transplantation; allogeneic|
|38232||bone marrow harvesting for transplnation; autologous|
|38240||Bone marrow or blod-derived [eropheral stem-cell transplatation; allogeneic|
|ICD-9 Procedure||41.00||Bone marrow transplant, not otherwise specified|
|41.01||Autologous bone marrow transplant without purging|
|41.02||Allogeneic hone marrow transplant with purging|
|41.03||Allogeneic bone marrow transplant without purging|
|41.04||Autologous hematopoietic stem-cell transplant without purging|
|41.05||Allogeneic hematopoietic stem cell transplant without purging|
|41.06||Cord blood stem cell transplant|
|41.07||Autologous hematopoietic stem-cell transplant with purging|
|41.08||Allogeneic hematopoietic stem-cell transplant with purging|
|41.09||Autologous bone marrow transplant with purging|
|41.91||Aspiration of bone marrow from donor for transplant|
|99.79||Other therapeutic apheresis (includes harvest of stem cells)|
|ICD-9 Diagnosis||191.0–191.9||Malignant neoplasm of brain code range|
|HCPCS||Q0083, Q0084, Q0085||Chemotherapy administration code range|
J9000, J9001, J9010, J9015, J9017, J9020, J9025, J9027, J9031, J9035, J9041, J9045, J9050, J9055, J9060, J9062, J9065, J9070, J9080, J9090, J9091, J9092, J9093, J9094, J9095, J9096, J9097, J9098, J9100, J9110, J9120, J9130, J9140, J9150, J9151, J9160, J9165, J9170, J9175, J9178, J9181, J9182, J9185, J9190, J9200, J9201, J9202, J9206, J9208, J9209, J9211, J9212, J9213, J9214, J9215, J9216, J9217, J9218, J9219, J9225, J9226, J9230, J9245, J9250, J9260, J9261, J9263, J9264, J9265, J9266, J9268, J9270, J9280, J9290, J9291, J9293, J9300, J9303, J9305, J9310, J9320, J9340, J9350, J9355, J9357, J9360, J9370, J9375, J9380, J9390, J9395, J9600, J9999
|Chemotherapy drugs code range|
|G0265||Bryopreservation, freezing and storage of cells for thereapeutic use, each cell line|
|G0266||Thawing and expansion of frozen cells for therapeuticuse, each cell line|
|G0267||Bone marrow or peripheral stem-cell harvest, modification or treatment to eliminate cell type(s) (e.g., T cells, metastic carcinoma)|
|S2150||Bone marrow or blood-derived peripheral stem-cell harvesting and transplantation, allogeneic or autologous, including pheresis, high-dose chemotherapy, and the number of days of post-transplant care in the global definition (including drugs; hospitalization; medical surgical, diagnostic and emergency services)|
|ICD-10-CM (effective 10/1/15)||C71.0-C71.9||Malignant neoplasm of brain|
|ICD-10-PCS (effective 10/1/15)||ICD-10-PCS codes are only used for inpatient services.|
|30243G0, 30243X0, 30243Y0||Percutaneous transfusion, central vein, bone marrow or stem cells, autologous, code list|
|30243G1, 30243X1, 30243Y1||Percutaneous transfusion, central vein, bone marrow or stem cells, nonautologous, code list|
|07DQ0ZZ, 07DQ3ZZ, 07DR0ZZ, 07DR3ZZ, 07DS0ZZ, 07DS3ZZ||Surgical, lymphatic and hemic systems, extraction, bone marrow, code list|
|Type of Service||Therapy|
|Place of Service||Inpatient/Outpatient|
Ependymoma, High-dose Chemotherapy
Ependymoblastoma, High-dose Chemotherapy
High-dose chemotherapy with autologous stem-cell support for PNET and ependymoma
Medulloblastoma, High-dose Chemotherapy
Neuroblastoma, Central, High-dose Chemotherapy
Pinealblastoma, High-dose Chemotherapy
Primitive Neuroectodermal Tumors (PNET), High-dose Chemotherapy
|12/01/99||Add to Therapy section||New policy
Policy represents revision of 8.01.15 to focus entirely on PNET. |
J9140 | Dacarbazine 200 MG inj | HCPCS | 2007;49(1):34-40. - National Comprehensive Cancer Network (NCCN). Central Nervous System Cancers 2014; http://www.nccn.org/professionals/physician_gls/PDF/cns.pdf. Accessed September 10, 2014. |CPT||38204||Management of recipient hematopoietic cell donor search and cell acquisition|
|38205||Blood-derived hematopoietic progenitor cell harvesting for transplantaion, per collection, allogeneic|
|38208||Transplant preparation of hematopoietic progenitor cells; thawing of previously frozen harvest, without washing, per donor|
|38209||;thawing of previously frozen harvest with washing, per donor|
|38210||Specific cell depletion with harvest, T cell depletion|
|38211||Tumor cell depletion|
|38212||Red blood cell removal|
|38214||Plasma (volume) depletion|
|38215||Cell concentration in plasma, mononuclear, or buffy coat layer|
|38220||Bone marrow; aspiration only|
|38221||Bone marrow; biopsy, needle or trocar|
|38230||Bone marrow harvesting for transplantation; allogeneic|
|38232||bone marrow harvesting for transplnation; autologous|
|38240||Bone marrow or blod-derived [eropheral stem-cell transplatation; allogeneic|
|ICD-9 Procedure||41.00||Bone marrow transplant, not otherwise specified|
|41.01||Autologous bone marrow transplant without purging|
|41.02||Allogeneic hone marrow transplant with purging|
|41.03||Allogeneic bone marrow transplant without purging|
|41.04||Autologous hematopoietic stem-cell transplant without purging|
|41.05||Allogeneic hematopoietic stem cell transplant without purging|
|41.06||Cord blood stem cell transplant|
|41.07||Autologous hematopoietic stem-cell transplant with purging|
|41.08||Allogeneic hematopoietic stem-cell transplant with purging|
|41.09||Autologous bone marrow transplant with purging|
|41.91||Aspiration of bone marrow from donor for transplant|
|99.79||Other therapeutic apheresis (includes harvest of stem cells)|
|ICD-9 Diagnosis||191.0–191.9||Malignant neoplasm of brain code range|
|HCPCS||Q0083, Q0084, Q0085||Chemotherapy administration code range|
J9000, J9001, J9010, J9015, J9017, J9020, J9025, J9027, J9031, J9035, J9041, J9045, J9050, J9055, J9060, J9062, J9065, J9070, J9080, J9090, J9091, J9092, J9093, J9094, J9095, J9096, J9097, J9098, J9100, J9110, J9120, J9130, J9140, J9150, J9151, J9160, J9165, J9170, J9175, J9178, J9181, J9182, J9185, J9190, J9200, J9201, J9202, J9206, J9208, J9209, J9211, J9212, J9213, J9214, J9215, J9216, J9217, J9218, J9219, J9225, J9226, J9230, J9245, J9250, J9260, J9261, J9263, J9264, J9265, J9266, J9268, J9270, J9280, J9290, J9291, J9293, J9300, J9303, J9305, J9310, J9320, J9340, J9350, J9355, J9357, J9360, J9370, J9375, J9380, J9390, J9395, J9600, J9999
|Chemotherapy drugs code range|
|G0265||Bryopreservation, freezing and storage of cells for thereapeutic use, each cell line|
|G0266||Thawing and expansion of frozen cells for therapeuticuse, each cell line|
|G0267||Bone marrow or peripheral stem-cell harvest, modification or treatment to eliminate cell type(s) (e.g., T cells, metastic carcinoma)|
|S2150||Bone marrow or blood-derived peripheral stem-cell harvesting and transplantation, allogeneic or autologous, including pheresis, high-dose chemotherapy, and the number of days of post-transplant care in the global definition (including drugs; hospitalization; medical surgical, diagnostic and emergency services)|
|ICD-10-CM (effective 10/1/15)||C71.0-C71.9||Malignant neoplasm of brain|
|ICD-10-PCS (effective 10/1/15)||ICD-10-PCS codes are only used for inpatient services.|
|30243G0, 30243X0, 30243Y0||Percutaneous transfusion, central vein, bone marrow or stem cells, autologous, code list|
|30243G1, 30243X1, 30243Y1||Percutaneous transfusion, central vein, bone marrow or stem cells, nonautologous, code list|
|07DQ0ZZ, 07DQ3ZZ, 07DR0ZZ, 07DR3ZZ, 07DS0ZZ, 07DS3ZZ||Surgical, lymphatic and hemic systems, extraction, bone marrow, code list|
|Type of Service||Therapy|
|Place of Service||Inpatient/Outpatient|
Ependymoma, High-dose Chemotherapy
Ependymoblastoma, High-dose Chemotherapy
High-dose chemotherapy with autologous stem-cell support for PNET and ependymoma
Medulloblastoma, High-dose Chemotherapy
Neuroblastoma, Central, High-dose Chemotherapy
Pinealblastoma, High-dose Chemotherapy
Primitive Neuroectodermal Tumors (PNET), High-dose Chemotherapy
|12/01/99||Add to Therapy section||New policy
Policy represents revision of 8.01.15 to focus entirely on PNET. |
J9100 | INJECTION, CYTARABINE, 100 MG | HCPCS | 2007;49(1):34-40. - National Comprehensive Cancer Network (NCCN). Central Nervous System Cancers 2014; http://www.nccn.org/professionals/physician_gls/PDF/cns.pdf. Accessed September 10, 2014. |CPT||38204||Management of recipient hematopoietic cell donor search and cell acquisition|
|38205||Blood-derived hematopoietic progenitor cell harvesting for transplantaion, per collection, allogeneic|
|38208||Transplant preparation of hematopoietic progenitor cells; thawing of previously frozen harvest, without washing, per donor|
|38209||;thawing of previously frozen harvest with washing, per donor|
|38210||Specific cell depletion with harvest, T cell depletion|
|38211||Tumor cell depletion|
|38212||Red blood cell removal|
|38214||Plasma (volume) depletion|
|38215||Cell concentration in plasma, mononuclear, or buffy coat layer|
|38220||Bone marrow; aspiration only|
|38221||Bone marrow; biopsy, needle or trocar|
|38230||Bone marrow harvesting for transplantation; allogeneic|
|38232||bone marrow harvesting for transplnation; autologous|
|38240||Bone marrow or blod-derived [eropheral stem-cell transplatation; allogeneic|
|ICD-9 Procedure||41.00||Bone marrow transplant, not otherwise specified|
|41.01||Autologous bone marrow transplant without purging|
|41.02||Allogeneic hone marrow transplant with purging|
|41.03||Allogeneic bone marrow transplant without purging|
|41.04||Autologous hematopoietic stem-cell transplant without purging|
|41.05||Allogeneic hematopoietic stem cell transplant without purging|
|41.06||Cord blood stem cell transplant|
|41.07||Autologous hematopoietic stem-cell transplant with purging|
|41.08||Allogeneic hematopoietic stem-cell transplant with purging|
|41.09||Autologous bone marrow transplant with purging|
|41.91||Aspiration of bone marrow from donor for transplant|
|99.79||Other therapeutic apheresis (includes harvest of stem cells)|
|ICD-9 Diagnosis||191.0–191.9||Malignant neoplasm of brain code range|
|HCPCS||Q0083, Q0084, Q0085||Chemotherapy administration code range|
J9000, J9001, J9010, J9015, J9017, J9020, J9025, J9027, J9031, J9035, J9041, J9045, J9050, J9055, J9060, J9062, J9065, J9070, J9080, J9090, J9091, J9092, J9093, J9094, J9095, J9096, J9097, J9098, J9100, J9110, J9120, J9130, J9140, J9150, J9151, J9160, J9165, J9170, J9175, J9178, J9181, J9182, J9185, J9190, J9200, J9201, J9202, J9206, J9208, J9209, J9211, J9212, J9213, J9214, J9215, J9216, J9217, J9218, J9219, J9225, J9226, J9230, J9245, J9250, J9260, J9261, J9263, J9264, J9265, J9266, J9268, J9270, J9280, J9290, J9291, J9293, J9300, J9303, J9305, J9310, J9320, J9340, J9350, J9355, J9357, J9360, J9370, J9375, J9380, J9390, J9395, J9600, J9999
|Chemotherapy drugs code range|
|G0265||Bryopreservation, freezing and storage of cells for thereapeutic use, each cell line|
|G0266||Thawing and expansion of frozen cells for therapeuticuse, each cell line|
|G0267||Bone marrow or peripheral stem-cell harvest, modification or treatment to eliminate cell type(s) (e.g., T cells, metastic carcinoma)|
|S2150||Bone marrow or blood-derived peripheral stem-cell harvesting and transplantation, allogeneic or autologous, including pheresis, high-dose chemotherapy, and the number of days of post-transplant care in the global definition (including drugs; hospitalization; medical surgical, diagnostic and emergency services)|
|ICD-10-CM (effective 10/1/15)||C71.0-C71.9||Malignant neoplasm of brain|
|ICD-10-PCS (effective 10/1/15)||ICD-10-PCS codes are only used for inpatient services.|
|30243G0, 30243X0, 30243Y0||Percutaneous transfusion, central vein, bone marrow or stem cells, autologous, code list|
|30243G1, 30243X1, 30243Y1||Percutaneous transfusion, central vein, bone marrow or stem cells, nonautologous, code list|
|07DQ0ZZ, 07DQ3ZZ, 07DR0ZZ, 07DR3ZZ, 07DS0ZZ, 07DS3ZZ||Surgical, lymphatic and hemic systems, extraction, bone marrow, code list|
|Type of Service||Therapy|
|Place of Service||Inpatient/Outpatient|
Ependymoma, High-dose Chemotherapy
Ependymoblastoma, High-dose Chemotherapy
High-dose chemotherapy with autologous stem-cell support for PNET and ependymoma
Medulloblastoma, High-dose Chemotherapy
Neuroblastoma, Central, High-dose Chemotherapy
Pinealblastoma, High-dose Chemotherapy
Primitive Neuroectodermal Tumors (PNET), High-dose Chemotherapy
|12/01/99||Add to Therapy section||New policy
Policy represents revision of 8.01.15 to focus entirely on PNET. |
J9010 | DOXORUBICIN HCL, 50 MG | HCPCS | 2007;49(1):34-40. - National Comprehensive Cancer Network (NCCN). Central Nervous System Cancers 2014; http://www.nccn.org/professionals/physician_gls/PDF/cns.pdf. Accessed September 10, 2014. |CPT||38204||Management of recipient hematopoietic cell donor search and cell acquisition|
|38205||Blood-derived hematopoietic progenitor cell harvesting for transplantaion, per collection, allogeneic|
|38208||Transplant preparation of hematopoietic progenitor cells; thawing of previously frozen harvest, without washing, per donor|
|38209||;thawing of previously frozen harvest with washing, per donor|
|38210||Specific cell depletion with harvest, T cell depletion|
|38211||Tumor cell depletion|
|38212||Red blood cell removal|
|38214||Plasma (volume) depletion|
|38215||Cell concentration in plasma, mononuclear, or buffy coat layer|
|38220||Bone marrow; aspiration only|
|38221||Bone marrow; biopsy, needle or trocar|
|38230||Bone marrow harvesting for transplantation; allogeneic|
|38232||bone marrow harvesting for transplnation; autologous|
|38240||Bone marrow or blod-derived [eropheral stem-cell transplatation; allogeneic|
|ICD-9 Procedure||41.00||Bone marrow transplant, not otherwise specified|
|41.01||Autologous bone marrow transplant without purging|
|41.02||Allogeneic hone marrow transplant with purging|
|41.03||Allogeneic bone marrow transplant without purging|
|41.04||Autologous hematopoietic stem-cell transplant without purging|
|41.05||Allogeneic hematopoietic stem cell transplant without purging|
|41.06||Cord blood stem cell transplant|
|41.07||Autologous hematopoietic stem-cell transplant with purging|
|41.08||Allogeneic hematopoietic stem-cell transplant with purging|
|41.09||Autologous bone marrow transplant with purging|
|41.91||Aspiration of bone marrow from donor for transplant|
|99.79||Other therapeutic apheresis (includes harvest of stem cells)|
|ICD-9 Diagnosis||191.0–191.9||Malignant neoplasm of brain code range|
|HCPCS||Q0083, Q0084, Q0085||Chemotherapy administration code range|
J9000, J9001, J9010, J9015, J9017, J9020, J9025, J9027, J9031, J9035, J9041, J9045, J9050, J9055, J9060, J9062, J9065, J9070, J9080, J9090, J9091, J9092, J9093, J9094, J9095, J9096, J9097, J9098, J9100, J9110, J9120, J9130, J9140, J9150, J9151, J9160, J9165, J9170, J9175, J9178, J9181, J9182, J9185, J9190, J9200, J9201, J9202, J9206, J9208, J9209, J9211, J9212, J9213, J9214, J9215, J9216, J9217, J9218, J9219, J9225, J9226, J9230, J9245, J9250, J9260, J9261, J9263, J9264, J9265, J9266, J9268, J9270, J9280, J9290, J9291, J9293, J9300, J9303, J9305, J9310, J9320, J9340, J9350, J9355, J9357, J9360, J9370, J9375, J9380, J9390, J9395, J9600, J9999
|Chemotherapy drugs code range|
|G0265||Bryopreservation, freezing and storage of cells for thereapeutic use, each cell line|
|G0266||Thawing and expansion of frozen cells for therapeuticuse, each cell line|
|G0267||Bone marrow or peripheral stem-cell harvest, modification or treatment to eliminate cell type(s) (e.g., T cells, metastic carcinoma)|
|S2150||Bone marrow or blood-derived peripheral stem-cell harvesting and transplantation, allogeneic or autologous, including pheresis, high-dose chemotherapy, and the number of days of post-transplant care in the global definition (including drugs; hospitalization; medical surgical, diagnostic and emergency services)|
|ICD-10-CM (effective 10/1/15)||C71.0-C71.9||Malignant neoplasm of brain|
|ICD-10-PCS (effective 10/1/15)||ICD-10-PCS codes are only used for inpatient services.|
|30243G0, 30243X0, 30243Y0||Percutaneous transfusion, central vein, bone marrow or stem cells, autologous, code list|
|30243G1, 30243X1, 30243Y1||Percutaneous transfusion, central vein, bone marrow or stem cells, nonautologous, code list|
|07DQ0ZZ, 07DQ3ZZ, 07DR0ZZ, 07DR3ZZ, 07DS0ZZ, 07DS3ZZ||Surgical, lymphatic and hemic systems, extraction, bone marrow, code list|
|Type of Service||Therapy|
|Place of Service||Inpatient/Outpatient|
Ependymoma, High-dose Chemotherapy
Ependymoblastoma, High-dose Chemotherapy
High-dose chemotherapy with autologous stem-cell support for PNET and ependymoma
Medulloblastoma, High-dose Chemotherapy
Neuroblastoma, Central, High-dose Chemotherapy
Pinealblastoma, High-dose Chemotherapy
Primitive Neuroectodermal Tumors (PNET), High-dose Chemotherapy
|12/01/99||Add to Therapy section||New policy
Policy represents revision of 8.01.15 to focus entirely on PNET. |
38240 | Transplt allo hct/donor | HCPCS | 2007;49(1):34-40. - National Comprehensive Cancer Network (NCCN). Central Nervous System Cancers 2014; http://www.nccn.org/professionals/physician_gls/PDF/cns.pdf. Accessed September 10, 2014. |CPT||38204||Management of recipient hematopoietic cell donor search and cell acquisition|
|38205||Blood-derived hematopoietic progenitor cell harvesting for transplantaion, per collection, allogeneic|
|38208||Transplant preparation of hematopoietic progenitor cells; thawing of previously frozen harvest, without washing, per donor|
|38209||;thawing of previously frozen harvest with washing, per donor|
|38210||Specific cell depletion with harvest, T cell depletion|
|38211||Tumor cell depletion|
|38212||Red blood cell removal|
|38214||Plasma (volume) depletion|
|38215||Cell concentration in plasma, mononuclear, or buffy coat layer|
|38220||Bone marrow; aspiration only|
|38221||Bone marrow; biopsy, needle or trocar|
|38230||Bone marrow harvesting for transplantation; allogeneic|
|38232||bone marrow harvesting for transplnation; autologous|
|38240||Bone marrow or blod-derived [eropheral stem-cell transplatation; allogeneic|
|ICD-9 Procedure||41.00||Bone marrow transplant, not otherwise specified|
|41.01||Autologous bone marrow transplant without purging|
|41.02||Allogeneic hone marrow transplant with purging|
|41.03||Allogeneic bone marrow transplant without purging|
|41.04||Autologous hematopoietic stem-cell transplant without purging|
|41.05||Allogeneic hematopoietic stem cell transplant without purging|
|41.06||Cord blood stem cell transplant|
|41.07||Autologous hematopoietic stem-cell transplant with purging|
|41.08||Allogeneic hematopoietic stem-cell transplant with purging|
|41.09||Autologous bone marrow transplant with purging|
|41.91||Aspiration of bone marrow from donor for transplant|
|99.79||Other therapeutic apheresis (includes harvest of stem cells)|
|ICD-9 Diagnosis||191.0–191.9||Malignant neoplasm of brain code range|
|HCPCS||Q0083, Q0084, Q0085||Chemotherapy administration code range|
J9000, J9001, J9010, J9015, J9017, J9020, J9025, J9027, J9031, J9035, J9041, J9045, J9050, J9055, J9060, J9062, J9065, J9070, J9080, J9090, J9091, J9092, J9093, J9094, J9095, J9096, J9097, J9098, J9100, J9110, J9120, J9130, J9140, J9150, J9151, J9160, J9165, J9170, J9175, J9178, J9181, J9182, J9185, J9190, J9200, J9201, J9202, J9206, J9208, J9209, J9211, J9212, J9213, J9214, J9215, J9216, J9217, J9218, J9219, J9225, J9226, J9230, J9245, J9250, J9260, J9261, J9263, J9264, J9265, J9266, J9268, J9270, J9280, J9290, J9291, J9293, J9300, J9303, J9305, J9310, J9320, J9340, J9350, J9355, J9357, J9360, J9370, J9375, J9380, J9390, J9395, J9600, J9999
|Chemotherapy drugs code range|
|G0265||Bryopreservation, freezing and storage of cells for thereapeutic use, each cell line|
|G0266||Thawing and expansion of frozen cells for therapeuticuse, each cell line|
|G0267||Bone marrow or peripheral stem-cell harvest, modification or treatment to eliminate cell type(s) (e.g., T cells, metastic carcinoma)|
|S2150||Bone marrow or blood-derived peripheral stem-cell harvesting and transplantation, allogeneic or autologous, including pheresis, high-dose chemotherapy, and the number of days of post-transplant care in the global definition (including drugs; hospitalization; medical surgical, diagnostic and emergency services)|
|ICD-10-CM (effective 10/1/15)||C71.0-C71.9||Malignant neoplasm of brain|
|ICD-10-PCS (effective 10/1/15)||ICD-10-PCS codes are only used for inpatient services.|
|30243G0, 30243X0, 30243Y0||Percutaneous transfusion, central vein, bone marrow or stem cells, autologous, code list|
|30243G1, 30243X1, 30243Y1||Percutaneous transfusion, central vein, bone marrow or stem cells, nonautologous, code list|
|07DQ0ZZ, 07DQ3ZZ, 07DR0ZZ, 07DR3ZZ, 07DS0ZZ, 07DS3ZZ||Surgical, lymphatic and hemic systems, extraction, bone marrow, code list|
|Type of Service||Therapy|
|Place of Service||Inpatient/Outpatient|
Ependymoma, High-dose Chemotherapy
Ependymoblastoma, High-dose Chemotherapy
High-dose chemotherapy with autologous stem-cell support for PNET and ependymoma
Medulloblastoma, High-dose Chemotherapy
Neuroblastoma, Central, High-dose Chemotherapy
Pinealblastoma, High-dose Chemotherapy
Primitive Neuroectodermal Tumors (PNET), High-dose Chemotherapy
|12/01/99||Add to Therapy section||New policy
Policy represents revision of 8.01.15 to focus entirely on PNET. |
J9015 | Injection, aldesleukin, per single use vial | HCPCS | 2007;49(1):34-40. - National Comprehensive Cancer Network (NCCN). Central Nervous System Cancers 2014; http://www.nccn.org/professionals/physician_gls/PDF/cns.pdf. Accessed September 10, 2014. |CPT||38204||Management of recipient hematopoietic cell donor search and cell acquisition|
|38205||Blood-derived hematopoietic progenitor cell harvesting for transplantaion, per collection, allogeneic|
|38208||Transplant preparation of hematopoietic progenitor cells; thawing of previously frozen harvest, without washing, per donor|
|38209||;thawing of previously frozen harvest with washing, per donor|
|38210||Specific cell depletion with harvest, T cell depletion|
|38211||Tumor cell depletion|
|38212||Red blood cell removal|
|38214||Plasma (volume) depletion|
|38215||Cell concentration in plasma, mononuclear, or buffy coat layer|
|38220||Bone marrow; aspiration only|
|38221||Bone marrow; biopsy, needle or trocar|
|38230||Bone marrow harvesting for transplantation; allogeneic|
|38232||bone marrow harvesting for transplnation; autologous|
|38240||Bone marrow or blod-derived [eropheral stem-cell transplatation; allogeneic|
|ICD-9 Procedure||41.00||Bone marrow transplant, not otherwise specified|
|41.01||Autologous bone marrow transplant without purging|
|41.02||Allogeneic hone marrow transplant with purging|
|41.03||Allogeneic bone marrow transplant without purging|
|41.04||Autologous hematopoietic stem-cell transplant without purging|
|41.05||Allogeneic hematopoietic stem cell transplant without purging|
|41.06||Cord blood stem cell transplant|
|41.07||Autologous hematopoietic stem-cell transplant with purging|
|41.08||Allogeneic hematopoietic stem-cell transplant with purging|
|41.09||Autologous bone marrow transplant with purging|
|41.91||Aspiration of bone marrow from donor for transplant|
|99.79||Other therapeutic apheresis (includes harvest of stem cells)|
|ICD-9 Diagnosis||191.0–191.9||Malignant neoplasm of brain code range|
|HCPCS||Q0083, Q0084, Q0085||Chemotherapy administration code range|
J9000, J9001, J9010, J9015, J9017, J9020, J9025, J9027, J9031, J9035, J9041, J9045, J9050, J9055, J9060, J9062, J9065, J9070, J9080, J9090, J9091, J9092, J9093, J9094, J9095, J9096, J9097, J9098, J9100, J9110, J9120, J9130, J9140, J9150, J9151, J9160, J9165, J9170, J9175, J9178, J9181, J9182, J9185, J9190, J9200, J9201, J9202, J9206, J9208, J9209, J9211, J9212, J9213, J9214, J9215, J9216, J9217, J9218, J9219, J9225, J9226, J9230, J9245, J9250, J9260, J9261, J9263, J9264, J9265, J9266, J9268, J9270, J9280, J9290, J9291, J9293, J9300, J9303, J9305, J9310, J9320, J9340, J9350, J9355, J9357, J9360, J9370, J9375, J9380, J9390, J9395, J9600, J9999
|Chemotherapy drugs code range|
|G0265||Bryopreservation, freezing and storage of cells for thereapeutic use, each cell line|
|G0266||Thawing and expansion of frozen cells for therapeuticuse, each cell line|
|G0267||Bone marrow or peripheral stem-cell harvest, modification or treatment to eliminate cell type(s) (e.g., T cells, metastic carcinoma)|
|S2150||Bone marrow or blood-derived peripheral stem-cell harvesting and transplantation, allogeneic or autologous, including pheresis, high-dose chemotherapy, and the number of days of post-transplant care in the global definition (including drugs; hospitalization; medical surgical, diagnostic and emergency services)|
|ICD-10-CM (effective 10/1/15)||C71.0-C71.9||Malignant neoplasm of brain|
|ICD-10-PCS (effective 10/1/15)||ICD-10-PCS codes are only used for inpatient services.|
|30243G0, 30243X0, 30243Y0||Percutaneous transfusion, central vein, bone marrow or stem cells, autologous, code list|
|30243G1, 30243X1, 30243Y1||Percutaneous transfusion, central vein, bone marrow or stem cells, nonautologous, code list|
|07DQ0ZZ, 07DQ3ZZ, 07DR0ZZ, 07DR3ZZ, 07DS0ZZ, 07DS3ZZ||Surgical, lymphatic and hemic systems, extraction, bone marrow, code list|
|Type of Service||Therapy|
|Place of Service||Inpatient/Outpatient|
Ependymoma, High-dose Chemotherapy
Ependymoblastoma, High-dose Chemotherapy
High-dose chemotherapy with autologous stem-cell support for PNET and ependymoma
Medulloblastoma, High-dose Chemotherapy
Neuroblastoma, Central, High-dose Chemotherapy
Pinealblastoma, High-dose Chemotherapy
Primitive Neuroectodermal Tumors (PNET), High-dose Chemotherapy
|12/01/99||Add to Therapy section||New policy
Policy represents revision of 8.01.15 to focus entirely on PNET. |
38210 | T-cell depletion of harvest | HCPCS | 2007;49(1):34-40. - National Comprehensive Cancer Network (NCCN). Central Nervous System Cancers 2014; http://www.nccn.org/professionals/physician_gls/PDF/cns.pdf. Accessed September 10, 2014. |CPT||38204||Management of recipient hematopoietic cell donor search and cell acquisition|
|38205||Blood-derived hematopoietic progenitor cell harvesting for transplantaion, per collection, allogeneic|
|38208||Transplant preparation of hematopoietic progenitor cells; thawing of previously frozen harvest, without washing, per donor|
|38209||;thawing of previously frozen harvest with washing, per donor|
|38210||Specific cell depletion with harvest, T cell depletion|
|38211||Tumor cell depletion|
|38212||Red blood cell removal|
|38214||Plasma (volume) depletion|
|38215||Cell concentration in plasma, mononuclear, or buffy coat layer|
|38220||Bone marrow; aspiration only|
|38221||Bone marrow; biopsy, needle or trocar|
|38230||Bone marrow harvesting for transplantation; allogeneic|
|38232||bone marrow harvesting for transplnation; autologous|
|38240||Bone marrow or blod-derived [eropheral stem-cell transplatation; allogeneic|
|ICD-9 Procedure||41.00||Bone marrow transplant, not otherwise specified|
|41.01||Autologous bone marrow transplant without purging|
|41.02||Allogeneic hone marrow transplant with purging|
|41.03||Allogeneic bone marrow transplant without purging|
|41.04||Autologous hematopoietic stem-cell transplant without purging|
|41.05||Allogeneic hematopoietic stem cell transplant without purging|
|41.06||Cord blood stem cell transplant|
|41.07||Autologous hematopoietic stem-cell transplant with purging|
|41.08||Allogeneic hematopoietic stem-cell transplant with purging|
|41.09||Autologous bone marrow transplant with purging|
|41.91||Aspiration of bone marrow from donor for transplant|
|99.79||Other therapeutic apheresis (includes harvest of stem cells)|
|ICD-9 Diagnosis||191.0–191.9||Malignant neoplasm of brain code range|
|HCPCS||Q0083, Q0084, Q0085||Chemotherapy administration code range|
J9000, J9001, J9010, J9015, J9017, J9020, J9025, J9027, J9031, J9035, J9041, J9045, J9050, J9055, J9060, J9062, J9065, J9070, J9080, J9090, J9091, J9092, J9093, J9094, J9095, J9096, J9097, J9098, J9100, J9110, J9120, J9130, J9140, J9150, J9151, J9160, J9165, J9170, J9175, J9178, J9181, J9182, J9185, J9190, J9200, J9201, J9202, J9206, J9208, J9209, J9211, J9212, J9213, J9214, J9215, J9216, J9217, J9218, J9219, J9225, J9226, J9230, J9245, J9250, J9260, J9261, J9263, J9264, J9265, J9266, J9268, J9270, J9280, J9290, J9291, J9293, J9300, J9303, J9305, J9310, J9320, J9340, J9350, J9355, J9357, J9360, J9370, J9375, J9380, J9390, J9395, J9600, J9999
|Chemotherapy drugs code range|
|G0265||Bryopreservation, freezing and storage of cells for thereapeutic use, each cell line|
|G0266||Thawing and expansion of frozen cells for therapeuticuse, each cell line|
|G0267||Bone marrow or peripheral stem-cell harvest, modification or treatment to eliminate cell type(s) (e.g., T cells, metastic carcinoma)|
|S2150||Bone marrow or blood-derived peripheral stem-cell harvesting and transplantation, allogeneic or autologous, including pheresis, high-dose chemotherapy, and the number of days of post-transplant care in the global definition (including drugs; hospitalization; medical surgical, diagnostic and emergency services)|
|ICD-10-CM (effective 10/1/15)||C71.0-C71.9||Malignant neoplasm of brain|
|ICD-10-PCS (effective 10/1/15)||ICD-10-PCS codes are only used for inpatient services.|
|30243G0, 30243X0, 30243Y0||Percutaneous transfusion, central vein, bone marrow or stem cells, autologous, code list|
|30243G1, 30243X1, 30243Y1||Percutaneous transfusion, central vein, bone marrow or stem cells, nonautologous, code list|
|07DQ0ZZ, 07DQ3ZZ, 07DR0ZZ, 07DR3ZZ, 07DS0ZZ, 07DS3ZZ||Surgical, lymphatic and hemic systems, extraction, bone marrow, code list|
|Type of Service||Therapy|
|Place of Service||Inpatient/Outpatient|
Ependymoma, High-dose Chemotherapy
Ependymoblastoma, High-dose Chemotherapy
High-dose chemotherapy with autologous stem-cell support for PNET and ependymoma
Medulloblastoma, High-dose Chemotherapy
Neuroblastoma, Central, High-dose Chemotherapy
Pinealblastoma, High-dose Chemotherapy
Primitive Neuroectodermal Tumors (PNET), High-dose Chemotherapy
|12/01/99||Add to Therapy section||New policy
Policy represents revision of 8.01.15 to focus entirely on PNET. |
38230 | PR BONE MARROW HARVEST TRANSPLANTATION ALLOGENEIC | HCPCS | 2007;49(1):34-40. - National Comprehensive Cancer Network (NCCN). Central Nervous System Cancers 2014; http://www.nccn.org/professionals/physician_gls/PDF/cns.pdf. Accessed September 10, 2014. |CPT||38204||Management of recipient hematopoietic cell donor search and cell acquisition|
|38205||Blood-derived hematopoietic progenitor cell harvesting for transplantaion, per collection, allogeneic|
|38208||Transplant preparation of hematopoietic progenitor cells; thawing of previously frozen harvest, without washing, per donor|
|38209||;thawing of previously frozen harvest with washing, per donor|
|38210||Specific cell depletion with harvest, T cell depletion|
|38211||Tumor cell depletion|
|38212||Red blood cell removal|
|38214||Plasma (volume) depletion|
|38215||Cell concentration in plasma, mononuclear, or buffy coat layer|
|38220||Bone marrow; aspiration only|
|38221||Bone marrow; biopsy, needle or trocar|
|38230||Bone marrow harvesting for transplantation; allogeneic|
|38232||bone marrow harvesting for transplnation; autologous|
|38240||Bone marrow or blod-derived [eropheral stem-cell transplatation; allogeneic|
|ICD-9 Procedure||41.00||Bone marrow transplant, not otherwise specified|
|41.01||Autologous bone marrow transplant without purging|
|41.02||Allogeneic hone marrow transplant with purging|
|41.03||Allogeneic bone marrow transplant without purging|
|41.04||Autologous hematopoietic stem-cell transplant without purging|
|41.05||Allogeneic hematopoietic stem cell transplant without purging|
|41.06||Cord blood stem cell transplant|
|41.07||Autologous hematopoietic stem-cell transplant with purging|
|41.08||Allogeneic hematopoietic stem-cell transplant with purging|
|41.09||Autologous bone marrow transplant with purging|
|41.91||Aspiration of bone marrow from donor for transplant|
|99.79||Other therapeutic apheresis (includes harvest of stem cells)|
|ICD-9 Diagnosis||191.0–191.9||Malignant neoplasm of brain code range|
|HCPCS||Q0083, Q0084, Q0085||Chemotherapy administration code range|
J9000, J9001, J9010, J9015, J9017, J9020, J9025, J9027, J9031, J9035, J9041, J9045, J9050, J9055, J9060, J9062, J9065, J9070, J9080, J9090, J9091, J9092, J9093, J9094, J9095, J9096, J9097, J9098, J9100, J9110, J9120, J9130, J9140, J9150, J9151, J9160, J9165, J9170, J9175, J9178, J9181, J9182, J9185, J9190, J9200, J9201, J9202, J9206, J9208, J9209, J9211, J9212, J9213, J9214, J9215, J9216, J9217, J9218, J9219, J9225, J9226, J9230, J9245, J9250, J9260, J9261, J9263, J9264, J9265, J9266, J9268, J9270, J9280, J9290, J9291, J9293, J9300, J9303, J9305, J9310, J9320, J9340, J9350, J9355, J9357, J9360, J9370, J9375, J9380, J9390, J9395, J9600, J9999
|Chemotherapy drugs code range|
|G0265||Bryopreservation, freezing and storage of cells for thereapeutic use, each cell line|
|G0266||Thawing and expansion of frozen cells for therapeuticuse, each cell line|
|G0267||Bone marrow or peripheral stem-cell harvest, modification or treatment to eliminate cell type(s) (e.g., T cells, metastic carcinoma)|
|S2150||Bone marrow or blood-derived peripheral stem-cell harvesting and transplantation, allogeneic or autologous, including pheresis, high-dose chemotherapy, and the number of days of post-transplant care in the global definition (including drugs; hospitalization; medical surgical, diagnostic and emergency services)|
|ICD-10-CM (effective 10/1/15)||C71.0-C71.9||Malignant neoplasm of brain|
|ICD-10-PCS (effective 10/1/15)||ICD-10-PCS codes are only used for inpatient services.|
|30243G0, 30243X0, 30243Y0||Percutaneous transfusion, central vein, bone marrow or stem cells, autologous, code list|
|30243G1, 30243X1, 30243Y1||Percutaneous transfusion, central vein, bone marrow or stem cells, nonautologous, code list|
|07DQ0ZZ, 07DQ3ZZ, 07DR0ZZ, 07DR3ZZ, 07DS0ZZ, 07DS3ZZ||Surgical, lymphatic and hemic systems, extraction, bone marrow, code list|
|Type of Service||Therapy|
|Place of Service||Inpatient/Outpatient|
Ependymoma, High-dose Chemotherapy
Ependymoblastoma, High-dose Chemotherapy
High-dose chemotherapy with autologous stem-cell support for PNET and ependymoma
Medulloblastoma, High-dose Chemotherapy
Neuroblastoma, Central, High-dose Chemotherapy
Pinealblastoma, High-dose Chemotherapy
Primitive Neuroectodermal Tumors (PNET), High-dose Chemotherapy
|12/01/99||Add to Therapy section||New policy
Policy represents revision of 8.01.15 to focus entirely on PNET. |
J9303 | panitumumab per 10 mg | HCPCS | 2007;49(1):34-40. - National Comprehensive Cancer Network (NCCN). Central Nervous System Cancers 2014; http://www.nccn.org/professionals/physician_gls/PDF/cns.pdf. Accessed September 10, 2014. |CPT||38204||Management of recipient hematopoietic cell donor search and cell acquisition|
|38205||Blood-derived hematopoietic progenitor cell harvesting for transplantaion, per collection, allogeneic|
|38208||Transplant preparation of hematopoietic progenitor cells; thawing of previously frozen harvest, without washing, per donor|
|38209||;thawing of previously frozen harvest with washing, per donor|
|38210||Specific cell depletion with harvest, T cell depletion|
|38211||Tumor cell depletion|
|38212||Red blood cell removal|
|38214||Plasma (volume) depletion|
|38215||Cell concentration in plasma, mononuclear, or buffy coat layer|
|38220||Bone marrow; aspiration only|
|38221||Bone marrow; biopsy, needle or trocar|
|38230||Bone marrow harvesting for transplantation; allogeneic|
|38232||bone marrow harvesting for transplnation; autologous|
|38240||Bone marrow or blod-derived [eropheral stem-cell transplatation; allogeneic|
|ICD-9 Procedure||41.00||Bone marrow transplant, not otherwise specified|
|41.01||Autologous bone marrow transplant without purging|
|41.02||Allogeneic hone marrow transplant with purging|
|41.03||Allogeneic bone marrow transplant without purging|
|41.04||Autologous hematopoietic stem-cell transplant without purging|
|41.05||Allogeneic hematopoietic stem cell transplant without purging|
|41.06||Cord blood stem cell transplant|
|41.07||Autologous hematopoietic stem-cell transplant with purging|
|41.08||Allogeneic hematopoietic stem-cell transplant with purging|
|41.09||Autologous bone marrow transplant with purging|
|41.91||Aspiration of bone marrow from donor for transplant|
|99.79||Other therapeutic apheresis (includes harvest of stem cells)|
|ICD-9 Diagnosis||191.0–191.9||Malignant neoplasm of brain code range|
|HCPCS||Q0083, Q0084, Q0085||Chemotherapy administration code range|
J9000, J9001, J9010, J9015, J9017, J9020, J9025, J9027, J9031, J9035, J9041, J9045, J9050, J9055, J9060, J9062, J9065, J9070, J9080, J9090, J9091, J9092, J9093, J9094, J9095, J9096, J9097, J9098, J9100, J9110, J9120, J9130, J9140, J9150, J9151, J9160, J9165, J9170, J9175, J9178, J9181, J9182, J9185, J9190, J9200, J9201, J9202, J9206, J9208, J9209, J9211, J9212, J9213, J9214, J9215, J9216, J9217, J9218, J9219, J9225, J9226, J9230, J9245, J9250, J9260, J9261, J9263, J9264, J9265, J9266, J9268, J9270, J9280, J9290, J9291, J9293, J9300, J9303, J9305, J9310, J9320, J9340, J9350, J9355, J9357, J9360, J9370, J9375, J9380, J9390, J9395, J9600, J9999
|Chemotherapy drugs code range|
|G0265||Bryopreservation, freezing and storage of cells for thereapeutic use, each cell line|
|G0266||Thawing and expansion of frozen cells for therapeuticuse, each cell line|
|G0267||Bone marrow or peripheral stem-cell harvest, modification or treatment to eliminate cell type(s) (e.g., T cells, metastic carcinoma)|
|S2150||Bone marrow or blood-derived peripheral stem-cell harvesting and transplantation, allogeneic or autologous, including pheresis, high-dose chemotherapy, and the number of days of post-transplant care in the global definition (including drugs; hospitalization; medical surgical, diagnostic and emergency services)|
|ICD-10-CM (effective 10/1/15)||C71.0-C71.9||Malignant neoplasm of brain|
|ICD-10-PCS (effective 10/1/15)||ICD-10-PCS codes are only used for inpatient services.|
|30243G0, 30243X0, 30243Y0||Percutaneous transfusion, central vein, bone marrow or stem cells, autologous, code list|
|30243G1, 30243X1, 30243Y1||Percutaneous transfusion, central vein, bone marrow or stem cells, nonautologous, code list|
|07DQ0ZZ, 07DQ3ZZ, 07DR0ZZ, 07DR3ZZ, 07DS0ZZ, 07DS3ZZ||Surgical, lymphatic and hemic systems, extraction, bone marrow, code list|
|Type of Service||Therapy|
|Place of Service||Inpatient/Outpatient|
Ependymoma, High-dose Chemotherapy
Ependymoblastoma, High-dose Chemotherapy
High-dose chemotherapy with autologous stem-cell support for PNET and ependymoma
Medulloblastoma, High-dose Chemotherapy
Neuroblastoma, Central, High-dose Chemotherapy
Pinealblastoma, High-dose Chemotherapy
Primitive Neuroectodermal Tumors (PNET), High-dose Chemotherapy
|12/01/99||Add to Therapy section||New policy
Policy represents revision of 8.01.15 to focus entirely on PNET. |
J9213 | Interferon alfa-2a inj | HCPCS | 2007;49(1):34-40. - National Comprehensive Cancer Network (NCCN). Central Nervous System Cancers 2014; http://www.nccn.org/professionals/physician_gls/PDF/cns.pdf. Accessed September 10, 2014. |CPT||38204||Management of recipient hematopoietic cell donor search and cell acquisition|
|38205||Blood-derived hematopoietic progenitor cell harvesting for transplantaion, per collection, allogeneic|
|38208||Transplant preparation of hematopoietic progenitor cells; thawing of previously frozen harvest, without washing, per donor|
|38209||;thawing of previously frozen harvest with washing, per donor|
|38210||Specific cell depletion with harvest, T cell depletion|
|38211||Tumor cell depletion|
|38212||Red blood cell removal|
|38214||Plasma (volume) depletion|
|38215||Cell concentration in plasma, mononuclear, or buffy coat layer|
|38220||Bone marrow; aspiration only|
|38221||Bone marrow; biopsy, needle or trocar|
|38230||Bone marrow harvesting for transplantation; allogeneic|
|38232||bone marrow harvesting for transplnation; autologous|
|38240||Bone marrow or blod-derived [eropheral stem-cell transplatation; allogeneic|
|ICD-9 Procedure||41.00||Bone marrow transplant, not otherwise specified|
|41.01||Autologous bone marrow transplant without purging|
|41.02||Allogeneic hone marrow transplant with purging|
|41.03||Allogeneic bone marrow transplant without purging|
|41.04||Autologous hematopoietic stem-cell transplant without purging|
|41.05||Allogeneic hematopoietic stem cell transplant without purging|
|41.06||Cord blood stem cell transplant|
|41.07||Autologous hematopoietic stem-cell transplant with purging|
|41.08||Allogeneic hematopoietic stem-cell transplant with purging|
|41.09||Autologous bone marrow transplant with purging|
|41.91||Aspiration of bone marrow from donor for transplant|
|99.79||Other therapeutic apheresis (includes harvest of stem cells)|
|ICD-9 Diagnosis||191.0–191.9||Malignant neoplasm of brain code range|
|HCPCS||Q0083, Q0084, Q0085||Chemotherapy administration code range|
J9000, J9001, J9010, J9015, J9017, J9020, J9025, J9027, J9031, J9035, J9041, J9045, J9050, J9055, J9060, J9062, J9065, J9070, J9080, J9090, J9091, J9092, J9093, J9094, J9095, J9096, J9097, J9098, J9100, J9110, J9120, J9130, J9140, J9150, J9151, J9160, J9165, J9170, J9175, J9178, J9181, J9182, J9185, J9190, J9200, J9201, J9202, J9206, J9208, J9209, J9211, J9212, J9213, J9214, J9215, J9216, J9217, J9218, J9219, J9225, J9226, J9230, J9245, J9250, J9260, J9261, J9263, J9264, J9265, J9266, J9268, J9270, J9280, J9290, J9291, J9293, J9300, J9303, J9305, J9310, J9320, J9340, J9350, J9355, J9357, J9360, J9370, J9375, J9380, J9390, J9395, J9600, J9999
|Chemotherapy drugs code range|
|G0265||Bryopreservation, freezing and storage of cells for thereapeutic use, each cell line|
|G0266||Thawing and expansion of frozen cells for therapeuticuse, each cell line|
|G0267||Bone marrow or peripheral stem-cell harvest, modification or treatment to eliminate cell type(s) (e.g., T cells, metastic carcinoma)|
|S2150||Bone marrow or blood-derived peripheral stem-cell harvesting and transplantation, allogeneic or autologous, including pheresis, high-dose chemotherapy, and the number of days of post-transplant care in the global definition (including drugs; hospitalization; medical surgical, diagnostic and emergency services)|
|ICD-10-CM (effective 10/1/15)||C71.0-C71.9||Malignant neoplasm of brain|
|ICD-10-PCS (effective 10/1/15)||ICD-10-PCS codes are only used for inpatient services.|
|30243G0, 30243X0, 30243Y0||Percutaneous transfusion, central vein, bone marrow or stem cells, autologous, code list|
|30243G1, 30243X1, 30243Y1||Percutaneous transfusion, central vein, bone marrow or stem cells, nonautologous, code list|
|07DQ0ZZ, 07DQ3ZZ, 07DR0ZZ, 07DR3ZZ, 07DS0ZZ, 07DS3ZZ||Surgical, lymphatic and hemic systems, extraction, bone marrow, code list|
|Type of Service||Therapy|
|Place of Service||Inpatient/Outpatient|
Ependymoma, High-dose Chemotherapy
Ependymoblastoma, High-dose Chemotherapy
High-dose chemotherapy with autologous stem-cell support for PNET and ependymoma
Medulloblastoma, High-dose Chemotherapy
Neuroblastoma, Central, High-dose Chemotherapy
Pinealblastoma, High-dose Chemotherapy
Primitive Neuroectodermal Tumors (PNET), High-dose Chemotherapy
|12/01/99||Add to Therapy section||New policy
Policy represents revision of 8.01.15 to focus entirely on PNET. |
J9380 | TECLISTAMAB-CQYV 90 MG/ML SUBCUTANEOUS SOLUTION | HCPCS | 2007;49(1):34-40. - National Comprehensive Cancer Network (NCCN). Central Nervous System Cancers 2014; http://www.nccn.org/professionals/physician_gls/PDF/cns.pdf. Accessed September 10, 2014. |CPT||38204||Management of recipient hematopoietic cell donor search and cell acquisition|
|38205||Blood-derived hematopoietic progenitor cell harvesting for transplantaion, per collection, allogeneic|
|38208||Transplant preparation of hematopoietic progenitor cells; thawing of previously frozen harvest, without washing, per donor|
|38209||;thawing of previously frozen harvest with washing, per donor|
|38210||Specific cell depletion with harvest, T cell depletion|
|38211||Tumor cell depletion|
|38212||Red blood cell removal|
|38214||Plasma (volume) depletion|
|38215||Cell concentration in plasma, mononuclear, or buffy coat layer|
|38220||Bone marrow; aspiration only|
|38221||Bone marrow; biopsy, needle or trocar|
|38230||Bone marrow harvesting for transplantation; allogeneic|
|38232||bone marrow harvesting for transplnation; autologous|
|38240||Bone marrow or blod-derived [eropheral stem-cell transplatation; allogeneic|
|ICD-9 Procedure||41.00||Bone marrow transplant, not otherwise specified|
|41.01||Autologous bone marrow transplant without purging|
|41.02||Allogeneic hone marrow transplant with purging|
|41.03||Allogeneic bone marrow transplant without purging|
|41.04||Autologous hematopoietic stem-cell transplant without purging|
|41.05||Allogeneic hematopoietic stem cell transplant without purging|
|41.06||Cord blood stem cell transplant|
|41.07||Autologous hematopoietic stem-cell transplant with purging|
|41.08||Allogeneic hematopoietic stem-cell transplant with purging|
|41.09||Autologous bone marrow transplant with purging|
|41.91||Aspiration of bone marrow from donor for transplant|
|99.79||Other therapeutic apheresis (includes harvest of stem cells)|
|ICD-9 Diagnosis||191.0–191.9||Malignant neoplasm of brain code range|
|HCPCS||Q0083, Q0084, Q0085||Chemotherapy administration code range|
J9000, J9001, J9010, J9015, J9017, J9020, J9025, J9027, J9031, J9035, J9041, J9045, J9050, J9055, J9060, J9062, J9065, J9070, J9080, J9090, J9091, J9092, J9093, J9094, J9095, J9096, J9097, J9098, J9100, J9110, J9120, J9130, J9140, J9150, J9151, J9160, J9165, J9170, J9175, J9178, J9181, J9182, J9185, J9190, J9200, J9201, J9202, J9206, J9208, J9209, J9211, J9212, J9213, J9214, J9215, J9216, J9217, J9218, J9219, J9225, J9226, J9230, J9245, J9250, J9260, J9261, J9263, J9264, J9265, J9266, J9268, J9270, J9280, J9290, J9291, J9293, J9300, J9303, J9305, J9310, J9320, J9340, J9350, J9355, J9357, J9360, J9370, J9375, J9380, J9390, J9395, J9600, J9999
|Chemotherapy drugs code range|
|G0265||Bryopreservation, freezing and storage of cells for thereapeutic use, each cell line|
|G0266||Thawing and expansion of frozen cells for therapeuticuse, each cell line|
|G0267||Bone marrow or peripheral stem-cell harvest, modification or treatment to eliminate cell type(s) (e.g., T cells, metastic carcinoma)|
|S2150||Bone marrow or blood-derived peripheral stem-cell harvesting and transplantation, allogeneic or autologous, including pheresis, high-dose chemotherapy, and the number of days of post-transplant care in the global definition (including drugs; hospitalization; medical surgical, diagnostic and emergency services)|
|ICD-10-CM (effective 10/1/15)||C71.0-C71.9||Malignant neoplasm of brain|
|ICD-10-PCS (effective 10/1/15)||ICD-10-PCS codes are only used for inpatient services.|
|30243G0, 30243X0, 30243Y0||Percutaneous transfusion, central vein, bone marrow or stem cells, autologous, code list|
|30243G1, 30243X1, 30243Y1||Percutaneous transfusion, central vein, bone marrow or stem cells, nonautologous, code list|
|07DQ0ZZ, 07DQ3ZZ, 07DR0ZZ, 07DR3ZZ, 07DS0ZZ, 07DS3ZZ||Surgical, lymphatic and hemic systems, extraction, bone marrow, code list|
|Type of Service||Therapy|
|Place of Service||Inpatient/Outpatient|
Ependymoma, High-dose Chemotherapy
Ependymoblastoma, High-dose Chemotherapy
High-dose chemotherapy with autologous stem-cell support for PNET and ependymoma
Medulloblastoma, High-dose Chemotherapy
Neuroblastoma, Central, High-dose Chemotherapy
Pinealblastoma, High-dose Chemotherapy
Primitive Neuroectodermal Tumors (PNET), High-dose Chemotherapy
|12/01/99||Add to Therapy section||New policy
Policy represents revision of 8.01.15 to focus entirely on PNET. |
38212 | Rbc depletion of harvest | HCPCS | 2007;49(1):34-40. - National Comprehensive Cancer Network (NCCN). Central Nervous System Cancers 2014; http://www.nccn.org/professionals/physician_gls/PDF/cns.pdf. Accessed September 10, 2014. |CPT||38204||Management of recipient hematopoietic cell donor search and cell acquisition|
|38205||Blood-derived hematopoietic progenitor cell harvesting for transplantaion, per collection, allogeneic|
|38208||Transplant preparation of hematopoietic progenitor cells; thawing of previously frozen harvest, without washing, per donor|
|38209||;thawing of previously frozen harvest with washing, per donor|
|38210||Specific cell depletion with harvest, T cell depletion|
|38211||Tumor cell depletion|
|38212||Red blood cell removal|
|38214||Plasma (volume) depletion|
|38215||Cell concentration in plasma, mononuclear, or buffy coat layer|
|38220||Bone marrow; aspiration only|
|38221||Bone marrow; biopsy, needle or trocar|
|38230||Bone marrow harvesting for transplantation; allogeneic|
|38232||bone marrow harvesting for transplnation; autologous|
|38240||Bone marrow or blod-derived [eropheral stem-cell transplatation; allogeneic|
|ICD-9 Procedure||41.00||Bone marrow transplant, not otherwise specified|
|41.01||Autologous bone marrow transplant without purging|
|41.02||Allogeneic hone marrow transplant with purging|
|41.03||Allogeneic bone marrow transplant without purging|
|41.04||Autologous hematopoietic stem-cell transplant without purging|
|41.05||Allogeneic hematopoietic stem cell transplant without purging|
|41.06||Cord blood stem cell transplant|
|41.07||Autologous hematopoietic stem-cell transplant with purging|
|41.08||Allogeneic hematopoietic stem-cell transplant with purging|
|41.09||Autologous bone marrow transplant with purging|
|41.91||Aspiration of bone marrow from donor for transplant|
|99.79||Other therapeutic apheresis (includes harvest of stem cells)|
|ICD-9 Diagnosis||191.0–191.9||Malignant neoplasm of brain code range|
|HCPCS||Q0083, Q0084, Q0085||Chemotherapy administration code range|
J9000, J9001, J9010, J9015, J9017, J9020, J9025, J9027, J9031, J9035, J9041, J9045, J9050, J9055, J9060, J9062, J9065, J9070, J9080, J9090, J9091, J9092, J9093, J9094, J9095, J9096, J9097, J9098, J9100, J9110, J9120, J9130, J9140, J9150, J9151, J9160, J9165, J9170, J9175, J9178, J9181, J9182, J9185, J9190, J9200, J9201, J9202, J9206, J9208, J9209, J9211, J9212, J9213, J9214, J9215, J9216, J9217, J9218, J9219, J9225, J9226, J9230, J9245, J9250, J9260, J9261, J9263, J9264, J9265, J9266, J9268, J9270, J9280, J9290, J9291, J9293, J9300, J9303, J9305, J9310, J9320, J9340, J9350, J9355, J9357, J9360, J9370, J9375, J9380, J9390, J9395, J9600, J9999
|Chemotherapy drugs code range|
|G0265||Bryopreservation, freezing and storage of cells for thereapeutic use, each cell line|
|G0266||Thawing and expansion of frozen cells for therapeuticuse, each cell line|
|G0267||Bone marrow or peripheral stem-cell harvest, modification or treatment to eliminate cell type(s) (e.g., T cells, metastic carcinoma)|
|S2150||Bone marrow or blood-derived peripheral stem-cell harvesting and transplantation, allogeneic or autologous, including pheresis, high-dose chemotherapy, and the number of days of post-transplant care in the global definition (including drugs; hospitalization; medical surgical, diagnostic and emergency services)|
|ICD-10-CM (effective 10/1/15)||C71.0-C71.9||Malignant neoplasm of brain|
|ICD-10-PCS (effective 10/1/15)||ICD-10-PCS codes are only used for inpatient services.|
|30243G0, 30243X0, 30243Y0||Percutaneous transfusion, central vein, bone marrow or stem cells, autologous, code list|
|30243G1, 30243X1, 30243Y1||Percutaneous transfusion, central vein, bone marrow or stem cells, nonautologous, code list|
|07DQ0ZZ, 07DQ3ZZ, 07DR0ZZ, 07DR3ZZ, 07DS0ZZ, 07DS3ZZ||Surgical, lymphatic and hemic systems, extraction, bone marrow, code list|
|Type of Service||Therapy|
|Place of Service||Inpatient/Outpatient|
Ependymoma, High-dose Chemotherapy
Ependymoblastoma, High-dose Chemotherapy
High-dose chemotherapy with autologous stem-cell support for PNET and ependymoma
Medulloblastoma, High-dose Chemotherapy
Neuroblastoma, Central, High-dose Chemotherapy
Pinealblastoma, High-dose Chemotherapy
Primitive Neuroectodermal Tumors (PNET), High-dose Chemotherapy
|12/01/99||Add to Therapy section||New policy
Policy represents revision of 8.01.15 to focus entirely on PNET. |
J9268 | Pentostatin injection | HCPCS | 2007;49(1):34-40. - National Comprehensive Cancer Network (NCCN). Central Nervous System Cancers 2014; http://www.nccn.org/professionals/physician_gls/PDF/cns.pdf. Accessed September 10, 2014. |CPT||38204||Management of recipient hematopoietic cell donor search and cell acquisition|
|38205||Blood-derived hematopoietic progenitor cell harvesting for transplantaion, per collection, allogeneic|
|38208||Transplant preparation of hematopoietic progenitor cells; thawing of previously frozen harvest, without washing, per donor|
|38209||;thawing of previously frozen harvest with washing, per donor|
|38210||Specific cell depletion with harvest, T cell depletion|
|38211||Tumor cell depletion|
|38212||Red blood cell removal|
|38214||Plasma (volume) depletion|
|38215||Cell concentration in plasma, mononuclear, or buffy coat layer|
|38220||Bone marrow; aspiration only|
|38221||Bone marrow; biopsy, needle or trocar|
|38230||Bone marrow harvesting for transplantation; allogeneic|
|38232||bone marrow harvesting for transplnation; autologous|
|38240||Bone marrow or blod-derived [eropheral stem-cell transplatation; allogeneic|
|ICD-9 Procedure||41.00||Bone marrow transplant, not otherwise specified|
|41.01||Autologous bone marrow transplant without purging|
|41.02||Allogeneic hone marrow transplant with purging|
|41.03||Allogeneic bone marrow transplant without purging|
|41.04||Autologous hematopoietic stem-cell transplant without purging|
|41.05||Allogeneic hematopoietic stem cell transplant without purging|
|41.06||Cord blood stem cell transplant|
|41.07||Autologous hematopoietic stem-cell transplant with purging|
|41.08||Allogeneic hematopoietic stem-cell transplant with purging|
|41.09||Autologous bone marrow transplant with purging|
|41.91||Aspiration of bone marrow from donor for transplant|
|99.79||Other therapeutic apheresis (includes harvest of stem cells)|
|ICD-9 Diagnosis||191.0–191.9||Malignant neoplasm of brain code range|
|HCPCS||Q0083, Q0084, Q0085||Chemotherapy administration code range|
J9000, J9001, J9010, J9015, J9017, J9020, J9025, J9027, J9031, J9035, J9041, J9045, J9050, J9055, J9060, J9062, J9065, J9070, J9080, J9090, J9091, J9092, J9093, J9094, J9095, J9096, J9097, J9098, J9100, J9110, J9120, J9130, J9140, J9150, J9151, J9160, J9165, J9170, J9175, J9178, J9181, J9182, J9185, J9190, J9200, J9201, J9202, J9206, J9208, J9209, J9211, J9212, J9213, J9214, J9215, J9216, J9217, J9218, J9219, J9225, J9226, J9230, J9245, J9250, J9260, J9261, J9263, J9264, J9265, J9266, J9268, J9270, J9280, J9290, J9291, J9293, J9300, J9303, J9305, J9310, J9320, J9340, J9350, J9355, J9357, J9360, J9370, J9375, J9380, J9390, J9395, J9600, J9999
|Chemotherapy drugs code range|
|G0265||Bryopreservation, freezing and storage of cells for thereapeutic use, each cell line|
|G0266||Thawing and expansion of frozen cells for therapeuticuse, each cell line|
|G0267||Bone marrow or peripheral stem-cell harvest, modification or treatment to eliminate cell type(s) (e.g., T cells, metastic carcinoma)|
|S2150||Bone marrow or blood-derived peripheral stem-cell harvesting and transplantation, allogeneic or autologous, including pheresis, high-dose chemotherapy, and the number of days of post-transplant care in the global definition (including drugs; hospitalization; medical surgical, diagnostic and emergency services)|
|ICD-10-CM (effective 10/1/15)||C71.0-C71.9||Malignant neoplasm of brain|
|ICD-10-PCS (effective 10/1/15)||ICD-10-PCS codes are only used for inpatient services.|
|30243G0, 30243X0, 30243Y0||Percutaneous transfusion, central vein, bone marrow or stem cells, autologous, code list|
|30243G1, 30243X1, 30243Y1||Percutaneous transfusion, central vein, bone marrow or stem cells, nonautologous, code list|
|07DQ0ZZ, 07DQ3ZZ, 07DR0ZZ, 07DR3ZZ, 07DS0ZZ, 07DS3ZZ||Surgical, lymphatic and hemic systems, extraction, bone marrow, code list|
|Type of Service||Therapy|
|Place of Service||Inpatient/Outpatient|
Ependymoma, High-dose Chemotherapy
Ependymoblastoma, High-dose Chemotherapy
High-dose chemotherapy with autologous stem-cell support for PNET and ependymoma
Medulloblastoma, High-dose Chemotherapy
Neuroblastoma, Central, High-dose Chemotherapy
Pinealblastoma, High-dose Chemotherapy
Primitive Neuroectodermal Tumors (PNET), High-dose Chemotherapy
|12/01/99||Add to Therapy section||New policy
Policy represents revision of 8.01.15 to focus entirely on PNET. |
38220 | PR DIAGNOSTIC BONE MARROW ASPIRATIONS | HCPCS | 2007;49(1):34-40. - National Comprehensive Cancer Network (NCCN). Central Nervous System Cancers 2014; http://www.nccn.org/professionals/physician_gls/PDF/cns.pdf. Accessed September 10, 2014. |CPT||38204||Management of recipient hematopoietic cell donor search and cell acquisition|
|38205||Blood-derived hematopoietic progenitor cell harvesting for transplantaion, per collection, allogeneic|
|38208||Transplant preparation of hematopoietic progenitor cells; thawing of previously frozen harvest, without washing, per donor|
|38209||;thawing of previously frozen harvest with washing, per donor|
|38210||Specific cell depletion with harvest, T cell depletion|
|38211||Tumor cell depletion|
|38212||Red blood cell removal|
|38214||Plasma (volume) depletion|
|38215||Cell concentration in plasma, mononuclear, or buffy coat layer|
|38220||Bone marrow; aspiration only|
|38221||Bone marrow; biopsy, needle or trocar|
|38230||Bone marrow harvesting for transplantation; allogeneic|
|38232||bone marrow harvesting for transplnation; autologous|
|38240||Bone marrow or blod-derived [eropheral stem-cell transplatation; allogeneic|
|ICD-9 Procedure||41.00||Bone marrow transplant, not otherwise specified|
|41.01||Autologous bone marrow transplant without purging|
|41.02||Allogeneic hone marrow transplant with purging|
|41.03||Allogeneic bone marrow transplant without purging|
|41.04||Autologous hematopoietic stem-cell transplant without purging|
|41.05||Allogeneic hematopoietic stem cell transplant without purging|
|41.06||Cord blood stem cell transplant|
|41.07||Autologous hematopoietic stem-cell transplant with purging|
|41.08||Allogeneic hematopoietic stem-cell transplant with purging|
|41.09||Autologous bone marrow transplant with purging|
|41.91||Aspiration of bone marrow from donor for transplant|
|99.79||Other therapeutic apheresis (includes harvest of stem cells)|
|ICD-9 Diagnosis||191.0–191.9||Malignant neoplasm of brain code range|
|HCPCS||Q0083, Q0084, Q0085||Chemotherapy administration code range|
J9000, J9001, J9010, J9015, J9017, J9020, J9025, J9027, J9031, J9035, J9041, J9045, J9050, J9055, J9060, J9062, J9065, J9070, J9080, J9090, J9091, J9092, J9093, J9094, J9095, J9096, J9097, J9098, J9100, J9110, J9120, J9130, J9140, J9150, J9151, J9160, J9165, J9170, J9175, J9178, J9181, J9182, J9185, J9190, J9200, J9201, J9202, J9206, J9208, J9209, J9211, J9212, J9213, J9214, J9215, J9216, J9217, J9218, J9219, J9225, J9226, J9230, J9245, J9250, J9260, J9261, J9263, J9264, J9265, J9266, J9268, J9270, J9280, J9290, J9291, J9293, J9300, J9303, J9305, J9310, J9320, J9340, J9350, J9355, J9357, J9360, J9370, J9375, J9380, J9390, J9395, J9600, J9999
|Chemotherapy drugs code range|
|G0265||Bryopreservation, freezing and storage of cells for thereapeutic use, each cell line|
|G0266||Thawing and expansion of frozen cells for therapeuticuse, each cell line|
|G0267||Bone marrow or peripheral stem-cell harvest, modification or treatment to eliminate cell type(s) (e.g., T cells, metastic carcinoma)|
|S2150||Bone marrow or blood-derived peripheral stem-cell harvesting and transplantation, allogeneic or autologous, including pheresis, high-dose chemotherapy, and the number of days of post-transplant care in the global definition (including drugs; hospitalization; medical surgical, diagnostic and emergency services)|
|ICD-10-CM (effective 10/1/15)||C71.0-C71.9||Malignant neoplasm of brain|
|ICD-10-PCS (effective 10/1/15)||ICD-10-PCS codes are only used for inpatient services.|
|30243G0, 30243X0, 30243Y0||Percutaneous transfusion, central vein, bone marrow or stem cells, autologous, code list|
|30243G1, 30243X1, 30243Y1||Percutaneous transfusion, central vein, bone marrow or stem cells, nonautologous, code list|
|07DQ0ZZ, 07DQ3ZZ, 07DR0ZZ, 07DR3ZZ, 07DS0ZZ, 07DS3ZZ||Surgical, lymphatic and hemic systems, extraction, bone marrow, code list|
|Type of Service||Therapy|
|Place of Service||Inpatient/Outpatient|
Ependymoma, High-dose Chemotherapy
Ependymoblastoma, High-dose Chemotherapy
High-dose chemotherapy with autologous stem-cell support for PNET and ependymoma
Medulloblastoma, High-dose Chemotherapy
Neuroblastoma, Central, High-dose Chemotherapy
Pinealblastoma, High-dose Chemotherapy
Primitive Neuroectodermal Tumors (PNET), High-dose Chemotherapy
|12/01/99||Add to Therapy section||New policy
Policy represents revision of 8.01.15 to focus entirely on PNET. |
J9130 | dacarbazine per 200 mg | HCPCS | 2007;49(1):34-40. - National Comprehensive Cancer Network (NCCN). Central Nervous System Cancers 2014; http://www.nccn.org/professionals/physician_gls/PDF/cns.pdf. Accessed September 10, 2014. |CPT||38204||Management of recipient hematopoietic cell donor search and cell acquisition|
|38205||Blood-derived hematopoietic progenitor cell harvesting for transplantaion, per collection, allogeneic|
|38208||Transplant preparation of hematopoietic progenitor cells; thawing of previously frozen harvest, without washing, per donor|
|38209||;thawing of previously frozen harvest with washing, per donor|
|38210||Specific cell depletion with harvest, T cell depletion|
|38211||Tumor cell depletion|
|38212||Red blood cell removal|
|38214||Plasma (volume) depletion|
|38215||Cell concentration in plasma, mononuclear, or buffy coat layer|
|38220||Bone marrow; aspiration only|
|38221||Bone marrow; biopsy, needle or trocar|
|38230||Bone marrow harvesting for transplantation; allogeneic|
|38232||bone marrow harvesting for transplnation; autologous|
|38240||Bone marrow or blod-derived [eropheral stem-cell transplatation; allogeneic|
|ICD-9 Procedure||41.00||Bone marrow transplant, not otherwise specified|
|41.01||Autologous bone marrow transplant without purging|
|41.02||Allogeneic hone marrow transplant with purging|
|41.03||Allogeneic bone marrow transplant without purging|
|41.04||Autologous hematopoietic stem-cell transplant without purging|
|41.05||Allogeneic hematopoietic stem cell transplant without purging|
|41.06||Cord blood stem cell transplant|
|41.07||Autologous hematopoietic stem-cell transplant with purging|
|41.08||Allogeneic hematopoietic stem-cell transplant with purging|
|41.09||Autologous bone marrow transplant with purging|
|41.91||Aspiration of bone marrow from donor for transplant|
|99.79||Other therapeutic apheresis (includes harvest of stem cells)|
|ICD-9 Diagnosis||191.0–191.9||Malignant neoplasm of brain code range|
|HCPCS||Q0083, Q0084, Q0085||Chemotherapy administration code range|
J9000, J9001, J9010, J9015, J9017, J9020, J9025, J9027, J9031, J9035, J9041, J9045, J9050, J9055, J9060, J9062, J9065, J9070, J9080, J9090, J9091, J9092, J9093, J9094, J9095, J9096, J9097, J9098, J9100, J9110, J9120, J9130, J9140, J9150, J9151, J9160, J9165, J9170, J9175, J9178, J9181, J9182, J9185, J9190, J9200, J9201, J9202, J9206, J9208, J9209, J9211, J9212, J9213, J9214, J9215, J9216, J9217, J9218, J9219, J9225, J9226, J9230, J9245, J9250, J9260, J9261, J9263, J9264, J9265, J9266, J9268, J9270, J9280, J9290, J9291, J9293, J9300, J9303, J9305, J9310, J9320, J9340, J9350, J9355, J9357, J9360, J9370, J9375, J9380, J9390, J9395, J9600, J9999
|Chemotherapy drugs code range|
|G0265||Bryopreservation, freezing and storage of cells for thereapeutic use, each cell line|
|G0266||Thawing and expansion of frozen cells for therapeuticuse, each cell line|
|G0267||Bone marrow or peripheral stem-cell harvest, modification or treatment to eliminate cell type(s) (e.g., T cells, metastic carcinoma)|
|S2150||Bone marrow or blood-derived peripheral stem-cell harvesting and transplantation, allogeneic or autologous, including pheresis, high-dose chemotherapy, and the number of days of post-transplant care in the global definition (including drugs; hospitalization; medical surgical, diagnostic and emergency services)|
|ICD-10-CM (effective 10/1/15)||C71.0-C71.9||Malignant neoplasm of brain|
|ICD-10-PCS (effective 10/1/15)||ICD-10-PCS codes are only used for inpatient services.|
|30243G0, 30243X0, 30243Y0||Percutaneous transfusion, central vein, bone marrow or stem cells, autologous, code list|
|30243G1, 30243X1, 30243Y1||Percutaneous transfusion, central vein, bone marrow or stem cells, nonautologous, code list|
|07DQ0ZZ, 07DQ3ZZ, 07DR0ZZ, 07DR3ZZ, 07DS0ZZ, 07DS3ZZ||Surgical, lymphatic and hemic systems, extraction, bone marrow, code list|
|Type of Service||Therapy|
|Place of Service||Inpatient/Outpatient|
Ependymoma, High-dose Chemotherapy
Ependymoblastoma, High-dose Chemotherapy
High-dose chemotherapy with autologous stem-cell support for PNET and ependymoma
Medulloblastoma, High-dose Chemotherapy
Neuroblastoma, Central, High-dose Chemotherapy
Pinealblastoma, High-dose Chemotherapy
Primitive Neuroectodermal Tumors (PNET), High-dose Chemotherapy
|12/01/99||Add to Therapy section||New policy
Policy represents revision of 8.01.15 to focus entirely on PNET. |
J9160 | INJ DENILEUKIN DIFTITOX 300 MCG | HCPCS | 2007;49(1):34-40. - National Comprehensive Cancer Network (NCCN). Central Nervous System Cancers 2014; http://www.nccn.org/professionals/physician_gls/PDF/cns.pdf. Accessed September 10, 2014. |CPT||38204||Management of recipient hematopoietic cell donor search and cell acquisition|
|38205||Blood-derived hematopoietic progenitor cell harvesting for transplantaion, per collection, allogeneic|
|38208||Transplant preparation of hematopoietic progenitor cells; thawing of previously frozen harvest, without washing, per donor|
|38209||;thawing of previously frozen harvest with washing, per donor|
|38210||Specific cell depletion with harvest, T cell depletion|
|38211||Tumor cell depletion|
|38212||Red blood cell removal|
|38214||Plasma (volume) depletion|
|38215||Cell concentration in plasma, mononuclear, or buffy coat layer|
|38220||Bone marrow; aspiration only|
|38221||Bone marrow; biopsy, needle or trocar|
|38230||Bone marrow harvesting for transplantation; allogeneic|
|38232||bone marrow harvesting for transplnation; autologous|
|38240||Bone marrow or blod-derived [eropheral stem-cell transplatation; allogeneic|
|ICD-9 Procedure||41.00||Bone marrow transplant, not otherwise specified|
|41.01||Autologous bone marrow transplant without purging|
|41.02||Allogeneic hone marrow transplant with purging|
|41.03||Allogeneic bone marrow transplant without purging|
|41.04||Autologous hematopoietic stem-cell transplant without purging|
|41.05||Allogeneic hematopoietic stem cell transplant without purging|
|41.06||Cord blood stem cell transplant|
|41.07||Autologous hematopoietic stem-cell transplant with purging|
|41.08||Allogeneic hematopoietic stem-cell transplant with purging|
|41.09||Autologous bone marrow transplant with purging|
|41.91||Aspiration of bone marrow from donor for transplant|
|99.79||Other therapeutic apheresis (includes harvest of stem cells)|
|ICD-9 Diagnosis||191.0–191.9||Malignant neoplasm of brain code range|
|HCPCS||Q0083, Q0084, Q0085||Chemotherapy administration code range|
J9000, J9001, J9010, J9015, J9017, J9020, J9025, J9027, J9031, J9035, J9041, J9045, J9050, J9055, J9060, J9062, J9065, J9070, J9080, J9090, J9091, J9092, J9093, J9094, J9095, J9096, J9097, J9098, J9100, J9110, J9120, J9130, J9140, J9150, J9151, J9160, J9165, J9170, J9175, J9178, J9181, J9182, J9185, J9190, J9200, J9201, J9202, J9206, J9208, J9209, J9211, J9212, J9213, J9214, J9215, J9216, J9217, J9218, J9219, J9225, J9226, J9230, J9245, J9250, J9260, J9261, J9263, J9264, J9265, J9266, J9268, J9270, J9280, J9290, J9291, J9293, J9300, J9303, J9305, J9310, J9320, J9340, J9350, J9355, J9357, J9360, J9370, J9375, J9380, J9390, J9395, J9600, J9999
|Chemotherapy drugs code range|
|G0265||Bryopreservation, freezing and storage of cells for thereapeutic use, each cell line|
|G0266||Thawing and expansion of frozen cells for therapeuticuse, each cell line|
|G0267||Bone marrow or peripheral stem-cell harvest, modification or treatment to eliminate cell type(s) (e.g., T cells, metastic carcinoma)|
|S2150||Bone marrow or blood-derived peripheral stem-cell harvesting and transplantation, allogeneic or autologous, including pheresis, high-dose chemotherapy, and the number of days of post-transplant care in the global definition (including drugs; hospitalization; medical surgical, diagnostic and emergency services)|
|ICD-10-CM (effective 10/1/15)||C71.0-C71.9||Malignant neoplasm of brain|
|ICD-10-PCS (effective 10/1/15)||ICD-10-PCS codes are only used for inpatient services.|
|30243G0, 30243X0, 30243Y0||Percutaneous transfusion, central vein, bone marrow or stem cells, autologous, code list|
|30243G1, 30243X1, 30243Y1||Percutaneous transfusion, central vein, bone marrow or stem cells, nonautologous, code list|
|07DQ0ZZ, 07DQ3ZZ, 07DR0ZZ, 07DR3ZZ, 07DS0ZZ, 07DS3ZZ||Surgical, lymphatic and hemic systems, extraction, bone marrow, code list|
|Type of Service||Therapy|
|Place of Service||Inpatient/Outpatient|
Ependymoma, High-dose Chemotherapy
Ependymoblastoma, High-dose Chemotherapy
High-dose chemotherapy with autologous stem-cell support for PNET and ependymoma
Medulloblastoma, High-dose Chemotherapy
Neuroblastoma, Central, High-dose Chemotherapy
Pinealblastoma, High-dose Chemotherapy
Primitive Neuroectodermal Tumors (PNET), High-dose Chemotherapy
|12/01/99||Add to Therapy section||New policy
Policy represents revision of 8.01.15 to focus entirely on PNET. |
J9375 | Vincristine sulfate 2 MG inj | HCPCS | 2007;49(1):34-40. - National Comprehensive Cancer Network (NCCN). Central Nervous System Cancers 2014; http://www.nccn.org/professionals/physician_gls/PDF/cns.pdf. Accessed September 10, 2014. |CPT||38204||Management of recipient hematopoietic cell donor search and cell acquisition|
|38205||Blood-derived hematopoietic progenitor cell harvesting for transplantaion, per collection, allogeneic|
|38208||Transplant preparation of hematopoietic progenitor cells; thawing of previously frozen harvest, without washing, per donor|
|38209||;thawing of previously frozen harvest with washing, per donor|
|38210||Specific cell depletion with harvest, T cell depletion|
|38211||Tumor cell depletion|
|38212||Red blood cell removal|
|38214||Plasma (volume) depletion|
|38215||Cell concentration in plasma, mononuclear, or buffy coat layer|
|38220||Bone marrow; aspiration only|
|38221||Bone marrow; biopsy, needle or trocar|
|38230||Bone marrow harvesting for transplantation; allogeneic|
|38232||bone marrow harvesting for transplnation; autologous|
|38240||Bone marrow or blod-derived [eropheral stem-cell transplatation; allogeneic|
|ICD-9 Procedure||41.00||Bone marrow transplant, not otherwise specified|
|41.01||Autologous bone marrow transplant without purging|
|41.02||Allogeneic hone marrow transplant with purging|
|41.03||Allogeneic bone marrow transplant without purging|
|41.04||Autologous hematopoietic stem-cell transplant without purging|
|41.05||Allogeneic hematopoietic stem cell transplant without purging|
|41.06||Cord blood stem cell transplant|
|41.07||Autologous hematopoietic stem-cell transplant with purging|
|41.08||Allogeneic hematopoietic stem-cell transplant with purging|
|41.09||Autologous bone marrow transplant with purging|
|41.91||Aspiration of bone marrow from donor for transplant|
|99.79||Other therapeutic apheresis (includes harvest of stem cells)|
|ICD-9 Diagnosis||191.0–191.9||Malignant neoplasm of brain code range|
|HCPCS||Q0083, Q0084, Q0085||Chemotherapy administration code range|
J9000, J9001, J9010, J9015, J9017, J9020, J9025, J9027, J9031, J9035, J9041, J9045, J9050, J9055, J9060, J9062, J9065, J9070, J9080, J9090, J9091, J9092, J9093, J9094, J9095, J9096, J9097, J9098, J9100, J9110, J9120, J9130, J9140, J9150, J9151, J9160, J9165, J9170, J9175, J9178, J9181, J9182, J9185, J9190, J9200, J9201, J9202, J9206, J9208, J9209, J9211, J9212, J9213, J9214, J9215, J9216, J9217, J9218, J9219, J9225, J9226, J9230, J9245, J9250, J9260, J9261, J9263, J9264, J9265, J9266, J9268, J9270, J9280, J9290, J9291, J9293, J9300, J9303, J9305, J9310, J9320, J9340, J9350, J9355, J9357, J9360, J9370, J9375, J9380, J9390, J9395, J9600, J9999
|Chemotherapy drugs code range|
|G0265||Bryopreservation, freezing and storage of cells for thereapeutic use, each cell line|
|G0266||Thawing and expansion of frozen cells for therapeuticuse, each cell line|
|G0267||Bone marrow or peripheral stem-cell harvest, modification or treatment to eliminate cell type(s) (e.g., T cells, metastic carcinoma)|
|S2150||Bone marrow or blood-derived peripheral stem-cell harvesting and transplantation, allogeneic or autologous, including pheresis, high-dose chemotherapy, and the number of days of post-transplant care in the global definition (including drugs; hospitalization; medical surgical, diagnostic and emergency services)|
|ICD-10-CM (effective 10/1/15)||C71.0-C71.9||Malignant neoplasm of brain|
|ICD-10-PCS (effective 10/1/15)||ICD-10-PCS codes are only used for inpatient services.|
|30243G0, 30243X0, 30243Y0||Percutaneous transfusion, central vein, bone marrow or stem cells, autologous, code list|
|30243G1, 30243X1, 30243Y1||Percutaneous transfusion, central vein, bone marrow or stem cells, nonautologous, code list|
|07DQ0ZZ, 07DQ3ZZ, 07DR0ZZ, 07DR3ZZ, 07DS0ZZ, 07DS3ZZ||Surgical, lymphatic and hemic systems, extraction, bone marrow, code list|
|Type of Service||Therapy|
|Place of Service||Inpatient/Outpatient|
Ependymoma, High-dose Chemotherapy
Ependymoblastoma, High-dose Chemotherapy
High-dose chemotherapy with autologous stem-cell support for PNET and ependymoma
Medulloblastoma, High-dose Chemotherapy
Neuroblastoma, Central, High-dose Chemotherapy
Pinealblastoma, High-dose Chemotherapy
Primitive Neuroectodermal Tumors (PNET), High-dose Chemotherapy
|12/01/99||Add to Therapy section||New policy
Policy represents revision of 8.01.15 to focus entirely on PNET. |
J9291 | Mitomycin 40 MG inj | HCPCS | 2007;49(1):34-40. - National Comprehensive Cancer Network (NCCN). Central Nervous System Cancers 2014; http://www.nccn.org/professionals/physician_gls/PDF/cns.pdf. Accessed September 10, 2014. |CPT||38204||Management of recipient hematopoietic cell donor search and cell acquisition|
|38205||Blood-derived hematopoietic progenitor cell harvesting for transplantaion, per collection, allogeneic|
|38208||Transplant preparation of hematopoietic progenitor cells; thawing of previously frozen harvest, without washing, per donor|
|38209||;thawing of previously frozen harvest with washing, per donor|
|38210||Specific cell depletion with harvest, T cell depletion|
|38211||Tumor cell depletion|
|38212||Red blood cell removal|
|38214||Plasma (volume) depletion|
|38215||Cell concentration in plasma, mononuclear, or buffy coat layer|
|38220||Bone marrow; aspiration only|
|38221||Bone marrow; biopsy, needle or trocar|
|38230||Bone marrow harvesting for transplantation; allogeneic|
|38232||bone marrow harvesting for transplnation; autologous|
|38240||Bone marrow or blod-derived [eropheral stem-cell transplatation; allogeneic|
|ICD-9 Procedure||41.00||Bone marrow transplant, not otherwise specified|
|41.01||Autologous bone marrow transplant without purging|
|41.02||Allogeneic hone marrow transplant with purging|
|41.03||Allogeneic bone marrow transplant without purging|
|41.04||Autologous hematopoietic stem-cell transplant without purging|
|41.05||Allogeneic hematopoietic stem cell transplant without purging|
|41.06||Cord blood stem cell transplant|
|41.07||Autologous hematopoietic stem-cell transplant with purging|
|41.08||Allogeneic hematopoietic stem-cell transplant with purging|
|41.09||Autologous bone marrow transplant with purging|
|41.91||Aspiration of bone marrow from donor for transplant|
|99.79||Other therapeutic apheresis (includes harvest of stem cells)|
|ICD-9 Diagnosis||191.0–191.9||Malignant neoplasm of brain code range|
|HCPCS||Q0083, Q0084, Q0085||Chemotherapy administration code range|
J9000, J9001, J9010, J9015, J9017, J9020, J9025, J9027, J9031, J9035, J9041, J9045, J9050, J9055, J9060, J9062, J9065, J9070, J9080, J9090, J9091, J9092, J9093, J9094, J9095, J9096, J9097, J9098, J9100, J9110, J9120, J9130, J9140, J9150, J9151, J9160, J9165, J9170, J9175, J9178, J9181, J9182, J9185, J9190, J9200, J9201, J9202, J9206, J9208, J9209, J9211, J9212, J9213, J9214, J9215, J9216, J9217, J9218, J9219, J9225, J9226, J9230, J9245, J9250, J9260, J9261, J9263, J9264, J9265, J9266, J9268, J9270, J9280, J9290, J9291, J9293, J9300, J9303, J9305, J9310, J9320, J9340, J9350, J9355, J9357, J9360, J9370, J9375, J9380, J9390, J9395, J9600, J9999
|Chemotherapy drugs code range|
|G0265||Bryopreservation, freezing and storage of cells for thereapeutic use, each cell line|
|G0266||Thawing and expansion of frozen cells for therapeuticuse, each cell line|
|G0267||Bone marrow or peripheral stem-cell harvest, modification or treatment to eliminate cell type(s) (e.g., T cells, metastic carcinoma)|
|S2150||Bone marrow or blood-derived peripheral stem-cell harvesting and transplantation, allogeneic or autologous, including pheresis, high-dose chemotherapy, and the number of days of post-transplant care in the global definition (including drugs; hospitalization; medical surgical, diagnostic and emergency services)|
|ICD-10-CM (effective 10/1/15)||C71.0-C71.9||Malignant neoplasm of brain|
|ICD-10-PCS (effective 10/1/15)||ICD-10-PCS codes are only used for inpatient services.|
|30243G0, 30243X0, 30243Y0||Percutaneous transfusion, central vein, bone marrow or stem cells, autologous, code list|
|30243G1, 30243X1, 30243Y1||Percutaneous transfusion, central vein, bone marrow or stem cells, nonautologous, code list|
|07DQ0ZZ, 07DQ3ZZ, 07DR0ZZ, 07DR3ZZ, 07DS0ZZ, 07DS3ZZ||Surgical, lymphatic and hemic systems, extraction, bone marrow, code list|
|Type of Service||Therapy|
|Place of Service||Inpatient/Outpatient|
Ependymoma, High-dose Chemotherapy
Ependymoblastoma, High-dose Chemotherapy
High-dose chemotherapy with autologous stem-cell support for PNET and ependymoma
Medulloblastoma, High-dose Chemotherapy
Neuroblastoma, Central, High-dose Chemotherapy
Pinealblastoma, High-dose Chemotherapy
Primitive Neuroectodermal Tumors (PNET), High-dose Chemotherapy
|12/01/99||Add to Therapy section||New policy
Policy represents revision of 8.01.15 to focus entirely on PNET. |
J9000 | INJECTION, DOXORUBICIN HYDROCHLORIDE, 10 MG | HCPCS | 2007;49(1):34-40. - National Comprehensive Cancer Network (NCCN). Central Nervous System Cancers 2014; http://www.nccn.org/professionals/physician_gls/PDF/cns.pdf. Accessed September 10, 2014. |CPT||38204||Management of recipient hematopoietic cell donor search and cell acquisition|
|38205||Blood-derived hematopoietic progenitor cell harvesting for transplantaion, per collection, allogeneic|
|38208||Transplant preparation of hematopoietic progenitor cells; thawing of previously frozen harvest, without washing, per donor|
|38209||;thawing of previously frozen harvest with washing, per donor|
|38210||Specific cell depletion with harvest, T cell depletion|
|38211||Tumor cell depletion|
|38212||Red blood cell removal|
|38214||Plasma (volume) depletion|
|38215||Cell concentration in plasma, mononuclear, or buffy coat layer|
|38220||Bone marrow; aspiration only|
|38221||Bone marrow; biopsy, needle or trocar|
|38230||Bone marrow harvesting for transplantation; allogeneic|
|38232||bone marrow harvesting for transplnation; autologous|
|38240||Bone marrow or blod-derived [eropheral stem-cell transplatation; allogeneic|
|ICD-9 Procedure||41.00||Bone marrow transplant, not otherwise specified|
|41.01||Autologous bone marrow transplant without purging|
|41.02||Allogeneic hone marrow transplant with purging|
|41.03||Allogeneic bone marrow transplant without purging|
|41.04||Autologous hematopoietic stem-cell transplant without purging|
|41.05||Allogeneic hematopoietic stem cell transplant without purging|
|41.06||Cord blood stem cell transplant|
|41.07||Autologous hematopoietic stem-cell transplant with purging|
|41.08||Allogeneic hematopoietic stem-cell transplant with purging|
|41.09||Autologous bone marrow transplant with purging|
|41.91||Aspiration of bone marrow from donor for transplant|
|99.79||Other therapeutic apheresis (includes harvest of stem cells)|
|ICD-9 Diagnosis||191.0–191.9||Malignant neoplasm of brain code range|
|HCPCS||Q0083, Q0084, Q0085||Chemotherapy administration code range|
J9000, J9001, J9010, J9015, J9017, J9020, J9025, J9027, J9031, J9035, J9041, J9045, J9050, J9055, J9060, J9062, J9065, J9070, J9080, J9090, J9091, J9092, J9093, J9094, J9095, J9096, J9097, J9098, J9100, J9110, J9120, J9130, J9140, J9150, J9151, J9160, J9165, J9170, J9175, J9178, J9181, J9182, J9185, J9190, J9200, J9201, J9202, J9206, J9208, J9209, J9211, J9212, J9213, J9214, J9215, J9216, J9217, J9218, J9219, J9225, J9226, J9230, J9245, J9250, J9260, J9261, J9263, J9264, J9265, J9266, J9268, J9270, J9280, J9290, J9291, J9293, J9300, J9303, J9305, J9310, J9320, J9340, J9350, J9355, J9357, J9360, J9370, J9375, J9380, J9390, J9395, J9600, J9999
|Chemotherapy drugs code range|
|G0265||Bryopreservation, freezing and storage of cells for thereapeutic use, each cell line|
|G0266||Thawing and expansion of frozen cells for therapeuticuse, each cell line|
|G0267||Bone marrow or peripheral stem-cell harvest, modification or treatment to eliminate cell type(s) (e.g., T cells, metastic carcinoma)|
|S2150||Bone marrow or blood-derived peripheral stem-cell harvesting and transplantation, allogeneic or autologous, including pheresis, high-dose chemotherapy, and the number of days of post-transplant care in the global definition (including drugs; hospitalization; medical surgical, diagnostic and emergency services)|
|ICD-10-CM (effective 10/1/15)||C71.0-C71.9||Malignant neoplasm of brain|
|ICD-10-PCS (effective 10/1/15)||ICD-10-PCS codes are only used for inpatient services.|
|30243G0, 30243X0, 30243Y0||Percutaneous transfusion, central vein, bone marrow or stem cells, autologous, code list|
|30243G1, 30243X1, 30243Y1||Percutaneous transfusion, central vein, bone marrow or stem cells, nonautologous, code list|
|07DQ0ZZ, 07DQ3ZZ, 07DR0ZZ, 07DR3ZZ, 07DS0ZZ, 07DS3ZZ||Surgical, lymphatic and hemic systems, extraction, bone marrow, code list|
|Type of Service||Therapy|
|Place of Service||Inpatient/Outpatient|
Ependymoma, High-dose Chemotherapy
Ependymoblastoma, High-dose Chemotherapy
High-dose chemotherapy with autologous stem-cell support for PNET and ependymoma
Medulloblastoma, High-dose Chemotherapy
Neuroblastoma, Central, High-dose Chemotherapy
Pinealblastoma, High-dose Chemotherapy
Primitive Neuroectodermal Tumors (PNET), High-dose Chemotherapy
|12/01/99||Add to Therapy section||New policy
Policy represents revision of 8.01.15 to focus entirely on PNET. |
J9094 | CYCLOPHOSPHAMIDE LYOPHILIZED 200 MG | HCPCS | 2007;49(1):34-40. - National Comprehensive Cancer Network (NCCN). Central Nervous System Cancers 2014; http://www.nccn.org/professionals/physician_gls/PDF/cns.pdf. Accessed September 10, 2014. |CPT||38204||Management of recipient hematopoietic cell donor search and cell acquisition|
|38205||Blood-derived hematopoietic progenitor cell harvesting for transplantaion, per collection, allogeneic|
|38208||Transplant preparation of hematopoietic progenitor cells; thawing of previously frozen harvest, without washing, per donor|
|38209||;thawing of previously frozen harvest with washing, per donor|
|38210||Specific cell depletion with harvest, T cell depletion|
|38211||Tumor cell depletion|
|38212||Red blood cell removal|
|38214||Plasma (volume) depletion|
|38215||Cell concentration in plasma, mononuclear, or buffy coat layer|
|38220||Bone marrow; aspiration only|
|38221||Bone marrow; biopsy, needle or trocar|
|38230||Bone marrow harvesting for transplantation; allogeneic|
|38232||bone marrow harvesting for transplnation; autologous|
|38240||Bone marrow or blod-derived [eropheral stem-cell transplatation; allogeneic|
|ICD-9 Procedure||41.00||Bone marrow transplant, not otherwise specified|
|41.01||Autologous bone marrow transplant without purging|
|41.02||Allogeneic hone marrow transplant with purging|
|41.03||Allogeneic bone marrow transplant without purging|
|41.04||Autologous hematopoietic stem-cell transplant without purging|
|41.05||Allogeneic hematopoietic stem cell transplant without purging|
|41.06||Cord blood stem cell transplant|
|41.07||Autologous hematopoietic stem-cell transplant with purging|
|41.08||Allogeneic hematopoietic stem-cell transplant with purging|
|41.09||Autologous bone marrow transplant with purging|
|41.91||Aspiration of bone marrow from donor for transplant|
|99.79||Other therapeutic apheresis (includes harvest of stem cells)|
|ICD-9 Diagnosis||191.0–191.9||Malignant neoplasm of brain code range|
|HCPCS||Q0083, Q0084, Q0085||Chemotherapy administration code range|
J9000, J9001, J9010, J9015, J9017, J9020, J9025, J9027, J9031, J9035, J9041, J9045, J9050, J9055, J9060, J9062, J9065, J9070, J9080, J9090, J9091, J9092, J9093, J9094, J9095, J9096, J9097, J9098, J9100, J9110, J9120, J9130, J9140, J9150, J9151, J9160, J9165, J9170, J9175, J9178, J9181, J9182, J9185, J9190, J9200, J9201, J9202, J9206, J9208, J9209, J9211, J9212, J9213, J9214, J9215, J9216, J9217, J9218, J9219, J9225, J9226, J9230, J9245, J9250, J9260, J9261, J9263, J9264, J9265, J9266, J9268, J9270, J9280, J9290, J9291, J9293, J9300, J9303, J9305, J9310, J9320, J9340, J9350, J9355, J9357, J9360, J9370, J9375, J9380, J9390, J9395, J9600, J9999
|Chemotherapy drugs code range|
|G0265||Bryopreservation, freezing and storage of cells for thereapeutic use, each cell line|
|G0266||Thawing and expansion of frozen cells for therapeuticuse, each cell line|
|G0267||Bone marrow or peripheral stem-cell harvest, modification or treatment to eliminate cell type(s) (e.g., T cells, metastic carcinoma)|
|S2150||Bone marrow or blood-derived peripheral stem-cell harvesting and transplantation, allogeneic or autologous, including pheresis, high-dose chemotherapy, and the number of days of post-transplant care in the global definition (including drugs; hospitalization; medical surgical, diagnostic and emergency services)|
|ICD-10-CM (effective 10/1/15)||C71.0-C71.9||Malignant neoplasm of brain|
|ICD-10-PCS (effective 10/1/15)||ICD-10-PCS codes are only used for inpatient services.|
|30243G0, 30243X0, 30243Y0||Percutaneous transfusion, central vein, bone marrow or stem cells, autologous, code list|
|30243G1, 30243X1, 30243Y1||Percutaneous transfusion, central vein, bone marrow or stem cells, nonautologous, code list|
|07DQ0ZZ, 07DQ3ZZ, 07DR0ZZ, 07DR3ZZ, 07DS0ZZ, 07DS3ZZ||Surgical, lymphatic and hemic systems, extraction, bone marrow, code list|
|Type of Service||Therapy|
|Place of Service||Inpatient/Outpatient|
Ependymoma, High-dose Chemotherapy
Ependymoblastoma, High-dose Chemotherapy
High-dose chemotherapy with autologous stem-cell support for PNET and ependymoma
Medulloblastoma, High-dose Chemotherapy
Neuroblastoma, Central, High-dose Chemotherapy
Pinealblastoma, High-dose Chemotherapy
Primitive Neuroectodermal Tumors (PNET), High-dose Chemotherapy
|12/01/99||Add to Therapy section||New policy
Policy represents revision of 8.01.15 to focus entirely on PNET. |
J9265 | Paclitaxel injection | HCPCS | 2007;49(1):34-40. - National Comprehensive Cancer Network (NCCN). Central Nervous System Cancers 2014; http://www.nccn.org/professionals/physician_gls/PDF/cns.pdf. Accessed September 10, 2014. |CPT||38204||Management of recipient hematopoietic cell donor search and cell acquisition|
|38205||Blood-derived hematopoietic progenitor cell harvesting for transplantaion, per collection, allogeneic|
|38208||Transplant preparation of hematopoietic progenitor cells; thawing of previously frozen harvest, without washing, per donor|
|38209||;thawing of previously frozen harvest with washing, per donor|
|38210||Specific cell depletion with harvest, T cell depletion|
|38211||Tumor cell depletion|
|38212||Red blood cell removal|
|38214||Plasma (volume) depletion|
|38215||Cell concentration in plasma, mononuclear, or buffy coat layer|
|38220||Bone marrow; aspiration only|
|38221||Bone marrow; biopsy, needle or trocar|
|38230||Bone marrow harvesting for transplantation; allogeneic|
|38232||bone marrow harvesting for transplnation; autologous|
|38240||Bone marrow or blod-derived [eropheral stem-cell transplatation; allogeneic|
|ICD-9 Procedure||41.00||Bone marrow transplant, not otherwise specified|
|41.01||Autologous bone marrow transplant without purging|
|41.02||Allogeneic hone marrow transplant with purging|
|41.03||Allogeneic bone marrow transplant without purging|
|41.04||Autologous hematopoietic stem-cell transplant without purging|
|41.05||Allogeneic hematopoietic stem cell transplant without purging|
|41.06||Cord blood stem cell transplant|
|41.07||Autologous hematopoietic stem-cell transplant with purging|
|41.08||Allogeneic hematopoietic stem-cell transplant with purging|
|41.09||Autologous bone marrow transplant with purging|
|41.91||Aspiration of bone marrow from donor for transplant|
|99.79||Other therapeutic apheresis (includes harvest of stem cells)|
|ICD-9 Diagnosis||191.0–191.9||Malignant neoplasm of brain code range|
|HCPCS||Q0083, Q0084, Q0085||Chemotherapy administration code range|
J9000, J9001, J9010, J9015, J9017, J9020, J9025, J9027, J9031, J9035, J9041, J9045, J9050, J9055, J9060, J9062, J9065, J9070, J9080, J9090, J9091, J9092, J9093, J9094, J9095, J9096, J9097, J9098, J9100, J9110, J9120, J9130, J9140, J9150, J9151, J9160, J9165, J9170, J9175, J9178, J9181, J9182, J9185, J9190, J9200, J9201, J9202, J9206, J9208, J9209, J9211, J9212, J9213, J9214, J9215, J9216, J9217, J9218, J9219, J9225, J9226, J9230, J9245, J9250, J9260, J9261, J9263, J9264, J9265, J9266, J9268, J9270, J9280, J9290, J9291, J9293, J9300, J9303, J9305, J9310, J9320, J9340, J9350, J9355, J9357, J9360, J9370, J9375, J9380, J9390, J9395, J9600, J9999
|Chemotherapy drugs code range|
|G0265||Bryopreservation, freezing and storage of cells for thereapeutic use, each cell line|
|G0266||Thawing and expansion of frozen cells for therapeuticuse, each cell line|
|G0267||Bone marrow or peripheral stem-cell harvest, modification or treatment to eliminate cell type(s) (e.g., T cells, metastic carcinoma)|
|S2150||Bone marrow or blood-derived peripheral stem-cell harvesting and transplantation, allogeneic or autologous, including pheresis, high-dose chemotherapy, and the number of days of post-transplant care in the global definition (including drugs; hospitalization; medical surgical, diagnostic and emergency services)|
|ICD-10-CM (effective 10/1/15)||C71.0-C71.9||Malignant neoplasm of brain|
|ICD-10-PCS (effective 10/1/15)||ICD-10-PCS codes are only used for inpatient services.|
|30243G0, 30243X0, 30243Y0||Percutaneous transfusion, central vein, bone marrow or stem cells, autologous, code list|
|30243G1, 30243X1, 30243Y1||Percutaneous transfusion, central vein, bone marrow or stem cells, nonautologous, code list|
|07DQ0ZZ, 07DQ3ZZ, 07DR0ZZ, 07DR3ZZ, 07DS0ZZ, 07DS3ZZ||Surgical, lymphatic and hemic systems, extraction, bone marrow, code list|
|Type of Service||Therapy|
|Place of Service||Inpatient/Outpatient|
Ependymoma, High-dose Chemotherapy
Ependymoblastoma, High-dose Chemotherapy
High-dose chemotherapy with autologous stem-cell support for PNET and ependymoma
Medulloblastoma, High-dose Chemotherapy
Neuroblastoma, Central, High-dose Chemotherapy
Pinealblastoma, High-dose Chemotherapy
Primitive Neuroectodermal Tumors (PNET), High-dose Chemotherapy
|12/01/99||Add to Therapy section||New policy
Policy represents revision of 8.01.15 to focus entirely on PNET. |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.